<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Blood biomarkers for the non‐invasive diagnosis of endometriosis - Nisenblat, V - 2016 | Cochrane Library</title> <meta content="Blood biomarkers for the non‐invasive diagnosis of endometriosis - Nisenblat, V - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012179/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Blood biomarkers for the non‐invasive diagnosis of endometriosis - Nisenblat, V - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012179/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012179" name="dc.identifier" scheme="DOI"/> <meta content="Blood biomarkers for the non‐invasive diagnosis of endometriosis" name="citation_title"/> <meta content="Vicki Nisenblat" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="vnisenblat@gmail.com" name="citation_author_email"/> <meta content="Patrick MM Bossuyt" name="citation_author"/> <meta content="Academic Medical Center, University of Amsterdam" name="citation_author_institution"/> <meta content="Rabia Shaikh" name="citation_author"/> <meta content="IVF Australia" name="citation_author_institution"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Vanessa Jordan" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Carola S Scheffers" name="citation_author"/> <meta content="University of Groningen" name="citation_author_institution"/> <meta content="Ben Willem J Mol" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="Neil Johnson" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="M Louise Hull" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012179" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/05/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012179/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012179/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012179/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Autoantibodies [blood]; Biomarkers [*blood]; CA-125 Antigen [blood]; CA-19-9 Antigen [blood]; Endometriosis [*diagnosis]; Endometrium [immunology]; Interleukin-6 [blood]; Ovarian Diseases [*diagnosis]; Pelvis; Peritoneal Diseases [*diagnosis]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012179&amp;doi=10.1002/14651858.CD012179&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012179\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012179\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012179\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012179",title:"Blood biomarkers for the non\\u2010invasive diagnosis of endometriosis",firstPublishedDate:"May 1, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012179&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012179';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012179/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012179/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012179%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012179/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012179/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012179/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012179/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012179" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012179/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012179" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012179/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012179/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12225 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012179" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-sec-0163"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-sec-0045"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-sec-0159"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012179/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/appendices#CD012179-sec-0168"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/table_n/CD012179StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/table_n/CD012179StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012179/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012179/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012179/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012179/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012179/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Blood biomarkers for the non‐invasive diagnosis of endometriosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vicki Nisenblat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0003">Patrick MM Bossuyt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0004">Rabia Shaikh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0005">Cindy Farquhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0006">Vanessa Jordan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0007">Carola S Scheffers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0008">Ben Willem J Mol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0009">Neil Johnson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012179/information#CD012179-cr-0010">M Louise Hull</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012179/information/en#CD012179-sec-0186">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 May 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012179/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012179">https://doi.org/10.1002/14651858.CD012179</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012179-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012179-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012179-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012179-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012179-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012179-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012179-abs-0001" lang="en"> <section id="CD012179-sec-0001"> <h3 class="title" id="CD012179-sec-0001">Background</h3> <p>About 10% of reproductive‐aged women suffer from endometriosis, a costly chronic disease causing pelvic pain and subfertility. Laparoscopy is the gold standard diagnostic test for endometriosis, but is expensive and carries surgical risks. Currently, there are no non‐invasive or minimally invasive tests available in clinical practice to accurately diagnose endometriosis. Although other reviews have assessed the ability of blood tests to diagnose endometriosis, this is the first review to use Cochrane methods, providing an update on the rapidly expanding literature in this field. </p> </section> <section id="CD012179-sec-0002"> <h3 class="title" id="CD012179-sec-0002">Objectives</h3> <p>To evaluate blood biomarkers as replacement tests for diagnostic surgery and as triage tests to inform decisions on surgery for endometriosis. Specific objectives include: </p> <p>1. To provide summary estimates of the diagnostic accuracy of blood biomarkers for the diagnosis of peritoneal, ovarian and deep infiltrating pelvic endometriosis, compared to surgical diagnosis as a reference standard. </p> <p>2. To assess the diagnostic utility of biomarkers that could differentiate ovarian endometrioma from other ovarian masses. </p> </section> <section id="CD012179-sec-0003"> <h3 class="title" id="CD012179-sec-0003">Search methods</h3> <p>We did not restrict the searches to particular study designs, language or publication dates. We searched CENTRAL to July 2015, MEDLINE and EMBASE to May 2015, as well as these databases to 20 April 2015: CINAHL, PsycINFO, Web of Science, LILACS, OAIster, TRIP, ClinicalTrials.gov, DARE and PubMed. </p> </section> <section id="CD012179-sec-0004"> <h3 class="title" id="CD012179-sec-0004">Selection criteria</h3> <p>We considered published, peer‐reviewed, randomised controlled or cross‐sectional studies of any size, including prospectively collected samples from any population of reproductive‐aged women suspected of having one or more of the following target conditions: ovarian, peritoneal or deep infiltrating endometriosis (DIE). We included studies comparing the diagnostic test accuracy of one or more blood biomarkers with the findings of surgical visualisation of endometriotic lesions. </p> </section> <section id="CD012179-sec-0005"> <h3 class="title" id="CD012179-sec-0005">Data collection and analysis</h3> <p>Two authors independently collected and performed a quality assessment of data from each study. For each diagnostic test, we classified the data as positive or negative for the surgical detection of endometriosis, and we calculated sensitivity and specificity estimates. We used the bivariate model to obtain pooled estimates of sensitivity and specificity whenever sufficient datasets were available. The predetermined criteria for a clinically useful blood test to replace diagnostic surgery were a sensitivity of 0.94 and a specificity of 0.79 to detect endometriosis. We set the criteria for triage tests at a sensitivity of ≥ 0.95 and a specificity of ≥ 0.50, which 'rules out' the diagnosis with high accuracy if there is a negative test result (SnOUT test), or a sensitivity of ≥ 0.50 and a specificity of ≥ 0.95, which 'rules in' the diagnosis with high accuracy if there is a positive result (SpIN test). </p> </section> <section id="CD012179-sec-0006"> <h3 class="title" id="CD012179-sec-0006">Main results</h3> <p>We included 141 studies that involved 15,141 participants and evaluated 122 blood biomarkers. All the studies were of poor methodological quality. Studies evaluated the blood biomarkers either in a specific phase of the menstrual cycle or irrespective of the cycle phase, and they tested for them in serum, plasma or whole blood. Included women were a selected population with a high frequency of endometriosis (10% to 85%), in which surgery was indicated for endometriosis, infertility work‐up or ovarian mass. Seventy studies evaluated the diagnostic performance of 47 blood biomarkers for endometriosis (44 single‐marker tests and 30 combined tests of two to six blood biomarkers). These were angiogenesis/growth factors, apoptosis markers, cell adhesion molecules, high‐throughput markers, hormonal markers, immune system/inflammatory markers, oxidative stress markers, microRNAs, tumour markers and other proteins. Most of these biomarkers were assessed in small individual studies, often using different cut‐off thresholds, and we could only perform meta‐analyses on the data sets for anti‐endometrial antibodies, interleukin‐6 (IL‐6), cancer antigen‐19.9 (CA‐19.9) and CA‐125. Diagnostic estimates varied significantly between studies for each of these biomarkers, and CA‐125 was the only marker with sufficient data to reliably assess sources of heterogeneity. </p> <p>The mean sensitivities and specificities of anti‐endometrial antibodies (4 studies, 759 women) were 0.81 (95% confidence interval (CI) 0.76 to 0.87) and 0.75 (95% CI 0.46 to 1.00). For IL‐6, with a cut‐off value of &gt; 1.90 to 2.00 pg/ml (3 studies, 309 women), sensitivity was 0.63 (95% CI 0.52 to 0.75) and specificity was 0.69 (95% CI 0.57 to 0.82). For CA‐19.9, with a cut‐off value of &gt; 37.0 IU/ml (3 studies, 330 women), sensitivity was 0.36 (95% CI 0.26 to 0.45) and specificity was 0.87 (95% CI 0.75 to 0.99). </p> <p>Studies assessed CA‐125 at different thresholds, demonstrating the following mean sensitivities and specificities: for cut‐off &gt; 10.0 to 14.7 U/ml: 0.70 (95% CI 0.63 to 0.77) and 0.64 (95% CI 0.47 to 0.82); for cut‐off &gt; 16.0 to 17.6 U/ml: 0.56 (95% CI 0.24, 0.88) and 0.91 (95% CI 0.75, 1.00); for cut‐off &gt; 20.0 U/ml: 0.67 (95% CI 0.50 to 0.85) and 0.69 (95% CI 0.58 to 0.80); for cut‐off &gt; 25.0 to 26.0 U/ml: 0.73 (95% CI 0.67 to 0.79) and 0.70 (95% CI 0.63 to 0.77); for cut‐off &gt; 30.0 to 33.0 U/ml: 0.62 (95% CI 0.45 to 0.79) and 0.76 (95% CI 0.53 to 1.00); and for cut‐off &gt; 35.0 to 36.0 U/ml: 0.40 (95% CI 0.32 to 0.49) and 0.91 (95% CI 0.88 to 0.94). </p> <p>We could not statistically evaluate other biomarkers meaningfully, including biomarkers that were assessed for their ability to differentiate endometrioma from other benign ovarian cysts. </p> <p>Eighty‐two studies evaluated 97 biomarkers that did not differentiate women with endometriosis from disease‐free controls. Of these, 22 biomarkers demonstrated conflicting results, with some studies showing differential expression and others no evidence of a difference between the endometriosis and control groups. </p> </section> <section id="CD012179-sec-0007"> <h3 class="title" id="CD012179-sec-0007">Authors' conclusions</h3> <p>Of the biomarkers that were subjected to meta‐analysis, none consistently met the criteria for a replacement or triage diagnostic test. A subset of blood biomarkers could prove useful either for detecting pelvic endometriosis or for differentiating ovarian endometrioma from other benign ovarian masses, but there was insufficient evidence to draw meaningful conclusions. Overall, none of the biomarkers displayed enough accuracy to be used clinically outside a research setting. We also identified blood biomarkers that demonstrated no diagnostic value in endometriosis and recommend focusing research resources on evaluating other more clinically useful biomarkers. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012179-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012179-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012179-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012179-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012179-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012179-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012179-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012179-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012179-abs-0005" lang="en"> <h3>Blood biomarkers for the non‐invasive diagnosis of endometriosis</h3> <p><b>Review Question</b> </p> <p>How accurate are blood tests in detecting endometriosis? Can any blood test be accurate enough to replace or reduce the need for surgery in the diagnosis of endometriosis? </p> <p><b>Background</b> </p> <p>Women with endometriosis have endometrial tissue (the tissue that lines the womb and is shed during menstruation) growing outside the womb within the pelvic cavity. This tissue responds to reproductive hormones, causing painful periods, chronic lower abdominal pain and difficulty conceiving. Currently, the only reliable way of diagnosing endometriosis is to perform keyhole surgery and visualise the endometrial deposits inside the abdomen. Because surgery is risky and expensive, we evaluated whether the results of blood tests (blood biomarkers) can help to detect endometriosis non‐invasively. An accurate blood test could lead to the diagnosis of endometriosis without the need for surgery, or it could reduce the need for diagnostic surgery to a group of women who were most likely to have endometriosis. Separate Cochrane reviews from this series evaluate other non‐invasive ways of diagnosing endometriosis using urine, imaging, endometrial and combination tests. </p> <p><b>Study characteristics</b> </p> <p>The evidence included in this review is current to July 2015. We included 141 studies involving 15,141 participants. All studies evaluated reproductive‐aged women who were undertaking diagnostic surgery because they were suspected of having one or more of the following target conditions: ovarian, peritoneal or deep infiltrating endometriosis (DIE). Cancer antigen‐125 (CA‐125) was the most common blood biomarker studied. Seventy studies evaluated 47 blood biomarkers that were expressed differently in women with and without endometriosis, and 82 studies identified 97 biomarkers that did not distinguish between the two groups. Twenty‐two biomarkers were in both categories. </p> <p><b>Key results</b> </p> <p>Only four of the assessed biomarkers (anti‐endometrial Abs (anti‐endometrial autoantibodies), interleukin‐6 (IL‐6), CA‐19.9 and CA‐125) were evaluated by enough studies to provide a meaningful assessment of test accuracy. None of these tests was accurate enough to replace diagnostic surgery. Several studies identified biomarkers that might be of value in diagnosing endometriosis, but there are too few reports to be sure of their diagnostic benefit. Overall, there is not enough evidence to recommend testing for any blood biomarker in clinical practice to diagnose endometriosis. </p> <p><b>Quality of the evidence</b> </p> <p>Generally, the reports were of low methodological quality, and most blood tests were only assessed by a single or a small number of studies. When the same biomarker was studied, there were significant differences in how studies were conducted, the group of women studied and the cut‐offs used to determine a positive result. </p> <p><b>Future research</b> </p> <p>More high quality research trials are necessary to accurately assess the diagnostic potential of certain blood biomarkers, whose diagnostic value for endometriosis was suggested by a limited number of studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012179-sec-0163" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012179-sec-0163"></div> <h3 class="title" id="CD012179-sec-0164">Implications for practice</h3> <section id="CD012179-sec-0164"> <p>CA‐125 was the most studied technique, but showed only moderate sensitivity and moderate specificity for pelvic endometriosis, which did not meet the criteria for a replacement or triage test. This is consistent with international guidelines, which do not recommend CA‐125 testing in women with suspected endometriosis (<a href="./references#CD012179-bbs2-0379" title="The American College of Obstetricians and Gynecologists. Practice bulletin no. 114: management of endometriosis. Obstetrics and Gynecology2010;116(1):223‐36. ">ACOG 2010</a>; <a href="./references#CD012179-bbs2-0398" title="DunselmanGA , VermeulenN , BeckerC , Calhaz‐JorgeC , D'HoogheT , DeBieB , et al. ESHRE guideline: management of women with endometriosis. Human Reproduction2014;29(3):400‐12. ">Dunselman 2014</a>; <a href="./references#CD012179-bbs2-0434" title="Society of Obstetricians Gynaecologists of Canada. Endometriosis: diagnosis and management. SOGC clinical practice guideline no. 244. Journal of Obstetrics and Gynaecology Canada2010;32:S1‐S28. ">SOGC 2010</a>). </p> <p>CA‐19.9 (cut‐off &gt; 37.0 U/ml), IL‐6 (cut‐off &gt; 1.90 to 2.00 pg/ml) and anti‐endometrial antibodies demonstrated an unsatisfactory diagnostic performance in detecting endometriosis and hence have no role in clinical practice. </p> <p>We suggest cautious interpretation of the presented results. Although studies demonstrated diagnostic potential for a number of tests, the level of heterogeneity, wide confidence intervals and high/unclear risk of bias in most studies included from this review series undermine reliability of the presented results, and hence these data are insufficient to confidently inform clinical practice. </p> <p>Additional biomarkers, reported in individual studies, displayed diagnostic estimates that qualified for either replacement or triage tests; however, there were not enough data for a meaningful recommendation on the use of any of these tests. </p> <p>As there is an absence of well‐established criteria for an adequate diagnostic test, the diagnostic criteria for replacement and triage tests were determined by the authors of this review in a way that we believe will aid the interpretation for clinically active readers. However, we encourage readers to apply different criteria according to each clinical population and situation. </p> <p>There is wide recognition that an accurate non‐invasive test for endometriosis is likely to confer several advantages over a surgical diagnosis for women with symptoms of endometriosis. These potential advantages include a reduction in cost (both in direct medical costs and in time off work), reduced discomfort, shorter recovery times and a reduction in the rare but serious complications of anaesthesia and surgery. Another benefit of an accurate, non‐invasive diagnostic test for endometriosis is the prospect of early diagnosis and timely therapeutic interventions to minimise progression of disease, which can occur in up to 50% of women (<a href="./references#CD012179-bbs2-0394" title="D’HoogheTM , DebrockS . Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Human Reproduction Update2002;8(1):84‐8. ">D'Hooghe 2002</a>). </p> <p>An accurate 'negative' non‐invasive test is expected to reduce the need for diagnostic surgery in 50 ‐ 70% of women with chronic pelvic pain or infertility (<a href="./references#CD012179-bbs2-0404" title="GiudiceLC , KaoLC . Endometriosis. Lancet2004;364:1789‐99. ">Giudice 2004</a>), although it is likely that some women with a negative test would still require surgery to explore other pathologies. An accurate 'positive' non‐invasive test for endometriosis is likely to increase the need for surgery in women with mild symptoms or subfertility (<a href="./references#CD012179-bbs2-0395" title="D’HoogheTM , MihalyiAM , SimsaP , KyamaCK , PeeraerK , DeLoeckerP , et al. Why we need a non‐invasive diagnostic test for minimal to mild endometriosis with a highsensitivity. Gynecologic and Obstetric Investigation2006;62(3):136‐8. ">D'Hooghe 2006</a>). Thus, until an accurate non‐invasive diagnostic test is developed and tested in large clinical populations, it is impossible to accurately predict its impact on surgical uptake and the number of women that would benefit from performing the test. </p> </section> <h3 class="title" id="CD012179-sec-0165">Implications for research</h3> <section id="CD012179-sec-0165"> <p>Currently, randomised controlled treatment trials require women with and without endometriosis to have had diagnostic surgery for accurate group allocation. For ethical reasons, therapeutic surgery is usually performed at the same time, potentially biasing treatment trial outcomes. Thus our current inability to diagnose and assess the progression of endometriosis in a non‐invasive way is a significant limitation to the advancement of clinical research in endometriosis. </p> <p>Several blood biomarkers reported in this review showed promisingly high diagnostic estimates for detecting endometriosis, but there were too few evaluations to determine their value as replacement or triage tests for a laparoscopic diagnosis. Further well‐designed diagnostic studies are necessary to establish the diagnostic test accuracy and clinical utility of these blood tests. </p> <p>In this review we identified a list of biomarkers that have no value in detecting endometriosis and hence are not recommended for evaluation in future diagnostic studies. This is important for appropriate allocation of research resources and to guide clinically relevant experimental work in the field. These biomarkers comprise: glycodelin, IGFBP‐3, leptin, sICAM‐1, MCP‐1, hs‐CRP, IFN‐γ, MIF, TNF‐α, WBC, IL‐1β, IL‐2, IL‐4, IL‐8, IL‐10, IL‐12, IL‐18, sGM‐CSF and the above‐mentioned tests evaluated in the meta‐analyses. </p> <p>The QUADAS‐2 quality assessment of the included studies identified several weakness in study design that can impede an objective evaluation of the findings. We recommend that future authors consider: </p> <p> <ol id="CD012179-list-0078"> <li> <p>including large cohorts after pre‐defining the sample size via a power calculation (<a href="./references#CD012179-bbs2-0416" title="LiuA , SchistermanEF , MazumdarM , HuJ . Power and sample size calculation of comparative diagnostic accuracy studies with multiple correlated test results. Biometrical Journal2005;47(2):140‐50. ">Liu 2005</a>); </p> </li> <li> <p>focusing on a single‐gate design that only includes a clinically relevant population (<a href="./references#CD012179-bbs2-0430" title="RutjesAWS , ReitsmaJB , VandenbrouckeJP , GlasAS , BossuytPMM . Case–control and two‐gate designs in diagnostic accuracy studies. Clinical Chemistry2005;51(8):1335‐41. ">Rutjes 2005</a>); </p> </li> <li> <p>utilising a diagnostic accuracy study design that adheres to the recommendations of the Standards for Reporting of Diagnostic Accuracy (STARD) initiative (<a href="./references#CD012179-bbs2-0387" title="BossuytPM , ReitsmaJB , BrunsDE , GatsonisCA , GlasziouPP , IrwigLM , et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ2003;326(7379):41‐4. ">Bossuyt 2003</a>); </p> </li> <li> <p>incorporating the QUADAS checklist into the study design (<a href="./references#CD012179-bbs2-0443" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al. the QUADAS‐2 Group. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>); </p> </li> <li> <p>formally assessing inter‐ and intraobserver variability of the laboratory methods;</p> </li> <li> <p>establishing universally acceptable laboratory methodologies and a diagnostic criteria for a positive test (<a href="./references#CD012179-bbs2-0426" title="RahmiogluN , FassbenderA , VitonisAF , TworogerSS , HummelshojL , D’HoogheTM , et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking armonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. Fertility and Sterility2014;102(5):1233‐43. ">Rahimoglu 2014</a>); </p> </li> <li> <p>utilising universally acceptable methods of performing laparoscopy as the reference standard test (<a href="./references#CD012179-bbs2-0385" title="BeckerCM , LauferMR , StrattonP , Hummelshojl , MissmerSA , ZondervanKT , et al. World Endometriosis Research Foundation Endometriosis Phenome and biobanking harmonization project: I. Surgical phenotype data collection in endometriosis research. Fertility and Sterility2014;102(5):1213‐22. ">Becker 2014</a>); </p> </li> <li> <p>implementing validation techniques to assess how the results of a statistical analysis will generalise to an independent data set; </p> </li> <li> <p>undertaking direct comparisons of promising tests in conjunction with a cost‐effectiveness analysis; </p> </li> <li> <p>applying testing to different clinical phenotypes rather than to women classified according to rASRM staging (<a href="./references#CD012179-bbs2-0441" title="VitonisAF , VincentK , RahmiogluN , FassbenderA , Buck LouisG , HummelshojL , et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: II. Clinical and covariate phenotype data collection in endometriosis research. Fertility and Sterility2014;102(5):1223‐32. ">Vitonis 2014</a>); and </p> </li> <li> <p>assessing the long term outcomes and lifetime healthcare costs of women that have participated in diagnostic test accuracy trials of specific diagnostic tests. </p> </li> </ol> </p> <p>Specific opportunities for further research identified by this review include:</p> <p> <ol id="CD012179-list-0079"> <li> <p>assessing the diagnostic potential of anti‐endometrial antibodies and the tests identified as promising replacement or triage tests in detecting pelvic endometriosis in larger, high quality studies; </p> </li> <li> <p>exploring the value of sequential testing, implementing SnOUT and SpIN triage tests in diagnosing endometriosis in conjunction with a cost‐effectiveness evaluation of such testing; </p> </li> <li> <p>directly comparing promising biomarkers in well‐designed diagnostic accuracy studies;</p> </li> <li> <p>evaluation of the whole spectrum of disease across all phases of menstrual cycle, aiming to identify the most appropriate target population and the best time of testing; </p> </li> <li> <p>attempting testing in the populations that differ by clinical phenotype rather than by rASRM staging in view of the poor correlation of this classification with clinical presentations and treatment outcomes; </p> </li> <li> <p>adding separate evaluations of blood biomarkers, particularly urocortin and follistatin, CA‐125 with the cut‐off values above 30 to 42 U/ml and a combination of CA‐125 and CA‐19.9 to determine if ovarian endometrioma can be distinguished from other ovarian masses in reproductive‐aged women; and </p> </li> <li> <p>assessing the long‐term outcomes and lifetime healthcare costs of women in diagnostic test accuracy trials that have evaluated specific diagnostic blood tests. </p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012179-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012179-sec-0029"></div> <div class="table" id="CD012179-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Biomarkers evaluated as a diagnostic test for endometriosis</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Review question</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>What is the diagnostic accuracy of the blood biomarkers in detecting pelvic endometriosis (peritoneal endometriosis, endometrioma, deep infiltrating endometriosis)? </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Importance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>A simple and reliable non‐invasive test for endometriosis with the potential to either replace laparoscopy or to triage patients in order to reduce surgery, would minimise surgical risk and reduce diagnostic delay </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Reproductive aged women with suspected endometriosis or persistent ovarian mass, or women undergoing infertility work‐up or gynaecological laparoscopy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Settings</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Hospitals (public or private of any level), outpatient clinics (general gynaecology, reproductive medicine, pelvic pain) or research laboratories </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Reference standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Cross‐sectional of a single‐gate design (N = 25) or a two‐gate design (N = 44); unable to determine if single‐ or two‐gate design for 1 study; prospective enrolment; a single study could assess more than one test </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="5" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Overall judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Poor quality of most of the studies (no study had a 'low risk' assessment in all 4 domains) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Patient selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High risk: 31 studies; unclear risk: 32 studies; low risk: 7 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Index test interpretation bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High risk: 56 studies; unclear risk: 12 studies; low risk: 2 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Reference standard interpretation bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>High risk: 0 studies; unclear risk: 30 studies; low risk: 40 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Flow and timing selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>High risk: 11 studies; unclear risk: 3 studies; low risk: 56 studies</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Applicability concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Concerns regarding patient selection</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High concern: 32 studies; unclear concern: 5 studies; low concern: 33 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Concerns regarding index test</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High concern: 0 studies; unclear concern: 4 studies; low concern: 66 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Concerns regarding reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>High concern: 0 studies; unclear concern: 0 studies; low concern: 70 studies</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Diagnostic criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Replacement test: sensitivity ≥ 94 and specificity ≥ 79<br/> SnOUT triage test: sensitivity ≥ 95 and specificity ≥ 50<br/> SpIN triage test: sensitivity ≥ 50 and specificity ≥ 95 </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> Test </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> N participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> Diagnostic estimates (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> Implications</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>True positives</b> </p> <p><b>(endometriosis)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>False positives (incorrectly classified as endometriosis)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>True negatives (disease‐free)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>False negatives (incorrectly</b> </p> <p><b>classified as disease‐free)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>1. Angiogenesis and growth factors and their receptors</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycodelin‐A</p> <p>cut‐off threshold &gt; 2.07 ng/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM stage I‐IV<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.70 to 0.91);</p> <p>spec = 0.79 (0.63 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycodelin<sup>a#</sup> </p> <p>cut‐off threshold &gt; 9.0 ng/ml</p> <p>follicular cycle phase</p> <p>rASRM stage I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.51 to 0.87);</p> <p>spec = 0.35 (0.14 to 0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycodelin<sup>a#</sup> </p> <p>cut‐off threshold &gt; 18 ng/ml</p> <p>any cycle phase</p> <p>rASRM stage I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.62 (0.48 to 0.74);</p> <p>spec = 0.44 (0.28 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGFBP‐3 (insulin‐like growth factor‐binding protein‐3)<sup>a*</sup> </p> <p>cut‐off threshold &gt; 200 ng/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.51 to 0.87);</p> <p>spec = 0.29 (0.10 to 0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGFBP‐3 (insulin‐like growth factor‐binding protein‐3)<sup>a*</sup> </p> <p>cut‐off threshold &gt; 210 ng/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.55 (0.42 to 0.68);</p> <p>spec = 0.44 (0.28 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF (vascular endothelial growth factor)</p> <p>cut‐off threshold &gt; 1.5 pg/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.50 (0.37 to 0.63);</p> <p>spec = 0.61 (0.45 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF (vascular endothelial growth factor)</p> <p>cut‐off threshold &gt; 236 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.92 (0.83 to 0.97);</p> <p>spec = 0.77 (0.58 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches the criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF (vascular endothelial growth factor)</p> <p>cut‐off threshold &gt; 680 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.93 (0.78 to 0.99);</p> <p>spec = 0.97 (0.83 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test and approaches criteria for a replacement test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urocortin<sup>a&amp;</sup> </p> <p>cut‐off threshold &gt; 29 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.97 (0.87 to 1.00);</p> <p>spec = 0.85 (0.70 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urocortin<sup>a&amp;</sup> </p> <p>cut‐off threshold &gt; 33 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.88 (0.73 to 0.96);</p> <p>spec = 0.90 (0.76 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urocortin</p> <p>cut‐off threshold &gt; 41.6 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.76 (0.61 to 0.88);</p> <p>spec = 0.46 (0.31 to 0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>2. Apoptosis markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survivin</p> <p>cut‐off threshold not reported</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.07 (0.02 to 0.20);<br/> spec = 0.90 (0.68 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>3. Cell adhesion molecules and other matrix‐related proteins</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a#</sup> </p> <p>cut‐off threshold &lt; 243 ng/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.55 (0.42 to 0.68);</p> <p>spec = 0.50 (0.34 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a#</sup> </p> <p>cut‐off threshold &lt; 254.6 ng/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.39 to 0.94);</p> <p>spec = 0.29 (0.10 to 0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)</p> <p>cut‐off threshold &gt; 241.46 µg/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.60 (0.41 to 0.77);</p> <p>spec = 0.87 (0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LN‐1 (laminin‐1)</p> <p>cut‐off threshold &gt; 1110.0 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM II‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.72 (0.58 to 0.83);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>4. High‐throughput molecular markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metabolome by ESI‐MS/MS</p> <p>(SMOH C16:1 + PCaa C36:2/ PCae C34:2)</p> <p>any cycle phase</p> <p>rASRM III‐IV<sup>e</sup> </p> <p>age/body mass index‐adjusted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.76 to 0.97);</p> <p>spec = 0.85 (0.72 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria of a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF‐MS</p> <p>(3 peaks with the MW 3956.00, 11,710.00 and 6986.00 Da)</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.88 (0.62 to 0.98);</p> <p>spec = 0.80 (0.52 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 4159.00, 5264.00, 5603.00, 9861.00 and 10,533.00 Da) </p> <p>follicular/ luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.65 to 0.89);</p> <p>spec = 0.59 (0.42 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 9926.31, 10,072.2, 6753.04, 4302.67, 9328.49 Da) </p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.40 (0.26 to 0.56);</p> <p>spec = 0.82 (0.60 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 2831.02, 7554.66, 4241.29, 2953.25, 9927.73 Da) </p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.38 (0.27 to 0.51);</p> <p>spec = 0.85 (0.68 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 11,366.3, 5712.69, 10,070.7, 3017.68, 3824.44 Da) </p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.53 (0.39to 0.66);</p> <p>spec = 0.82 (0.65 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF‐MS</p> <p>(6 peaks with MW 1629, 3047, 3526, 3774, 5046 and 5068 Da)</p> <p>any cycle phase</p> <p>rASRM II‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.66 (0.52 to 0.77);</p> <p>spec = 0.99 (0.93 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>5. Hormonal markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolactin<sup>1a^</sup> </p> <p>cut‐off threshold &gt; 14.8 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.44 (0.32 to 0.58);</p> <p>spec = 0.94 (0.80 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolactin<sup>1a^</sup> </p> <p>cut‐off threshold &gt; 20 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.21 (0.11 to 0.33);</p> <p>spec = 1.00 (0.90 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>6. Immune system and inflammatory markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐endometrial Abs</p> <p>cut‐off threshold ‐ definitions for positive result varied</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM I‐IV in 3 studies; not reported in 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>759 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.81 (0.76 to 0.87);</p> <p>spec = 0.75 (0.46 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates did not meet the predetermined criteria for triage or replacement test; varying methodologies and populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐endometrial Abs (MW of 26/34/42 kd)</p> <p>cut‐off threshold: dark band in the blot for at least 1 Ab</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 1.00 (0.81 to 1.00);</p> <p>spec = 0.39 (0.17 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐laminin auto Abs</p> <p>cut‐off threshold &gt; 1 U/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.40 (0.26 to 0.57);</p> <p>spec = 0.88 (0.70 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sCD23 (soluble CD23)</p> <p>cut‐off threshold: absorbance value of ELISA &gt; control mean ± 2SD (standard deviations)</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.25 (0.14 to 0.38);</p> <p>spec = 0.93 (0.80 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCP‐1 (monocyte chemotactic protein‐1)</p> <p>cut‐off threshold &gt; 100 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.51 to 0.77);</p> <p>spec = 0.61 (0.45 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Copeptin</p> <p>cut‐off threshold &gt; 251.2 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.50 to 0.78);</p> <p>spec = 0.58 (0.41 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.62 mg/l</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.62 (0.55 to 0.68);</p> <p>spec = 0.56 (0.45 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.73 mg/l</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.52 to 0.82);</p> <p>spec = 0.47 (0.24 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.61 mg/l</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.54 (0.43 to 0.65);</p> <p>spec = 0.50 (0.33 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)</p> <p>cut‐off threshold &gt;438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.83 (0.72 to 0.91);</p> <p>spec = 0.87 (0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.70 mg/l</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.59 (0.47 to 0.70);</p> <p>spec = 0.64 (0.46 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.41 (0.30 to 0.53);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ (interferon‐gamma)</p> <p>cut‐off threshold &lt; 76 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.48 to 0.84);</p> <p>spec = 0.65 (0.38 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MIF (macrophage migration inhibitory factor)</p> <p>cut‐off threshold &gt; 0.57 ng/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.51 to 0.78);</p> <p>spec = 0.66 (0.49 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (tumour necrosis factor alpha)</p> <p>cut‐off threshold &gt;12.45 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.89 (0.79 to 0.96);</p> <p>spec = 0.87 (0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (tumour necrosis factor alpha)</p> <p>cut‐off threshold &lt; 45.6 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.48 to 0.84);</p> <p>spec = 0.35 (0.14 to 0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (tumour necrosis factor alpha)</p> <p>cut‐off threshold not reported</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.79 (0.69 to 0.88);<br/> spec = 0.74 (0.57 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutrophils</p> <p>cut‐off threshold &gt; 4058 cells/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.53 to 0.80);</p> <p>spec = 0.60 (0.45 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NLR (neutrophil‐to‐lymphocyte ratio)</p> <p>cut‐off threshold &gt; 2.19</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.76 (0.62 to 0.87);</p> <p>spec = 0.82 (0.69 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (white blood cells)</p> <p>cut‐off threshold &gt; 6400 cells/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.64 (0.49 to 0.77);</p> <p>spec = 0.54 (0.39 to 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐1β (interleukin ‐ 1beta)</p> <p>cut‐off threshold &lt; 0.9 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.63 to 0.94);</p> <p>spec = 0.35 (0.14 to 0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐4 (interleukin ‐ 4)</p> <p>cut‐off threshold ≥ 3 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.64 (0.45 to 0.80);</p> <p>spec = 0.65 (0.38 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 1.03 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.81 (0.70 to 0.89);</p> <p>spec = 0.51 (0.39 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a$, a^</sup> </p> <p>cut‐off threshold &gt; 1.9‐2.0 pg/ml</p> <p>cycle phase varied</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.63 (0.52 to 0.75);</p> <p>spec = 0.69 (0.57 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates did not meet the predetermined criteria for a triage or replacement test; varying cycle phase across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 2.6 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.60 (0.48 to 0.72);</p> <p>spec = 0.70 (0.58 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a^</sup> </p> <p>cut‐off threshold &gt; 4 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.74 to 0.94);</p> <p>spec = 0.80 (0.63 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a^</sup> </p> <p>cut‐off threshold &gt; 7.5 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.90);</p> <p>spec = 0.86 (0.70 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &lt; 10 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.51 to 0.87);</p> <p>spec = 0.18 (0.04 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &gt; 12.2 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.95 (0.87 to 0.99);</p> <p>spec = 0.83 (0.65 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &gt; 15.4 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.89 (0.75 to 0.97);</p> <p>spec = 0.82 (0.67 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &gt; 25.75 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.39 to 0.94);</p> <p>spec = 0.83 (0.73 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.59 (0.47 to 0.70);</p> <p>spec = 0.76 (0.60 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐8 (interleukin ‐ 8)</p> <p>cut‐off threshold &gt; 24 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.76 (0.60 to 0.89);</p> <p>spec = 0.73 (0.58 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐8 (interleukin ‐ 8)</p> <p>cut‐off threshold &gt; 25 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.59 to 0.82);</p> <p>spec = 0.81 (0.58 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐8 (interleukin ‐ 8)</p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.49 (0.37 to 0.60);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>7. Other peptides and proteins shown to influence key events implicated in endometriosis</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follistatin</p> <p>cut‐off threshold &gt; 1433 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.92 (0.81 to 0.98);</p> <p>spec = 0.92 (0.81 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement and SnOUT or SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>STX‐5 (syntaxin ‐ 5)</p> <p>cut‐off threshold &gt; 55 ng/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.66 to 0.88);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>8. Oxidative stress markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyls</p> <p>cut‐off threshold &lt; 14.9 μM</p> <p>cycle phase not specified</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.94 (0.85 to 0.98);</p> <p>spec = 0.51 (0.35 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PON‐1 (paraoxonase‐1)</p> <p>cut‐off threshold &lt; 141.5 U/l</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.98 (0.89 to 1.00);</p> <p>spec = 0.80 (0.64 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement or SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiols cut‐off threshold &lt; 396.44 μM cycle phase not specified</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.61 to 0.83);</p> <p>spec = 0.80 (0.65 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>9. Post‐transcriptional regulators of gene expression (microRNAs)</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐9*</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.55 to 0.80);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐17‐5</p> <p>cut‐off threshold &lt; 0.9057</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.70 (0.46 to 0.88);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐20a</p> <p>cut‐off threshold &lt; 0.6879</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.60 (0.36 to 0.81);</p> <p>spec = 0.90 (0.68 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐22</p> <p>cut‐off threshold &lt; 0.5647</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.68 to 0.99);</p> <p>spec = 0.80 (0.56 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement or SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐122</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.89);</p> <p>spec = 0.76 (0.55 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐141*</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.72 (0.59 to 0.83);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐145*</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.70 (0.57 to 0.81);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.66 to 0.88);</p> <p>spec = 0.76 (0.55 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐532‐3p</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.89);</p> <p>spec = 0.92 (0.74 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>10. Tumour markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐15.3 (cancer antigen‐15.3)</p> <p>cut‐off threshold &gt; 15.04 U/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.50 to 0.78);</p> <p>spec = 0.62 (0.45 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐15.3 (cancer antigen‐15.3)</p> <p>cut‐off threshold &gt; 30 U/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.04 (0.01 to 0.10);</p> <p>spec = 0.92 (0.79 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a#</sup> </p> <p>cut‐off threshold &gt; 7.5 IU/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.57 to 0.85);</p> <p>spec = 0.56 (0.38 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a#</sup> </p> <p>cut‐off threshold &gt;9.5 IU/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.55 (0.45 to 0.64);</p> <p>spec = 0.58 (0.47 to 0.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)</p> <p>cut‐off threshold &gt; 10.67 IU/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.50 to 0.78);</p> <p>spec = 0.62 (0.45 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)</p> <p>cut‐off threshold ≥ 12 IU/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.62 (0.45 to 0.77);</p> <p>spec = 0.70 (0.58 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5. CA‐19.9 (cancer antigen‐19.9)</p> <p>cut‐off threshold &gt; 37 IU/ml</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.36 (0.26 to 0.45);</p> <p>spec = 0.87 (0.75 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates did not meet the predetermined criteria for a triage or replacement test; varying cycle phase across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a#</sup> </p> <p>cut‐off threshold not specified</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>d,e</sup> </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.53 (0.36 to 0.68);</p> <p>spec = 0.90 (0.68 to 0.99)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.36 (0.25 to 0.48);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; varying populations across the studies; unclear thresholds </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐72 (TAG‐72) (cancer antigen‐72 or tumour</p> <p>associated glycoprotein‐72)</p> <p>cut‐off threshold &gt; 4 U/ml</p> <p>follicular cycle phase</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.05 (0.00 to 0.26);</p> <p>spec = 0.75 (0.48 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐72 (TAG‐72) (cancer antigen‐72 or tumour</p> <p>associated glycoprotein‐72)</p> <p>cut‐off threshold &gt; 6 U/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.09 (0.04 to 0.17);</p> <p>spec = 0.89 (0.75 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a!, a%, a*</sup> </p> <p>cut‐off threshold &gt; 10‐14.7 U/ml</p> <p>cycle phase varied</p> <p>rASRM stage varied</p> <p>2 evaluations excluded as overlapping populations (CA‐125 cut‐off &gt; 11.5 U/ml and cut‐off &gt; 13.5 U/ml, <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.70 (0.63 to 0.77);</p> <p>spec = 0.64 (0.47 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a!</sup> </p> <p>cut‐off threshold &gt; 11.5 U/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> (excluded from the above group as overlapping evaluation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.67 to 0.96);</p> <p>spec = 0.65 (0.38 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125) <sup>a!</sup> </p> <p>cut‐off threshold &gt; 13.5 U/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>b</sup> (excluded from the above group as overlapping evaluation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.79 (0.54 to 0.94);</p> <p>spec = 0.31 (0.11 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a#</sup> </p> <p>cut‐off value &gt; 16‐17.6 U/ml</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM stage varied (I in 1 study, I‐IV in 4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.56 (0.24 to 0.88);</p> <p>spec = 0.91 (0.75 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates approach the criteria for a SpIN triage test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a@, a^, a&amp;, a*, a!!</sup> </p> <p>cut‐off value &gt; 20 IU/ml</p> <p>cycle phase varied</p> <p>rASRM stage varied (1 study<sup>c</sup>, 2 studies<sup>d</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1304 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.67 (0.50 to 0.85);</p> <p>spec = 0.69 (0.58 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a^, a&amp;</sup> </p> <p>cut‐off value &gt; 25‐26 U/ml</p> <p>cycle phase varied; not specified in 1 study</p> <p>rASRM stage varied (1 study<sup>d</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>963 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.73 (0.67 to 0.79);</p> <p>spec = 0.70 (0.63 to 0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a$, a&amp;</sup> </p> <p>cut‐off value &gt; 30‐33 U/ml (1 study &gt; 33 U/ml)</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM stage varied (2 studies<sup>d</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.62 (0.45 to 0.79);</p> <p>spec = 0.76 (0.53 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a@, a#, a$, a%, a&amp;, a!!</sup> </p> <p>cut‐off value &gt; 35‐36 U/ml (1 study &gt; 36 U/ml)</p> <p>cycle phase varied; not specified in 7 studies</p> <p>rASRM stage varied; not reported in 2 studies (1 study<sup>c</sup>, 2 studies<sup>d</sup>, 1 study<sup>e</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3447 (27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.40 (0.32 to 0.49);</p> <p>spec = 0.91 (0.88 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125);<sup>a$</sup> </p> <p>cut‐off value &gt; 42 U/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.44 (0.30 to 0.59);</p> <p>spec = 0.90 (0.79 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)</p> <p>cut‐off value &gt; 43 U/ml</p> <p>cycle phase not reported</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 1.00 (0.92 to 1.00);</p> <p>spec = 0.80 (0.56 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)</p> <p>cut‐off value not specified</p> <p>menstrual cycle phase<sup>a##</sup> </p> <p>rASRM I‐IV</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>follicular cycle phase<sup>a##</sup> </p> <p>rASRM I‐IV</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>d,e</sup> </p> <p><sup>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</sup> </p> <p>luteal cycle phase<sup>a##</sup> </p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>119 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>60 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>54</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>33</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>2</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>26</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>18</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>29</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>7</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.72 (0.56 to 0.85);</p> <p>spec = 0.79 (0.54 to 0.94)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.65 (0.54 to 0.75);</p> <p>spec = 0.72 (0.55 to 0.86)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.82 (0.67 to 0.93);</p> <p>spec = 0.90 (0.68 to 0.99)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.68 (0.56 to 0.78);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; 1 study approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended with defined cut‐off value; varying populations and undefined cut‐off values; not combined in meta‐analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>11. Combined test ‐ 2 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/or CA‐19.9 U/ml<sup>a#</sup> </p> <p>cut‐of threshold CA‐125 ≥ 25 U/ml; CA‐19.9 ≥ 12 U/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.76 to 0.97);</p> <p>spec = 0.41 (0.30 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 U/ml<sup>a#</sup> </p> <p>cut‐of threshold CA‐125 ≥ 25 U/ml; CA‐19.9 ≥ 12 U/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.54 (0.37 to 0.70);</p> <p>spec = 0.90 (0.81 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + Prolactin<sup>a$</sup> </p> <p>cut‐off threshold CA‐125 &gt; 19.8 U/l; Prolactin &gt; 14.8 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.66 to 0.87);</p> <p>spec = 0.88 (0.73 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + Prolactin<sup>a$</sup> </p> <p>cut‐off threshold CA‐125 &gt; 35 U/l; Prolactin &gt; 20 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.44 (0.32 to 0.58);</p> <p>spec = 0.44 (0.32 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF</p> <p>cut‐off threshold CA‐125 &gt; 17.6 U/ml; VEGF &gt; 236 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.77 (0.65 to 0.86);</p> <p>spec = 0.93 (0.78 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + anti‐endometrial Abs</p> <p>cut‐off threshold CA‐125 &gt; 20 U/l; anti‐endometrial Abs &gt; 0.3 A‐value</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> <p>selection or classification method not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens= 0.61 (0.41 to 0.78);</p> <p>spec = 0.79 (0.49 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 x NLR</p> <p>cut‐off threshold &gt; 43.1</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> <p>combined test ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.66 to 0.90);</p> <p>spec = 0.86 (0.73 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/or IL‐8</p> <p>cut‐off threshold CA‐125 &gt; 30 U/ml; IL‐8 ≥ 25 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> <p>combined test ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.75 to 0.93);</p> <p>spec = 0.72 (0.47 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + IL‐8</p> <p>cut‐off threshold not specified</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and by ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.64 to 0.77);</p> <p>spec= 0.71 (0.61 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 + TNF‐α</p> <p>cut‐off threshold IL‐6 &gt; 12.2 pg/ml; TNF‐α &gt; 12.45 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.70 (0.57 to 0.80);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 + CRP</p> <p>cut‐off threshold IL‐6 &gt;12.2 pg/ml; CRP &gt; 438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.75 (0.63 to 0.85);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α + CRP</p> <p>cut‐off threshold NF‐α &gt; 12.45 pg/ml; CRP &gt; 438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.74 (0.61 to 0.84);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a + miR‐542‐3p</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by discriminant and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.97 (0.88 to 1.00);</p> <p>spec = 0.88 (0.69 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a + miR‐122</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by discriminant and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.89);</p> <p>spec = 0.80 (0.59 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>12. Combined test ‐ 3 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19‐9 + survivin</p> <p>cut‐off threshold not specified</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>e</sup> </p> <p>combined test by logistic regression and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.88 (0.73 to 0.96);</p> <p>spec = 0.90 (0.68 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + STX‐5 + LN‐1</p> <p>cut‐off threshold not specified</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> <p>combined test by multivariate logistic regression and ROC<br/> analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.95 (0.86 to 0.99);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SnOUT triage test and approaches criteria for a replacement test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/or CA‐19.9 +/or IL‐6</p> <p>cut‐off threshold CA‐125 &gt; 35 U/ml; CA‐19.9 &gt; 37 U/ml; IL‐6 &gt; 2 pg/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.42 (0.28 to 0.58);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/ or CCR1 +/or MCP‐1</p> <p>CA‐125 &gt; 50 U/ml; CCR1 &gt; 1.16; MCP‐1 &gt; 140 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>selection or classification method not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.92 (0.85 to 0.97);</p> <p>spec = 0.82 (0.68 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + MCP‐1 + Leptin</p> <p>cut‐off threshold CA‐125 &gt; 20 U/ml; MCP‐1 &gt; 152.7 pg/ml; Leptin &gt; 3.14 ng/ml</p> <p>any cycle phase</p> <p>rASRM II‐IV</p> <p>combined test by a two‐tiered algorithm using classification and regression tree (CART)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.49 (0.36 to 0.62);</p> <p>spec = 0.94 (0.86 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + IL‐8 + TNF‐α</p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.81 to 0.95);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 + TNF‐α + CRP</p> <p>cut‐off threshold IL‐6 &gt; 12.2 pg/ml; TNF‐α &gt; 12.45 pg/ml; CRP &gt; 438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.63 (0.50 to 0.75);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>13. Combined test ‐ 4 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF + annexin V + glycodelin<sup>a#</sup> </p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> <p>combined test by multivariate logistic regression and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.48 to 0.98);</p> <p>spec = 0.75 (0.35 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF + annexin V + glycodelin<sup>a#</sup> </p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> <p>combined test by a least squares support vector machines model (LS‐SVM) and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.48 to 0.98);</p> <p>spec = 0.63 (0.24 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF + annexin V + sICAM‐1</p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> <p>combined test by either multivariate logistic regression or a least squares support vector machines model (LS‐SVM) and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.48 to 0.98);</p> <p>spec = 0.75 (0.35 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + MCP‐1 + Leptin + MIF</p> <p>cut‐off threshold CA‐125 &gt; 20 U/ml; MCP‐1 &gt; 53.5 pg/ml; Leptin &gt; 29.1 ng/ml; MIF &gt; 14.7 ng/ml </p> <p>any cycle phase</p> <p>rASRM II‐IV</p> <p>combined test by a two‐tiered algorithm using classification and regression tree (CART)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 1.00 (0.94 to 1.00);</p> <p>spec = 0.35 (0.24 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by discriminant and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.93 (0.84 to 0.98);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test and approaches criteria for a replacement test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>14. Combined test ‐ 6 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.85 to 0.94);</p> <p>spec = 0.53 (0.42 to 0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP <sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.76 to 0.97);</p> <p>spec = 0.74 (0.49 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.58 (0.46 to 0.69);</p> <p>spec = 0.72 (0.55 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.76 to 0.93);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><sup>a</sup> Same biomarker was tested in the same/overlapping cohort; similar symbol designates studies/groups of studies with overlapping cohorts, hence can not be combined in meta‐analysis </p> <p><sup>b</sup> Only for US‐negative endometriosis </p> <p><sup>c</sup> Only peritoneal endometriosis </p> <p><sup>d</sup> Only ovarian endometriosis versus other benign ovarian cysts </p> <p><sup>e</sup> Only deep infiltrating endometriosis or endometrioma + deep infiltrating endometriosis </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>MW</b> : molecular weight; <b>rASRM</b> : revised American Society for Reproductive Medicine; <b>ROC</b>: receiver operating characteristic </p> <p>For a comprehensive list of all biomarkers with their biological annotation, please see <a href="./appendices#CD012179-sec-0169">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012179-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012179-sec-0030"></div> <section id="CD012179-sec-0031"> <h3 class="title" id="CD012179-sec-0031">Target condition being diagnosed</h3> <section id="CD012179-sec-0032"> <h4 class="title">Endometriosis</h4> <p>Endometriosis is defined as an inflammatory condition characterised by endometrial‐like tissue at sites outside the uterus (<a href="./references#CD012179-bbs2-0410" title="JohnsonNP , HummelshojL . Consensus on current management of endometriosis. Human Reproduction2013;28(6):1552‐68. ">Johnson 2013</a>). Endometriotic lesions can occur at different locations, including the pelvic peritoneum and the ovary, or they can penetrate pelvic structures below the surface of the peritoneum (defined as deeply infiltrating endometriosis, or DIE). Current knowledge suggests that each of these types of endometriosis is a separate clinical entity, but they can coexist in the same woman. Rarely, endometriotic implants can be found at more distant sites, including the lung, liver, pancreas and operative scars, with consequent variations in presenting symptoms. </p> <p>Endometriosis afflicts 10% of reproductive‐aged women, causing dysmenorrhoea (painful periods), dyspareunia (painful intercourse), chronic pelvic pain and infertility (<a href="./references#CD012179-bbs2-0440" title="ViganoP , ParazziniF , SomiglianaE , VercelliniP . Endometriosis: epidemiology and aetiological factors. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2004;18(2):177‐200. ">Vigano 2004</a>). The clinical presentation can vary from asymptomatic and unexplained infertility to severe dysmenorrhoea and chronic pain. These symptoms can occur with bowel or urinary symptoms, an abnormal pelvic examination or the presence of a pelvic mass; however, no symptom is specific to endometriosis. The estimated prevalence of endometriosis in the symptomatic population is 35% to 50% (<a href="./references#CD012179-bbs2-0404" title="GiudiceLC , KaoLC . Endometriosis. Lancet2004;364:1789‐99. ">Giudice 2004</a>). </p> <p>Women with endometriosis are also at increased risk of developing several cancers and autoimmune disorders (<a href="./references#CD012179-bbs2-0433" title="SinaiiN , ClearySD , BallwegML , NiemanLK , StrattonP . High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: A survey analysis. Human Reproduction2002;17(10):2715‐24. ">Sinaii 2002</a>; <a href="./references#CD012179-bbs2-0435" title="SomiglianaE , ViganoP , ParazziniF , StoppelliS , GiambattistaE , VercelliniP . Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecologic Oncology2006;101(2):331‐41. ">Somigliana 2006</a>). The presence of disease is associated with changes in the immune response, vascularisation, neural function, the peritoneal environment and the eutopic endometrium (tissue lining the uterine cavity), suggesting that endometriosis is a systemic rather than localised condition (<a href="./references#CD012179-bbs2-0404" title="GiudiceLC , KaoLC . Endometriosis. Lancet2004;364:1789‐99. ">Giudice 2004</a>). Endometriosis has a profound effect on psychological and social well‐being and imposes a substantial economic burden on society. Women with endometriosis may incur significant direct medical expenses from diagnostic and therapeutic surgeries, hospital admissions and fertility treatments, while indirect costs, including absenteeism and loss of productivity, compound the economic impact (<a href="./references#CD012179-bbs2-0403" title="GaoX , YehYC , OutleyJ , SimonJ , BottemanM , SpaldingJ . Health‐related quality of life burden of women with endometriosis: a literature review. Current Medical Research and Opinion2006;22:1787‐97. ">Gao 2006;</a><a href="./references#CD012179-bbs2-0432" title="SimoensS , DunselmanG , DirksenC , HummelshojL , BokorA , BrandesI , et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Human Reproduction2012;27(5):1292‐9. ">Simoens 2012</a>). In the United States, the financial burden of endometriosis is about USD 12,419 per woman (<a href="./references#CD012179-bbs2-0432" title="SimoensS , DunselmanG , DirksenC , HummelshojL , BokorA , BrandesI , et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Human Reproduction2012;27(5):1292‐9. ">Simoens 2012</a>). </p> <p>Although research has not been able to fully elucidate the pathogenesis of endometriosis, specialists commonly believe that it occurs when endometrial tissue contained within the menstrual fluid implants at an ectopic site within the pelvic cavity through retrograde flow (<a href="./references#CD012179-bbs2-0431" title="SampsonJA . Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. American Journal of Obstetrics and Gynecology1927;14:442‐69. ">Sampson 1927</a>). However, this theory does not explain the fact that only 10% of women develop endometriosis, while retrograde menstruation occurs in up to 90% of women (<a href="./references#CD012179-bbs2-0407" title="HalmeJ , HammondMG , HulkaJF , RajSG , TalbertLM . Retrograde menstruation in healthy women and in patients with endometriosis. Obstetrics and Gynecology1984;64(2):151‐4. ">Halme 1984</a>). There is evidence that a variety of environmental, immunological and hormonal factors are associated with endometriosis and genetic loci that confer a risk of endometriosis, but the relative contribution of these and other causal factors is still unclear (<a href="./references#CD012179-bbs2-0425" title="NyholtDR , LowSK , AndersonCA , PainterJN , UnoS , MorrisAP , et al. Genome‐wide association meta‐analysis identifies new endometriosis risk loci. Nature Genetics2012;44(12):1355‐9. ">Nyholt 2012</a>; <a href="./references#CD012179-bbs2-0440" title="ViganoP , ParazziniF , SomiglianaE , VercelliniP . Endometriosis: epidemiology and aetiological factors. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2004;18(2):177‐200. ">Vigano 2004</a>). </p> <p>Although it is impossible to time the onset of disease, on average, women have a 6‐ to 12‐year history of symptoms before obtaining a surgical diagnosis, indicative of considerable diagnostic delay (<a href="./references#CD012179-bbs2-0420" title="MatsuzakiS , CanisM , PoulyJL , RabischongB , BotchorishviliR , MageG . Relationship between delay of surgical diagnosis and severity of disease in patients with symptomatic deep infiltrating endometriosis. Fertility and Sterility2006;86:1314‐6. ">Matsuzaki 2006</a>). Untreated endometriosis is associated with reduced quality of life and contributes to outcomes such as depression, inability to work, sexual dysfunction and missed opportunity for motherhood (<a href="./references#CD012179-bbs2-0403" title="GaoX , YehYC , OutleyJ , SimonJ , BottemanM , SpaldingJ . Health‐related quality of life burden of women with endometriosis: a literature review. Current Medical Research and Opinion2006;22:1787‐97. ">Gao 2006</a>). Since endometriosis is a progressive disease in up to 50% of women, early diagnosis has the potential to offer early treatment and prevent progression (<a href="./references#CD012179-bbs2-0394" title="D’HoogheTM , DebrockS . Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Human Reproduction Update2002;8(1):84‐8. ">D'Hooghe 2002</a>). </p> </section> <section id="CD012179-sec-0033"> <h4 class="title">Treatment of endometriosis</h4> <p>There is no cure for endometriosis. Treatment options include expectant management, pharmacological (hormonal) therapy and surgery (<a href="./references#CD012179-bbs2-0410" title="JohnsonNP , HummelshojL . Consensus on current management of endometriosis. Human Reproduction2013;28(6):1552‐68. ">Johnson 2013</a>). Treatment is individualised, taking into consideration a therapeutic goal (pain relief or conception) and the location of the disease. Current pharmacological therapies such as the combined oral contraceptive pill, progestogens, weak androgens and GnRH agonists and antagonists act to reduce the effect of oestrogen on endometrial tissues and suppress menstruation. These drugs can ameliorate the symptoms of dysmenorrhoea and chronic pelvic pain but are associated with side effects such as breast discomfort, irritability, androgenic symptoms and bone loss. Surgical excision of endometriotic lesions can reduce pain symptoms, but it is associated with high recurrence rates of 40% to 50% at five years postsurgery (<a href="./references#CD012179-bbs2-0405" title="GuoSW . Recurrence of endometriosis and its control. Human Reproduction Update2009;15(4):441‐61. ">Guo 2009</a>). Early treatment of endometriosis improves pain levels as well as physical and psychological functioning. Furthermore, improvements in menstrual management (the use of the intrauterine system (hormonal coil) and the continuous use of the combined contraceptive pill) and fertility preservation (oocyte vitrification) raise the possibility of suppressing the progression of endometriosis and prospectively managing subfertility in endometriosis sufferers. The potential success of these preventive strategies depends on an accurate and early diagnosis. A major impediment to earlier and more efficacious treatment of this disease is diagnostic delay, due to the invasive nature of standard diagnostic tests (<a href="./references#CD012179-bbs2-0397" title="DmowskiWP , LesniewiczR , RanaN , PeppingP , NoursalehiM . Changing trends in the diagnosis of endometriosis: a comparative study of women with pelvic endometriosis presenting with chronic pelvic pain or infertility. Fertility and Sterility1997;67:238‐43. ">Dmowski 1997</a>). </p> </section> <section id="CD012179-sec-0034"> <h4 class="title">Diagnosis of endometriosis</h4> <p>Clinical history and pelvic examination can raise the possibility of a diagnosis of endometriosis, but the heterogeneity in clinical presentation, the high prevalence of asymptomatic endometriosis (2% to 50%) and the poor association between presenting symptoms and severity of the disease contribute to the difficulty in obtaining a reliable diagnosis based solely on presenting symptoms (<a href="./references#CD012179-bbs2-0383" title="BallardKD , SeamanHE , DeVriesCS , WrightJT . Can symptomatology help in the diagnosis of endometriosis? Findings from a national case‐control study ‐ Part 1. BJOG: an International Journal of Obstetrics and Gynaecology2008;115(11):1382‐91. ">Ballard 2008</a>; <a href="./references#CD012179-bbs2-0401" title="FauconnierA , ChapronC . Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Human Reproduction Update2005;11:595‐606. ">Fauconnier 2005</a>; <a href="./references#CD012179-bbs2-0436" title="SpaczynskiRZ , DulebaAJ . Diagnosis of endometriosis. Seminars in Reproductive Medicine2003;21:193‐208. ">Spaczynski 2003</a>). Although an abnormal pelvic examination correlates with the presence of endometriosis on laparoscopy in 70% to 90% of cases (<a href="./references#CD012179-bbs2-0415" title="LingF . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Obstetrics and Gynecology1999;93:51‐8. ">Ling 1999</a>), there is a wide differential diagnosis for most positive physical findings. Furthermore, a normal clinical examination does not exclude endometriosis, as laparoscopically proven disease has been diagnosed in more than 50% of women with a clinically normal pelvic examination (<a href="./references#CD012179-bbs2-0399" title="EskenaziB , WarnerM , BosignoreL , OliveD , SamuelsS , VercelliniP . Validation study of nonsurgical diagnosis of endometriosis. Fertility and Sterility2001;76:929‐35. ">Eskenazi 2001</a>). A variety of tests utilising pelvic imaging, blood markers, eutopic endometrium characteristics, urinary markers or peritoneal fluid components have been suggested as diagnostic measures for endometriosis. Although large numbers of the reported markers distinguish women with and without endometriosis in small pilot studies, many do not show convincing potential as a diagnostic test when they are evaluated in larger studies by different research groups. The diagnostic value of these tests has not previously been fully systematically evaluated and summarised using Cochrane methods. Currently, there is no simple non‐invasive test for the diagnosis of endometriosis that is routinely implemented in clinical practice. </p> <p>Surgical diagnostic procedures for endometriosis include laparoscopy (minimal access, or keyhole surgery) or laparotomy (open surgery via an abdominal incision). In the last several decades, laparoscopy has become an increasingly common procedure and has largely replaced traditional open surgery in patients suspected of having endometriosis (<a href="./references#CD012179-bbs2-0446" title="YeungPPJr , ShwayderJ , PasicRP . Laparoscopic management of endometriosis: comprehensive review of best evidence. Journal of Minimally Invasive Gynecology2009;16:269‐81. ">Yeung 2009</a>). Laparoscopy has significant advantages over laparotomy, including fewer complications and shorter recovery times. Furthermore, a magnified view at laparoscopy allows better visualisation of the peritoneal cavity. Despite continuing controversy in the literature with regard to the superiority of one surgical modality over another in treating pelvic pathology, laparoscopy is the preferred technique to evaluate the pelvis and abdomen and to treat benign conditions such as ovarian endometriomas (<a href="./references#CD012179-bbs2-0423" title="MedeirosLR , RosaDD , BozzettiMC , FachelJM , FurnessS , GarryR , et al. Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD004751.pub3] ">Medeiros 2009</a>). Surgery is currently also the only acceptable method of determining the extent and severity of endometriosis. There are several different classification systems for endometriosis (<a href="./references#CD012179-bbs2-0380" title="AdamsonGD . Endometriosis Fertility Index (EFI): the new validated endometriosis staging system. Art and science of endometriosis. Proceedings of the Tenth World Congress on Endometriosis; 2008 March 11‐14; Melbourne (Vic). 2008. ">Adamson 2008</a>; <a href="./references#CD012179-bbs2-0384" title="BattR , MitwallyMF . Endometriosis from thelarche to midteens: pathogenesis and prognosis, prevention and pedagogy. Journal of Pediatric and Adolescent Gynecology2003;16(6):333‐47. ">Batt 2003</a>; <a href="./references#CD012179-bbs2-0390" title="ChapronC , FauconnierA , VieiraM , Barakat DoussetHB , PansiniV , Vacher‐LavenuMC , et al. Anatomical distribution of deeply infiltrating endometriosis: surgical implications and proposition for a classification. Human Reproduction2003;18:157‐61. ">Chapron 2003a</a>; <a href="./references#CD012179-bbs2-0418" title="MartinDC . Applying STARD criteria to the laparoscopic identification of endometriosis (abstract) . Fertility and Sterility. 2006; Vol. 86 Suppl 2:270. ">Martin 2006</a>), but most researchers and clinicians use the revised American Society for Reproductive Medicine (rASRM) classification, which is internationally accepted as a respected tool for the objective assessment of the disease (<a href="./references#CD012179-bbs2-0382" title="American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertility and Sterility1997;67(5):817‐21. ">ASRM 1997</a>). The rASRM classification system considers the appearance, size and depth of peritoneal or ovarian implants and adhesions that are visualised during laparoscopy and allows uniform documentation of the extent of disease (<a href="#CD012179-tbl-0002">Table 1</a>). Unfortunately, this classification system has little value in clinical practice due to the lack of correlation between laparoscopic staging, the severity of symptoms and response to treatment (<a href="./references#CD012179-bbs2-0391" title="ChapronC , FauconnierA , DubuissonJB , BarakatH , VieiraM , BréartG . Deep infiltrating endometriosis: relation between severity of dysmenorrhea and extent of disease. Human Reproduction2003;18:760‐6. ">Chapron 2003b</a>; <a href="./references#CD012179-bbs2-0406" title="GuzickDS , SillimanNP , AdamsonGD , ButtramVCJr , CanisM , MalinakLR , et al. Prediction of pregnancy in infertile women based on the American Society for Reproductive Medicines revised classification of endometriosis. Fertility and Sterility1997;67(5):822‐9. ">Guzick 1997</a>; <a href="./references#CD012179-bbs2-0439" title="VercelliniP , TrespidiL , DeGiorgiO , CortesiI , ParazziniF , CrosignaniGP . Endometriosis and pelvic pain: relation to disease stage and localization. Fertility and Sterility1996;65:299‐304. ">Vercellini 1996</a>). The World Endometriosis Society has recently undertaken an endeavour to attain consensus around the optimal classification for endometriosis (<a href="./references#CD012179-bbs2-0411" title="JohnsonNP , HummelshojL , AdamsonGD , KecsteinJ , TaylorH , AbraoMS , et al. Consensus on the classification of endometriosis. Human Reproduction2016 in press. ">Johnson 2015</a>). </p> <div class="table" id="CD012179-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Staging of endometriosis, rASRM classification</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Location of endometriosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Extent</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Depth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 1 cm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1‐3 cm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 3 cm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Peritoneum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Superficial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ovary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R Superficial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L Superficial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Posterior cul‐de‐sac obliteration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Partial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Complete</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adhesions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&lt; 1/3 Enclosure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/3‐2/3 Enclosure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 2/3 Enclosure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ovary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Tube</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Stage ·1 (Minimal) ‐ score 1‐5; Stage II (Mild) ‐ score 6‐15; Stage III (Moderate) ‐ score 16‐40; Stage IV (Severe) ‐ score &gt;40 </p> <p><sup>a</sup>If the fimbriated end of the fallopian tube is completely enclosed, change the point assignment to 16 (<a href="./references#CD012179-bbs2-0382" title="American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertility and Sterility1997;67(5):817‐21. ">ASRM 1997</a>) </p> </div> </div> <p>The European Society of Human Reproduction and Embryology (ESHRE) Special Interest Group for Endometriosis stated in their diagnostic and treatment guidelines that for most forms of endometriosis, women presenting with symptoms cannot obtain a definitive diagnosis without visual inspection of the pelvis at laparoscopy as the gold standard investigation (<a href="./references#CD012179-bbs2-0413" title="KennedyS , BergqvistA , ChapronC , D'HoogheT , DunselmanG , GrebR , et al. ESHRE Special Interest Group for Endometriosis. ESHRE guideline for the diagnosis and treatment of endometriosis. Human Reproduction2005;20(10):2698‐704. ">Kennedy 2005</a>). Currently the visual or histological identification of endometriotic tissue in the pelvic cavity during surgery is not just the best available but the only diagnostic test for endometriosis in clinical practice. </p> <p>The disadvantages of laparoscopic surgery include (but are not limited to) the high cost, the need for general anaesthesia and the potential for adhesion formation postprocedure. Laparoscopy has been associated with a 2% risk of injury to pelvic organs, a 0.001% risk of damaging a major blood vessel and a mortality rate of 0.0001% (<a href="./references#CD012179-bbs2-0392" title="ChapronC , CravelloL , ChopinN , KreikerG , BlancB , DubuissonJB . Complications during set‐up procedures for laparoscopy in gynecology: open laparoscopy does not reduce the risk of major complications. Acta Obstetrica et Gynecologica Scandinavica2003;82:1125‐9. ">Chapron 2003c</a>). Even though the major complications of laparoscopy are rare, it is difficult to determine the exact incidence of complications, and delayed recognition adds to surgical morbidity and mortality. Only a third of women who undertake a laparoscopic procedure will receive a diagnosis of endometriosis; therefore many disease‐free women are unnecessarily exposed to surgical risk (<a href="./references#CD012179-bbs2-0402" title="FrishmanGN , SalakJR . Conservative surgical management of endometriosis in women with pelvic pain. Journal of Minimally Invasive Gynecology2006;13:546‐58. ">Frishman 2006</a>). </p> <p>The validity of laparoscopy as a reference test for endometriosis has is highly dependent on the skills of the surgeon. The diagnostic accuracy of laparoscopic visualisation has been compared with histological confirmation in a sole systematic review, and it was estimated as having a sensitivity of 0.94 and specificity of 0.79 (<a href="./references#CD012179-bbs2-0444" title="WykesCB , ClarkTJ , KhanKS . Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG ‐ an International Journal of Obstetrics and Gynaecology2004;111:1204‐12. ">Wykes 2004</a>). Subsequent studies suggested that incorporating histological verification in the diagnosis of endometriosis may improve diagnostic accuracy (<a href="./references#CD012179-bbs2-0381" title="Almeida FilhoDP , OliveiraLJ , AmaralVF . Accuracy of laparoscopy for assessing patients with endometriosis. Sao Paulo Medical Journal2008;126:305‐8. ">Almeida Filho 2008</a>; <a href="./references#CD012179-bbs2-0417" title="MarchinoGL , GennarelliG , EnriaR , BongioanniF , LipariG , MassobrioM . Diagnosis of pelvic endometriosis with use of macroscopic versus histologic findings. Fertility and Sterility2005;84:12‐5. ">Marchino 2005</a>; <a href="./references#CD012179-bbs2-0437" title="StegmannBJ , SinaiiN , LiuS , SegarsJ , MerinoM , NiemanLK , et al. Using location, color, size, and depth to characterize and identify endometriosis lesions in a cohort of 133 women. Fertility and Sterility2008;89:1632‐6. ">Stegmann 2008</a>), but these papers have not been systematically reviewed. The clinical significance of histological verification remains debatable, and a diagnosis based on visual findings is generally reliable as long as properly trained and experienced surgeons perform an appropriate inspection of the abdominal cavity (<a href="./references#CD012179-bbs2-0427" title="RedwineDB . 'Invisible' microscopic endometriosis: a review. Gynecologic and Obstetric Investigation2003;55(2):63‐7. ">Redwine 2003</a>). Furthermore, excised potential endometriotic tissues are rarely serially sectioned in clinical practice, and pathologists can miss small lesions in mild disease. Thus, sampling inconsistencies are also likely to influence the accuracy of histological reporting. </p> </section> <section id="CD012179-sec-0035"> <h4 class="title">Summary</h4> <p>A diagnostic test without the need for surgery would reduce the associated surgical risks, increase accessibility to a diagnostic test and improve treatment outcomes. The need for an accurate non‐invasive diagnostic test for endometriosis continues to encourage extensive research in the field and was endorsed at the international consensus workshop at the 10<sup>th</sup> World Congress of Endometriosis in 2008 (<a href="./references#CD012179-bbs2-0429" title="RogersPA , D'HoogheTM , FazleabasA , GargettCE , GiudiceLC , MontgomeryGW , et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reproductive Sciences2009;16(4):335‐46. ">Rogers 2009</a>). Although multiple markers and imaging techniques have been explored as diagnostic tests for endometriosis, none of them have been implemented routinely in clinical practice, and many have not been subject to a systematic review. </p> </section> </section> <section id="CD012179-sec-0036"> <h3 class="title" id="CD012179-sec-0036">Index test(s)</h3> <p>This review assesses blood‐based biomarkers that have been proposed as non‐invasive tests for the diagnosis of endometriosis as part of the review series on non‐invasive diagnostic tests for endometriosis (<a href="#CD012179-tbl-0003">Table 2</a>). The other reviews from this series include 'Imaging modalities for the non‐invasive diagnosis of endometriosis', 'Endometrial biomarkers for the non‐invasive diagnosis of endometriosis', 'Urinary biomarkers for the non‐invasive diagnosis of endometriosis', and 'Combination of the non‐invasive tests for the diagnosis of endometriosis', which also summarises all the reviews from the series. </p> <div class="table" id="CD012179-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood biomarkers evaluated in this review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Biomarker</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Angiogenesis and growth factors and their receptors</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycodelin‐A (PP14 or PAEP) (or placental protein 14 or progestogen‐associated endometrial protein)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF (vascular endothelial growth factor)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGFBP‐3 (insulin‐like growth factor‐binding protein‐3)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urocortin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leptin<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Apoptosis markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Annexin V<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Survivin</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Cell adhesion molecules and other matrix‐related proteins</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LN‐1 (laminin‐1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>High‐throughput molecular markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proteome</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Hormonal markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prolactin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Immune system and inflammatory markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Autoantibodies</p> <p> <ul id="CD012179-list-0001"> <li> <p>Anti‐endometrial Abs (anti‐endometrial auto antibodies)<sup>a</sup> </p> </li> <li> <p>Anti‐laminin‐1 Abs (anti‐laminin auto antibodies)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immune cells</p> <p> <ul id="CD012179-list-0002"> <li> <p>Neutrophils<sup>a</sup> </p> </li> <li> <p>NLR (neutrophil‐to‐lymphocyte ratio)<sup>a</sup> </p> </li> <li> <p>WBC (white blood cells)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemokines</p> <p> <ul id="CD012179-list-0003"> <li> <p>CCR1 (C‐C motif receptor 1)</p> </li> <li> <p>MCP‐1 (monocyte chemotactic protein‐1)<sup>a</sup> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interleukins</p> <p> <ul id="CD012179-list-0004"> <li> <p>IL‐1β (interleukin ‐ 1β)<sup>a</sup> </p> </li> <li> <p>IL‐4 (interleukin ‐ 4)<sup>a</sup> </p> </li> <li> <p>IL‐6 (interleukin ‐ 6)<sup>a</sup> </p> </li> <li> <p>IL‐8 (interleukin ‐ 8)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other cytokines</p> <p> <ul id="CD012179-list-0005"> <li> <p>IFN‐γ (interferon‐gamma)<sup>a</sup> </p> </li> <li> <p>MIF (macrophage migration inhibitory factor)<sup>a</sup> </p> </li> <li> <p>TNF‐α (tumour necrosis factor alpha)<sup>a</sup> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other immune/inflammatory markers</p> <p> <ul id="CD012179-list-0006"> <li> <p>sCD23 (soluble CD23, low‐affinity IgE receptor)<sup>a</sup> </p> </li> </ul> <ul id="CD012179-list-0007"> <li> <p>Copeptin, <i>vasopressin surrogate</i> </p> </li> <li> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Other peptides and proteins shown to influence key events implicated in endometriosis</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Follistatin, <i>activin‐binding protein; involved in diverse activities from embryonic development to cell secretion</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>STX‐5 (syntaxin‐5), <i>protein belonging to syntaxin‐family, a vesicular membrane fusion protein receptor in endoplasmic reticulum membrane</i> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Oxidative stress markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbonyls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thiols</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PON‐1 (paraoxonase‐1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Post‐transcriptional regulators of gene expression (microRNAs)</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐9*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐141*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐17‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐145*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐20a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐199a</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐532‐3p</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Tumour markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐15.3 (cancer antigen‐15.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐72 (TAG‐72) (cancer antigen‐72 or (tumour associated glycoprotein‐72])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 (cancer antigen‐125)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Blood biomarkers that did not exhibit differential expression in endometriosis and for which diagnostic performance was not assessed</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Angiogenesis and growth factors and their receptors</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angiogenic activity of serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGF‐1 (insulin‐like growth factor‐1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAC (circulating angiogenic cells)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGF‐2 (insulin‐like growth factor‐2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EGF (epidermal growth factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGFBP‐3 (insulin‐like growth factor binding protein‐3)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sEGF‐R (soluble epidermal growth factor‐receptor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leptin<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sFlt‐1 (sVEGFR‐1] (soluble fms‐like tyrosine kinase or variant of VEGF receptor 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDGF (platelet derived growth factor)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycodelin‐A (PP14 or PAEP] (or placental protein 14 or progestogen‐associated endometrial protein)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF (vascular endothelial growth factor)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGF (hepatocyte growth factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Apoptosis markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Annexin V<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sFas (soluble Fas)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apoptotic cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>anti‐survivin Abs (anti‐survivin antibodies)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Cell adhesion molecules and other matrix‐related proteins</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biglycan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sE‐selectin (soluble E selectin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMP‐9 (matrix metalloproteinase‐9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Cytoskeleton molecules</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CK 19 (Cytokeratin‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i><b>DNA‐repair and telomere maintenance molecules</b> </i> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TL (telomere length)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Hormonal markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E2 (oestradiol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LH (luteinizing hormone)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH (follicle stimulating hormone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progesterone</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Immune system and inflammatory markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Autoantibodies</p> <p> <ul id="CD012179-list-0008"> <li> <p>Anti‐endometrial Abs (anti‐endometrial auto antibodies)<sup>a</sup> </p> </li> <li> <p>Anti‐sperm Abs (anti‐sperm auto antibodies)</p> </li> <li> <p>Anti‐ZP Abs (anti‐zona pellucida auto antibodies)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Interleukins</p> <p> <ul id="CD012179-list-0009"> <li> <p>IL‐1β<sup>a</sup> </p> </li> <li> <p>IL‐2</p> </li> <li> <p>IL‐4 <sup>a</sup> </p> </li> <li> <p>IL‐6 <sup>a</sup> </p> </li> <li> <p>IL‐8 <sup>a</sup> </p> </li> <li> <p>IL‐10</p> </li> <li> <p>IL‐12</p> </li> <li> <p>IL‐15</p> </li> <li> <p>IL‐16</p> </li> <li> <p>IL‐18</p> </li> <li> <p>IL‐13</p> </li> <li> <p>IL‐17</p> </li> <li> <p>IL‐23</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemokines</p> <p> <ul id="CD012179-list-0010"> <li> <p>MCP‐1 (monocyte chemotactic protein‐1)<sup>a</sup> </p> </li> </ul> </p> <p>other Cytokines</p> <p> <ul id="CD012179-list-0011"> <li> <p>Epo (erythropoietin)</p> </li> <li> <p>GM‐CSF (granulocyte/macrophage‐colony stimulating factor)</p> </li> <li> <p>IFN‐γ (interferon‐gamma)<sup>a</sup> MIF (macrophage migration inhibitory factor)<sup>a</sup> </p> </li> <li> <p>TNF‐α (tumour necrosis factor alpha)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immune cells</p> <p> <ul id="CD012179-list-0012"> <li> <p>Peripheral blood mononuclear cells:</p> <ul id="CD012179-list-0013"> <li> <p>Lymphocytes (overall and subpopulations of B‐ and T‐cells)</p> </li> <li> <p>Monocytes/macrophages</p> </li> <li> <p>Neutrophils<sup>a</sup> </p> </li> <li> <p>NLR (neutrophil‐to‐lymphocyte ratio)<sup>a</sup> </p> </li> <li> <p>NK (natural killer cells)</p> </li> <li> <p>NKR (natural killer cells receptors)</p> </li> <li> <p>Tregs (Regulatory T cells)</p> </li> <li> <p>WBC (white blood cells)<sup>a</sup> </p> </li> </ul> </li> <li> <p>Other blood cells and blood cell parameters</p> <ul id="CD012179-list-0014"> <li> <p>Haemoglobin</p> </li> <li> <p>MPV (mean platelet volume)</p> </li> <li> <p>Platelet count</p> </li> <li> <p>PLR (platelet/lymphocyte ratio</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other immune/inflammatory markers</p> <p> <ul id="CD012179-list-0015"> <li> <p>C3a (anaphylatoxin)</p> </li> </ul> <ul id="CD012179-list-0016"> <li> <p>sCD23 (soluble CD23, low‐affinity IgE receptor)<sup>a</sup> </p> </li> </ul> <ul id="CD012179-list-0017"> <li> <p>sCD163 (soluble haemoglobin scavenger receptor)</p> </li> </ul> <ul id="CD012179-list-0018"> <li> <p>CRP (C‐reactive protein)<sup>a</sup> </p> </li> </ul> <ul id="CD012179-list-0019"> <li> <p>sHLA‐I (soluble human leukocyte class I antigens)</p> </li> </ul> <ul id="CD012179-list-0020"> <li> <p>Immunoglobulins: IgA, IgG</p> </li> <li> <p>MPO (myeloperoxidase)</p> </li> </ul> <ul id="CD012179-list-0021"> <li> <p>NAG (N‐acetyl‐b‐Dglucosaminidase)</p> </li> </ul> <ul id="CD012179-list-0022"> <li> <p>PGE2 (prostaglandin E2)</p> </li> </ul> <ul id="CD012179-list-0023"> <li> <p>Phospholipid fatty acids</p> </li> </ul> <ul id="CD012179-list-0024"> <li> <p>PLA2G2A (phospholipase A2 group IIA)</p> </li> </ul> <ul id="CD012179-list-0025"> <li> <p>RANTES (regulated on activation, normal T cell expressed and secreted)</p> </li> </ul> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Nerve growth markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CNTF (ciliary Neurotrophic Factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NGF (nerve growth factor)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDNF (glial cell‐derived neurotrophic factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NT4 (neurotrophin 4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Other peptides and proteins shown to influence key events implicated in endometriosis</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>DBP (vitamin D binding protein), <i>component of Gc‐globulin and is the major plasma carrier protein of vitamin D metabolites, responsible for the transport of fat and endotoxins, important factor in the actin scavenging system, plays an important role in the immune system</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Enolase (phosphopyruvate hydratase], <i>a glycolytic enzyme, frequently associated with autoimmune diseases</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>PDPK1 (phosphoinositide dependent protein kinase 1), <i>a master kinase involved in the signalling pathways</i> </p> <p><i>activated by several growth factors and hormones (glucose metabolism, cellular proliferation, cellular survival, and angiogenesis)</i> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Oxidative stress markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ascorbic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrotyrosine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSH (glutathione)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOD3 (superoxide dismutase‐3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HSP70 (heat shock protein 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TRX (Thioredoxin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IMA (Ischemia‐modified albumin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malondialdehyde</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Tumour markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AFP (alpha‐fetoprotein)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>c‐erbB‐2 (HER‐2/neu] (erythroblastosis oncogene B or human epidermal growth factor receptor‐2 derived from glioblastoma) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HE4 (human epididymal secretory protein E4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 (cancer antigen‐125)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><sup>a</sup> Biomarkers that belong to both groups (evaluated as a diagnostic test for endometriosis in some studies and did not exhibit differential expression in endometriosis in the other studies). </p> <p>For a comprehensive list of all biomarkers with their biological annotation, please see <a href="./appendices#CD012179-sec-0169">Appendix 1</a>. </p> </td> </tr> </tbody> </table> </div> <p>The definition of 'non‐invasive' varies between medical dictionaries but refers to a procedure that does not involve penetration of skin or physical entrance to the body (<a href="./references#CD012179-bbs2-0422" title="SegenJC . McGraw‐Hill Concise Dictionary of Modern Medicine. 2nd Edition. New York: The McGraw‐Hill Companies, Inc, 2006. ">McGraw‐Hill Dictionary of Medicine 2006</a>; <a href="./references#CD012179-bbs2-0438" title="OlendorfD , JeryanC , BoydenK (editors) . The Gale Encyclopedia of Medicine (5 volume set). 4th Edition. Detroit: The Gale Group, Inc, 2011. ">The Gale Encyclopedia of Medicine 2011</a>). Although venipuncture for blood collection is invasive by this definition, blood tests are generally considered to be non‐invasive or minimally invasive when compared to diagnostic surgery. For the purpose of these reviews, we will define all tests that do not involve anaesthesia and surgery as non‐invasive. </p> <p>The advantages of using a blood test for the diagnosis of endometriosis are that it is minimally invasive, readily available, acceptable to women, provides a rapid result and is more cost‐effective when compared to surgery. However, blood testing is dependent on the reliability of laboratory techniques and quality control protocols. Blood biomarker levels may also be susceptible to variation during the menstrual cycle. </p> <p>Research has identified cellular and molecular processes that characterise ectopic endometrium and peritoneal fluid in human and animal models (<a href="./references#CD012179-bbs2-0393" title="D'HoogheTM , BambraCS , XiaoL , PeixeK , HillJA . Effect of menstruation and intrapelvic injection of endometrium on inflammatory parameters of peritoneal fluid in the baboon (Papio anubis and Papio cynocephalus). American Journal of Obstetrics and Gynecology2001;184(5):917‐25. ">D'Hooghe 2001</a>; <a href="./references#CD012179-bbs2-0409" title="HullML , EscarenoCR , GodslandJM , DoigJR , JohnsonCM , PhillipsSC , et al. Endometrial‐peritoneal interactions during endometriotic lesion establishment. American Journal of Pathology2008;173(3):700‐15. ">Hull 2008</a>; <a href="./references#CD012179-bbs2-0412" title="KaoLC , GermeyerA , TulacS , LoboS , YangJP , TaylorRN , et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease‐based implantation failure and infertility. Endocrinology2003;144(7):2870‐81. ">Kao 2003</a>). Different studies have evaluated markers of these pathophysiological processes in blood samples as a single test or a combination of several biomarkers. Categories of blood markers include: angiogenic and growth factors; markers of apoptosis; cell adhesion molecules and other matrix‐related proteins; cytoskeleton molecules; DNA‐repair/telomere maintenance molecules; hormonal markers; high‐throughput molecular markers; hormonal markers; immune system and inflammatory markers; nerve growth markers; oxidative stress markers; post‐transcriptional regulators of gene expression (circulating nuclear DNAs, microRNAs); tumour markers; and other peptides/proteins shown to influence key events implicated in endometriosis. Most blood‐based tests have only been evaluated in a limited number of small studies with varying methods, laboratory techniques and types of assay.The most extensively studied biomarker for endometriosis is cancer antigen‐125 (CA‐125), a glycoprotein expressed on coelomic epithelial tissues such as the peritoneum. An older meta‐analysis concluded that CA‐125 had a limited ability to diagnose endometriosis (<a href="./references#CD012179-bbs2-0424" title="MolBW , BayramN , LijmerJG , WiegerinckMA , BongersMY , Van derVeenF , et al. The performance of CA‐125 measurement in the detection of endometriosis: a meta‐analysis. Fertility and Sterility1998;70:1101‐8. ">Mol 1998</a>). However, the review did not describe the selection process to include studies. Since then, further studies evaluating CA‐125 have been published, and the methodologies of diagnostic test reviews have improved, so an updated review of CA‐125 is warranted (<a href="./references#CD012179-bbs2-0389" title="BrosensJ , TimmermanD , Strazinski‐PowitzA , BrosensI . Noninvasive diagnosis of endometriosis: the role of imaging and markers. Obstetrics and Gynecology Clinics of North America2003;30(1):95‐114. ">Brosens 2003</a>; <a href="./references#CD012179-bbs2-0386" title="BedaiwyM , FalconeT . Laboratory testing for endometriosis. Clinica Chimica Acta2004;340(1‐2):41‐56. ">Bedaiwy 2004</a>; <a href="./references#CD012179-bbs2-0419" title="MatalliotakisIM , VassiliadisS , GoumenouAG , FragouliY , AthanassakisI . Suggested markers for the diagnosis of endometriosis. Current Women's Health Reviews2008;4:25‐8. ">Matalliotakis 2008</a>; <a href="./references#CD012179-bbs2-0445" title="YangWC , ChenHW , AuHK , ChangCW , HuangCT , YenYH , et al. Serum and endometrial markers. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2004;18(2):305‐18. ">Yang 2004</a>). </p> <p>A large systematic review of all proposed biomarkers for endometriosis in serum, plasma and urine identified over 100 putative biomarkers, but the authors were unable to identify any biomarker (single or in a panel) that they could recommend for use in clinical practice (<a href="./references#CD012179-bbs2-0421" title="MayKE , Conduit‐HulbertSA , VillarJ , KirtleyS , KennedySH , BeckerCM . Peripheral biomarkers of endometriosis: A systematic review. Human Reproduction Update2010;16(6):651‐74. ">May 2010</a>). A more recent narrative review concurred with this conclusion (<a href="./references#CD012179-bbs2-0400" title="FassbenderA , BurneyRO , DorienFO , D’HoogheT , GiudiceL . Update on biomarkers for the detection of endometriosis. BioMed Research International 2015 Jul 9 [Epub ahead of print]. ">Fassbender 2015</a>). There is a current need to re‐evaluate the diagnotic test accuracy of blood tests for endometriosis using Cochrane methods. </p> </section> <section id="CD012179-sec-0037"> <h3 class="title" id="CD012179-sec-0037">Clinical pathway</h3> <p>Women presenting with symptoms of endometriosis (dysmenorrhoea, dyspareunia, chronic pelvic pain or difficulty conceiving) are generally investigated with a pelvic ultrasound scan to exclude other pathologies, which is in line with international guidelines (<a href="./references#CD012179-bbs2-0379" title="The American College of Obstetricians and Gynecologists. Practice bulletin no. 114: management of endometriosis. Obstetrics and Gynecology2010;116(1):223‐36. ">ACOG 2010</a>; <a href="./references#CD012179-bbs2-0398" title="DunselmanGA , VermeulenN , BeckerC , Calhaz‐JorgeC , D'HoogheT , DeBieB , et al. ESHRE guideline: management of women with endometriosis. Human Reproduction2014;29(3):400‐12. ">Dunselman 2014</a>; <a href="./references#CD012179-bbs2-0434" title="Society of Obstetricians Gynaecologists of Canada. Endometriosis: diagnosis and management. SOGC clinical practice guideline no. 244. Journal of Obstetrics and Gynaecology Canada2010;32:S1‐S28. ">SOGC 2010</a>). There are no other standard investigative tests, and although evidence suggests that MRI is superior to ultrasound, it is used conservatively because of its cost. If patients seek pain management rather than conception, physicians generally initiate empirical treatment with progestogens or the combined oral contraceptive pill. Diagnostic laparoscopy is considered if empirical treatment fails or if women decline or do not tolerate empirical treatment. In women who have difficulty conceiving, laparoscopy can be undertaken before fertility treatment (particularly if severe pelvic pain or endometrioma are present) or after failed assisted reproductive technology (ART) treatments. Physicians may also diagnosis endometriosis during fertility investigations in women who have minimal or no pain symptomatology. </p> <p>On average there is a delay of 6 to 12 years from onset of symptoms to definitive diagnosis at surgery. Early referral to a gynaecologist with the capability to perform diagnostic surgery is associated with a shorter time to diagnosis. Collectively, young women, women in remote and rural locations and women of lower socioeconomic status have reduced access to surgery and are less likely to obtain a prompt diagnosis of endometriosis. </p> <section id="CD012179-sec-0038"> <h4 class="title">Prior test(s)</h4> <p>Most women presenting with symptoms suggestive of endometriosis have a full history and examination and a routine gynaecological ultrasound before physicians recommend they undergo diagnostic surgery. However, there is no consensus on whether any other test should be routinely used as part of a standardised approach. </p> </section> <section id="CD012179-sec-0039"> <h4 class="title">Role of index test(s)</h4> <p>A new diagnostic test can fulfil one of three roles.</p> <p> <ol id="CD012179-list-0026"> <li> <p>Replacement: replacing an existing test due to better accuracy or a similar accuracy with other advantages. </p> </li> <li> <p>Triage: used as an initial step in a diagnostic pathway to identify the group of patients who need further testing with an existing test. Although ideally a triage test has a high sensitivity and specificity, it may have a lower sensitivity but higher specificity than the current test or vice versa. The triage test does not aim to improve the diagnostic accuracy of the existing test but rather to reduce the number of individuals having an unnecessary diagnostic test. </p> </li> <li> <p>Add‐on: used in addition to existing testing to improve diagnostic performance (<a href="./references#CD012179-bbs2-0388" title="BossuytPM , LeeflangMM . Chapter 6: Developing Criteria for Including Studies. In: Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.methods.cochrane.org/sdt/handbook‐dta‐reviews. ">Bossuyt 2008</a>). </p> </li> </ol> </p> <p>Ideally a diagnostic test is expected to correctly identify all patients with a disease and to exclude all patients without that disease; in other words, it should have a sensitivity and specificity of 1.00. A high sensitivity indicates that there are a low number of patients who have a negative test and do have the disease (i.e. a low number of false negative results). High specificity corresponds to a low number of patients who have a positive test but do not have the disease (i.e. low false positive results). In practice, however, it is extremely rare to find a test with equally high sensitivity and specificity. An acceptable replacement test would need to have a similar or higher sensitivity and specificity than the current gold standard. In the case of laparoscopy for diagnosis of endometriosis, the only systematic review reported a sensitivity of 0.94 and a specificity of 0.79, and we have taken this as a cut‐off for a replacement test (<a href="./references#CD012179-bbs2-0444" title="WykesCB , ClarkTJ , KhanKS . Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG ‐ an International Journal of Obstetrics and Gynaecology2004;111:1204‐12. ">Wykes 2004</a>). </p> <p>The purpose of triage tests can vary depending on the clinical context and patients' priorities. One reasonable approach is to exclude the diagnosis to avoid further unnecessary and expensive diagnostic investigations. High sensitivity tests have few false negative results and act to rule conditions out (SnOUT). A negative result from a test with high sensitivity will exclude the disease with high certainty independent of the specificity. As women without disease would be assured of having a negative test, unnecessary invasive interventions can be avoided. However, a positive result has less diagnostic value, particularly when the specificity is low. We predetermined that a clinically useful SnOUT triage test should have a sensitivity of 0.95 or more and a specificity of 0.50 and above. We set the sensitivity cut‐off for a SnOUT triage test at 0.95 and above, assuming that a 0.05 false negative rate is statistically and clinically acceptable. We set the specificity cut‐off at 0.50 and above, to avoid diagnostic uncertainty in more than 50% of the population with a positive result. </p> <p>An alternative approach would be to avoid a missed diagnosis. High specificity tests have few false positive results and act to rule conditions 'in' (SpIN). A positive result for a highly specific triage test indicates a high likelihood of having endometriosis. This information could be used to prioritise these patients for surgical treatment. A positive SpIN test could also provide a clinical rationale to start targeted disease‐specific medical management in a patient without a surgical diagnosis, under the assumption that disease is present. Surgical management could then be reserved for cases when conservative treatment fails. This is particularly relevant in some populations where the therapeutic benefits of surgery for endometriosis have to be carefully balanced with the disadvantages (e.g. young women, women with medical conditions or pain‐free patients with a history of infertility). In this scenario we considered a sensitivity of 0.50 and above and a specificity of 0.95 and higher as suitable cut‐offs for a SpIN triage test. </p> <p>We evaluated blood tests for their potential to replace surgery (replacement test) or to improve the selection of women for surgery (triage test to rule out (SnOUT) or rule in (SpIN) the disease). Both types of triage tests are clinically useful, minimising the number of unnecessary interventions. Sequential implementation of SnOUT and SpIN tests can also optimise a diagnostic algorithm (<a href="#CD012179-fig-0001">Figure 1</a>). We did not assess any test as an add‐on test, as we sought tests that reduce the need for surgery and not tests that improve the accuracy of the currently available surgical diagnosis. </p> <div class="figure" id="CD012179-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Sequential approach to non‐invasive testing of endometriosis." data-id="CD012179-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sequential approach to non‐invasive testing of endometriosis.</p> </div> </div> </div> </section> <section id="CD012179-sec-0040"> <h4 class="title">Alternative test(s)</h4> <p>There are no routine alternative tests for the diagnosis of endometriosis in clinical practice. </p> </section> </section> <section id="CD012179-sec-0041"> <h3 class="title" id="CD012179-sec-0041">Rationale</h3> <p>Many women with endometriosis suffer longstanding pelvic pain and infertility prior to a diagnosis. Surgery is the only current method of diagnosing endometriosis, but it is associated with high costs and surgical risks. A simple and reliable non‐invasive test for endometriosis, with the potential to either replace laparoscopy or to triage women in order to reduce surgery, would minimise surgical risk and reduce diagnostic delay. Physicians could then detect endometriosis at less advanced stages and institute earlier interventions. Early diagnosis would provide the opportunity for a preventive approach for this debilitating disease, potentially reducing healthcare‐related costs and favouring more cost‐effective and efficient treatments. Furthermore, identifying blood biomarkers that do not pertain to endometriotic disease would help clinicians and researchers focus on clinically relevant biomarker detection. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012179-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012179-sec-0042"></div> <section id="CD012179-sec-0043"> <h3 class="title" id="CD012179-sec-0043">Primary objectives</h3> <p>To evaluate blood biomarkers as replacement tests for diagnostic surgery and as triage tests to inform decisions to undertake surgery for endometriosis. Specific objectives include the following. </p> <p> <ol id="CD012179-list-0027"> <li> <p>To provide summary estimates of the diagnostic accuracy of blood biomarkers for the diagnosis of peritoneal, ovarian and deep infiltrating pelvic endometriosis, compared to surgical diagnosis as a reference standard. </p> </li> <li> <p>To assess the diagnostic utility of biomarkers that could differentiate ovarian endometrioma from other ovarian masses. </p> </li> </ol> </p> </section> <section id="CD012179-sec-0044"> <h3 class="title" id="CD012179-sec-0044">Secondary objectives</h3> <p> <ol id="CD012179-list-0028"> <li> <p>To investigate the influence of heterogeneity on the diagnostic accuracy of blood biomarkers for endometriosis. Potential sources of heterogeneity include: </p> <ol id="CD012179-list-0029"> <li> <p>participant characteristics: age (adolescents versus later reproductive years), clinical presentation (subfertility, pelvic pain, ovarian mass, asymptomatic women), stage of disease (rASRM classification system), geographic location of study; </p> </li> <li> <p>histological confirmation in conjunction with laparoscopic visualisation compared to laparoscopic visualisation alone; </p> </li> <li> <p>changes in technology over time: year of publication, modifications applied to conventional laboratory techniques; </p> </li> <li> <p>methodological quality: differences in the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) evaluation (<a href="#CD012179-tbl-0004">Table 3</a>), including low versus unclear or high risk; consecutive versus non‐consecutive enrolment; and blinding of surgeons to the results of index tests; </p> </li> <li> <p>study design (single‐gate design versus two‐gate design studies).</p> </li> </ol> </li> <li> <p>To assess biomarkers that were not affected by endometriosis and hence were unlikely to discriminate between women with and without the disease. </p> </li> </ol> </p> <div class="table" id="CD012179-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Application of the QUADAS‐2 tool for assessment of methodological quality of the included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 1 ‐ Patient selection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe methods of patient selection and included patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection bias, spectrum bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review Question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women of reproductive age with clinically suspected endometriosis (symptoms, clinical examination ± presence of pelvic mass), scheduled for surgical exploration of pelvic/abdominal cavity for confirmation of the diagnosis ± treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study objectives, study population, selection (inclusion/exclusion criteria), study design, clinical presentation, age, number of enrolled and number of available for analysis, setting, place and period of the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was a consecutive or random sample of patients enrolled?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If a consecutive sample or a random sample of the eligible participants was included in the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If a consecutive sample or a random sample of the eligible participants was not included in the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Did the study avoid inappropriate exclusions?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If inclusion and exclusion criteria were presented and all participants with suspected endometriosis were included, with an exception for those who either had a history of medical conditions or were on medical therapy that would have potentially interfered with interpretation of index test (e.g. malignancy, pregnancy, autoimmune disorders, infectious diseases, treatment with hormonal or immunomodulator substances); refused to participate in the study; or were unfit for surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study excluded the participants based on education level, psychosocial factors, genetic testing or phenotype or excluded participants with any comorbidities commonly present in general population, including a population that could have undergone a testing for endometriosis in clinical setting (hypertension, asthma, obesity, benign gastrointestinal or renal disease, etc) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study did not provide clear definition of the selection (inclusion/exclusion) criteria and 'no' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 3</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was a 'two‐gate' design avoided?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study had a single set of inclusion criteria, defined by the clinical presentation (i.e. only participants in whom the target condition is suspected) ‐ a single‐gate design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study had more than one set of inclusion criteria in respect to clinical presentation (i.e. participants suspected of target condition and participants with alternative diagnosis in whom the target condition would not be suspected in clinical practice) ‐ a two‐gate study design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If it was unclear whether a two‐gate deign was avoided or not</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the selection of patients have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for all the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 3 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns about applicability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Are there concerns that the included patients do not match the review question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study includes only clinically relevant population that would have undergone index test in real practice and includes representative form of target condition </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study population differed from the population defined in the review question in terms of demographic features and comorbidity (e.g. studies with multiple sets of inclusion criteria with respect to clinical presentation including either healthy controls or alternative diagnosis controls that would not have undergone index test in real practice). Further, if target condition diagnosed in the study population was not representative of the entire spectrum of disease, such as limited spectrum of severity (e.g. only mild forms) or limited type of endometriosis (e.g. only deep infiltrating endometriosis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear (e.g. severity of endometriosis was not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 2 ‐ Index test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the index test, how it was conducted and interpreted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test review bias, clinical review bias, interobserver variation bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any type of blood‐based biomarker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index test name, description of positive case definition by index test as reported, threshold for positive result, examiners (number, level of expertise, blinding), interobserver variability, conflict of interests </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Were the index test results interpreted without knowledge of the results of the reference standard?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the operators performing/interpreting index test were unaware of the results of the reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the operators performing/interpreting index test were not blinded to the results of the reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>If a threshold was used, was it pre‐specified?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If study clearly provided a threshold for positive result and was defined before execution/interpretation of index test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If a threshold for positive result was not provided or not defined prior to test execution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If it was unclear whether a threshold was pre‐specified or not</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 3</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was a menstrual cycle phase considered in interpreting the index test?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all the included participants were in the same phase of menstrual cycle, if the study reported subgroup analyses per cycle phase, or if study reported the pooled estimates after impact of the cycle phase on biomarker expression was not detected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If study included participants in different phases of menstrual cycle, but effect of cycle phase on index test was not assessed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the cycle phase was not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the conduct or interpretation of the index test have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for all the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 3 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns about applicability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We considered all types of blood‐based biomarkers as eligible, therefore all the included studies were classified as 'low concern', unless 'unclear' judgement was applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not consider the studies where index tests other than blood‐based biomarkers were included (or excluded information on other index tests reported in addition to blood tests) or where index test looked at other target conditions not specified in the review (e.g. studies aimed at classifying pelvic masses as benign and malignant); therefore none of the included studies was classified as 'high concern' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If study reported, but did not present sufficient information on any of the following: laboratory method, sample handling, reagents used or experience of the test operators </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 3 ‐ Reference standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the reference standard, how it was conducted and interpreted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Verification bias, bias in estimation of diagnostic accuracy due to inadequate reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Target condition ‐ pelvic endometriosis, ovarian endometriosis, deep infiltrating endometriosis. Reference standard ‐ visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Target condition, prevalence of target condition in the sample, reference standard, description of positive case definition by reference test as reported, examiners (number, level of expertise, blinding), interobserver variability, conflict of interests </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Is the reference standard likely to correctly classify the target condition?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study reported at least one of the following: surgical procedure was described in sufficient detail; criteria for positive reference standard were stated; diagnosis was confirmed by histopathology; or the procedure was performed by a team with high level of expertise in diagnosis/surgical treatment of target condition, including tertiary referral centres for endometriosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If reference standard did not classify target condition correctly; considering the inclusion criteria and nature of the reference standard, none of the studies were classified as 'no' for this item </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If information on execution of the reference standard, its interpretation or operators was unclear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Were the reference standard results interpreted without knowledge of the results of the index tests?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If operators performing the reference test were unaware of the results of the index test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If operators performing the reference test were aware of the results of the index test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for both of the above 2 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 2 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 2 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns about applicability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Considering the inclusion criteria, all the studies were classified as 'low concern', unless 'unclear' judgement was applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We excluded the studies where participants did not undergo surgery for diagnosis of endometriosis; therefore none of the included studies were classified as 'high concern' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only studies where laparoscopy/laparotomy served as a reference test were included; therefore none of the included studies were classified as 'unclear concern' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 4 ‐ Flow and timing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe any participants who did not receive the index tests or reference standard or who were excluded from the 2 x 2 table; describe the interval and any interventions between index tests (sample collection) and the reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease progression bias, bias of diagnostic performance due to missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 12‐month interval between index test (sample collection) and reference standard ‐ endometriosis may progress over the time, so we had chosen an arbitrary time interval of 12 months as an acceptable time interval between the index test and surgical confirmation of diagnosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time interval between index test (sample collection) and reference standard, withdrawals (overall number of reported and if explanation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was there an appropriate interval between index test (sample collection) and reference standard?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If time interval was reported and was less than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We excluded all the studies where time interval was longer than 12 months; therefore none of the included studies were classified as 'no' for this item </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If time interval was not stated clearly, but authors description allowed us to assume that the interval was reasonably short </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Did all patients receive the same reference standard?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all participants underwent laparoscopy/laparotomy as a reference standard. Considering the inclusion criteria, all the studies were classified as 'yes' for this item, as anticipated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all participants did not undergo surgery or had alternative reference standard or if only a subset of participants had surgery as reference standard, but the information on this population was not available in isolation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear. Considering the inclusion criteria, none of the included studies were classified as 'unclear' for this item </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 3</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Were all patients included in the analysis?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all the participants were included in the analysis or if the participants were excluded because they did not meet inclusion criteria prior to execution of index test or if the withdrawals were less than 5% of the enrolled population (arbitrary selected cut‐off) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If any participants were excluded from the analysis because of uninterpretable results, inability to undergo either index test or reference standard, or unclear reasons </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the patient flow have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for all the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 3 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012179-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012179-sec-0045"></div> <section id="CD012179-sec-0046"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012179-sec-0047"> <h4 class="title">Types of studies</h4> <p>Published peer‐reviewed studies that compared the results of one or several types of blood biomarker tests with the results obtained from a surgical diagnosis of endometriosis. </p> <p>We included the following types of studies.</p> <p> <ol id="CD012179-list-0030"> <li> <p>Randomised controlled trials (RCTs).</p> </li> <li> <p>Observational studies with the following designs.</p> <ol id="CD012179-list-0031"> <li> <p>Single‐gate design (studies with a single set of inclusion criteria defined by clinical presentation). All participants had clinically suspected endometriosis. </p> </li> <li> <p>Two‐gate design (studies where participants are sampled from distinct populations with respect to clinical presentation). The same study includes participants with a clinical suspicion of having the target condition (e.g. women with pelvic pain) and also participants in whom the target condition is not suspected (e.g. women admitted for tubal ligation). Two‐gate studies were eligible only where all cases and controls belonged to the same population with respect to the reference standard (i.e. all the participants were scheduled for laparoscopy) (<a href="./references#CD012179-bbs2-0430" title="RutjesAWS , ReitsmaJB , VandenbrouckeJP , GlasAS , BossuytPMM . Case–control and two‐gate designs in diagnostic accuracy studies. Clinical Chemistry2005;51(8):1335‐41. ">Rutjes 2005</a>). </p> </li> </ol> </li> <li> <p>Studies performed on prospectively collected samples, irrespective of the actual time of the test assay. The timing of sample collection relative to surgery is important because the surgical excision of endometriotic lesions could influence blood biomarker expression and hence bias the results. Therefore, we only included studies that drew blood before the surgical procedure, i.e. 'prospectively collected'. We considered to be eligible the studies performed on tissue bank samples collected from prospectively recruited, well‐defined populations, which prevented the omission of valuable data from adequately designed studies. The time interval between sample collection and laboratory testing may influence test outcomes, which could be dependent on sample storage conditions and the stability of each individual biomarker during storage and freeze‐thawing. This information was not readily available for most molecules, and we did not address it in this review, but we will consider it in future updates if more evidence emerges. </p> </li> </ol> </p> <p>We did not impose limits on eligibility related to the healthcare settings where the study took place, the language of publication, the number of participants in the included studies or the number of studies that evaluated each index test. </p> <p>We excluded the following types of studies.</p> <p> <ol id="CD012179-list-0032"> <li> <p>Narrative or systematic reviews.</p> </li> <li> <p>Studies of retrospective design where investigators collected samples after execution of the reference test. </p> </li> <li> <p>Studies of retrospective design where investigators selected participants from retrospective review of the case notes/archived samples and where information on recruitment methods or study population was not available. </p> </li> <li> <p>Case reports or case series.</p> </li> <li> <p>Studies reported only in abstract form or in conference proceedings where the full text was not available. We applied this limitation after facing substantial difficulty in obtaining the information from the abstracts, which precluded a reliable assessment of eligibility and methodological quality. </p> </li> </ol> </p> </section> <section id="CD012179-sec-0048"> <h4 class="title">Participants</h4> <p>Study participants included reproductive‐aged women (puberty to menopause) with suspected endometriosis based on clinical symptoms, pelvic examination or both, who undertook the index test as well as the reference standard. </p> <p>Participants came from populations of women undergoing abdominal surgery for the following indications. </p> <p> <ul id="CD012179-list-0033"> <li> <p>Clinically suspected endometriosis (pelvic pain, infertility, abnormal pelvic examination, or a combination of the above). </p> </li> <li> <p>Ovarian mass, regardless of symptoms.</p> </li> <li> <p>A mixed group consisting of women with suspected endometriosis/ovarian mass or women with other benign gynaecological conditions (e.g. surgical sterilisation, fibroid uterus, etc). </p> </li> <li> <p>Asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication. </p> </li> </ul> </p> <p>Studies that included participants of postmenopausal age were eligible when the data for the reproductive age group was available in isolation. We excluded studies with participants that clearly would not undergo the index test in the relevant clinical situation or would not benefit from the test (e.g. women with ectopic pregnancies or acute pelvic inflammatory disease). We also excluded publications that only analysed participants with a positive index test or reference standard and did not provide data for the whole cohort. </p> </section> <section id="CD012179-sec-0049"> <h4 class="title">Index tests</h4> <p>We assessed any type of blood‐based biomarker for endometriosis either separately or in combination with other blood tests. We included index tests performed on whole blood, plasma or serum. We present the assessed index tests in <a href="#CD012179-tbl-0003">Table 2</a> (classified by biological subgroups) and in <a href="./appendices#CD012179-sec-0169">Appendix 1</a> (alphabetical order with annotation for biological subgroups). We included the tests performed in one or several phases of menstrual cycle. </p> <p>The combined evaluations of blood biomarkers with other methods for diagnosing endometriosis (e.g. pelvic examination, imaging, urine or endometrial tests) are beyond the scope of this review and are presented separately in another review, 'Combined tests for the non‐invasive diagnosis of endometriosis'. We excluded studies that solely assessed specific technical aspects, presented qualitative descriptions of lesion appearance or reported interobserver variability of the index tests, without reporting the data on diagnostic performance. When the evaluated biomarker(s) showed differential expression between the groups of women with and without endometriosis, we only considered the study if it reported data with sufficient detail for the construction of 2 x 2 contingency tables. However, when the contingency tables were not available because the expression level of index test did not significantly differ between the groups and the inclusion criteria were otherwise met, we made a critical appraisal and presented the study in the descriptive part of the review. Thus, we evaluated the adequately designed studies that identified biomarkers without diagnostic value, as they provide information that is likely to focus future research on other more clinically useful biomarkers.This methodology also identified biomarkers that were associated with endometriosis in some but not other studies. We did not include evaluations of screening or predictive accuracy tests in this review. </p> <p>We considered the diagnostic performance of an index test to be high when the test reached the criteria for a replacement test (sensitivity of equal or greater than 0.94 with specificity of equal or greater than 0.79) or triage test (sensitivity of equal or greater than 0.95 with specificity of equal or greater than 0.50 or vice versa) or approached these criteria (diagnostic estimates within 0.05 of the set thresholds). We considered all other diagnostic estimates to be low. </p> </section> <section id="CD012179-sec-0050"> <h4 class="title">Target conditions</h4> <p>Pelvic endometriosis, defined as endometrial tissue located in the pelvic cavity: involving any of the following: pelvic organs, peritoneum and pouch of Douglas. </p> <p>We assessed three types of pelvic endometriosis.</p> <p> <ol id="CD012179-list-0034"> <li> <p>Peritoneal endometriosis, defined as endometrial deposits detected on peritoneum covering pelvic organs, pelvic side walls or pouch of Douglas. </p> </li> <li> <p>Ovarian endometriosis (endometrioma), defined as an ovarian cyst lined by endometrial tissue, appearing as an ovarian mass of varying size. </p> </li> <li> <p>Deep infiltrating endometriosis (DIE), defined as subperitoneal infiltration of endometrial implants, i.e. when the endometriotic implants penetrate the retroperitoneal space at a distance of 5 mm or more (<a href="./references#CD012179-bbs2-0414" title="KoninckxPR , MeulemanC , DemeyereS , LesaffreE , CornillieFJ . Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertility and Sterility1991;55(4):759‐65. ">Koninckx 1991</a>). DIE may be present in multiple locations, involving either the anterior or posterior pelvic compartments, or both. </p> </li> </ol> </p> <p>We did not include certain rare types of endometriosis such as extrapelvic, bladder and ureteric endometriosis because the majority were reported in case reports or case series, and laparoscopy or laparotomy are not reliable reference standards for these conditions. </p> <p>We excluded the studies where diagnosis of endometriosis was not the primary outcome (e.g. malignant versus benign masses or normal versus abnormal pelvis) and separate data for endometriosis was not available. </p> <p>We also excluded the studies where the findings of the index test formed the basis of selection for the reference standard, because this was likely to distort an assessment of the diagnostic value of the index test. </p> <p>We did include studies that recruited selected populations of women with endometriosis (i.e. those with specific rASRM stages), because there is a poor correlation between the rASRM classification and infertility or pain symptoms. Exclusion of these studies could result in the loss of potentially important diagnostic information from otherwise eligible publications. Where possible, we addressed the impact of these studies in the assessment of heterogeneity. When a study analysed a large population with a wide spectrum of endometriosis and additionally reported a subgroup analysis of the different stages of disease severity, we only considered estimates for the entire population. This is because a subgroup analysis would not directly address the review question regarding the clinical utility of the biomarker in disease detection. </p> </section> <section id="CD012179-sec-0051"> <h4 class="title">Reference standards</h4> <p>The reference standard was visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation, as this is currently the best available test for endometriosis. If reported, we reviewed information regarding the inter‐ and intraobserver correlation of the reference standard. </p> <p>We only included studies in which the reference test was performed within 12 months of the blood sample collection, on the assumption that disease status could change within a period of one year or longer, either naturally or as a result of treatment. We excluded studies in which the participants did not undergo the reference standard or where the findings of the index test formed the basis of selection for undertaking the reference standard, as this was likely to distort an assessment of the diagnostic value of the index test. </p> <section id="CD012179-sec-0052"> <h5 class="title">Summary of inclusion and exclusion criteria</h5> <section id="CD012179-sec-0053"> <h6 class="title">Inclusion criteria</h6> <p> <ol id="CD012179-list-0035"> <li> <p>Types of studies</p> <ol id="CD012179-list-0036"> <li> <p>Published and peer‐reviewed</p> </li> <li> <p>RCTs</p> </li> <li> <p>Observational designs, including:</p> <ol id="CD012179-list-0037"> <li> <p>single‐gate design (single set of inclusion criteria defined by clinical presentation): all the participants had clinically suspected endometriosis; </p> </li> <li> <p>two‐gate design (two sets of inclusion criteria with respect to clinical presentation and one set of inclusion criteria with respect to reference standard): the participants with or without a clinical suspicion of endometriosis scheduled for abdominal surgery. </p> </li> </ol> </li> <li> <p>Published in any language</p> </li> <li> <p>Performed in any healthcare setting</p> </li> <li> <p>Any sample size</p> </li> </ol> </li> <li> <p>Participants</p> <ol id="CD012179-list-0038"> <li> <p>Reproductive‐aged women</p> </li> <li> <p>Clinically suspected endometriosis, including:</p> <ol id="CD012179-list-0039"> <li> <p>women who underwent abdominal surgery for other benign gynaecological conditions and had a surgical assessment for presence/absence of endometriosis; </p> </li> <li> <p>asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication. </p> </li> </ol> </li> <li> <p>Undertook both the index test and reference standard</p> </li> </ol> </li> <li> <p>Index tests</p> <ol id="CD012179-list-0040"> <li> <p>One or several types of blood biomarkers</p> </li> <li> <p>Data reported in sufficient detail for the construction of 2 x 2 tables for the tests that showed differential expression between the groups </p> </li> <li> <p>Biomarkers where a 2 x 2 tables could not be constructed because the results did not differ between women with and without endometriosis, but all other inclusion criteria were met. </p> </li> </ol> </li> <li> <p>Target condition</p> <ol id="CD012179-list-0041"> <li> <p>Pelvic endometriosis</p> <ol id="CD012179-list-0042"> <li> <p>Peritoneal endometriosis</p> </li> <li> <p>Ovarian endometrioma</p> </li> <li> <p>DIE</p> </li> <li> <p>Combinations of the above</p> </li> </ol> </li> </ol> </li> <li> <p>Reference standard</p> <ol id="CD012179-list-0043"> <li> <p>Surgical visualisation of lesions for the diagnosis of endometriosis (laparoscopy or laparotomy) with or without histological verification </p> </li> <li> <p>Performed within 12 months of the endometrial sample collection</p> </li> </ol> </li> </ol> </p> </section> <section id="CD012179-sec-0054"> <h6 class="title">Exclusion criteria</h6> <p> <ol id="CD012179-list-0044"> <li> <p>Types of studies</p> <ol id="CD012179-list-0045"> <li> <p>Narrative or systematic reviews</p> </li> <li> <p>Retrospective design where the execution of reference test preceded the collection of the blood sample </p> </li> <li> <p>Prospectively collected samples that were selected from the archived material, but where information on the study population or the selection process was unclear </p> </li> <li> <p>Case reports or case series</p> </li> <li> <p>Conference proceedings</p> </li> </ol> </li> <li> <p>Participants</p> <ol id="CD012179-list-0046"> <li> <p>Included cohort was not representative of the target population that would benefit from the test (e.g. women with known genital tract malignancy, ectopic pregnancies or acute pelvic inflammatory disease) </p> </li> <li> <p>Study included participants of postmenopausal age, and the data for the reproductive age group were not available in isolation </p> </li> <li> <p>Analysis only included participants with positive index test or positive reference standard </p> </li> </ol> </li> <li> <p>Index tests</p> <ol id="CD012179-list-0047"> <li> <p>Blood biomarkers presented in combination with other diagnostic tests for endometriosis, and separate information for blood biomarkers was not available </p> </li> <li> <p>Study presented only specific technical aspects of an index test or focused on the biological events, rather than diagnostic performance of the test </p> </li> <li> <p>Study assessed screening or predictive test accuracy</p> </li> </ol> </li> <li> <p>Target condition</p> <ol id="CD012179-list-0048"> <li> <p>Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis) </p> </li> <li> <p>Atypical, rare sites of endometriosis</p> </li> </ol> </li> <li> <p>Reference standard</p> <ol id="CD012179-list-0049"> <li> <p>Reference standard performed only in a subset of study/control group</p> </li> <li> <p>Findings of the index test formed the basis of selection for the reference standard</p> </li> <li> <p>Other than specified in inclusion criteria</p> </li> </ol> </li> </ol> </p> </section> </section> </section> </section> <section id="CD012179-sec-0055"> <h3 class="title">Search methods for identification of studies</h3> <p>We developed the search strategy in collaboration with the Trials Search Coordinator of the Gynaecology and Fertility Review Group, following recommendations of the <i>Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy</i> (<a href="./references#CD012179-bbs2-0396" title="DeVetHCW , EisingaA , RiphagenII , AertgeertsB , PewsnerD . Chapter 7: Searching for Studies. In: Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.methods.cochrane.org/sdt/handbook‐dta‐reviews. ">De Vet 2008</a>). We did not limit the searches to particular types of study design or impose language or publication date restrictions. The search strategy incorporated words in the title, abstract, text words across the record and the medical subject headings (MeSH). We initially created the search for one broad review looking at all diagnostic markers for endometriosis, but due to complexity, the review team split the originally planned review into five separate reviews. We designed two separate search strategies: one for all the biomarkers‐based tests, and another for the imaging tests; we used the former in this review. We performed all searches from database inception to April ‐ July 2015. We present the search strategies for each database and the number of hits per search in <a href="./appendices#CD012179-sec-0170">Appendix 2</a>; <a href="./appendices#CD012179-sec-0171">Appendix 3</a>; <a href="./appendices#CD012179-sec-0172">Appendix 4</a>; <a href="./appendices#CD012179-sec-0174">Appendix 5</a>; <a href="./appendices#CD012179-sec-0175">Appendix 6</a>. The summary of the results is presented in <a href="#CD012179-sec-0068">Results of the search</a>. </p> <section id="CD012179-sec-0056"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases to identify the published studies that assessed the diagnostic value of blood biomarkers for endometriosis. </p> <p> <ul class="plain" id="CD012179-list-0050"> <li> <ul id="CD012179-list-0051"> <li> <p>CENTRAL (2015, July).</p> </li> <li> <p>MEDLINE (inception to May 2015).</p> </li> <li> <p>EMBASE (inception to May 2015).</p> </li> <li> <p>CINAHL (inception to April 2015).</p> </li> <li> <p>PsycINFO (inception to April 2015).</p> </li> <li> <p>Web of Science (inception to April 2015).</p> </li> <li> <p>LILACS (inception to April 2015).</p> </li> <li> <p>OAIster (inception to April 2015).</p> </li> <li> <p>TRIP (inception to April 2015).</p> </li> <li> <p>Databases of the trial registers.</p> <ul id="CD012179-list-0052"> <li> <p>ClinicalTrials.gov (inception to April 2015).</p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (inception to April 2015). </p> </li> </ul> </li> <li> <p>Databases to identify reviews and guidelines as sources of references to potentially relevant studies. </p> <ul id="CD012179-list-0053"> <li> <p>MEDION (inception to January 2014, the last available date).</p> </li> <li> <p>DARE (inception to April 2015).</p> </li> <li> <p>PubMed, a 'Systematic Review' search under the 'Clinical Queries' link (inception to April 2015). </p> </li> </ul> </li> <li> <p>Searches for papers recently published and not yet indexed in the major databases:</p> <ul id="CD012179-list-0054"> <li> <p>PubMed (simple search for the 6 months to April 2015).</p> </li> </ul> </li> </ul> </li> </ul> </p> </section> <section id="CD012179-sec-0057"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference list of all relevant publications (retrieved full texts of the key articles and identified reviews). </p> <p>We abandoned an initial attempt to locate the grey literature (unpublished studies and conference proceedings), as we faced substantial difficulty in obtaining full text publications or further details of studies reported in an abstract form. </p> </section> </section> <section id="CD012179-sec-0058"> <h3 class="title" id="CD012179-sec-0058">Data collection and analysis</h3> <section id="CD012179-sec-0059"> <h4 class="title">Selection of studies</h4> <p>Three authors of this review (RS, DA, VN) and three authors from the other reviews in this series (Emily Liu, Devashana Gupta and Lucy Prentice) scanned the titles of studies identified by our search to remove any clearly irrelevant articles. We reviewed the titles and abstracts of the remaining studies to select potentially relevant publications, and we divided the relevant articles into four categories of endometriosis biomarkers: blood, endometrial, urinary and combined tests. Two out of four review authors (of VN, LH, RS and DA) independently reviewed each of the full text versions of the articles that we had selected by title and abstract, assessing them for eligibility based on the criteria listed in '<a href="#CD012179-sec-0046">Criteria for considering studies for this review</a>'. A single failed eligibility criterion was sufficient for a study to be excluded from the review. </p> <p>The review authors who assessed the relevance of the studies and eligibility for inclusion were not blind to the information about each article, including the publishing journal, the names of authors, the institution and the results. We resolved any disagreements by discussion and, if necessary, in consultation with a third review author (VJ) who is an expert in methodological aspects of Cochrane systematic reviews. </p> <p>When papers updated previous publications and were performed on the same study population at different recruitment points, we used the most complete data set that superseded previous publications to avoid double counting participants or studies. We retrieved missing data directly by contacting authors to clarify study eligibility. When we found potentially relevant studies in languages other than English, we had them translated. For excluded studies, we documented the reasons for exclusion and details of which criteria were not met. We present the characteristics of included studies, excluded studies and studies awaiting classification in '<a href="./references#CD012179-sec-0193" title="">Characteristics of included studies</a>', '<a href="./references#CD012179-sec-0194" title="">Characteristics of excluded studies</a>' and 'Characteristics of studies awaiting classification', respectively. </p> </section> <section id="CD012179-sec-0060"> <h4 class="title">Data extraction and management</h4> <p>Two out of five review authors (of VN, LH, RS, DA and CS) extracted data from each eligible study, resolving any disagreements by adjudication from the third review author (VJ). If required, we contacted study investigators to resolve any questions regarding the data. </p> <p>To collect details from included studies, we used a purpose‐designed data extraction form, designed specifically for this review and pilot tested on three studies of diagnostic accuracy tests for endometriosis. The following information was recorded for each study. </p> <p> <ul id="CD012179-list-0055"> <li> <p>General information and study design: first author, year of publication, country, language, setting, objectives, inclusion/exclusion criteria, type of enrolment. </p> </li> <li> <p>Characteristics of the study participants: age, symptoms/history/previous tests, type of target condition and its prevalence in the study population, number of participants enrolled and available for analysis, reasons for withdrawal. </p> </li> <li> <p>Features of the index test and reference standard: type, diagnostic criteria, number and experience of the operators, blinding of the operators to other tests or clinical data, interobserver variability, time interval between index test and reference standard. </p> </li> <li> <p>The reported number of true positives (TP), false negatives (FN), true negatives (TN) and false positives (FP), which we used to construct a 2 x 2 table for each index test. If studies did not report these values, we attempted to reconstruct the 2 x 2 tables from the summary estimates presented in the study. </p> </li> </ul> </p> <p>We extracted data into Review Manager 5 software (<a href="./references#CD012179-bbs2-0428" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), which we used to graphically display the quality assessment, the diagnostic estimates data and the descriptive analyses. </p> </section> <section id="CD012179-sec-0061"> <h4 class="title">Assessment of methodological quality</h4> <p>To assess the quality of each included study, we used QUADAS‐2, a modified version of the QUADAS tool for systematic reviews of diagnostic accuracy studies (<a href="./references#CD012179-bbs2-0443" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al. the QUADAS‐2 Group. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>). </p> <p>We present the review‐specific QUADAS‐2 tool and explanatory document in <a href="#CD012179-tbl-0004">Table 3</a>. We judged each study to be at 'low', 'high' or 'unclear' risk for each of four domains, and we assessed concerns about applicability in three domains. We considered studies as having low methodological quality when they were at high or unclear risk of bias or when we had a high concern regarding applicability at least in one domain. Two out of the four reviewers (of RS, DA, VN and LH) independently performed the assessment of each included study, settling disagreements with a third author (VJ) or by consensus. Two review authors (VN, RS) independently piloted the topic‐specific tool to rate four of the included studies with a high level of agreement. We made modifications specific to the blood biomarkers review to the signalling questions of the original QUADAS‐2 tool as follows. </p> <p>Domain 1: We rephrased an original signalling question, 'Was a case‐control design avoided?' as 'Was a two‐gate design avoided?'. The diagnostic studies are cross‐sectional in nature, aiming to compare the result of an index test with the result of the reference standard in the same group of participants. Study investigators measure the parameters at a single point in time and classify the groups by the outcome of the reference standard, albeit they perform the analysis retrospectively. Therefore, unlike epidemiological studies, the terminology 'cohort' and 'case‐control' is less informative for diagnostic test trials, so we substituted them for 'single‐gate' and 'two‐gate' designs. We included this question because a two‐gate design has more potential to introduce selection bias. </p> <p>Domain 2: We introduced an additional signalling question, 'Was the phase of the menstrual cycle considered in interpreting the index test?' to assess bias in the interpretation of the test results. Some biochemical markers are sensitive to fluctuation in steroid sex hormone levels across a menstrual cycle, which could result in the differential expression of endometriosis biomarkers at different cycle phases. </p> <p>We undertook the assessment of methodological quality for each domain, but we did not calculate a summary score to estimate the overall quality of studies (<a href="./references#CD012179-bbs2-0442" title="WhitingPF , HarbordR , KleijnenJ . No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Medical Research Methodology2005;5:19. ">Whiting 2005</a>). </p> </section> <section id="CD012179-sec-0062"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We generated the estimates of sensitivity and specificity in forest plots and plotted them in the receiver operating characteristic (ROC) space for each index test using Review Manager 5 software (<a href="./references#CD012179-bbs2-0428" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We investigated the diagnostic performance of each test and visually explored interstudy variation in the performance of each index test in relation to patient characteristics, study design and study quality considerations. When there were two or more tests evaluated in the same cohort, we included them as separate data sets, since the unit of analysis was the test result, not the patient. </p> <p>For studies that reported subgroup analyses per phase of the menstrual cycle, we presented the data in a clinically relevant way. For instance, we presented pooled estimates when there was no statistically significant difference in biomarker expression between cycle phases. Alternatively, where putative biomarkers demonstrated cycle‐dependent expression or were noted to be modulated by ovarian hormones, we reported the test performance either at several time points across the menstrual cycle or in the phase that demonstrated the most distinct difference between groups. </p> <p>We estimated the expected operating point (mean sensitivity and specificity) and corresponding 95% confidence region using the bivariate logit normal random‐effects model for all meta‐analyses with four studies or more. When the number of studies was fewer than four, we did not attempt to estimate the covariance and reported a zero. To estimate the performance of the other tests in small meta‐analyses (two or three data sets), we performed fixed‐effect meta‐analysis of sensitivity and specificity, in the absence of substantial heterogeneity. We performed the meta‐analyses using SAS NLMIXED software (Cary, NC: SAS Institute Inc). We entered results from SAS into Review Manager 5 to provide plots of the mean or summary point(s) and confidence region(s), superimposed on the study specific estimates of sensitivity and specificity (<a href="./references#CD012179-bbs2-0428" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>We assessed the comparative accuracy of index tests in two ways. In direct, fully paired comparisons where all the study participants received more than one index test as well as the reference standard, we plotted the estimates in Review Manager 5 (<a href="./references#CD012179-bbs2-0428" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). If meta‐analysis was possible, we used test‐level covariates in the bivariate logit normal model to identify statistically significant differences. Otherwise we reported the available comparative data in a narrative way and illustrated it using forest and ROC plots. </p> <p>When judging test performance against the predetermined diagnostic criteria, we considered the point estimates of sensitivity and specificity as the most informative presentation of test performance. We acknowledge that tests with point estimates that did not reach the predetermined criteria, but with confidence intervals (CIs) that contained values above the threshold, could have diagnostic value. Furthermore, tests with point estimates that reached the criteria but with CIs containing values below the threshold could have an overestimated diagnostic value. If we use the range of the CIs rather than the point estimates of the data, the predetermined cut‐off becomes meaningless. Therefore we did not consider CIs in qualifying the test performance but used this information in interpreting the reliability of the obtained data. </p> <section id="CD012179-sec-0063"> <h5 class="title">Dealing with missing data</h5> <p>We defined missing data as any information on the study population, index tests or reference standard that were not available from the publication and that were required to determine the eligibility of the study for inclusion, assess the methodological quality, or construct the results table. If we identified missing data, we contacted the authors in an attempt to obtain them. If missing data prevented a clear judgment regarding applicability for inclusion or the construction of accurate 2 x 2 tables and the data were unavailable from the primary investigators (for example we were unable to locate the contact details of the authors, there was no reply from the authors or the authors replied that the requested information was unavailable), we excluded the study from the review. </p> </section> </section> <section id="CD012179-sec-0064"> <h4 class="title">Investigations of heterogeneity</h4> <p>We initially assessed heterogeneity by visually examining the forest plots of sensitivities and specificities and the ROC plots for each index test. We describe the potential sources of heterogeneity in the <a href="#CD012179-sec-0044">Secondary objectives</a>. For diagnostic tests where there were more than 10 eligible studies, we initially planned to formally explore heterogeneity by using study level covariates, and to assess the sensitivity of results to the inclusion and exclusion of outlier studies in all analyses. However, we refrained from taking these steps because of the small numbers of studies in most analyses. It is important to use caution when interpreting small meta‐analyses (few studies) with a limited total sample size. </p> </section> <section id="CD012179-sec-0065"> <h4 class="title">Sensitivity analyses</h4> <p>We planned to conduct sensitivity analyses to assess the impact of the methodological quality of included studies on the results of any meta‐analyses if sufficient data were available. We defined low quality studies as those for which we identified a high risk of bias for one or more QUADAS‐2 domains. We also planned to use the 'leave‐one‐out' procedure (<a href="./references#CD012179-bbs2-0408" title="HigginsJPT . Commentary: Heterogeneity in meta‐analysis should be expected and appropriately quantified. [International Journal of Epidemiology]. Oxford Journals2008;37(7):1158‐60. ">Higgins 2008</a>) to assess the impact of each study on the meta‐analysis results (leading study effect). However, we could not undertake this action due to the paucity of studies evaluating each biomarker, except CA‐125. </p> </section> <section id="CD012179-sec-0066"> <h4 class="title">Assessment of reporting bias</h4> <p>A comprehensive search of multiple sources for eligible studies, a search of trial registers and no language restrictions minimised the risk of reporting bias. However, publication bias generally arises when studies have a higher chance of being published if their results are positive. Therefore we initially searched and evaluated unpublished and published study databases and conference proceedings. During the process of qualifying the studies for inclusion in this review, we faced substantial difficulty in obtaining full text publications or further details of studies published in an abstract form. This precluded a reliable assessment of eligibility and methodological quality, and we decided not to include these publication sources in this review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012179-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012179-sec-0067"></div> <section id="CD012179-sec-0068"> <h3 class="title" id="CD012179-sec-0068">Results of the search</h3> <p>The literature search identified 33,438 references in the following databases: CENTRAL (N = 226), MEDLINE (N = 10,328), EMBASE (N = 10,313), CINAHL (N = 1131), PsycINFO (N = 174), Web of Science (N = 7425), LILACS (N = 420), OAIster (N = 446), Trip (N = 1648), trial registers for ongoing and registered trials (N = 523), MEDION (N = 2), DARE (N = 99), PubMed, a 'systematic review' search (N = 418) and simple search (N = 267). We present the flow of the selection process in <a href="#CD012179-fig-0002">Figure 2</a>. We screened titles to exclude duplicates (N = 9312) and clearly irrelevant studies (N = 21,534). We eliminated a further 2212 references after reviewing the abstracts because they either did not address the research question or clearly did not meet the inclusion criteria. We retrieved the full texts of the remaining 376 records and assessed them for eligibility. Data from 86 studies required additional clarification from the authors, and we had 42 non‐English publications translated. Ultimately, 141 studies were eligible and provided data for the review, while we excluded 235 studies. We identified four ongoing trials through clinical trials registries (<a href="./references#CD012179-sec-0195" title="">Characteristics of ongoing studies</a>), but as trial outcomes were not available, we will address the progress of these studies in future updates. </p> <div class="figure" id="CD012179-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Flow of the studies identified in literature search for systematic review on imaging modalities for a non‐invasive diagnosis of endometriosis." data-id="CD012179-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow of the studies identified in literature search for systematic review on imaging modalities for a non‐invasive diagnosis of endometriosis. </p> </div> </div> </div> <section id="CD012179-sec-0069"> <h4 class="title">Basic features of the included studies</h4> <p>We present a list of the details of the included studies in '<a href="./references#CD012179-sec-0193" title="">Characteristics of included studies</a>'. The 141 eligible studies included 15,141 participants, with a median of 88 women per study (range 17 to 834). Of these studies, 70 estimated the diagnostic accuracy of blood biomarkers, 82 reported negative findings and 11 were in both groups. Seventy studies included enough data to estimate the diagnostic performance of an investigated test (N = 8716 participants, median 97, range 35 to 775 women). Each study evaluated one or several biomarkers, and some authors reported several estimates for the same biomarker at different menstrual cycle phases, different cut‐off thresholds or both. When this occurred, we considered every estimation to be a separate test; however, we did not combine the diagnostic data sets for the biomarker of interest in one meta‐analysis if obtained from the same or an overlapping cohort. Most studies reported diagnostic estimates for biomarkers that demonstrated differential expression between women with and without endometriosis, although in eight studies this assessment was undertaken for biomarkers that demonstrated no differential expression (<a href="./references#CD012179-bbs2-0026" title="FerreiraCA , CamargosAF . Assessement of serum concentration CA‐125 in the diagnosis of endometriosis [Avaliaçåo da dosagem do CA‐125 sérico no diagnóstico da endometriose]. Jornal Brasileiro de Gynecologia1994;104(9):311‐4. ">Ferreira 1994</a>; <a href="./references#CD012179-bbs2-0041" title="GurganT , KisnisciH , YaraliH , AksuT , ZeynelogluH , DeveliogluO . Serum and peritoneal fluid CA‐125 levels in early stage endometriosis. Gynecologic and Obstetric Investigation1990;30:105‐8. ">Gurgan 1990</a>; <a href="./references#CD012179-bbs2-0088" title="MoloMW , KellyM , RadwanskaE , BinorZ . Preoperative serum CA‐125 and CA‐72 in predicting endometriosis in infertility patients. Journal of Reproductive Medicine1994;39(12):964‐6. ">Molo 1994</a>; <a href="./references#CD012179-bbs2-0090" title="MuscatelloR , CucinelliF , FulghesuA , LanzoneA , CarusoA , MancusoS . Multiple serum marker assay in the diagnosis of endometriosis. Gynecological Endocrinology1992;6:265‐9. ">Muscatello 1992</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>; <a href="./references#CD012179-bbs2-0119" title="TokmakA , UgurM , TongucE , VarT , MoralogluO , OzaksitG . The value of urocortin and Ca‐125 in the diagnosis of endometrioma. Archives of Gynecology and Obstetrics2011;283(5):1075‐9. ">Tokmak 2011</a>; <a href="./references#CD012179-bbs2-0124" title="VigilPP , AglonyIM , KolbachRM , RubioAV , Villarroel Del PinoL . Endometriosis and CA 125 in women of reproductive age [Endometriosis y CA 125 en mujeres en edad reproductiva]. Revista Chilena de Obstetrica y Ginecologia1999; Vol. 64, issue 5:385‐8. ">Vigil 1999</a>; <a href="./references#CD012179-bbs2-0135" title="YangF , FangAH , GuRF . Value of CA125 (carbon hydrate tumor‐associated antigen) and endometrial antibodies for the detections of endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]1994;29(3):147‐149, 189. Chinese. ">Yang 1994</a>). Eighty‐two studies did not show any difference in the expression between the women with and without endometriosis, and they did not evaluate the diagnostic test accuracy of the blood biomarker (N = 7482 participants, median 73, range 17 to 834 women). This set of studies were methodologically eligible, but the biomarkers identified are unlikely to be of diagnostic utility and hence may not be worthy of further investigation. </p> <p>Seventy of the included studies took place in Europe, 31 in Asia, 17 in North America, 14 in South America, 5 in the Middle East, 2 in Australia and 2 in unspecified locations. Ninety‐five per cent (130/137) of the studies took place in university hospitals, of which at least 14 were referral centres for endometriosis. The earliest study was published in 1986, 107 studies were published after 2000, and 44 studies were published after 2010. All the included studies assessed women of reproductive age, and two focused exclusively on adolescent girls after menarche. All the studies were observational, mainly of cross‐sectional design. Seventy‐eight studies had a single‐gate design, where both cases and controls were from the same patient population. Of these, 57 studies included women with suspected endometriosis based on clinical presentation (women presenting with pelvic pain, infertility, ovarian mass or a combination of these), 10 studies included only women undergoing an infertility work‐up, eight studies included only a population with a persistent ovarian mass, two studies reported pelvic pain as a sole presenting symptom and one study evaluated asymptomatic women. Sixty‐one studies had a two‐gate design and included a wider group of participants who were undergoing surgery for various indications. Two studies presented insufficient information to determine whether they used a single‐ or two‐gate design. Laparoscopy was the predominant surgical modality in the included studies; surgeons used either laparoscopy or laparotomy in 29 studies, and three studies did not report information on the type of surgery. Seventy‐five of the included studies used histopathology to confirm the surgical diagnosis. </p> <p>Most of the studies (N = 123) evaluated pelvic endometriosis, 13 studies addressed only ovarian endometriosis, two studies focused on a combination of ovarian endometriosis and DIE, two studies looked only at peritoneal endometriosis, and one study considered only ultrasound‐negative endometriosis.The reported prevalence of endometriosis varied from 16% to 84%. Eleven studies included only participants with minimal‐mild endometriosis (rASRM stage I‐II), 15 studies included only participants with moderate‐severe endometriosis (rASRM stage III to IV), and eight studies did not report information regarding the severity of the disease. Fifty‐one studies received financial support, of which 8 reported funding by biotech or pharmaceutical companies. In six of the eight commercially supported studies, there was no statement regarding a conflict of interest. For the remaining two studies, one group of authors reported that most of the authors worked in the biotechnology industry, and one group had nothing to declare. Overall, the authors of 33 studies declared no conflict of interest, with five reporting that there was no financial support from any external source. Three groups reported conflicts of interest (employee of a biotech company, lecturing honorarium from pharmaceutical companies and not specified), and no information was available from the remaining studies. </p> </section> <section id="CD012179-sec-0070"> <h4 class="title">Basic features of the excluded studies</h4> <p>We present the list and descriptions of the excluded studies in '<a href="./references#CD012179-sec-0194" title="">Characteristics of excluded studies</a>'. Based on a full text assessment, we excluded 235 studies, of which 23 were retrospective with the blood samples being collected after the surgical procedure. A further 88 studies reported biomarker levels that were statistically significant when the study and control groups were compared, but they did not provide enough information for the construction of 2 x 2 contingency tables. Forty‐six of the excluded studies used a reference standard other than abdominal surgery and did not provide information regarding the surgical diagnosis. We excluded an additional 20 studies because they did not provide enough detail on the research methods, the study population or both to assess eligibility, and this information was not available from the authors. In 24 studies, the index test was outside the inclusion criteria, including comparisons between different types or stages of endometriosis without including a disease‐free group (N = 13); reports on biological events or technical aspects of the test without direct comparison of biomarker levels between the groups (N = 6); evaluations of a screening or predictive rather than a diagnostic test (N = 3); or use of male or umbilical cord samples as control group (N = 2). In nine studies, the population was outside the inclusion criteria because they enrolled postmenopausal women, pregnant women or women with genital tract malignancies, and an independent assessment of reproductive‐aged women without these conditions was not possible. We excluded a further nine studies as their population cohort overlapped with another updated, included study. In five of the excluded studies, the target condition was outside the inclusion criteria, comparing a benign versus malignant mass or normal versus abnormal pelvis without any independent data for endometriosis. We excluded three studies because they were review articles, and we were unable to locate the full text for another three studies. </p> </section> </section> <section id="CD012179-sec-0071"> <h3 class="title">Methodological quality of included studies</h3> <p>We illustrate the quality of the included studies in the QUADAS‐2 results summary (<a href="#CD012179-fig-0003">Figure 3</a>; <a href="#CD012179-fig-0004">Figure 4</a>). Overall, the studies were of poor methodological quality, and all studies had an unclear or high risk of bias in at least one domain. </p> <div class="figure" id="CD012179-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD012179-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012179-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <p>Thirteen studies presented a low risk of patient selection bias (<a href="./references#CD012179-bbs2-0013" title="ChenFP , SoongYK , LeeN , LoSK . The use of serum CA‐125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis. Acta Obstetricia et Gynecologica Scandinavica1998;77(6):665‐70. ">Chen 1998</a>; <a href="./references#CD012179-bbs2-0022" title="FairbanksF , AbraoMS , PodgaecS , DiasJAJr , deOliveiraRM , RizzoLV . Interleukin‐12 but not interleukin‐18 is associated with severe endometriosis. Fertility and Sterility2009;91(2):320‐4. ">Fairbanks 2009</a>; <a href="./references#CD012179-bbs2-0039" title="GuerrieroS , AjossaS , PaolettiAM , MaisV , AngiolucciM , MelisGB . Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma. Obstetrics and Gynecology1996;88(3):403‐7. ">Guerriero 1996a</a>; <a href="./references#CD012179-bbs2-0040" title="GuerrieroS , MaisV , AjossaS , PaolettiAM , AngiolucciM , MelisGB . Transvaginal ultrasonography combined with CA‐125 plasma levels in the diagnosis of endometrioma. Fertility and Sterility1996;65(2):293‐8. ">Guerriero 1996b</a>; <a href="./references#CD012179-bbs2-0065" title="KoninckxPR , MeulemanC , OosterlynckD , CornillieFJ . Diagnosis of deep endometriosis by clinical examination during menstruation and plasma CA‐125 concentration. Fertility and Sterility1996;65(2):280‐7. ">Koninckx 1996</a>; <a href="./references#CD012179-bbs2-0088" title="MoloMW , KellyM , RadwanskaE , BinorZ . Preoperative serum CA‐125 and CA‐72 in predicting endometriosis in infertility patients. Journal of Reproductive Medicine1994;39(12):964‐6. ">Molo 1994</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; <a href="./references#CD012179-bbs2-0102" title="RamosIML , PodgaecS , AbraoMS , deOliveiraR , BaracatEC . Evaluation of CA‐125 and soluble CD‐23 in patients with pelvic endometriosis: A case‐control study. Revista da Associacao Medica Brasileira2012;58(1):26‐32. ">Ramos 2012</a>; <a href="./references#CD012179-bbs2-0105" title="RosaE Silva ACJS , RosaE Silva JC , FerrianiRA . Serum CA‐125 in the diagnosis of endometriosis. International Journal of Gynaecology and Obstetrics2007;96(3):206‐7. ">Rosa E Silva 2007</a>; <a href="./references#CD012179-bbs2-0110" title="SomiglianaE , ViganoP , CandianiM , FelicettaI , DiBlasioAM , VignaliM . Use of serum‐soluble intercellular adhesion molecule‐1 as a new marker of endometriosis. Fertility &amp; Sterility2002;77(5):1028‐31. ">Somigliana 2002</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>; <a href="./references#CD012179-bbs2-0121" title="VercelliniP , DeBenedettiF , RossiE , ColomboA , TrespidiL , CrosignaniPG , et al. Tumor necrosis factor in plasma and peritoneal fluid of women with and without endometriosis. Gynecologic and Obstetric Investigation1993; Vol. 36, issue 1:39‐41. ">Vercellini 1993</a>; <a href="./references#CD012179-bbs2-0123" title="ViganoP , SomiglianaE , MatroneR , DubiniA , BarronC , VignaliM , et al. Serum leptin concentrations in endometriosis. Journal of Clinical Endocrinology and Metabolism2002;87(3):1085‐7. ">Vigano 2002</a>), 53 studies demonstrated an unclear risk, and 75 studies were assessed at high risk for this domain. Non‐consecutive or non‐random patient selection, utilisation of a two‐gate design for patient selection, the absence of a clear definition of inclusion/exclusion criteria and use of a highly selected group of women were the main reasons for a high risk assessment of bias. </p> <p>One study demonstrated a low risk of index test interpretation bias (<a href="./references#CD012179-bbs2-0100" title="PittawayDE , DouglasJW . Serum CA‐125 in women with endometriosis and chronic pelvic pain. Fertility and Sterility1989;51(1):68‐70. ">Pittaway 1989</a>), 14 studies demonstrated an unclear risk and 126 studies carried a high risk. A lack of clear pre‐specified criteria for a positive diagnosis and index test operators not being blind to the results of reference standard were the main reasons for a high risk assessment. We also assigned a high risk of bias for this domain to studies where the phase of menstrual cycle was not considered when interpreting the index test. This was considered an important criterion, since varying ovarian hormones across the cycle could influence biomarker expression and undermine the reliability of the results. Studies rarely reported the skill level of a test operator or the interobserver variability, both of which directly relate to test performance. As the positive index test criteria were variable between the studies and the index test protocols were not standardised, quality judgements for the index test were complex. </p> <p>Eighty‐six studies were at low risk of bias in the reference standard domain (<a href="./references#CD012179-bbs2-0002" title="AgicA , DjalaliS , WolflerMM , HalisG , DiedrichK , HornungD . Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reproductive Sciences2008;15(9):906‐11. ">Agic 2008</a>; <a href="./references#CD012179-bbs2-0006" title="BarbosaCP , SouzaAM , BiancoB , ChristofoliniD , BachFAM , LimaGR . Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. Sao Paulo Medical Journal = Revista Paulista de Medicina2009;127(6):342‐5. ">Barbosa 2009</a>; <a href="./references#CD012179-bbs2-0007" title="BarczE , RozewskaES , KaminskiP , DemkowU , BobrowskaK , MarianowskiL . Angiogenic activity and IL‐8 concentrations in peritoneal fluid and sera in endometriosis. International Journal of Gynaecology and Obstetrics2002;79(3):229‐35. ">Barcz 2002</a>; <a href="./references#CD012179-bbs2-0009" title="BilibioJP , SouzaCA , RodiniGP , AndreoliCG , GenroVK , deContoE , et al. Serum prolactin and CA‐125 levels as biomarkers of peritoneal endometriosis. Gynecologic and Obstetric Investigation2014;78(1):45‐52. ">Bilibio 2014</a>; <a href="./references#CD012179-bbs2-0010" title="BorkowskiJ , GmyrekGB , MadejJP , NowackiW , GoludaM , GabrysM , et al. Serum and peritoneal evaluation of vitamin D‐binding protein in women with endometriosis. Postepy Higieny i Medycyny Doswiadczalnej (Online)2008;62:103‐9. ">Borkowski 2008</a>; <a href="./references#CD012179-bbs2-0012" title="CaliennoC , TrioC , MontiB , IedaN , CorteseM , VariscoE . MCP‐1 and IL‐8 in serum and ectopic endometrium in women with endometriosis. Italian Journal of Gynaecology and Obstetrics2008;20(1):12‐8. ">Calienno 2008</a>; <a href="./references#CD012179-bbs2-0013" title="ChenFP , SoongYK , LeeN , LoSK . The use of serum CA‐125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis. Acta Obstetricia et Gynecologica Scandinavica1998;77(6):665‐70. ">Chen 1998</a>; <a href="./references#CD012179-bbs2-0014" title="ChoSH , OhYJ , NamA , KimHY , ParkJH , KimJH , et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. American Journal of Reproductive Immunology2007;58(6):497‐504. ">Cho 2007</a>; <a href="./references#CD012179-bbs2-0017" title="Dayangan SayanC , OzaksitMG , SarikayaE , Gun EryilmazO , MollamahmutogluL , DeveerR . Serum interleukin‐8, CA‐125 levels, neutrophil‐to‐lymphocyte ratios, and combined markers in the diagnosis of endometriosis. Turkish Journal of Medical Sciences2013;43(3):417‐23. ">Dayangan Sayan 2013</a>; <a href="./references#CD012179-bbs2-0018" title="DePlacidoG , AlviggiC , DiP , CarravettaC , MatareseG , LandinoG , et al. Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule‐1 in endometriosis: Relationship with stage and non‐pigmented peritoneal lesions. Human Reproduction1998;13(11):3206‐10. ">De Placido 1998</a>; <a href="./references#CD012179-bbs2-0019" title="Drosdzol‐CopA , Skrzypulec‐PlintaV . Selected cytokines and glycodelin A levels in serum and peritoneal fluid in girls with endometriosis. Journal of Obstetrics and Gynaecology Research2012;38(10):1245‐53. ">Drosdzol‐Cop 2012a</a>; <a href="./references#CD012179-bbs2-0020" title="Drosdzol‐CopA , Skrzypulec‐PlintaV , StojkoR . Serum and peritoneal fluid immunological markers in adolescent girls with chronic pelvic pain. Obstetrical &amp; Gynecological Survey2012;67(6):374‐81. ">Drosdzol‐Cop 2012b</a>; <a href="./references#CD012179-bbs2-0021" title="Elgafor el SharkwyIA . Combination of non‐invasive and semi‐invasive tests for diagnosis of minimal to mild endometriosis. Archives of Gynecology and Obstetrics2013;288(4):793‐7. ">Elgafor el Sharkwy 2013</a>; <a href="./references#CD012179-bbs2-0022" title="FairbanksF , AbraoMS , PodgaecS , DiasJAJr , deOliveiraRM , RizzoLV . Interleukin‐12 but not interleukin‐18 is associated with severe endometriosis. Fertility and Sterility2009;91(2):320‐4. ">Fairbanks 2009</a>; <a href="./references#CD012179-bbs2-0023" title="FassbenderA , D'HoogheT , MihalyiA , KyamaC , SimsaP , LesseyBA . Plasma C3a‐des‐Arg levels in women with and without endometriosis. American Journal of Reproductive Immunology2009;62(3):187‐95. ">Fassbender 2009</a>; <a href="./references#CD012179-bbs2-0024" title="FassbenderA , WaelkensE , VerbeeckN , KyamaCM , BokorA , VodolazkaiaA , et al. Proteomics analysis of plasma for early diagnosis of endometriosis. Obstetrics and Gynecology2012;119(2 Pt 1):276‐85. ">Fassbender 2012</a>; <a href="./references#CD012179-bbs2-0025" title="FedeleL , ArcainiL , VercelliniP , MarchiniM , BaglioniA , BianchiS . Serum Ca‐125 concentrations in endometriosis. Acta Europaea Fertilitatis1989;20(3):137‐9. ">Fedele 1989</a>; <a href="./references#CD012179-bbs2-0026" title="FerreiraCA , CamargosAF . Assessement of serum concentration CA‐125 in the diagnosis of endometriosis [Avaliaçåo da dosagem do CA‐125 sérico no diagnóstico da endometriose]. Jornal Brasileiro de Gynecologia1994;104(9):311‐4. ">Ferreira 1994</a>; <a href="./references#CD012179-bbs2-0027" title="FerreroS , GillottDJ , AnseriniP , RemorgidaV , PriceKM , RagniN , et al. Vitamin D binding protein in endometriosis. Journal of the Society for Gynecologic Investigation2005;12(4):272‐7. ">Ferrero 2005a</a>; <a href="./references#CD012179-bbs2-0028" title="FlorioP , ReisFM , TorresPB , CalonaciF , TotiP , BocchiC , et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstetrics and Gynecology2007;110(3):594‐600. ">Florio 2007</a>; <a href="./references#CD012179-bbs2-0029" title="FlorioP , ReisFM , TorresPB , CalonaciF , AbraoMS , NascimentoLL , et al. High serum follistatin levels in women with ovarian endometriosis. Human Reproduction2009;24(10):2600‐6. ">Florio 2009</a>; <a href="./references#CD012179-bbs2-0032" title="GagneD , RivardM , PageM , LepineM , PlatonC , ShazandK , et al. Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA‐125 levels. Fertility and Sterility2003; Vol. 80, issue 4:876‐85. ">Gagne 2003a</a>; <a href="./references#CD012179-bbs2-0033" title="GagneD , PageM , RobitailleG , HugoP , GosselinD . Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Human Reproduction2003;18(8):1674‐80. ">Gagne 2003b</a>; <a href="./references#CD012179-bbs2-0034" title="GazvaniMR , ChristmasS , QuenbyS , KirwanJ , JohnsonPM , KingslandCR . Peritoneal fluid concentrations of interleukin‐8 in women with endometriosis: relationship to stage of disease. Human Reproduction1998;13(7):1957‐61. ">Gazvani 1998</a>; <a href="./references#CD012179-bbs2-0035" title="GlitzC , SouzaCA , RodiniGP , GenroV , BilibioJP , SengerM , et al. Peritoneal and serum interleukin‐18 levels are not increased in women with minimum or mild endometriosis. Brazilian Journal of Medical and Biological Research2009;42(11):1039‐43. ">Glitz 2009</a>; <a href="./references#CD012179-bbs2-0036" title="GogaczM , WinklerI , Bojarska‐JunakA , TabarkiewiczJ , SemczukA , RechbergerT , et al. T regulatory lymphocytes in patients with endometriosis. Molecular Medicine Reports2014;10(2):1072‐6. ">Gogacz 2014</a>; <a href="./references#CD012179-bbs2-0039" title="GuerrieroS , AjossaS , PaolettiAM , MaisV , AngiolucciM , MelisGB . Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma. Obstetrics and Gynecology1996;88(3):403‐7. ">Guerriero 1996a</a>; <a href="./references#CD012179-bbs2-0040" title="GuerrieroS , MaisV , AjossaS , PaolettiAM , AngiolucciM , MelisGB . Transvaginal ultrasonography combined with CA‐125 plasma levels in the diagnosis of endometrioma. Fertility and Sterility1996;65(2):293‐8. ">Guerriero 1996b</a>; <a href="./references#CD012179-bbs2-0042" title="GurganT , BukulmezO , YaraliH , TanirM , AkyildizS . Serum and peritoneal fluid levels of IGF I and II and insulinlike growth binding protein‐3 in endometriosis. Journal of Reproductive Medicine1999;44:450‐4. ">Gurgan 1999</a>; <a href="./references#CD012179-bbs2-0043" title="HallamaaM , SuvitieP , HuhtinenK , MatomakiJ , PoutanenM , PerheentupaA . Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecologic Oncology2012;125(3):667‐72. ">Hallamaa 2012</a>; <a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0050" title="JeeBC , SuhCS , KimSH , MoonSY . Serum soluble CD163 and interleukin‐6 levels in women with ovarian endometriomas. Gynecologic and Obstetric Investigation2008;66(1):47‐52. ">Jee 2008</a>; <a href="./references#CD012179-bbs2-0051" title="JiaSZ , YangY , LangJ , SunP , LengJ . Plasma miR‐17‐5p, miR‐20a and miR‐22 are down‐regulated in women with endometriosis. Human Reproduction2013;28(2):322‐30. ">Jia 2013</a>; <a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>; <a href="./references#CD012179-bbs2-0054" title="KhanKN , MasuzakiH , FujishitaA , KitajimaM , HirakiK , MiuraS , et al. Peritoneal fluid and serum levels of hepatocyte growth factor may predict the activity of endometriosis. Acta Obstetricia et Gynecologica Scandinavica2006;85(4):458‐66. ">Khan 2006</a>; <a href="./references#CD012179-bbs2-0055" title="KhanKN , KitajimaM , YamaguchiN , FujishitaA , NakashimaM , IshimaruT , et al. Role of prostaglandin E2 in bacterial growth in women with endometriosis. Human Reproduction2012;27(12):3417‐24. ">Khan 2012</a>; <a href="./references#CD012179-bbs2-0056" title="KhanKN , KitajimaM , InoueT , TateishiS , FujishitaA , NakashimaM , et al. Additive effects of inflammation and stress reaction on Toll‐like receptor 4‐mediated growth of endometriotic stromal cells. Human Reproduction2013;28(10):2794‐803. ">Khan 2013</a>; <a href="./references#CD012179-bbs2-0057" title="KhanakiK , NouriM , ArdekaniAM , GhassemzadehA , ShahnaziV , SadeghiMR , et al. Evaluation of the relationship between endometriosis and omega‐3 and omega‐6 polyunsaturated fatty acids. Iranian Biomedical Journal2012;16(1):38‐43. ">Khanaki 2012</a>; <a href="./references#CD012179-bbs2-0060" title="KimJY , KimH , SuhCS , KimSH , ChoiYM , KimJG . The G(‐2518)A polymorphism of monocyte chemotactic protein‐1 (MCP‐1) and its serum and peritoneal fluid levels in Korean women with endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;139(1):106‐10. ">Kim 2008</a>; <a href="./references#CD012179-bbs2-0061" title="KitawakiJ , IshiharaH , KoshibaH , KiyomizuM , TeramotoM , KitaokaY . Usefulness and limits of CA‐125 in diagnosis of endometriosis without associated ovarian endometriomas. Human Reproduction2005;20(7):1999‐2003. ">Kitawaki 2005</a>; <a href="./references#CD012179-bbs2-0062" title="KocbekV , VoukK , MuellerMD , RiznerTL , BersingerNA . Elevated glycodelin‐A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology2013;29(5):455‐9. ">Kocbek 2013</a>; <a href="./references#CD012179-bbs2-0063" title="KocbekV , BersingerNA , BrglezV , MuellerMD , PetanT , RiznerTL . Phospholipase A2 group IIA is elevated in endometriomas but not inperitoneal fluid and serum of ovarian endometriosis patients. Gynecological Endocrinology2014;31(3):214‐8. ">Kocbek 2014a</a>; <a href="./references#CD012179-bbs2-0064" title="KocbekV , Hevir‐KeneN , BersingerNA , MuellerMD , RiznerTL . Increased levels of biglycan in endometriomas and peritoneal fluid samples from ovarian endometriosis patients. Gynecological Endocrinology2014;30(7):520‐4. ">Kocbek 2014b</a>; <a href="./references#CD012179-bbs2-0066" title="KubatovaA , ErdemA , ErdemM , FiratMutluM , KorucuogluU . Serum cytokine and growth factor levels in patients with endometriosis. Central‐European Journal of Immunology2013;38(4):500‐4. ">Kubatova 2013</a>; <a href="./references#CD012179-bbs2-0067" title="KuesselL , Jaeger‐LanskyA , PateiskyP , RossbergN , SchulzA , SchmitzAA , et al. Cytokeratin‐19 as a biomarker in urine and in serum for the diagnosis of endometriosis ‐ a prospective study. Gynecological Endocrinology2014;30(1):38‐41. ">Kuessel 2014</a>; <a href="./references#CD012179-bbs2-0068" title="KurdogluZ , GursoyR , KurdogluM , ErdemM , ErdemO , ErdemA . Comparison of the clinical value of CA 19‐9 versus CA 125 for the diagnosis of endometriosis. Fertility and Sterility2009;92(5):1761‐3. ">Kurdoglu 2009</a>; <a href="./references#CD012179-bbs2-0069" title="LambrinoudakiIV , AugouleaA , ChristodoulakosGE , EconomouEV , KaparosG , KontoravdisA , et al. Measurable serum markers of oxidative stress response in women with endometriosis. Fertility and Sterility2009;91(1):46‐50. ">Lambrinoudaki 2009</a>; <a href="./references#CD012179-bbs2-0072" title="LiJX , DaiSZ , LiuH , CaoYM , LiuSQ . Study on the changes of T‐lymphocyte subsets in the patients with endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]2005;40(1):17‐20. Chinese. ">Li 2005</a>; <a href="./references#CD012179-bbs2-0074" title="LinJ , ZhangXM , DengL , ChenZY , ChenL . Determination of interleukine‐16 levels in peritoneal fluid and serum of women with endometriosis. Zhejiang Daxue Xuebao (Yixueban) [Journal of Zhejiang University (Medical Sciences)]2005;34(3):260‐2. Chinese. ">Lin 2005</a>; <a href="./references#CD012179-bbs2-0076" title="MabroukM , ElmakkyA , CaramelliE , FarinaA , MignemiG , VenturoliS , et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Archives of Gynecology and Obstetrics2012;285(5):1307‐12. ">Mabrouk 2012</a>; <a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>; <a href="./references#CD012179-bbs2-0087" title="MohamedML , ElBeheryMM , MansourSAEA . Comparative study between VEGF‐A and CA‐125 in diagnosis and follow‐up of advanced endometriosis after conservative laparoscopic surgery. Archives of Gynecology and Obstetrics2013;287(1):77‐82. ">Mohamed 2013</a>; <a href="./references#CD012179-bbs2-0091" title="OdukoyaO , BansalA , CookeI . Serum endometrial IgG antibodies and soluble CD23 concentrations in patients with endometriosis. Acta Obstetricia et Gynecologica Scandinavica1996;75(10):927‐31. ">Odukoya 1996</a>; <a href="./references#CD012179-bbs2-0092" title="OhataY , HaradaT , MiyakodaH , TaniguchiF , IwabeT , TerakawaN . Serum interleukin‐8 levels are elevated in patients with ovarian endometrioma. Fertility and Sterility2008;90(4):994‐9. ">Ohata 2008</a>; <a href="./references#CD012179-bbs2-0094" title="Olkowska‐TruchanowiczJ , BocianK , MaksymRB , BialoszewskaA , WlodarczykD , BaranowskiW , et al. CD4+ CD25+ FOXP3+ regulatory T cells in peripheral blood and peritoneal fluid of patients with endometriosis. Human Reproduction2013;28(1):119‐24. ">Olkowska‐Truchanowicz 2013</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; <a href="./references#CD012179-bbs2-0098" title="PattonPE , FieldCS , HarmsRW , CoulamCB . CA‐125 levels in endometriosis. Fertility and Sterility1986;45(6):770‐3. ">Patton 1986</a>; <a href="./references#CD012179-bbs2-0099" title="PhilippoussisF , GagneD , HugoP , GosselinD . Concentrations of alpha‐fetoprotein, insulin‐like growth factor binding protein‐3, c‐erbB‐2, and epidermal growth factor in serum of patients with endometriosis. Journal of the Society for Gynecologic Investigation2004;11(3):175‐81. ">Philippoussis 2004</a>; <a href="./references#CD012179-bbs2-0100" title="PittawayDE , DouglasJW . Serum CA‐125 in women with endometriosis and chronic pelvic pain. Fertility and Sterility1989;51(1):68‐70. ">Pittaway 1989</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; <a href="./references#CD012179-bbs2-0102" title="RamosIML , PodgaecS , AbraoMS , deOliveiraR , BaracatEC . Evaluation of CA‐125 and soluble CD‐23 in patients with pelvic endometriosis: A case‐control study. Revista da Associacao Medica Brasileira2012;58(1):26‐32. ">Ramos 2012</a>; <a href="./references#CD012179-bbs2-0106" title="RosaESJC , Do AmaraVF , MendoncaJL , RosaESACJDS , NakaoLS , NetoOBP , et al. Serum markers of oxidative stress and endometriosis. Clinical and Experimental Obstetrics &amp; Gynecology2014;41(4):371‐4. ">Rosa E Silva 2014</a>; <a href="./references#CD012179-bbs2-0107" title="SalehpourS , SeneAA , MehrjerdiEK , AkhoondMR . The correlation between serum and peritoneal fluid CA125 level in women with pelvic endometriosis. International Journal of Fertility &amp; Sterility2009;3(1):29‐34. ">Salehpour 2009</a>; <a href="./references#CD012179-bbs2-0110" title="SomiglianaE , ViganoP , CandianiM , FelicettaI , DiBlasioAM , VignaliM . Use of serum‐soluble intercellular adhesion molecule‐1 as a new marker of endometriosis. Fertility &amp; Sterility2002;77(5):1028‐31. ">Somigliana 2002</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>; <a href="./references#CD012179-bbs2-0115" title="SzczepanskaM , MikolajczykM , RaczynskaP , SkrzypczakJ . The evaluation of IL‐12 levels in peritoneal fluid and serum of women with endometriosis. Ginekologia Polska2001;72(5):408‐17. ">Szczepanska 2001b</a>; <a href="./references#CD012179-bbs2-0116" title="SzubertM , SuzinJ , WierzbowskiT , Kowalczyk‐AmicoK . CA‐125 concentration in serum and peritoneal fluid in patients with endometriosis ‐ preliminary results. Archives of Medical Science2012;8(3):504‐8. ">Szubert 2012</a>; <a href="./references#CD012179-bbs2-0118" title="ThubertT , SantulliP , MarcellinL , MenardS , M'BayeM , StreuliI , et al. Measurement of hs‐CRP is irrelevant to diagnose and stage endometriosis: prospective study of 834 patients. American Journal of Obstetrics and Gynecology2014;210(6):533 e1‐e10. ">Thubert 2014</a>; <a href="./references#CD012179-bbs2-0119" title="TokmakA , UgurM , TongucE , VarT , MoralogluO , OzaksitG . The value of urocortin and Ca‐125 in the diagnosis of endometrioma. Archives of Gynecology and Obstetrics2011;283(5):1075‐9. ">Tokmak 2011</a>; <a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a</a>; <a href="./references#CD012179-bbs2-0123" title="ViganoP , SomiglianaE , MatroneR , DubiniA , BarronC , VignaliM , et al. Serum leptin concentrations in endometriosis. Journal of Clinical Endocrinology and Metabolism2002;87(3):1085‐7. ">Vigano 2002</a>; <a href="./references#CD012179-bbs2-0125" title="VodolazkaiaA , BossuytX , FassbenderA , KyamaCM , MeulemanC , PeeraerK , et al. A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis. Reproductive Biology and Endocrinology2011;9:113. ">Vodolazkaia 2011</a>; <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>; <a href="./references#CD012179-bbs2-0127" title="VoukK , HevirN , Ribic‐PuceljM , HaarpaintnerG , ScherbH , OsredkarJ , et al. Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Human Reproduction2012;27(10):2955‐65. ">Vouk 2012</a>; <a href="./references#CD012179-bbs2-0128" title="WangWT , ZhaoYN , HanBW , HongSJ , ChenYQ , WangX , et al. Circulating microRNAs identified in a genome‐wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis [Study on polymorphism of human leukocyte antigen I in patients with endometriosis]. Journal of Clinical Endocrinology and Metabolism2013;98(1):281‐9. ">Wang 2013a</a>; <a href="./references#CD012179-bbs2-0129" title="WebsterKE , KennedySH , BeckerCM . Levels of circulating angiogenic cells are not altered in women with endometriosis. Human Reproduction2013;28(3):651‐7. ">Webster 2013</a>; <a href="./references#CD012179-bbs2-0130" title="WeiXQ , ZhangY , TangM . Leptin levels and infertile patients with endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(4):487‐8. Chinese. ">Wei 2005</a>; <a href="./references#CD012179-bbs2-0131" title="WildRA , HirisaveV , BiancoA , PodczaskiES , DemersLM . Endometrial antibodies versus CA‐125 for the detection of endometriosis. Fertility and Sterility1991;55(1):90‐4. ">Wild 1991a</a>; <a href="./references#CD012179-bbs2-0132" title="WolflerMM , SchwambornK , OttenD , HornungD , LiuHY , RathW . Mass spectrometry and serum pattern profiling for analyzing the individual risk for endometriosis: promising insights?. Fertility and Sterility2009;91(6):2331‐7. ">Wolfler 2009</a>; <a href="./references#CD012179-bbs2-0134" title="YagmurE , BastuE , Karamustafaoglu‐BalciB , AkhanSE , BuyruF . Non‐invasive diagnosis of endometriosis based on a combined analysis of four plasma biomarkers. Central‐European Journal of Immunology2013;38(2):154‐8. ">Yagmur 2013</a>; <a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>; <a href="./references#CD012179-bbs2-0138" title="ZhangX , LinJ , DengL , ChenZ , ChenL . Peritoneal fluid and serum concentration of interleukin‐16 in women with endometriosis. Acta Obstetricia et Gynecologica Scandinavica2005;84(3):297‐8. ">Zhang 2005a</a>; <a href="./references#CD012179-bbs2-0139" title="ZhangY , PengLX , MengL . Measurements of interleukin‐18 in peritoneal fluid and serum of patients with endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(6):731‐2. Chinese. ">Zhang 2005b</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; <a href="./references#CD012179-bbs2-0141" title="ZhangR , LuoR . Soluble intercellular adhesion molecule 1 in serum and peritoneal fluid on patients with endometriosis. Wuhan Yike Daxue Xuebao (Yixueban) [Medical Journal of Wuhan University]2006;27(1):97‐9. Chinese. ">Zhang 2006b</a>), while the rest (N = 55) were at unclear risk. No studies demonstrated a high risk. We assigned an unclear risk of bias if there was not enough information to assess how likely the reference standard was to have correctly classified the target condition. This could occur when authors did not adequately describe surgical procedures, state the positive reference standard criteria, clarify whether they used histology to confirm the surgical diagnosis or provide information regarding the expertise of the surgeons and pathologists involved. </p> <p>One hundred and ten studies presented a low risk of bias in the flow and timing domain (<a href="./references#CD012179-bbs2-0001" title="AcienP , ShawRW , IrvineL , BurfordG , GardnerR . CA 125 levels in endometriosis patients before, during and after treatment with danazol or LHRH agonists. European Journal of Obstetrics, Gynecology, and Reproductive Biology1989;32(3):241‐6. ">Acien 1989</a>; <a href="./references#CD012179-bbs2-0002" title="AgicA , DjalaliS , WolflerMM , HalisG , DiedrichK , HornungD . Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reproductive Sciences2008;15(9):906‐11. ">Agic 2008</a>; <a href="./references#CD012179-bbs2-0003" title="AkoumA , LemayA , McCollSR , ParadisI , MaheuxR . Increased monocyte chemotactic protein‐1 level and activity in the peripheral blood of women with endometriosis. Le Groupe d'Investigation en Gynecologie. American Journal of Obstetrics and Gynecology1996;175(6):1620‐5. ">Akoum 1996</a>; <a href="./references#CD012179-bbs2-0004" title="AndreoliCG , GenroVK , SouzaCA , MichelonT , BilibioJP , ScheffelC , et al. T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertility and Sterility2011;95(8):2477‐80. ">Andreoli 2011</a>; <a href="./references#CD012179-bbs2-0005" title="BarbatiA , CosmiEV , SpazianiR , VenturaR , MontaninoG . Serum and peritoneal fluid CA‐125 levels in patients with endometriosis. Fertility and Sterility1994;61(3):438‐42. ">Barbati 1994</a>; <a href="./references#CD012179-bbs2-0006" title="BarbosaCP , SouzaAM , BiancoB , ChristofoliniD , BachFAM , LimaGR . Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. Sao Paulo Medical Journal = Revista Paulista de Medicina2009;127(6):342‐5. ">Barbosa 2009</a>; <a href="./references#CD012179-bbs2-0009" title="BilibioJP , SouzaCA , RodiniGP , AndreoliCG , GenroVK , deContoE , et al. Serum prolactin and CA‐125 levels as biomarkers of peritoneal endometriosis. Gynecologic and Obstetric Investigation2014;78(1):45‐52. ">Bilibio 2014</a>; <a href="./references#CD012179-bbs2-0010" title="BorkowskiJ , GmyrekGB , MadejJP , NowackiW , GoludaM , GabrysM , et al. Serum and peritoneal evaluation of vitamin D‐binding protein in women with endometriosis. Postepy Higieny i Medycyny Doswiadczalnej (Online)2008;62:103‐9. ">Borkowski 2008</a>; <a href="./references#CD012179-bbs2-0011" title="BraunDP , GebelH , HouseR , RanaN , DmowskiWP . Spontaneous and induced synthesis of cytokines by peripheral blood monocytes in patients with endometriosis. Fertility and Sterility1996;65(6):1125‐9. ">Braun 1996</a>; <a href="./references#CD012179-bbs2-0012" title="CaliennoC , TrioC , MontiB , IedaN , CorteseM , VariscoE . MCP‐1 and IL‐8 in serum and ectopic endometrium in women with endometriosis. Italian Journal of Gynaecology and Obstetrics2008;20(1):12‐8. ">Calienno 2008</a>; <a href="./references#CD012179-bbs2-0013" title="ChenFP , SoongYK , LeeN , LoSK . The use of serum CA‐125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis. Acta Obstetricia et Gynecologica Scandinavica1998;77(6):665‐70. ">Chen 1998</a>; <a href="./references#CD012179-bbs2-0014" title="ChoSH , OhYJ , NamA , KimHY , ParkJH , KimJH , et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. American Journal of Reproductive Immunology2007;58(6):497‐504. ">Cho 2007</a>; <a href="./references#CD012179-bbs2-0015" title="ColacurciN , FortunatoN , DeFranciscisP , CardoneA . Relevance of CA‐125 in the evaluation of endometriosis. Clinical and Experimental Obstetrics &amp; Gynecology1996;23(3):150‐4. ">Colacurci 1996a</a>; <a href="./references#CD012179-bbs2-0018" title="DePlacidoG , AlviggiC , DiP , CarravettaC , MatareseG , LandinoG , et al. Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule‐1 in endometriosis: Relationship with stage and non‐pigmented peritoneal lesions. Human Reproduction1998;13(11):3206‐10. ">De Placido 1998</a>; <a href="./references#CD012179-bbs2-0019" title="Drosdzol‐CopA , Skrzypulec‐PlintaV . Selected cytokines and glycodelin A levels in serum and peritoneal fluid in girls with endometriosis. Journal of Obstetrics and Gynaecology Research2012;38(10):1245‐53. ">Drosdzol‐Cop 2012a</a>; <a href="./references#CD012179-bbs2-0020" title="Drosdzol‐CopA , Skrzypulec‐PlintaV , StojkoR . Serum and peritoneal fluid immunological markers in adolescent girls with chronic pelvic pain. Obstetrical &amp; Gynecological Survey2012;67(6):374‐81. ">Drosdzol‐Cop 2012b</a>; <a href="./references#CD012179-bbs2-0022" title="FairbanksF , AbraoMS , PodgaecS , DiasJAJr , deOliveiraRM , RizzoLV . Interleukin‐12 but not interleukin‐18 is associated with severe endometriosis. Fertility and Sterility2009;91(2):320‐4. ">Fairbanks 2009</a>; <a href="./references#CD012179-bbs2-0023" title="FassbenderA , D'HoogheT , MihalyiA , KyamaC , SimsaP , LesseyBA . Plasma C3a‐des‐Arg levels in women with and without endometriosis. American Journal of Reproductive Immunology2009;62(3):187‐95. ">Fassbender 2009</a>; <a href="./references#CD012179-bbs2-0024" title="FassbenderA , WaelkensE , VerbeeckN , KyamaCM , BokorA , VodolazkaiaA , et al. Proteomics analysis of plasma for early diagnosis of endometriosis. Obstetrics and Gynecology2012;119(2 Pt 1):276‐85. ">Fassbender 2012</a>; <a href="./references#CD012179-bbs2-0026" title="FerreiraCA , CamargosAF . Assessement of serum concentration CA‐125 in the diagnosis of endometriosis [Avaliaçåo da dosagem do CA‐125 sérico no diagnóstico da endometriose]. Jornal Brasileiro de Gynecologia1994;104(9):311‐4. ">Ferreira 1994</a>; <a href="./references#CD012179-bbs2-0027" title="FerreroS , GillottDJ , AnseriniP , RemorgidaV , PriceKM , RagniN , et al. Vitamin D binding protein in endometriosis. Journal of the Society for Gynecologic Investigation2005;12(4):272‐7. ">Ferrero 2005a</a>; <a href="./references#CD012179-bbs2-0028" title="FlorioP , ReisFM , TorresPB , CalonaciF , TotiP , BocchiC , et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstetrics and Gynecology2007;110(3):594‐600. ">Florio 2007</a>; <a href="./references#CD012179-bbs2-0029" title="FlorioP , ReisFM , TorresPB , CalonaciF , AbraoMS , NascimentoLL , et al. High serum follistatin levels in women with ovarian endometriosis. Human Reproduction2009;24(10):2600‐6. ">Florio 2009</a>; <a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>; <a href="./references#CD012179-bbs2-0032" title="GagneD , RivardM , PageM , LepineM , PlatonC , ShazandK , et al. Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA‐125 levels. Fertility and Sterility2003; Vol. 80, issue 4:876‐85. ">Gagne 2003a</a>; <a href="./references#CD012179-bbs2-0033" title="GagneD , PageM , RobitailleG , HugoP , GosselinD . Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Human Reproduction2003;18(8):1674‐80. ">Gagne 2003b</a>; <a href="./references#CD012179-bbs2-0035" title="GlitzC , SouzaCA , RodiniGP , GenroV , BilibioJP , SengerM , et al. Peritoneal and serum interleukin‐18 levels are not increased in women with minimum or mild endometriosis. Brazilian Journal of Medical and Biological Research2009;42(11):1039‐43. ">Glitz 2009</a>; <a href="./references#CD012179-bbs2-0036" title="GogaczM , WinklerI , Bojarska‐JunakA , TabarkiewiczJ , SemczukA , RechbergerT , et al. T regulatory lymphocytes in patients with endometriosis. Molecular Medicine Reports2014;10(2):1072‐6. ">Gogacz 2014</a>; <a href="./references#CD012179-bbs2-0037" title="GoludaM , KuliczkowskiK , JedrykaM . The concentration of exfoliative adhesion molecules (ICAM‐1 and E‐Selectin) in serum and peritoneal fluid of women with endometriosis. Ginekologia Polska1998;69(12):1175‐8. ">Goluda 1998</a>; <a href="./references#CD012179-bbs2-0038" title="GoraiI , IshikawaM , OnoseR , HiraharaF , MinaguchiH . Antiendometrial autoantibodies are generated in patients with endometriosis. American Journal of Reproductive Immunology1993;29(2):116‐23. ">Gorai 1993</a>; <a href="./references#CD012179-bbs2-0039" title="GuerrieroS , AjossaS , PaolettiAM , MaisV , AngiolucciM , MelisGB . Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma. Obstetrics and Gynecology1996;88(3):403‐7. ">Guerriero 1996a</a>; <a href="./references#CD012179-bbs2-0040" title="GuerrieroS , MaisV , AjossaS , PaolettiAM , AngiolucciM , MelisGB . Transvaginal ultrasonography combined with CA‐125 plasma levels in the diagnosis of endometrioma. Fertility and Sterility1996;65(2):293‐8. ">Guerriero 1996b</a>; <a href="./references#CD012179-bbs2-0041" title="GurganT , KisnisciH , YaraliH , AksuT , ZeynelogluH , DeveliogluO . Serum and peritoneal fluid CA‐125 levels in early stage endometriosis. Gynecologic and Obstetric Investigation1990;30:105‐8. ">Gurgan 1990</a>; <a href="./references#CD012179-bbs2-0042" title="GurganT , BukulmezO , YaraliH , TanirM , AkyildizS . Serum and peritoneal fluid levels of IGF I and II and insulinlike growth binding protein‐3 in endometriosis. Journal of Reproductive Medicine1999;44:450‐4. ">Gurgan 1999</a>; <a href="./references#CD012179-bbs2-0043" title="HallamaaM , SuvitieP , HuhtinenK , MatomakiJ , PoutanenM , PerheentupaA . Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecologic Oncology2012;125(3):667‐72. ">Hallamaa 2012</a>; <a href="./references#CD012179-bbs2-0045" title="HaradaT , KubotaT , AsoT . Usefulness of CA19‐9 versus CA125 for the diagnosis of endometriosis. Fertility and Sterility2002;78(4):733‐9. ">Harada 2002</a>; <a href="./references#CD012179-bbs2-0047" title="HornsteinMD , HarlowBL , ThomasPP , CheckJH . Use of a new CA 125 assay in the diagnosis of endometriosis. Human Reproduction1995;10(4):932‐4. ">Hornstein 1995</a>; <a href="./references#CD012179-bbs2-0049" title="IwasakiK , MakinoT , MaruyamaT , MatsubayashiH , NozawaS , YokokuraT . Leukocyte subpopulations and natural killer activity in endometriosis. International Journal of Fertility and Menopausal Studies1993;38(4):229‐34. ">Iwasaki 1993</a>; <a href="./references#CD012179-bbs2-0050" title="JeeBC , SuhCS , KimSH , MoonSY . Serum soluble CD163 and interleukin‐6 levels in women with ovarian endometriomas. Gynecologic and Obstetric Investigation2008;66(1):47‐52. ">Jee 2008</a>; <a href="./references#CD012179-bbs2-0051" title="JiaSZ , YangY , LangJ , SunP , LengJ . Plasma miR‐17‐5p, miR‐20a and miR‐22 are down‐regulated in women with endometriosis. Human Reproduction2013;28(2):322‐30. ">Jia 2013</a>; <a href="./references#CD012179-bbs2-0057" title="KhanakiK , NouriM , ArdekaniAM , GhassemzadehA , ShahnaziV , SadeghiMR , et al. Evaluation of the relationship between endometriosis and omega‐3 and omega‐6 polyunsaturated fatty acids. Iranian Biomedical Journal2012;16(1):38‐43. ">Khanaki 2012</a>; <a href="./references#CD012179-bbs2-0058" title="KianpourM , NematbakhshM , AhmadiSM . C‐reactive protein of serum and peritoneal fluid in endometriosis. Iranian Journal of Nursing and Midwifery Research2012;17(2 Suppl 1):S115‐9. ">Kianpour 2012</a>; <a href="./references#CD012179-bbs2-0059" title="KianpourM , NematbakhshM , AhmadiSM , JafarzadehM , HajjarianM , PezeshkiZ , et al. Serum and peritoneal fluid levels of vascular endothelial growth factor in women with endometriosis. International Journal of Fertility &amp; Sterility2013;7(2):96‐9. ">Kianpour 2013</a>; <a href="./references#CD012179-bbs2-0061" title="KitawakiJ , IshiharaH , KoshibaH , KiyomizuM , TeramotoM , KitaokaY . Usefulness and limits of CA‐125 in diagnosis of endometriosis without associated ovarian endometriomas. Human Reproduction2005;20(7):1999‐2003. ">Kitawaki 2005</a>; <a href="./references#CD012179-bbs2-0062" title="KocbekV , VoukK , MuellerMD , RiznerTL , BersingerNA . Elevated glycodelin‐A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology2013;29(5):455‐9. ">Kocbek 2013</a>; <a href="./references#CD012179-bbs2-0066" title="KubatovaA , ErdemA , ErdemM , FiratMutluM , KorucuogluU . Serum cytokine and growth factor levels in patients with endometriosis. Central‐European Journal of Immunology2013;38(4):500‐4. ">Kubatova 2013</a>; <a href="./references#CD012179-bbs2-0067" title="KuesselL , Jaeger‐LanskyA , PateiskyP , RossbergN , SchulzA , SchmitzAA , et al. Cytokeratin‐19 as a biomarker in urine and in serum for the diagnosis of endometriosis ‐ a prospective study. Gynecological Endocrinology2014;30(1):38‐41. ">Kuessel 2014</a>; <a href="./references#CD012179-bbs2-0069" title="LambrinoudakiIV , AugouleaA , ChristodoulakosGE , EconomouEV , KaparosG , KontoravdisA , et al. Measurable serum markers of oxidative stress response in women with endometriosis. Fertility and Sterility2009;91(1):46‐50. ">Lambrinoudaki 2009</a>; <a href="./references#CD012179-bbs2-0072" title="LiJX , DaiSZ , LiuH , CaoYM , LiuSQ . Study on the changes of T‐lymphocyte subsets in the patients with endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]2005;40(1):17‐20. Chinese. ">Li 2005</a>; <a href="./references#CD012179-bbs2-0073" title="LimaAP , RosaE Silva AAM , MouraMD . FSH, LH, estradiol, progesterone, and histamine concentrations in serum, peritoneal fluid and follicular fluid of women with and without endometriosis [Concentrações de FSH, LH, estradiol, progesterona e histamina no soro, no fluido peritoneal e no fluido folicular de mulheres com e sem endometriose]. Revista Brasileira de Ginecologia e Obstetrica2006;28(11):643‐51. ">Lima 2006</a>; <a href="./references#CD012179-bbs2-0074" title="LinJ , ZhangXM , DengL , ChenZY , ChenL . Determination of interleukine‐16 levels in peritoneal fluid and serum of women with endometriosis. Zhejiang Daxue Xuebao (Yixueban) [Journal of Zhejiang University (Medical Sciences)]2005;34(3):260‐2. Chinese. ">Lin 2005</a>; <a href="./references#CD012179-bbs2-0075" title="LiuHY , ZhengYH , ZhangJZ , LengJH , SunDW , LiuZF , et al. Establishment of endometriosis diagnostic model using plasma protein profiling. Chung‐Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics and Gynecology]2009;44(8):601‐4. Chinese. ">Liu 2009</a>; <a href="./references#CD012179-bbs2-0076" title="MabroukM , ElmakkyA , CaramelliE , FarinaA , MignemiG , VenturoliS , et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Archives of Gynecology and Obstetrics2012;285(5):1307‐12. ">Mabrouk 2012</a>; <a href="./references#CD012179-bbs2-0077" title="MaedaN , IzumiyaC , OguriH , KusumeT , YamamotoY , FukayaT . Aberrant expression of intercellular adhesion molecule‐1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertility and Sterility2002;77(4):679‐83. ">Maeda 2002a</a>; <a href="./references#CD012179-bbs2-0078" title="MaedaN , IzumiyaC , YamamotoY , OguriH , KusumeT , FukayaT . Increased killer inhibitory receptor KIR2DL1 expression among natural killer cells in women with pelvic endometriosis. Fertility and Sterility2002;77(2):297‐302. ">Maeda 2002b</a>; <a href="./references#CD012179-bbs2-0079" title="MaioranaA , CiceroneC , NicetaA , AllioL . Evaluation of serum CA 125 levels in patients with pelvic pain related to endometriosis. International Journal of Biological Markers2007;22:200‐2. ">Maiorana 2007</a>; <a href="./references#CD012179-bbs2-0080" title="MarkhamR , FraserIS , SongJY , YoungL , ChullapramT . Blood and peritoneal fluid concentrations of TNFalpha and RANTES in patients with and without endometriosis. Australian Journal of Medical Science1997;18(4):116‐8. ">Markham 1997a</a>; <a href="./references#CD012179-bbs2-0081" title="MartinezS , GarridoN , CoperiasJL , PardoF , DescoJ , Garcia‐VelascoJA , et al. Serum interleukin‐6 levels are elevated in women with minimal‐mild endometriosis. Human Reproduction2007;22(3):836‐42. ">Martinez 2007</a>; <a href="./references#CD012179-bbs2-0082" title="MatalliotakisIM , GoumenouAG , KoumantakisGE , NeonakiMA , KoumantakisEE , DionyssopoulouE , et al. Serum concentrations of growth factors in women with and without endometriosis: the action of anti‐endometriosis medicines. International Immunopharmacology2003;3(1):81‐9. ">Matalliotakis 2003a</a>; <a href="./references#CD012179-bbs2-0083" title="MatalliotakisIM , AriciA , GoumenouAG , KatassosT , KarkavitsasN , KoumantakisEE . Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA‐125 levels in women with endometriosis. International Journal of Fertility and Women's Medicine2004;49(2):75‐8. ">Matalliotakis 2004</a>; <a href="./references#CD012179-bbs2-0084" title="MatveevaNK , VolkovNI , PetrenkoEP , Mit'kinVV , PshenichnikovaTI , SukhikhGT . Immunological studies of peripheral blood in patients with external genital endometriosis and infertility. Akusherstvo i Ginekologiia1990;8:48‐51. ">Matveeva 1990</a>; <a href="./references#CD012179-bbs2-0085" title="Mier‐CabreraJ , Jimenez‐ZamudioL , Garcia‐LatorreE , Cruz‐OrozcoO , Hernandez‐GuerreroC . Quantitative and qualitative peritoneal immune profiles, T‐cell apoptosis and oxidative stress‐associated characteristics in women with minimal and mild endometriosis. BJOG: An International Journal of Obstetrics and Gynaecology2011;118(1):6‐16. ">Mier‐Cabrera 2011</a>; <a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>; <a href="./references#CD012179-bbs2-0087" title="MohamedML , ElBeheryMM , MansourSAEA . Comparative study between VEGF‐A and CA‐125 in diagnosis and follow‐up of advanced endometriosis after conservative laparoscopic surgery. Archives of Gynecology and Obstetrics2013;287(1):77‐82. ">Mohamed 2013</a>; <a href="./references#CD012179-bbs2-0088" title="MoloMW , KellyM , RadwanskaE , BinorZ . Preoperative serum CA‐125 and CA‐72 in predicting endometriosis in infertility patients. Journal of Reproductive Medicine1994;39(12):964‐6. ">Molo 1994</a>; <a href="./references#CD012179-bbs2-0089" title="MorinM , BellehumeurC , TherriaultMJ , MetzC , MaheuxR , AkoumA . Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis. Fertility and Sterility2005;83(4):865‐72. ">Morin 2005</a>; <a href="./references#CD012179-bbs2-0090" title="MuscatelloR , CucinelliF , FulghesuA , LanzoneA , CarusoA , MancusoS . Multiple serum marker assay in the diagnosis of endometriosis. Gynecological Endocrinology1992;6:265‐9. ">Muscatello 1992</a>; <a href="./references#CD012179-bbs2-0091" title="OdukoyaO , BansalA , CookeI . Serum endometrial IgG antibodies and soluble CD23 concentrations in patients with endometriosis. Acta Obstetricia et Gynecologica Scandinavica1996;75(10):927‐31. ">Odukoya 1996</a>; <a href="./references#CD012179-bbs2-0093" title="OkuH , TsujiY , KashiwamuraSI , AdachiS , KubotaA , OkamuraH , et al. Role of IL‐18 in pathogenesis of endometriosis. Human Reproduction2004;19(3):709‐14. ">Oku 2004</a>; <a href="./references#CD012179-bbs2-0094" title="Olkowska‐TruchanowiczJ , BocianK , MaksymRB , BialoszewskaA , WlodarczykD , BaranowskiW , et al. CD4+ CD25+ FOXP3+ regulatory T cells in peripheral blood and peritoneal fluid of patients with endometriosis. Human Reproduction2013;28(1):119‐24. ">Olkowska‐Truchanowicz 2013</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; <a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; <a href="./references#CD012179-bbs2-0098" title="PattonPE , FieldCS , HarmsRW , CoulamCB . CA‐125 levels in endometriosis. Fertility and Sterility1986;45(6):770‐3. ">Patton 1986</a>; <a href="./references#CD012179-bbs2-0099" title="PhilippoussisF , GagneD , HugoP , GosselinD . Concentrations of alpha‐fetoprotein, insulin‐like growth factor binding protein‐3, c‐erbB‐2, and epidermal growth factor in serum of patients with endometriosis. Journal of the Society for Gynecologic Investigation2004;11(3):175‐81. ">Philippoussis 2004</a>; <a href="./references#CD012179-bbs2-0100" title="PittawayDE , DouglasJW . Serum CA‐125 in women with endometriosis and chronic pelvic pain. Fertility and Sterility1989;51(1):68‐70. ">Pittaway 1989</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; <a href="./references#CD012179-bbs2-0102" title="RamosIML , PodgaecS , AbraoMS , deOliveiraR , BaracatEC . Evaluation of CA‐125 and soluble CD‐23 in patients with pelvic endometriosis: A case‐control study. Revista da Associacao Medica Brasileira2012;58(1):26‐32. ">Ramos 2012</a>; <a href="./references#CD012179-bbs2-0104" title="RileyCF , MoenMH , VidemV . Inflammatory markers in endometriosis: reduced peritoneal neutrophil response in minimal endometriosis. Acta Obstetricia et Gynecologica Scandinavica2007;86(7):877‐81. ">Riley 2007</a>; <a href="./references#CD012179-bbs2-0105" title="RosaE Silva ACJS , RosaE Silva JC , FerrianiRA . Serum CA‐125 in the diagnosis of endometriosis. International Journal of Gynaecology and Obstetrics2007;96(3):206‐7. ">Rosa E Silva 2007</a>; <a href="./references#CD012179-bbs2-0107" title="SalehpourS , SeneAA , MehrjerdiEK , AkhoondMR . The correlation between serum and peritoneal fluid CA125 level in women with pelvic endometriosis. International Journal of Fertility &amp; Sterility2009;3(1):29‐34. ">Salehpour 2009</a>; <a href="./references#CD012179-bbs2-0110" title="SomiglianaE , ViganoP , CandianiM , FelicettaI , DiBlasioAM , VignaliM . Use of serum‐soluble intercellular adhesion molecule‐1 as a new marker of endometriosis. Fertility &amp; Sterility2002;77(5):1028‐31. ">Somigliana 2002</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>; <a href="./references#CD012179-bbs2-0112" title="SteffAM , GagneD , PageM , RiouxA , HugoP , GosselinD . Serum concentrations of insulin‐like growth factor‐1, soluble tumor necrosis factor receptor‐1 and angiogenin in endometriosis patients. American Journal of Reproductive Immunology2004;51(2):166‐73. ">Steff 2004a</a>; <a href="./references#CD012179-bbs2-0113" title="SuenJL , ChangY , ChiuPR , HsiehTH , HsiE , ChenYC , et al. Serum level of IL‐10 is increased in patients with endometriosis, and IL‐10 promotes the growth of lesions in a murine model. American Journal of Pathology2014;184(2):464‐71. ">Suen 2014</a>; <a href="./references#CD012179-bbs2-0114" title="SzczepaskaM , SkrzypczakJ , KamienicznaM , KurpiszM . Antizona and antisperm antibodies in women with endometriosis and/or infertility. Fertility &amp; Sterility2001;75(1):97‐105. ">Szczepanska 2001a</a>; <a href="./references#CD012179-bbs2-0115" title="SzczepanskaM , MikolajczykM , RaczynskaP , SkrzypczakJ . The evaluation of IL‐12 levels in peritoneal fluid and serum of women with endometriosis. Ginekologia Polska2001;72(5):408‐17. ">Szczepanska 2001b</a>; <a href="./references#CD012179-bbs2-0116" title="SzubertM , SuzinJ , WierzbowskiT , Kowalczyk‐AmicoK . CA‐125 concentration in serum and peritoneal fluid in patients with endometriosis ‐ preliminary results. Archives of Medical Science2012;8(3):504‐8. ">Szubert 2012</a>; <a href="./references#CD012179-bbs2-0119" title="TokmakA , UgurM , TongucE , VarT , MoralogluO , OzaksitG . The value of urocortin and Ca‐125 in the diagnosis of endometrioma. Archives of Gynecology and Obstetrics2011;283(5):1075‐9. ">Tokmak 2011</a>; <a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a</a>; <a href="./references#CD012179-bbs2-0121" title="VercelliniP , DeBenedettiF , RossiE , ColomboA , TrespidiL , CrosignaniPG , et al. Tumor necrosis factor in plasma and peritoneal fluid of women with and without endometriosis. Gynecologic and Obstetric Investigation1993; Vol. 36, issue 1:39‐41. ">Vercellini 1993</a>; <a href="./references#CD012179-bbs2-0122" title="VeritFF , ErelO , CelikN . Serum paraoxonase‐1 activity in women with endometriosis and its relationship with the stage of the disease. Human Reproduction2008;23(1):100‐4. ">Verit 2008</a>; <a href="./references#CD012179-bbs2-0123" title="ViganoP , SomiglianaE , MatroneR , DubiniA , BarronC , VignaliM , et al. Serum leptin concentrations in endometriosis. Journal of Clinical Endocrinology and Metabolism2002;87(3):1085‐7. ">Vigano 2002</a>; <a href="./references#CD012179-bbs2-0125" title="VodolazkaiaA , BossuytX , FassbenderA , KyamaCM , MeulemanC , PeeraerK , et al. A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis. Reproductive Biology and Endocrinology2011;9:113. ">Vodolazkaia 2011</a>; <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>; <a href="./references#CD012179-bbs2-0127" title="VoukK , HevirN , Ribic‐PuceljM , HaarpaintnerG , ScherbH , OsredkarJ , et al. Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Human Reproduction2012;27(10):2955‐65. ">Vouk 2012</a>; <a href="./references#CD012179-bbs2-0128" title="WangWT , ZhaoYN , HanBW , HongSJ , ChenYQ , WangX , et al. Circulating microRNAs identified in a genome‐wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis [Study on polymorphism of human leukocyte antigen I in patients with endometriosis]. Journal of Clinical Endocrinology and Metabolism2013;98(1):281‐9. ">Wang 2013a</a>; <a href="./references#CD012179-bbs2-0129" title="WebsterKE , KennedySH , BeckerCM . Levels of circulating angiogenic cells are not altered in women with endometriosis. Human Reproduction2013;28(3):651‐7. ">Webster 2013</a>; <a href="./references#CD012179-bbs2-0131" title="WildRA , HirisaveV , BiancoA , PodczaskiES , DemersLM . Endometrial antibodies versus CA‐125 for the detection of endometriosis. Fertility and Sterility1991;55(1):90‐4. ">Wild 1991a</a>; <a href="./references#CD012179-bbs2-0132" title="WolflerMM , SchwambornK , OttenD , HornungD , LiuHY , RathW . Mass spectrometry and serum pattern profiling for analyzing the individual risk for endometriosis: promising insights?. Fertility and Sterility2009;91(6):2331‐7. ">Wolfler 2009</a>; <a href="./references#CD012179-bbs2-0133" title="WuMH , YangBC , HsuCC , LeeYC , HuangKE . The expression of soluble intercellular adhesion molecule‐1 in endometriosis. Fertility and Sterility1998;70(6):1139‐42. ">Wu 1998</a>; <a href="./references#CD012179-bbs2-0134" title="YagmurE , BastuE , Karamustafaoglu‐BalciB , AkhanSE , BuyruF . Non‐invasive diagnosis of endometriosis based on a combined analysis of four plasma biomarkers. Central‐European Journal of Immunology2013;38(2):154‐8. ">Yagmur 2013</a>; <a href="./references#CD012179-bbs2-0135" title="YangF , FangAH , GuRF . Value of CA125 (carbon hydrate tumor‐associated antigen) and endometrial antibodies for the detections of endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]1994;29(3):147‐149, 189. Chinese. ">Yang 1994</a>; <a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>; <a href="./references#CD012179-bbs2-0137" title="ZengF , XueM , ZevallosHBV , LaiD , ArthurJ , NgC , et al. Diagnostic value of the detection of aromatase cytochrome P450 and CA125 for endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(6):682‐5. Chinese. ">Zeng 2005</a>; <a href="./references#CD012179-bbs2-0138" title="ZhangX , LinJ , DengL , ChenZ , ChenL . Peritoneal fluid and serum concentration of interleukin‐16 in women with endometriosis. Acta Obstetricia et Gynecologica Scandinavica2005;84(3):297‐8. ">Zhang 2005a</a>; <a href="./references#CD012179-bbs2-0139" title="ZhangY , PengLX , MengL . Measurements of interleukin‐18 in peritoneal fluid and serum of patients with endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(6):731‐2. Chinese. ">Zhang 2005b</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; <a href="./references#CD012179-bbs2-0141" title="ZhangR , LuoR . Soluble intercellular adhesion molecule 1 in serum and peritoneal fluid on patients with endometriosis. Wuhan Yike Daxue Xuebao (Yixueban) [Medical Journal of Wuhan University]2006;27(1):97‐9. Chinese. ">Zhang 2006b</a>), nine studies demonstrated an unclear risk and 22 studies carried a high risk. All participants received the same reference standard. The time interval between the index test and the reference standard was 12 months or less, and the most commonly reported time interval was immediately before surgery. We assigned an unclear risk if authors did not clearly state the time interval, but if their descriptions suggested that the interval was reasonably short. We assigned a high risk of bias if there were unexplained withdrawals that exceeded 5% of the enrolled population or if the reason for withdrawal could introduce selection bias regarding the samples analysed. </p> <p>Sixty‐one studies presented a low concern for patient selection applicability (<a href="./references#CD012179-bbs2-0005" title="BarbatiA , CosmiEV , SpazianiR , VenturaR , MontaninoG . Serum and peritoneal fluid CA‐125 levels in patients with endometriosis. Fertility and Sterility1994;61(3):438‐42. ">Barbati 1994</a>; <a href="./references#CD012179-bbs2-0010" title="BorkowskiJ , GmyrekGB , MadejJP , NowackiW , GoludaM , GabrysM , et al. Serum and peritoneal evaluation of vitamin D‐binding protein in women with endometriosis. Postepy Higieny i Medycyny Doswiadczalnej (Online)2008;62:103‐9. ">Borkowski 2008</a>; <a href="./references#CD012179-bbs2-0013" title="ChenFP , SoongYK , LeeN , LoSK . The use of serum CA‐125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis. Acta Obstetricia et Gynecologica Scandinavica1998;77(6):665‐70. ">Chen 1998</a>; <a href="./references#CD012179-bbs2-0015" title="ColacurciN , FortunatoN , DeFranciscisP , CardoneA . Relevance of CA‐125 in the evaluation of endometriosis. Clinical and Experimental Obstetrics &amp; Gynecology1996;23(3):150‐4. ">Colacurci 1996a</a>; <a href="./references#CD012179-bbs2-0019" title="Drosdzol‐CopA , Skrzypulec‐PlintaV . Selected cytokines and glycodelin A levels in serum and peritoneal fluid in girls with endometriosis. Journal of Obstetrics and Gynaecology Research2012;38(10):1245‐53. ">Drosdzol‐Cop 2012a</a>; <a href="./references#CD012179-bbs2-0020" title="Drosdzol‐CopA , Skrzypulec‐PlintaV , StojkoR . Serum and peritoneal fluid immunological markers in adolescent girls with chronic pelvic pain. Obstetrical &amp; Gynecological Survey2012;67(6):374‐81. ">Drosdzol‐Cop 2012b</a>; <a href="./references#CD012179-bbs2-0022" title="FairbanksF , AbraoMS , PodgaecS , DiasJAJr , deOliveiraRM , RizzoLV . Interleukin‐12 but not interleukin‐18 is associated with severe endometriosis. Fertility and Sterility2009;91(2):320‐4. ">Fairbanks 2009</a>; <a href="./references#CD012179-bbs2-0023" title="FassbenderA , D'HoogheT , MihalyiA , KyamaC , SimsaP , LesseyBA . Plasma C3a‐des‐Arg levels in women with and without endometriosis. American Journal of Reproductive Immunology2009;62(3):187‐95. ">Fassbender 2009</a>; <a href="./references#CD012179-bbs2-0024" title="FassbenderA , WaelkensE , VerbeeckN , KyamaCM , BokorA , VodolazkaiaA , et al. Proteomics analysis of plasma for early diagnosis of endometriosis. Obstetrics and Gynecology2012;119(2 Pt 1):276‐85. ">Fassbender 2012</a>; <a href="./references#CD012179-bbs2-0025" title="FedeleL , ArcainiL , VercelliniP , MarchiniM , BaglioniA , BianchiS . Serum Ca‐125 concentrations in endometriosis. Acta Europaea Fertilitatis1989;20(3):137‐9. ">Fedele 1989</a>; <a href="./references#CD012179-bbs2-0026" title="FerreiraCA , CamargosAF . Assessement of serum concentration CA‐125 in the diagnosis of endometriosis [Avaliaçåo da dosagem do CA‐125 sérico no diagnóstico da endometriose]. Jornal Brasileiro de Gynecologia1994;104(9):311‐4. ">Ferreira 1994</a>; <a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>; <a href="./references#CD012179-bbs2-0031" title="FranchiM , BerettaP , ZanaboniF , DonadelloN , GhezziF . Use of serum CA125 measurement in patients with endometriosis. Italian Journal of Gynaecology and Obstetrics1993;5(4):149‐53. ">Franchi 1993</a>; <a href="./references#CD012179-bbs2-0036" title="GogaczM , WinklerI , Bojarska‐JunakA , TabarkiewiczJ , SemczukA , RechbergerT , et al. T regulatory lymphocytes in patients with endometriosis. Molecular Medicine Reports2014;10(2):1072‐6. ">Gogacz 2014</a>; <a href="./references#CD012179-bbs2-0042" title="GurganT , BukulmezO , YaraliH , TanirM , AkyildizS . Serum and peritoneal fluid levels of IGF I and II and insulinlike growth binding protein‐3 in endometriosis. Journal of Reproductive Medicine1999;44:450‐4. ">Gurgan 1999</a>; <a href="./references#CD012179-bbs2-0045" title="HaradaT , KubotaT , AsoT . Usefulness of CA19‐9 versus CA125 for the diagnosis of endometriosis. Fertility and Sterility2002;78(4):733‐9. ">Harada 2002</a>; <a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0047" title="HornsteinMD , HarlowBL , ThomasPP , CheckJH . Use of a new CA 125 assay in the diagnosis of endometriosis. Human Reproduction1995;10(4):932‐4. ">Hornstein 1995</a>; <a href="./references#CD012179-bbs2-0048" title="InagakiJ , Sugiura‐OgasawaraM , NomizuM , NakatsukaM , IkutaK , SuzukiN , et al. An association of IgG anti‐laminin‐1 autoantibodies with endometriosis in infertile patients. Human Reproduction2003;18(3):544‐9. ">Inagaki 2003</a>; <a href="./references#CD012179-bbs2-0049" title="IwasakiK , MakinoT , MaruyamaT , MatsubayashiH , NozawaS , YokokuraT . Leukocyte subpopulations and natural killer activity in endometriosis. International Journal of Fertility and Menopausal Studies1993;38(4):229‐34. ">Iwasaki 1993</a>; <a href="./references#CD012179-bbs2-0054" title="KhanKN , MasuzakiH , FujishitaA , KitajimaM , HirakiK , MiuraS , et al. Peritoneal fluid and serum levels of hepatocyte growth factor may predict the activity of endometriosis. Acta Obstetricia et Gynecologica Scandinavica2006;85(4):458‐66. ">Khan 2006</a>; <a href="./references#CD012179-bbs2-0055" title="KhanKN , KitajimaM , YamaguchiN , FujishitaA , NakashimaM , IshimaruT , et al. Role of prostaglandin E2 in bacterial growth in women with endometriosis. Human Reproduction2012;27(12):3417‐24. ">Khan 2012</a>; <a href="./references#CD012179-bbs2-0060" title="KimJY , KimH , SuhCS , KimSH , ChoiYM , KimJG . The G(‐2518)A polymorphism of monocyte chemotactic protein‐1 (MCP‐1) and its serum and peritoneal fluid levels in Korean women with endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;139(1):106‐10. ">Kim 2008</a>; <a href="./references#CD012179-bbs2-0070" title="LampM , SaareM , KadastikU , KarroH , SalumetsA , UiboR , et al. Survivin promoter polymorphisms and autoantibodies in endometriosis. Journal of Reproductive Immunology2012;96(1‐2):95‐100. ">Lamp 2012</a>; <a href="./references#CD012179-bbs2-0071" title="LanzoneA , MaranaR , MuscatelloR , FulghesuAM , DellacquaS , CarusoA , et al. Serum Ca‐125 Levels in the Diagnosis and Management of Endometriosis. Journal of Reproductive Medicine1991;36(8):603‐7. ">Lanzone 1991</a>; <a href="./references#CD012179-bbs2-0074" title="LinJ , ZhangXM , DengL , ChenZY , ChenL . Determination of interleukine‐16 levels in peritoneal fluid and serum of women with endometriosis. Zhejiang Daxue Xuebao (Yixueban) [Journal of Zhejiang University (Medical Sciences)]2005;34(3):260‐2. Chinese. ">Lin 2005</a>; <a href="./references#CD012179-bbs2-0075" title="LiuHY , ZhengYH , ZhangJZ , LengJH , SunDW , LiuZF , et al. Establishment of endometriosis diagnostic model using plasma protein profiling. Chung‐Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics and Gynecology]2009;44(8):601‐4. Chinese. ">Liu 2009</a>; <a href="./references#CD012179-bbs2-0076" title="MabroukM , ElmakkyA , CaramelliE , FarinaA , MignemiG , VenturoliS , et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Archives of Gynecology and Obstetrics2012;285(5):1307‐12. ">Mabrouk 2012</a>; <a href="./references#CD012179-bbs2-0082" title="MatalliotakisIM , GoumenouAG , KoumantakisGE , NeonakiMA , KoumantakisEE , DionyssopoulouE , et al. Serum concentrations of growth factors in women with and without endometriosis: the action of anti‐endometriosis medicines. International Immunopharmacology2003;3(1):81‐9. ">Matalliotakis 2003a</a>; <a href="./references#CD012179-bbs2-0083" title="MatalliotakisIM , AriciA , GoumenouAG , KatassosT , KarkavitsasN , KoumantakisEE . Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA‐125 levels in women with endometriosis. International Journal of Fertility and Women's Medicine2004;49(2):75‐8. ">Matalliotakis 2004</a>; <a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>; <a href="./references#CD012179-bbs2-0090" title="MuscatelloR , CucinelliF , FulghesuA , LanzoneA , CarusoA , MancusoS . Multiple serum marker assay in the diagnosis of endometriosis. Gynecological Endocrinology1992;6:265‐9. ">Muscatello 1992</a>; <a href="./references#CD012179-bbs2-0091" title="OdukoyaO , BansalA , CookeI . Serum endometrial IgG antibodies and soluble CD23 concentrations in patients with endometriosis. Acta Obstetricia et Gynecologica Scandinavica1996;75(10):927‐31. ">Odukoya 1996</a>; <a href="./references#CD012179-bbs2-0093" title="OkuH , TsujiY , KashiwamuraSI , AdachiS , KubotaA , OkamuraH , et al. Role of IL‐18 in pathogenesis of endometriosis. Human Reproduction2004;19(3):709‐14. ">Oku 2004</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; <a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; <a href="./references#CD012179-bbs2-0099" title="PhilippoussisF , GagneD , HugoP , GosselinD . Concentrations of alpha‐fetoprotein, insulin‐like growth factor binding protein‐3, c‐erbB‐2, and epidermal growth factor in serum of patients with endometriosis. Journal of the Society for Gynecologic Investigation2004;11(3):175‐81. ">Philippoussis 2004</a>; <a href="./references#CD012179-bbs2-0100" title="PittawayDE , DouglasJW . Serum CA‐125 in women with endometriosis and chronic pelvic pain. Fertility and Sterility1989;51(1):68‐70. ">Pittaway 1989</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; <a href="./references#CD012179-bbs2-0102" title="RamosIML , PodgaecS , AbraoMS , deOliveiraR , BaracatEC . Evaluation of CA‐125 and soluble CD‐23 in patients with pelvic endometriosis: A case‐control study. Revista da Associacao Medica Brasileira2012;58(1):26‐32. ">Ramos 2012</a>; <a href="./references#CD012179-bbs2-0105" title="RosaE Silva ACJS , RosaE Silva JC , FerrianiRA . Serum CA‐125 in the diagnosis of endometriosis. International Journal of Gynaecology and Obstetrics2007;96(3):206‐7. ">Rosa E Silva 2007</a>; <a href="./references#CD012179-bbs2-0107" title="SalehpourS , SeneAA , MehrjerdiEK , AkhoondMR . The correlation between serum and peritoneal fluid CA125 level in women with pelvic endometriosis. International Journal of Fertility &amp; Sterility2009;3(1):29‐34. ">Salehpour 2009</a>; <a href="./references#CD012179-bbs2-0110" title="SomiglianaE , ViganoP , CandianiM , FelicettaI , DiBlasioAM , VignaliM . Use of serum‐soluble intercellular adhesion molecule‐1 as a new marker of endometriosis. Fertility &amp; Sterility2002;77(5):1028‐31. ">Somigliana 2002</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>; <a href="./references#CD012179-bbs2-0115" title="SzczepanskaM , MikolajczykM , RaczynskaP , SkrzypczakJ . The evaluation of IL‐12 levels in peritoneal fluid and serum of women with endometriosis. Ginekologia Polska2001;72(5):408‐17. ">Szczepanska 2001b</a>; <a href="./references#CD012179-bbs2-0116" title="SzubertM , SuzinJ , WierzbowskiT , Kowalczyk‐AmicoK . CA‐125 concentration in serum and peritoneal fluid in patients with endometriosis ‐ preliminary results. Archives of Medical Science2012;8(3):504‐8. ">Szubert 2012</a>; <a href="./references#CD012179-bbs2-0117" title="SzubertM , SuzinJ , DuechlerM , SzuławskaA , CzyżM , Kowalczyk‐AmicoK . Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment. Reproduction, Fertility, and Development2014;26(3):414‐20. ">Szubert 2014</a>; <a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a</a>; <a href="./references#CD012179-bbs2-0121" title="VercelliniP , DeBenedettiF , RossiE , ColomboA , TrespidiL , CrosignaniPG , et al. Tumor necrosis factor in plasma and peritoneal fluid of women with and without endometriosis. Gynecologic and Obstetric Investigation1993; Vol. 36, issue 1:39‐41. ">Vercellini 1993</a>; <a href="./references#CD012179-bbs2-0123" title="ViganoP , SomiglianaE , MatroneR , DubiniA , BarronC , VignaliM , et al. Serum leptin concentrations in endometriosis. Journal of Clinical Endocrinology and Metabolism2002;87(3):1085‐7. ">Vigano 2002</a>; <a href="./references#CD012179-bbs2-0124" title="VigilPP , AglonyIM , KolbachRM , RubioAV , Villarroel Del PinoL . Endometriosis and CA 125 in women of reproductive age [Endometriosis y CA 125 en mujeres en edad reproductiva]. Revista Chilena de Obstetrica y Ginecologia1999; Vol. 64, issue 5:385‐8. ">Vigil 1999</a>; <a href="./references#CD012179-bbs2-0125" title="VodolazkaiaA , BossuytX , FassbenderA , KyamaCM , MeulemanC , PeeraerK , et al. A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis. Reproductive Biology and Endocrinology2011;9:113. ">Vodolazkaia 2011</a>; <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>; <a href="./references#CD012179-bbs2-0128" title="WangWT , ZhaoYN , HanBW , HongSJ , ChenYQ , WangX , et al. Circulating microRNAs identified in a genome‐wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis [Study on polymorphism of human leukocyte antigen I in patients with endometriosis]. Journal of Clinical Endocrinology and Metabolism2013;98(1):281‐9. ">Wang 2013a</a>; <a href="./references#CD012179-bbs2-0129" title="WebsterKE , KennedySH , BeckerCM . Levels of circulating angiogenic cells are not altered in women with endometriosis. Human Reproduction2013;28(3):651‐7. ">Webster 2013</a>; <a href="./references#CD012179-bbs2-0131" title="WildRA , HirisaveV , BiancoA , PodczaskiES , DemersLM . Endometrial antibodies versus CA‐125 for the detection of endometriosis. Fertility and Sterility1991;55(1):90‐4. ">Wild 1991a</a>; <a href="./references#CD012179-bbs2-0133" title="WuMH , YangBC , HsuCC , LeeYC , HuangKE . The expression of soluble intercellular adhesion molecule‐1 in endometriosis. Fertility and Sterility1998;70(6):1139‐42. ">Wu 1998</a>; <a href="./references#CD012179-bbs2-0134" title="YagmurE , BastuE , Karamustafaoglu‐BalciB , AkhanSE , BuyruF . Non‐invasive diagnosis of endometriosis based on a combined analysis of four plasma biomarkers. Central‐European Journal of Immunology2013;38(2):154‐8. ">Yagmur 2013</a>; <a href="./references#CD012179-bbs2-0135" title="YangF , FangAH , GuRF . Value of CA125 (carbon hydrate tumor‐associated antigen) and endometrial antibodies for the detections of endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]1994;29(3):147‐149, 189. Chinese. ">Yang 1994</a>; <a href="./references#CD012179-bbs2-0137" title="ZengF , XueM , ZevallosHBV , LaiD , ArthurJ , NgC , et al. Diagnostic value of the detection of aromatase cytochrome P450 and CA125 for endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(6):682‐5. Chinese. ">Zeng 2005</a>), eight demonstrated an unclear concern and 72 were of high concern. We assigned high concern in patient selection applicability if the study utilised two‐gate selection for cases and controls or if it only evaluated a limited spectrum of disease. In our view, any sampling deviation from a representative group of the entire clinically relevant population could skew the estimates of diagnostic accuracy in either direction. We reported unclear concern if this information was unclear, for example if the severity of endometriosis was not reported. </p> <p>In 136 studies there was a low concern in index test applicability, whereas in five studies the concern was unclear (<a href="./references#CD012179-bbs2-0012" title="CaliennoC , TrioC , MontiB , IedaN , CorteseM , VariscoE . MCP‐1 and IL‐8 in serum and ectopic endometrium in women with endometriosis. Italian Journal of Gynaecology and Obstetrics2008;20(1):12‐8. ">Calienno 2008</a>; <a href="./references#CD012179-bbs2-0068" title="KurdogluZ , GursoyR , KurdogluM , ErdemM , ErdemO , ErdemA . Comparison of the clinical value of CA 19‐9 versus CA 125 for the diagnosis of endometriosis. Fertility and Sterility2009;92(5):1761‐3. ">Kurdoglu 2009</a>; <a href="./references#CD012179-bbs2-0105" title="RosaE Silva ACJS , RosaE Silva JC , FerrianiRA . Serum CA‐125 in the diagnosis of endometriosis. International Journal of Gynaecology and Obstetrics2007;96(3):206‐7. ">Rosa E Silva 2007</a>; <a href="./references#CD012179-bbs2-0124" title="VigilPP , AglonyIM , KolbachRM , RubioAV , Villarroel Del PinoL . Endometriosis and CA 125 in women of reproductive age [Endometriosis y CA 125 en mujeres en edad reproductiva]. Revista Chilena de Obstetrica y Ginecologia1999; Vol. 64, issue 5:385‐8. ">Vigil 1999</a>; <a href="./references#CD012179-bbs2-0137" title="ZengF , XueM , ZevallosHBV , LaiD , ArthurJ , NgC , et al. Diagnostic value of the detection of aromatase cytochrome P450 and CA125 for endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(6):682‐5. Chinese. ">Zeng 2005</a>), and none of the studies presented a high concern. We assigned an unclear concern when the study did not present sufficient information regarding the conduct of the tests, such as the laboratory methods, reagents used or the level of expertise of the test operators. </p> <p>All 141 studies were of low concern for applicability with regard to the reference standard, and none had a high or unclear concern. All the included studies implemented pelvic surgery (laparoscopy or laparotomy) as a reference standard, which could be relied upon to match the review question. </p> </section> <section id="CD012179-sec-0072"> <h3 class="title" id="CD012179-sec-0072">Findings</h3> <p>We evaluated a total of 122 blood biomarkers in 141 included studies; 47 biomarkers had a diagnostic evaluation in 70 studies. Studies assessed 44 biomarkers as a single blood test, along with 29 combinations of two to six biomarkers (<a href="./full#CD012179-tbl-0001">summary of findings Table</a>). The presence of endometriosis did not alter 97 biomarkers evaluated in 79 studies (<a href="./appendices#CD012179-sec-0181">Appendix 7</a> ). Twenty‐two biomarkers demonstrated altered levels in endometriosis in some studies and showed no difference in expression in other studies. We report the findings for two separate groups: blood biomarkers that were evaluated for the diagnosis of pelvic endometriosis, when any type of endometriosis was assessed against disease‐free controls; and blood biomarkers that could differentiate ovarian endometrioma from other benign ovarian cysts in women of reproductive age, when assessing ovarian endometriosis against other types of ovarian masses. We have biologically subcategorised biomarkers and presented them under these categories in alphabetical order. To assist readers in the search for a specific biomarker, we present an index of the biomarkers with biological annotation in <a href="./appendices#CD012179-sec-0169">Appendix 1</a> . </p> <section id="CD012179-sec-0073"> <h4 class="title">Blood biomarkers evaluated for the diagnosis of pelvic endometriosis (peritoneal, ovarian and deep infiltrating) </h4> <section id="CD012179-sec-0074"> <h5 class="title">1. Angiogenesis/growth factors and their receptors</h5> <section id="CD012179-sec-0075"> <h6 class="title">1.1. Glycodelin‐A (PP14 or PAEP) (or placental protein 14 or progestogen‐associated endometrial protein) </h6> <p>Two studies, including three data sets with a total of 198 participants, assessed the value of glycodelin in detecting pelvic endometriosis (<a href="#CD012179-fig-0005">Figure 5</a>). Investigators assigned three different cut‐off thresholds in each data set. </p> <div class="figure" id="CD012179-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Summary ROC plot of Glycodelin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 9 ng/ml and &gt; 18 ng/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of Glycodelin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 9 ng/ml and &gt; 18 ng/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis. </p> </div> </div> </div> <p> <ol id="CD012179-list-0056"> <li> <p>&gt; 2.07 ng/ml (1 study, 99 participants, follicular or luteal cycle phase, rASRM I to IV), showing a sensitivity of 0.82 (95% CI 0.70 to 0.91) and a specificity of 0.79 (95% CI 0.63 to 0.90); <a href="./references#CD012179-bbs2-0062" title="KocbekV , VoukK , MuellerMD , RiznerTL , BersingerNA . Elevated glycodelin‐A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology2013;29(5):455‐9. ">Kocbek 2013</a>. </p> </li> <li> <p>&gt; 18 ng/ml (1 study, 99 participants, all cycle phases, rASRM I to IV), showing a sensitivity of 0.62 (95% CI 0.48 to 0.74) and a specificity of 0.44 (95% CI 0.28 to 0.60); <a href="./references#CD012179-bbs2-0062" title="KocbekV , VoukK , MuellerMD , RiznerTL , BersingerNA . Elevated glycodelin‐A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology2013;29(5):455‐9. ">Kocbek 2013</a>. </p> </li> <li> <p>&gt; 9.0 ng/ml (1 study, 45 participants, follicular cycle phase, rASRM I to IV), showing a sensitivity of 0.71 (95% CI 0.51 to 0.87) and a specificity of 0.35 (95% CI 0.14 to 0.62); <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>. </p> </li> </ol> </p> <p>The same study ( <a href="./references#CD012179-bbs2-0062" title="KocbekV , VoukK , MuellerMD , RiznerTL , BersingerNA . Elevated glycodelin‐A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology2013;29(5):455‐9. ">Kocbek 2013</a> ) performed two tests on an overlapping population of women, and other studies used varying thresholds, so it was not possible to combine studies in a meta‐analysis. In three contrasting studies (206 participants, rASRM I to IV), glycodelin concentrations did not change in women with endometriosis in the follicular phase (<a href="./references#CD012179-bbs2-0019" title="Drosdzol‐CopA , Skrzypulec‐PlintaV . Selected cytokines and glycodelin A levels in serum and peritoneal fluid in girls with endometriosis. Journal of Obstetrics and Gynaecology Research2012;38(10):1245‐53. ">Drosdzol‐Cop 2012a</a>), follicular or luteal phase (<a href="./references#CD012179-bbs2-0052" title="JoshiSG , ZamahNM , RaikarRS , ButtramVCJr , HenriquesES , GordonM . Serum and peritoneal fluid proteins in women with and without endometriosis. Fertility and Sterility1986;46(6):1077‐82. ">Joshi 1986</a>), or when the cycle phase was not specified (<a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>). It appears that there is little clinical value in using glycodelin‐A to diagnose endometriosis. </p> </section> <section id="CD012179-sec-0076"> <h6 class="title">1.2. IGFBP‐3 (insulin‐like growth factor‐binding protein‐3)</h6> <p>One study evaluated the accuracy of IGFBP‐3 in detecting pelvic endometriosis in 99 women with ultrasound negative, rASRM I to IV endometriosis (<a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>). This study included two evaluations: all the participants in all phases of menstrual cycle (cut‐off threshold &gt; 210 ng/ml), demonstrating a sensitivity of 0.55 (95% CI 0.42 to 0.68) and a specificity of 0.44 (95% CI 0.28 to 0.60); and only in participants in the follicular cycle phase (45 women, cut‐off threshold &gt; 200 ng/ml), with a sensitivity of 0.71 (95% CI 0.51 to 0.87) and a specificity of 0.29 (95% CI 0.10 to 0.56). There were no significant differences in for IGFBP‐3 levels between women with and without endometriosis in two additional studies (116 participants, follicular and luteal or only luteal cycle phase, rASRM I to IV) (<a href="./references#CD012179-bbs2-0042" title="GurganT , BukulmezO , YaraliH , TanirM , AkyildizS . Serum and peritoneal fluid levels of IGF I and II and insulinlike growth binding protein‐3 in endometriosis. Journal of Reproductive Medicine1999;44:450‐4. ">Gurgan 1999</a>; <a href="./references#CD012179-bbs2-0099" title="PhilippoussisF , GagneD , HugoP , GosselinD . Concentrations of alpha‐fetoprotein, insulin‐like growth factor binding protein‐3, c‐erbB‐2, and epidermal growth factor in serum of patients with endometriosis. Journal of the Society for Gynecologic Investigation2004;11(3):175‐81. ">Philippoussis 2004</a>). These data suggest that IGFBP‐3 is not sensitive or specific enough to be clinically useful in diagnosing endometriosis. </p> </section> <section id="CD012179-sec-0077"> <h6 class="title">1.3. Leptin</h6> <p>The diagnostic performance of leptin was assessed as a component of a combination of blood biomarkers (see below under 'Combined tests'). Four other studies (311 participants, rASRM I to IV) demonstrated that leptin levels alone did not differ between the groups of women with and without endometriosis when tested in all phases of menstrual cycle or when the cycle phase was not specified (<a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; <a href="./references#CD012179-bbs2-0123" title="ViganoP , SomiglianaE , MatroneR , DubiniA , BarronC , VignaliM , et al. Serum leptin concentrations in endometriosis. Journal of Clinical Endocrinology and Metabolism2002;87(3):1085‐7. ">Vigano 2002</a>; <a href="./references#CD012179-bbs2-0130" title="WeiXQ , ZhangY , TangM . Leptin levels and infertile patients with endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(4):487‐8. Chinese. ">Wei 2005</a>). Overall, leptin did not appear to be reliable as a marker for endometriosis. </p> </section> <section id="CD012179-sec-0078"> <h6 class="title">1.4. VEGF (vascular endothelial growth factor)</h6> <p>Three studies with a total of 254 participants evaluated VEGF for the diagnosis of pelvic endometriosis (<a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>; <a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>; <a href="./references#CD012179-bbs2-0087" title="MohamedML , ElBeheryMM , MansourSAEA . Comparative study between VEGF‐A and CA‐125 in diagnosis and follow‐up of advanced endometriosis after conservative laparoscopic surgery. Archives of Gynecology and Obstetrics2013;287(1):77‐82. ">Mohamed 2013</a>)(<a href="#CD012179-fig-0006">Figure 6</a>). Each study differed with regard to the population studied, the cycle phase and cut‐off thresholds. </p> <div class="figure" id="CD012179-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Summary ROC plot of VEGF for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of VEGF for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> </div> <p> <ul id="CD012179-list-0057"> <li> <p>VEGF with a cut‐off of &gt; 1.5 ng/ml (1 study, 99 participants in all phases of menstrual cycle, ultrasound negative endometriosis, rASRM I to IV) had a sensitivity of 0.50 (95% CI 0.37 to 0.63) and a specificity of 0.61 (95% CI 0.45 to 0.76); <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>. </p> </li> <li> <p>VEGF with a cut‐off of &gt; 236.00 pg/ml (1 study, 95 participants in follicular cycle phase, rASRM I to IV) showed a sensitivity of 0.92 (95% CI 0.83 to 0.97) and a specificity of 0.77 (95% CI 0.58 to 0.90); <a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>. </p> </li> <li> <p>VEGF with a cut‐off of &gt; 680.00 pg/ml (1 study, 60 participants in follicular cycle phase, rASRM III to IV) demonstrated a sensitivity of 0.93 (95% CI 0.78 to 0.99) and a specificity of 0.97 (95% CI 0.83 to 1.00); <a href="./references#CD012179-bbs2-0087" title="MohamedML , ElBeheryMM , MansourSAEA . Comparative study between VEGF‐A and CA‐125 in diagnosis and follow‐up of advanced endometriosis after conservative laparoscopic surgery. Archives of Gynecology and Obstetrics2013;287(1):77‐82. ">Mohamed 2013</a>. </p> </li> </ul> </p> <p>The last test had the highest diagnostic accuracy, but investigators only evaluated it for moderate‐severe disease. Substantial variations in the methodology and the populations studied precluded combining this data in a meta‐analysis. Another seven studies (842 women, rASRM I to IV) demonstrated that VEGF levels were not influenced by endometriosis in the follicular phase (<a href="./references#CD012179-bbs2-0016" title="DaSilvaCM , Vilaca BeloA , Passos AndradeS , Peixoto CamposP , Cristina Franca FerreiraM , Lopes da Silva‐FilhoA , et al. Identification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis. Biomedicine &amp; Pharmacotherapy2014;68(7):899‐904. ">Da Silva 2014</a>; <a href="./references#CD012179-bbs2-0076" title="MabroukM , ElmakkyA , CaramelliE , FarinaA , MignemiG , VenturoliS , et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Archives of Gynecology and Obstetrics2012;285(5):1307‐12. ">Mabrouk 2012</a>), luteal phase (<a href="./references#CD012179-bbs2-0033" title="GagneD , PageM , RobitailleG , HugoP , GosselinD . Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Human Reproduction2003;18(8):1674‐80. ">Gagne 2003b</a>), follicular or luteal phase (<a href="./references#CD012179-bbs2-0014" title="ChoSH , OhYJ , NamA , KimHY , ParkJH , KimJH , et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. American Journal of Reproductive Immunology2007;58(6):497‐504. ">Cho 2007</a>; <a href="./references#CD012179-bbs2-0059" title="KianpourM , NematbakhshM , AhmadiSM , JafarzadehM , HajjarianM , PezeshkiZ , et al. Serum and peritoneal fluid levels of vascular endothelial growth factor in women with endometriosis. International Journal of Fertility &amp; Sterility2013;7(2):96‐9. ">Kianpour 2013</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>), or when the cycle phase was not specified (<a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>). There is considerable inconsistency in the VEGF‐A data, although follicular phase VEGF‐A testing appears to have some potential in diagnosing endometriosis. Further work to confirm or refute this observation and determine the value of VEGF‐A blood testing to diagnose endometriosis is warranted. </p> </section> <section id="CD012179-sec-0079"> <h6 class="title">1.5. Urocortin</h6> <p>Two studies reported on urocortin, both of which assessed the accuracy of this biomarker in discriminating ovarian endometriosis from other benign ovarian masses. These studies are presented separately under 'Blood biomarkers that could differentiate ovarian endometrioma from other benign ovarian cysts in women of reproductive age'. </p> </section> <section id="CD012179-sec-0080"> <h6 class="title">1.6. Angiogenesis/growth factors that exhibited no differential expression in endometriosis</h6> <p>We present a detailed summary of other angiogenesis and growth factors that did not display significant differences in expression levels in women with endometriosis in <a href="./appendices#CD012179-sec-0181">Appendix 7</a>. The list includes: </p> <p> <ol id="CD012179-list-0058"> <li> <p>angiogenic activity of serum (<a href="./references#CD012179-bbs2-0007" title="BarczE , RozewskaES , KaminskiP , DemkowU , BobrowskaK , MarianowskiL . Angiogenic activity and IL‐8 concentrations in peritoneal fluid and sera in endometriosis. International Journal of Gynaecology and Obstetrics2002;79(3):229‐35. ">Barcz 2002</a>; 84 participants); </p> </li> <li> <p>CAC (<a href="./references#CD012179-bbs2-0129" title="WebsterKE , KennedySH , BeckerCM . Levels of circulating angiogenic cells are not altered in women with endometriosis. Human Reproduction2013;28(3):651‐7. ">Webster 2013</a>; 64 participants); </p> </li> <li> <p>EGF (<a href="./references#CD012179-bbs2-0099" title="PhilippoussisF , GagneD , HugoP , GosselinD . Concentrations of alpha‐fetoprotein, insulin‐like growth factor binding protein‐3, c‐erbB‐2, and epidermal growth factor in serum of patients with endometriosis. Journal of the Society for Gynecologic Investigation2004;11(3):175‐81. ">Philippoussis 2004</a>; 72 participants); </p> </li> <li> <p>sEGF‐R (<a href="./references#CD012179-bbs2-0082" title="MatalliotakisIM , GoumenouAG , KoumantakisGE , NeonakiMA , KoumantakisEE , DionyssopoulouE , et al. Serum concentrations of growth factors in women with and without endometriosis: the action of anti‐endometriosis medicines. International Immunopharmacology2003;3(1):81‐9. ">Matalliotakis 2003a</a>; 48 participants); </p> </li> <li> <p>sFlt‐1 (sVEGFR‐1) (<a href="./references#CD012179-bbs2-0014" title="ChoSH , OhYJ , NamA , KimHY , ParkJH , KimJH , et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. American Journal of Reproductive Immunology2007;58(6):497‐504. ">Cho 2007</a>; 70 participants); </p> </li> <li> <p>HGF (<a href="./references#CD012179-bbs2-0054" title="KhanKN , MasuzakiH , FujishitaA , KitajimaM , HirakiK , MiuraS , et al. Peritoneal fluid and serum levels of hepatocyte growth factor may predict the activity of endometriosis. Acta Obstetricia et Gynecologica Scandinavica2006;85(4):458‐66. ">Khan 2006</a>; 58 participants); </p> </li> <li> <p>IGF‐1 (<a href="./references#CD012179-bbs2-0082" title="MatalliotakisIM , GoumenouAG , KoumantakisGE , NeonakiMA , KoumantakisEE , DionyssopoulouE , et al. Serum concentrations of growth factors in women with and without endometriosis: the action of anti‐endometriosis medicines. International Immunopharmacology2003;3(1):81‐9. ">Matalliotakis 2003a</a>; <a href="./references#CD012179-bbs2-0112" title="SteffAM , GagneD , PageM , RiouxA , HugoP , GosselinD . Serum concentrations of insulin‐like growth factor‐1, soluble tumor necrosis factor receptor‐1 and angiogenin in endometriosis patients. American Journal of Reproductive Immunology2004;51(2):166‐73. ">Steff 2004a</a>; 196 participants); </p> </li> <li> <p>IGF‐2 (<a href="./references#CD012179-bbs2-0042" title="GurganT , BukulmezO , YaraliH , TanirM , AkyildizS . Serum and peritoneal fluid levels of IGF I and II and insulinlike growth binding protein‐3 in endometriosis. Journal of Reproductive Medicine1999;44:450‐4. ">Gurgan 1999</a>; 44 participants); </p> </li> <li> <p>PDGF (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>; 40 participants). </p> </li> </ol> </p> <p>Collectively, the results were discouraging, but not sufficient to draw conclusions regarding the role of the biomarkers in detecting endometriosis. </p> </section> </section> <section id="CD012179-sec-0081"> <h5 class="title">2. Apoptosis markers</h5> <section id="CD012179-sec-0082"> <h6 class="title">2.1. Annexin‐V</h6> <p>Investigators evaluated the diagnostic performance of annexin‐V in conjunction with other blood biomarkers as a part of combined test, and we report the findings below under 'Combined tests'. One additional study (101 participants, cycle phase not reported, rASRM I to IV) demonstrated that annexin‐V was not differentially expressed in women with and without endometriosis (<a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>). Further work in a well‐characterised population is needed to support this observation. </p> </section> <section id="CD012179-sec-0083"> <h6 class="title">2.2. Survivin</h6> <p>One study (60 participants, follicular cycle phase) evaluated survivin for the diagnosis of DIE and ovarian endometriosis and found a very low sensitivity of 0.07 (95% CI 0.02 to 0.20) and a specificity of 0.90 (95% CI 0.68 to 0.99). The authors did not report a cut‐off threshold. There were no other eligible studies that assessed this biomarker. </p> </section> <section id="CD012179-sec-0084"> <h6 class="title">2.3. Apoptosis markers that exhibited no differential expression in endometriosis</h6> <p>We present additional markers of apoptosis that were not altered in endometriosis in <a href="./appendices#CD012179-sec-0181">Appendix 7</a>, including: anti‐survivin antibody (<a href="./references#CD012179-bbs2-0070" title="LampM , SaareM , KadastikU , KarroH , SalumetsA , UiboR , et al. Survivin promoter polymorphisms and autoantibodies in endometriosis. Journal of Reproductive Immunology2012;96(1‐2):95‐100. ">Lamp 2012</a>; 145 participants); apoptotic cells (<a href="./references#CD012179-bbs2-0085" title="Mier‐CabreraJ , Jimenez‐ZamudioL , Garcia‐LatorreE , Cruz‐OrozcoO , Hernandez‐GuerreroC . Quantitative and qualitative peritoneal immune profiles, T‐cell apoptosis and oxidative stress‐associated characteristics in women with minimal and mild endometriosis. BJOG: An International Journal of Obstetrics and Gynaecology2011;118(1):6‐16. ">Mier‐Cabrera 2011</a>; 62 participants); and sFas (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>; 40 participants). Overall, there was insufficient data to make recommendations regarding these biomarkers. </p> </section> </section> <section id="CD012179-sec-0085"> <h5 class="title">3. Cell adhesion molecules and other matrix‐related proteins</h5> <section id="CD012179-sec-0086"> <h6 class="title">3.1. sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)</h6> <p>Two studies evaluated the accuracy of sICAM‐1 in detecting pelvic endometriosis. One study included women with ultrasound negative pelvic endometriosis, rASRM I to IV, and presented two overlapping data sets, which we therefore did not combine in a meta‐analysis (<a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>). One data set from this study included 99 participants at all phases of menstrual cycle and demonstrated a sensitivity of 0.55 (95% CI 0.42 to 0.68) and a specificity of 0.50 (95% CI 0.34 to 0.66) for a cut‐off threshold of &lt; 243 ng/ml. The second data set comprised 28 participants in the menstrual cycle phase and showed a sensitivity of 0.73 (95% CI 0.39 to 0.94) and a specificity of 0.29 (95% CI 0.10 to 0.56) for a cut‐off of &lt; 254.6 ng/ml. Another study (60 participants, rASRM I to IV, cycle phase not reported) demonstrated an opposite direction of differential expression of sICAM‐1 in endometriosis (higher sICAM‐1 levels in endometriosis as opposed to the former study where expression in endometriosis was lower than in controls (<a href="./references#CD012179-bbs2-0141" title="ZhangR , LuoR . Soluble intercellular adhesion molecule 1 in serum and peritoneal fluid on patients with endometriosis. Wuhan Yike Daxue Xuebao (Yixueban) [Medical Journal of Wuhan University]2006;27(1):97‐9. Chinese. ">Zhang 2006b</a>). Utilising a cut‐off threshold of &gt; 241.46 µg/ml, the sensitivity was 0.6 (95% CI 0.41 to 0.77) and the specificity was 0.87 (95% CI 0.69 to 0.96). Four studies reported negative findings for the same test (271 participants, various phases of menstrual cycle); three of those studies assessed a wide spectrum of pelvic endometriosis, rASRM I to IV (<a href="./references#CD012179-bbs2-0018" title="DePlacidoG , AlviggiC , DiP , CarravettaC , MatareseG , LandinoG , et al. Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule‐1 in endometriosis: Relationship with stage and non‐pigmented peritoneal lesions. Human Reproduction1998;13(11):3206‐10. ">De Placido 1998</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; <a href="./references#CD012179-bbs2-0110" title="SomiglianaE , ViganoP , CandianiM , FelicettaI , DiBlasioAM , VignaliM . Use of serum‐soluble intercellular adhesion molecule‐1 as a new marker of endometriosis. Fertility &amp; Sterility2002;77(5):1028‐31. ">Somigliana 2002</a>), and one study assessed only minimal‐mild disease, rASRM I‐II (<a href="./references#CD012179-bbs2-0037" title="GoludaM , KuliczkowskiK , JedrykaM . The concentration of exfoliative adhesion molecules (ICAM‐1 and E‐Selectin) in serum and peritoneal fluid of women with endometriosis. Ginekologia Polska1998;69(12):1175‐8. ">Goluda 1998</a>). This evidence suggests that sICAM‐1 molecule is not reliable as a diagnostic test for endometriosis. </p> </section> <section id="CD012179-sec-0087"> <h6 class="title">3.2. LN‐1 (laminin‐1)</h6> <p>One study evaluated the value of LN‐1 in detecting pelvic endometriosis (73 participants, cycle phase not specified, rASRM II to IV), demonstrating a sensitivity of 0.72 (95% CI 0.58 to 0.83) and a specificity of 0.70 (95% CI 0.46 to 0.88). There is insufficient evidence to comment on the diagnostic performance of this biomarker. </p> </section> <section id="CD012179-sec-0088"> <h6 class="title">3.3. Cell adhesion molecules that exhibited no differential expression in endometriosis</h6> <p>Three studies reported negative findings for three additional biomarkers from this group (<a href="./appendices#CD012179-sec-0181">Appendix 7</a>): biglycan (<a href="./references#CD012179-bbs2-0064" title="KocbekV , Hevir‐KeneN , BersingerNA , MuellerMD , RiznerTL . Increased levels of biglycan in endometriomas and peritoneal fluid samples from ovarian endometriosis patients. Gynecological Endocrinology2014;30(7):520‐4. ">Kocbek 2014b</a>; 96 participants); MMP‐9 (<a href="./references#CD012179-bbs2-0076" title="MabroukM , ElmakkyA , CaramelliE , FarinaA , MignemiG , VenturoliS , et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Archives of Gynecology and Obstetrics2012;285(5):1307‐12. ">Mabrouk 2012</a>; 60 participants); and sE‐selectin (<a href="./references#CD012179-bbs2-0037" title="GoludaM , KuliczkowskiK , JedrykaM . The concentration of exfoliative adhesion molecules (ICAM‐1 and E‐Selectin) in serum and peritoneal fluid of women with endometriosis. Ginekologia Polska1998;69(12):1175‐8. ">Goluda 1998</a>; 20 participants). In view of the paucity of data, the diagnostic role of these biomarkers in endometriosis requires further investigation. </p> </section> </section> <section id="CD012179-sec-0089"> <h5 class="title">4. Cytoskeleton molecules</h5> <section id="CD012179-sec-0090"> <h6 class="title">4.1. CK19 (Cytokeratin‐19) exhibited no differential expression in endometriosis</h6> <p>One study (79 participants, follicular or luteal cycle phase, severity not reported) evaluated expression of CK19 in pelvic endometriosis and demonstrated no significant differences in CK19 expression between the groups (<a href="./references#CD012179-bbs2-0067" title="KuesselL , Jaeger‐LanskyA , PateiskyP , RossbergN , SchulzA , SchmitzAA , et al. Cytokeratin‐19 as a biomarker in urine and in serum for the diagnosis of endometriosis ‐ a prospective study. Gynecological Endocrinology2014;30(1):38‐41. ">Kuessel 2014</a>). This observation provides too few data to draw conclusions regarding the diagnostic role of this blood biomarker in endometriosis. </p> </section> </section> <section id="CD012179-sec-0091"> <h5 class="title">5. DNA‐repair/telomere maintenance molecules</h5> <section id="CD012179-sec-0092"> <h6 class="title">5.1. Telomere length exhibited no differential expression in endometriosis</h6> <p>One study evaluated telomere length of peripheral blood mononuclear cells (50 participants, luteal cycle phase, rASRM I to IV) and demonstrated no significant difference between the women diagnosed with pelvic endometriosis and the disease‐free group (<a href="./references#CD012179-bbs2-0044" title="HapangamaDK , TurnerMA , DruryJA , QuenbyS , SaretzkiG , Martin‐RuizC , et al. Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length. Human Reproduction2008;23(7):1511‐9. ">Hapangama 2008</a>). Further studies are required before the diagnostic role of telomere length in peripheral blood cells in the diagnosis of endometriosis can be determined. </p> </section> </section> <section id="CD012179-sec-0093"> <h5 class="title">6. High‐throughput molecular markers</h5> <section id="CD012179-sec-0094"> <h6 class="title">6.1. Metabolome</h6> <p>One study assessed the accuracy of the metabolome in detecting endometriosis (92 participants, all phases of menstrual cycle, ovarian endometriosis, rASRM III to IV) using electrospray ionisation mass spectrometry (ESI‐MS/MS). A diagnostic model including hydroxy sphingomyelin SMOH C16:1 and the ratio of phosphatidylcholine PCaa C36:2 to ether‐phospholipid PCae C34:2 was selected using stepwise regression. When adjusted for age and BMI, it showed a sensitivity of 0.90 (95% CI 0.76 to 0.97) and a specificity of 0.85 (95% CI 0.72 to 0.93). These estimates approach the criteria for a SnOUT triage test; however, the trial assessed a limited spectrum of disease and did not provide the cut‐off thresholds. Although promising, these findings require further confirmation in a broader group of women with endometriosis. </p> </section> <section id="CD012179-sec-0095"> <h6 class="title">6.2. Proteome</h6> <p>Four studies included six data sets with a total of 425 participants, assessing the accuracy of the proteome in detecting endometriosis. All the included studies evaluated rASRM I to IV pelvic endometriosis and performed matrix‐assisted Surface‐Enhanced Laser Desorption Ionization Time‐of‐Flight Mass Spectrometry (SELDI‐TOF‐MS) (<a href="#CD012179-fig-0007">Figure 7</a>). The different groups took varying approaches to the data analysis and the construction of a diagnostic model. They described distinct sets of proteins as discriminating between women with and without endometriosis, precluding a meta‐analysis. One study (31 participants, cycle phase not reported) identified three protein peaks with molecular weights of 3,956.00 Da, 11,710.00 Da and 6,986.00 Da, and it reported a sensitivity of 0.88 (95% CI 0.62 to 0.98) and a specificity of 0.80 (95% CI 0.52 to 0.96) (<a href="./references#CD012179-bbs2-0075" title="LiuHY , ZhengYH , ZhangJZ , LengJH , SunDW , LiuZF , et al. Establishment of endometriosis diagnostic model using plasma protein profiling. Chung‐Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics and Gynecology]2009;44(8):601‐4. Chinese. ">Liu 2009</a>). Another group (139 participants, all phases of menstrual cycle) showed six protein peaks with molecular weights of 1629.00 Da, 3047.00 Da, 3526.00 Da, 3774.00 Da, 5046.00 Da and 5068.00 Da. This test demonstrated a sensitivity of 0.66 (95% CI 0.52 to 0.77) and a specificity of 0.99 (95% CI 0.93 to 1.00) (<a href="./references#CD012179-bbs2-0109" title="SeeberB , SammelMD , FanX , GertonGL , ShaunikA , ChittamsJ , et al. Proteomic analysis of serum yields six candidate proteins that are differentially regulated in a subset of women with endometriosis. Fertility &amp; Sterility2010;93(7):2137‐44. ">Seeber 2010</a>) which meets the criteria for a SpIN triage test. A further study (90 participants, follicular or luteal cycle phase), demonstrated that five protein peaks with molecular weights of 4159.00 Da, 5264.00 Da, 5603.00 Da, 9861.00 Da and 10,533.00 Da had a sensitivity of 0.78 (95% CI 0.65 to 0.89) and a specificity of 0.59 (95% CI 0.42 to 0.74) in detecting endometriosis (<a href="./references#CD012179-bbs2-0132" title="WolflerMM , SchwambornK , OttenD , HornungD , LiuHY , RathW . Mass spectrometry and serum pattern profiling for analyzing the individual risk for endometriosis: promising insights?. Fertility and Sterility2009;91(6):2331‐7. ">Wolfler 2009</a>). The most recent study reported three separate evaluations for each menstrual cycle phase with varying sets of proteins for each cycle phase (<a href="./references#CD012179-bbs2-0024" title="FassbenderA , WaelkensE , VerbeeckN , KyamaCM , BokorA , VodolazkaiaA , et al. Proteomics analysis of plasma for early diagnosis of endometriosis. Obstetrics and Gynecology2012;119(2 Pt 1):276‐85. ">Fassbender 2012</a>). Specifically, testing 67 participants in the menstrual cycle phase revealed five peaks with molecular weights of 9,926.31 Da, 10,072.20 Da, 6753.04 Da, 4302.67 Da and 9328.49 Da, with a sensitivity of 0.40 (95% CI 0.26 to 0.56) and a specificity of 0.82 (95% CI 0.60 to 0.95). Evaluation of 98 women in the follicular cycle phase showed that five peaks with molecular weight of 2831.02 Da, 7554.66 Da, 4241.29 Da, 2953.25 Da and 9927.73 Da had a sensitivity of 0.38 (95% CI 0.27 to 0.51) and a specificity of 0.85 (95% CI 0.68 to 0.95). In the same study, five protein peaks in 88 women in the luteal cycle phase had molecular weights of 11,366.30, 5712.69, 10,070.70, 3017.68, 3824.44 Da had a sensitivity of 0.53 (95% CI 0.39 to 0.66) and a specificity of 0.82 (95% CI 0.65 to 0.93) to detect endometriosis. None of the studies reported diagnostic cut‐off thresholds. Further evaluations of this diagnostic approach through using standardised analytical processes with similar sets of markers and defined cut‐off thresholds is required for a comprehensive assessment of this diagnostic tool. </p> <div class="figure" id="CD012179-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Summary ROC plot of proteome by SELDI‐TOF‐MS for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of proteins determined by molecular weight (MW) in daltons (Da). The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of proteome by SELDI‐TOF‐MS for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of proteins determined by molecular weight (MW) in daltons (Da). The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> </div> </section> </section> <section id="CD012179-sec-0096"> <h5 class="title">7. Hormonal markers</h5> <section id="CD012179-sec-0097"> <h6 class="title">7.1. Prolactin</h6> <p>One study that included two data sets with a total of 97 participants in the luteal cycle phase explored the diagnostic accuracy of prolactin for pelvic endometriosis, rASRM I to IV. The study evaluated two different cut‐off thresholds: &gt; 14.8 ng/ml, which demonstrated a sensitivity of 0.44 (95% CI 0.32 to 0.58) and a specificity of 0.94 (95% CI 0.80 to 0.99) and &gt; 20 ng/ml, with a sensitivity of 0.21 (95% CI 0.11 to 0.33) and a specificity of 1.00 (95% CI 0.90 to 1.00). Despite the high specificity, the sensitivity for the both thresholds remains unacceptably low even for a triage test. These data are not sufficient to draw meaningful conclusions. </p> </section> <section id="CD012179-sec-0098"> <h6 class="title">7.2. Hormonal biomarkers that exhibited no differential expression in endometriosis</h6> <p>Blood levels of the following hormonal markers showed no statistically significant difference in women with and without endometriosis (<a href="./appendices#CD012179-sec-0181">Appendix 7</a>): E2 and progesterone (<a href="./references#CD012179-bbs2-0044" title="HapangamaDK , TurnerMA , DruryJA , QuenbyS , SaretzkiG , Martin‐RuizC , et al. Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length. Human Reproduction2008;23(7):1511‐9. ">Hapangama 2008</a>; 50 participants); FSH and LH (<a href="./references#CD012179-bbs2-0073" title="LimaAP , RosaE Silva AAM , MouraMD . FSH, LH, estradiol, progesterone, and histamine concentrations in serum, peritoneal fluid and follicular fluid of women with and without endometriosis [Concentrações de FSH, LH, estradiol, progesterona e histamina no soro, no fluido peritoneal e no fluido folicular de mulheres com e sem endometriose]. Revista Brasileira de Ginecologia e Obstetrica2006;28(11):643‐51. ">Lima 2006</a>; 49 participants). Even though we only identified one study for each of these markers, the findings are consistent with other studies in the literature addressing hormonal alterations in endometriosis. We do not therefore recommend further research on the diagnostic accuracy of these biomarkers for endometriosis. </p> </section> </section> <section id="CD012179-sec-0099"> <h5 class="title">8. Immune system and inflammatory markers</h5> <section id="CD012179-sec-0100"> <h6 class="title">8.1. Autoantibodies</h6> <section id="CD012179-sec-0101"> <p><b>8.1.a. Anti‐endometrial autoantibodies (anti‐endometrial Abs)</b></p> <p>Five studies comprising 795 participants assessed the value of anti‐endometrial Abs in detecting pelvic endometriosis. Of these, four studies (759 participants, varying phases of menstrual cycle, rASRM I to IV (3 studies) or unclear severity (1 study)) evaluated IgG anti‐endometrial Abs using various immunofluorescence methods and different definitions of a positive test.The estimates for sensitivity ranged from 0.56 to 0.87 and for specificity from 0.57 to 0.93. The mean sensitivity and specificity of all these evaluations were 0.81 (95% CI 0.76 to 0.87) and 0.75 (95% CI 0.46 to 1.00), which did not meet the criteria for either a replacement or triage test. Forest plots (<a href="#CD012179-fig-0008">Figure 8</a>) and the ROC plot (<a href="#CD012179-fig-0009">Figure 9</a>) showed a high degree of heterogeneity for estimates of both sensitivity and specificity. An additional study (36 participants, cycle phase not reported, rASRM I to IV) demonstrated that anti‐endometrial Abs of a specific molecular weight (MW) were differentially expressed in endometriosis, and the expression of at least one of the antibodies with MWs of 26 kDa, 34 kDa or 42 kDa had a sensitivity of 1.00 (95% CI 0.81 to 1.00) and a specificity of 0.39 (95% CI 0.17 to 0.64) (<a href="./references#CD012179-bbs2-0038" title="GoraiI , IshikawaM , OnoseR , HiraharaF , MinaguchiH . Antiendometrial autoantibodies are generated in patients with endometriosis. American Journal of Reproductive Immunology1993;29(2):116‐23. ">Gorai 1993</a>) (<a href="#CD012179-fig-0009">Figure 9</a>; <a href="#CD012179-fig-0008">Figure 8</a>). This study could not be added to the meta‐analysis as the definition of the index test was different, and we considered it separately. The same study assessed an alternate set of antibodies with MWs of 28 kDa, 38 kDa and 64 kDa, the expression of which was not altered in presence of endometriosis. A further study (80 participants, cycle phase not reported, rASRM I to IV) also demonstrated that the serum levels of anti‐endometrial Abs were comparable between control and endometriosis groups (<a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>). </p> <div class="figure" id="CD012179-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of anti‐endometrial Abs for detection of endometriosis. Plot shows study‐specific estimates of sensitivity and specificity (squares) with 95% CI (black line), country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of anti‐endometrial Abs for detection of endometriosis. Plot shows study‐specific estimates of sensitivity and specificity (squares) with 95% CI (black line), country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Summary ROC plot of anti‐endometrial Abs, IgG for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 4 studies (the data for Anti‐endometrial Abs (MW 26/34/42 kd) were not included, considering it as a separate test)." data-id="CD012179-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of anti‐endometrial Abs, IgG for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 4 studies (the data for Anti‐endometrial Abs (MW 26/34/42 kd) were not included, considering it as a separate test). </p> </div> </div> </div> </section> <section id="CD012179-sec-0102"> <p><b>8.1.b. Anti‐laminin autoantibodies (anti‐laminin‐1 Abs)</b></p> <p>One study (68 participants, cycle phase not reported, rASRM I to IV) evaluated an accuracy of anti‐laminin‐1 Abs in detecting pelvic endometriosis. Using a cut‐off threshold of &gt; 1 U/ml, the test had a sensitivity of 0.40 (95% CI 0.26 to 0.57) and a specificity of 0.88 (95% CI 0.70 to 0.98). Although there is insufficient evidence to have certainty regarding the role of anti‐laminin‐1 Abs as a marker for endometriosis, these data suggest it is of limited value. </p> </section> <section id="CD012179-sec-0103"> <p><b>8.1.c. Autoantibodies that exhibited no differential expression in endometriosis</b></p> <p>Two additional types of autoantibodies, anti‐sperm and anti‐zona pellucida Abs, were evaluated in association with minimal endometriosis in one study (98 participants, luteal cycle phase, rASRM I) (<a href="./references#CD012179-bbs2-0114" title="SzczepaskaM , SkrzypczakJ , KamienicznaM , KurpiszM . Antizona and antisperm antibodies in women with endometriosis and/or infertility. Fertility &amp; Sterility2001;75(1):97‐105. ">Szczepanska 2001a</a>). The levels of these antibodies did not significantly differ in women with and without endometriosis; however, further data from additional studies for broader spectrum of disease is required to draw meaningful conclusions. </p> </section> </section> <section id="CD012179-sec-0104"> <h6 class="title">8.2. Chemokines</h6> <section id="CD012179-sec-0105"> <p><b>8.2.a. CCR1 (C‐C motif receptor 1)</b></p> <p>None of the eligible studies assessed the performance of CCR1 as a single test for detecting endometriosis. This biomarker was a part of a panel that constitutes a combined blood test for endometriosis, as presented below under 'Combined tests'. </p> </section> <section id="CD012179-sec-0106"> <p><b>8.2.b. MCP‐1 (monocyte chemotactic protein‐1)</b></p> <p>One study assessed the diagnostic accuracy of MCP‐1 in pelvic endometriosis (101 participants, menstrual cycle phase, rASRM I to IV) and demonstrated a sensitivity of 0.65 (95% CI 0.51 to 0.77) and a specificity of 0.61 (95% CI 0.45 to 0.76). Four other studies (361 participants, various phases of menstrual cycle) revealed that MCP‐1 levels were not altered by a wide spectrum of pelvic endometriosis, rASRM I to IV (<a href="./references#CD012179-bbs2-0020" title="Drosdzol‐CopA , Skrzypulec‐PlintaV , StojkoR . Serum and peritoneal fluid immunological markers in adolescent girls with chronic pelvic pain. Obstetrical &amp; Gynecological Survey2012;67(6):374‐81. ">Drosdzol‐Cop 2012b</a>; <a href="./references#CD012179-bbs2-0060" title="KimJY , KimH , SuhCS , KimSH , ChoiYM , KimJG . The G(‐2518)A polymorphism of monocyte chemotactic protein‐1 (MCP‐1) and its serum and peritoneal fluid levels in Korean women with endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;139(1):106‐10. ">Kim 2008</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>) or by only minimal‐mild disease, rASRM I‐II (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>). Based on the available evidence, MCP‐1 in blood appears to have little value as a diagnostic test for endometriosis. </p> </section> </section> <section id="CD012179-sec-0107"> <h6 class="title">8.3. Other Cytokines</h6> <section id="CD012179-sec-0108"> <p><b>8.3.a. IFN‐γ (interferon‐gamma)</b></p> <p>One study (45 participants, follicular cycle phase, rASRM I to IV) evaluated IFN‐γ and demonstrated a sensitivity of 0.68 (95% CI 0.48 to 0.84) and a specificity of 0.65 (95% CI 0.38 to 0.86) for the diagnosis of pelvic ultrasound negative endometriosis using a cut‐off value of &lt; 76.00 pg/ml. Another five studies (455 participants, rASRM I to IV) demonstrated no difference in IFN‐γ levels in women with and without pelvic endometriosis in the follicular phase (<a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>), follicular or luteal phase (<a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; <a href="./references#CD012179-bbs2-0108" title="SeeberB , SammelMD , FanX , GertonGL , ShaunikA , ChittamsJ , et al. Panel of markers can accurately predict endometriosis in a subset of patients. Fertility &amp; Sterility2008;89(5):1073‐81. ">Seeber 2008</a>), or when the cycle phase was not specified (<a href="./references#CD012179-bbs2-0082" title="MatalliotakisIM , GoumenouAG , KoumantakisGE , NeonakiMA , KoumantakisEE , DionyssopoulouE , et al. Serum concentrations of growth factors in women with and without endometriosis: the action of anti‐endometriosis medicines. International Immunopharmacology2003;3(1):81‐9. ">Matalliotakis 2003a</a>; <a href="./references#CD012179-bbs2-0133" title="WuMH , YangBC , HsuCC , LeeYC , HuangKE . The expression of soluble intercellular adhesion molecule‐1 in endometriosis. Fertility and Sterility1998;70(6):1139‐42. ">Wu 1998</a>). In view of the data available, IFN‐γ appears to be unreliable as a test for pelvic endometriosis. </p> </section> <section id="CD012179-sec-0109"> <p><b>8.3.b. MIF (macrophage migration inhibitory factor)</b></p> <p>One study evaluated the value of MIF in detecting pelvic endometriosis (93 participants, follicular or luteal cycle phase, rASRM I to IV), and showed a sensitivity of 0.65 (95% CI 0.51 to 0.78) and a specificity of 0.66 (95% CI 0.49 to 0.80) at a cut‐off threshold of &gt; 0.57 ng/ml. Three studies (322 participants, menstrual cycle phase not reported, rASRM I to IV) reported that MF levels were not altered in pelvic endometriosis in follicular or luteal cycle phase (<a href="./references#CD012179-bbs2-0108" title="SeeberB , SammelMD , FanX , GertonGL , ShaunikA , ChittamsJ , et al. Panel of markers can accurately predict endometriosis in a subset of patients. Fertility &amp; Sterility2008;89(5):1073‐81. ">Seeber 2008</a>) or when the cycle phase was not specified (<a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>), suggesting that MIF has little value in diagnosing endometriosis. </p> </section> <section id="CD012179-sec-0110"> <p><b>8.3.c. TNF‐α (tumour necrosis factor alpha)</b></p> <p>Three studies evaluated the accuracy of TNF‐α in detecting pelvic endometriosis (256 participants, rASRM I to IV), (<a href="#CD012179-fig-0010">Figure 10</a>). Two studies evaluated diagnostic test performance in the follicular phase, using contradictory cut‐off values of above 12.45 pg/ml (<a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>) and below 45.60 pg/ml (<a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>), and another study assessed the test in luteal cycle phase with no reported cut‐off value (<a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>). The estimates of sensitivity ranged from 0.68 to 0.89 and the estimates of specificity ranged from 0.35 to 0.87 (<a href="./full#CD012179-tbl-0001">summary of findings Table</a>). We did not perform a meta‐analysis because of the diverse definitions of a positive test. Alternatively, eight studies (633 participants, various phases of menstrual cycle) showed unchanged levels of TNF‐α in blood in a wide spectrum of pelvic endometriosis, rASRM I to IV (<a href="./references#CD012179-bbs2-0016" title="DaSilvaCM , Vilaca BeloA , Passos AndradeS , Peixoto CamposP , Cristina Franca FerreiraM , Lopes da Silva‐FilhoA , et al. Identification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis. Biomedicine &amp; Pharmacotherapy2014;68(7):899‐904. ">Da Silva 2014</a>; <a href="./references#CD012179-bbs2-0019" title="Drosdzol‐CopA , Skrzypulec‐PlintaV . Selected cytokines and glycodelin A levels in serum and peritoneal fluid in girls with endometriosis. Journal of Obstetrics and Gynaecology Research2012;38(10):1245‐53. ">Drosdzol‐Cop 2012a</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; <a href="./references#CD012179-bbs2-0108" title="SeeberB , SammelMD , FanX , GertonGL , ShaunikA , ChittamsJ , et al. Panel of markers can accurately predict endometriosis in a subset of patients. Fertility &amp; Sterility2008;89(5):1073‐81. ">Seeber 2008</a>; <a href="./references#CD012179-bbs2-0121" title="VercelliniP , DeBenedettiF , RossiE , ColomboA , TrespidiL , CrosignaniPG , et al. Tumor necrosis factor in plasma and peritoneal fluid of women with and without endometriosis. Gynecologic and Obstetric Investigation1993; Vol. 36, issue 1:39‐41. ">Vercellini 1993</a>; <a href="./references#CD012179-bbs2-0134" title="YagmurE , BastuE , Karamustafaoglu‐BalciB , AkhanSE , BuyruF . Non‐invasive diagnosis of endometriosis based on a combined analysis of four plasma biomarkers. Central‐European Journal of Immunology2013;38(2):154‐8. ">Yagmur 2013</a>) or in only minimal‐mild disease, rASRM I‐II (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>). These conflicting results indicate that TNF‐α for the detection of endometriosis is unlikely to be clinically useful. </p> <div class="figure" id="CD012179-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Summary ROC plot of TNF‐α for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of TNF‐α for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> </div> </section> <section id="CD012179-sec-0111"> <p><b>8.3.d. Other cytokines that exhibited no differential expression in endometriosis</b></p> <p>Additional cytokines evaluated in the included studies (<a href="./appendices#CD012179-sec-0181">Appendix 7</a>) were Epo (<a href="./references#CD012179-bbs2-0134" title="YagmurE , BastuE , Karamustafaoglu‐BalciB , AkhanSE , BuyruF . Non‐invasive diagnosis of endometriosis based on a combined analysis of four plasma biomarkers. Central‐European Journal of Immunology2013;38(2):154‐8. ">Yagmur 2013</a>; 55 participants) and sGM‐CSF (<a href="./references#CD012179-bbs2-0082" title="MatalliotakisIM , GoumenouAG , KoumantakisGE , NeonakiMA , KoumantakisEE , DionyssopoulouE , et al. Serum concentrations of growth factors in women with and without endometriosis: the action of anti‐endometriosis medicines. International Immunopharmacology2003;3(1):81‐9. ">Matalliotakis 2003a</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; 287 participants). While the data is scarce for Epo, it is sufficient to suggest that GM‐CSF is an inadequate marker for the diagnosis of pelvic endometriosis. </p> </section> </section> <section id="CD012179-sec-0112"> <h6 class="title">8.4. Immune cells</h6> <section id="CD012179-sec-0113"> <p><b>8.4.a. Neutrophils, NLR (neutrophil‐to‐lymphocyte ratio), WBC (white blood cells)</b></p> <p>One study (100 participants, menstrual phase, rASRM I to IV) evaluated the accuracy of immune cells in diagnosing pelvic endometriosis and reported unsatisfactory estimates for neutrophils at a cut‐off of &gt; 4058 cells/ml (sensitivity 0.68, 95% CI 0.53 to 0.80, specificity 0.60, 95% CI 0.45 to 0.74); for NLR (neutrophil lymphocyte ratio), at a cut‐off of &gt; 2.19 (sensitivity 0.76, 95% CI 0.62 to 0.87, specificity 0.82, 95% CI 0.69 to 0.91) and for WBC at a cut‐off of &gt; 6400 cells/ml (sensitivity 0.64, 95% CI 0.49 to 0.77, specificity 0.54, 95% CI 0.39 to 0.68). Other studies reported negative findings for these biomarkers, specifically for neutrophils and NLR (<a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>); 94 participants, cycle phase not reported, rASRM III to IV) and for WBC (3 studies, 222 participants, follicular or undetermined cycle phase, rASRM I to IV in <a href="./references#CD012179-bbs2-0036" title="GogaczM , WinklerI , Bojarska‐JunakA , TabarkiewiczJ , SemczukA , RechbergerT , et al. T regulatory lymphocytes in patients with endometriosis. Molecular Medicine Reports2014;10(2):1072‐6. ">Gogacz 2014</a> and <a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a)</a>, or rASRM III to IV in <a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>). These data indicate that WBC levels are not reliable as a diagnostic test for endometriosis, whilst the data for neutrophils and NLR are discouraging but scant. </p> </section> <section id="CD012179-sec-0114"> <p><b>8.4.b. Immune cells that exhibited no differential expression in endometriosis</b></p> <p>We investigated additional peripheral immune cells and found them to be similar in women with and without endometriosis, as presented in <a href="./appendices#CD012179-sec-0181">Appendix 7</a>. The tested markers from this subgroup included: </p> <p> <ol id="CD012179-list-0059"> <li> <p>lymphocytes (<a href="./references#CD012179-bbs2-0036" title="GogaczM , WinklerI , Bojarska‐JunakA , TabarkiewiczJ , SemczukA , RechbergerT , et al. T regulatory lymphocytes in patients with endometriosis. Molecular Medicine Reports2014;10(2):1072‐6. ">Gogacz 2014</a>; <a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0084" title="MatveevaNK , VolkovNI , PetrenkoEP , Mit'kinVV , PshenichnikovaTI , SukhikhGT . Immunological studies of peripheral blood in patients with external genital endometriosis and infertility. Akusherstvo i Ginekologiia1990;8:48‐51. ">Matveeva 1990</a>; <a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>; 352 participants); </p> </li> <li> <p>B‐lymphocytes (<a href="./references#CD012179-bbs2-0049" title="IwasakiK , MakinoT , MaruyamaT , MatsubayashiH , NozawaS , YokokuraT . Leukocyte subpopulations and natural killer activity in endometriosis. International Journal of Fertility and Menopausal Studies1993;38(4):229‐34. ">Iwasaki 1993</a>; <a href="./references#CD012179-bbs2-0077" title="MaedaN , IzumiyaC , OguriH , KusumeT , YamamotoY , FukayaT . Aberrant expression of intercellular adhesion molecule‐1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertility and Sterility2002;77(4):679‐83. ">Maeda 2002a</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; 223 participants); </p> </li> <li> <p>monocytes/macrophages (<a href="./references#CD012179-bbs2-0077" title="MaedaN , IzumiyaC , OguriH , KusumeT , YamamotoY , FukayaT . Aberrant expression of intercellular adhesion molecule‐1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertility and Sterility2002;77(4):679‐83. ">Maeda 2002a</a>; 54 participants); </p> </li> <li> <p>NK cells (<a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0049" title="IwasakiK , MakinoT , MaruyamaT , MatsubayashiH , NozawaS , YokokuraT . Leukocyte subpopulations and natural killer activity in endometriosis. International Journal of Fertility and Menopausal Studies1993;38(4):229‐34. ">Iwasaki 1993</a>; <a href="./references#CD012179-bbs2-0077" title="MaedaN , IzumiyaC , OguriH , KusumeT , YamamotoY , FukayaT . Aberrant expression of intercellular adhesion molecule‐1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertility and Sterility2002;77(4):679‐83. ">Maeda 2002a</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; 320 participants); </p> </li> <li> <p>NKR CD158b+ (KIR2DL2+NK) and NKR CD94+ (<a href="./references#CD012179-bbs2-0078" title="MaedaN , IzumiyaC , YamamotoY , OguriH , KusumeT , FukayaT . Increased killer inhibitory receptor KIR2DL1 expression among natural killer cells in women with pelvic endometriosis. Fertility and Sterility2002;77(2):297‐302. ">Maeda 2002b</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; 206 participants); </p> </li> <li> <p>T‐lymphocytes and specific T‐cell populations:</p> <ol id="CD012179-list-0060"> <li> <p>T‐cells (<a href="./references#CD012179-bbs2-0049" title="IwasakiK , MakinoT , MaruyamaT , MatsubayashiH , NozawaS , YokokuraT . Leukocyte subpopulations and natural killer activity in endometriosis. International Journal of Fertility and Menopausal Studies1993;38(4):229‐34. ">Iwasaki 1993</a>; <a href="./references#CD012179-bbs2-0077" title="MaedaN , IzumiyaC , OguriH , KusumeT , YamamotoY , FukayaT . Aberrant expression of intercellular adhesion molecule‐1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertility and Sterility2002;77(4):679‐83. ">Maeda 2002a</a>; <a href="./references#CD012179-bbs2-0084" title="MatveevaNK , VolkovNI , PetrenkoEP , Mit'kinVV , PshenichnikovaTI , SukhikhGT . Immunological studies of peripheral blood in patients with external genital endometriosis and infertility. Akusherstvo i Ginekologiia1990;8:48‐51. ">Matveeva 1990</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; 6 data sets, 342 participants); </p> </li> <li> <p>T‐inducers (<a href="./references#CD012179-bbs2-0049" title="IwasakiK , MakinoT , MaruyamaT , MatsubayashiH , NozawaS , YokokuraT . Leukocyte subpopulations and natural killer activity in endometriosis. International Journal of Fertility and Menopausal Studies1993;38(4):229‐34. ">Iwasaki 1993</a>; 45 participants); </p> </li> <li> <p>T‐helpers (<a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0049" title="IwasakiK , MakinoT , MaruyamaT , MatsubayashiH , NozawaS , YokokuraT . Leukocyte subpopulations and natural killer activity in endometriosis. International Journal of Fertility and Menopausal Studies1993;38(4):229‐34. ">Iwasaki 1993</a>; <a href="./references#CD012179-bbs2-0077" title="MaedaN , IzumiyaC , OguriH , KusumeT , YamamotoY , FukayaT . Aberrant expression of intercellular adhesion molecule‐1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertility and Sterility2002;77(4):679‐83. ">Maeda 2002a</a>; <a href="./references#CD012179-bbs2-0084" title="MatveevaNK , VolkovNI , PetrenkoEP , Mit'kinVV , PshenichnikovaTI , SukhikhGT . Immunological studies of peripheral blood in patients with external genital endometriosis and infertility. Akusherstvo i Ginekologiia1990;8:48‐51. ">Matveeva 1990</a>; <a href="./references#CD012179-bbs2-0085" title="Mier‐CabreraJ , Jimenez‐ZamudioL , Garcia‐LatorreE , Cruz‐OrozcoO , Hernandez‐GuerreroC . Quantitative and qualitative peritoneal immune profiles, T‐cell apoptosis and oxidative stress‐associated characteristics in women with minimal and mild endometriosis. BJOG: An International Journal of Obstetrics and Gynaecology2011;118(1):6‐16. ">Mier‐Cabrera 2011</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; 501 participants); </p> </li> <li> <p>T‐suppressors (<a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0077" title="MaedaN , IzumiyaC , OguriH , KusumeT , YamamotoY , FukayaT . Aberrant expression of intercellular adhesion molecule‐1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertility and Sterility2002;77(4):679‐83. ">Maeda 2002a</a>; <a href="./references#CD012179-bbs2-0084" title="MatveevaNK , VolkovNI , PetrenkoEP , Mit'kinVV , PshenichnikovaTI , SukhikhGT . Immunological studies of peripheral blood in patients with external genital endometriosis and infertility. Akusherstvo i Ginekologiia1990;8:48‐51. ">Matveeva 1990</a>; <a href="./references#CD012179-bbs2-0085" title="Mier‐CabreraJ , Jimenez‐ZamudioL , Garcia‐LatorreE , Cruz‐OrozcoO , Hernandez‐GuerreroC . Quantitative and qualitative peritoneal immune profiles, T‐cell apoptosis and oxidative stress‐associated characteristics in women with minimal and mild endometriosis. BJOG: An International Journal of Obstetrics and Gynaecology2011;118(1):6‐16. ">Mier‐Cabrera 2011</a>; <a href="./references#CD012179-bbs2-0140" title="ZhangC , MaedaN , IzumiyaC , YamamotoY , KusumeT , OguriH , et al. Killer immunoglobulin‐like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. American Journal of Reproductive Immunology2006;55(2):106‐14. ">Zhang 2006a</a>; 6 data sets, 456 participants); </p> </li> </ol> </li> <li> <p>Treg cells (regulatory T cells) (<a href="./references#CD012179-bbs2-0036" title="GogaczM , WinklerI , Bojarska‐JunakA , TabarkiewiczJ , SemczukA , RechbergerT , et al. T regulatory lymphocytes in patients with endometriosis. Molecular Medicine Reports2014;10(2):1072‐6. ">Gogacz 2014</a>; <a href="./references#CD012179-bbs2-0094" title="Olkowska‐TruchanowiczJ , BocianK , MaksymRB , BialoszewskaA , WlodarczykD , BaranowskiW , et al. CD4+ CD25+ FOXP3+ regulatory T cells in peripheral blood and peritoneal fluid of patients with endometriosis. Human Reproduction2013;28(1):119‐24. ">Olkowska‐Truchanowicz 2013</a>; 3 data sets, 74 participants); </p> </li> <li> <p>haemoglobin (<a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>; 94 participants); </p> </li> <li> <p>MPV (<a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>; 94 participants); </p> </li> <li> <p>platelet count (<a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>; 94 participants); </p> </li> <li> <p>PLR (<a href="./references#CD012179-bbs2-0136" title="YavuzcanA , CaglarM , UstunY , DilbazS , OzdemirI , YildizE , et al. Evaluation of mean platelet volume, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma [Endometrioma bulunan ileri evre endometrioziste ortalama trombosit hacmi, nötrofil/lenfosit orani ve trombosit/lenfosit oraninin degerlendirilmesi]. Journal of the Turkish German Gynecological Association2013;14(4):210‐5. ">Yavuzcan 2013</a>; 94 participants). </p> </li> </ol> </p> <p>This evidence clearly indicates that most of the evaluated peripheral blood mononuclear cells have no role as a diagnostic marker for endometriosis. The finding is consistent with the general theme of literature addressing other components of full blood count (haemoglobin, platelets, MPV). Therefore, except for the unexplored phenotypes of Treg cells, we do not recommend further research on the diagnostic accuracy of these biomarkers for endometriosis. </p> </section> </section> <section id="CD012179-sec-0115"> <h6 class="title">8.5. Interleukins</h6> <section id="CD012179-sec-0116"> <p><b>8.5.a. IL‐1β (interleukin‐1β)</b></p> <p>One study (45 participants, follicular cycle phase, rASRM I to IV) evaluated the diagnostic role of IL‐1β in ultrasound negative pelvic endometriosis, showing a sensitivity of 0.82 (95% CI 0.63 to 0.94) and a specificity of 0.35 (95% CI 0.14 to 0.62) for the cut‐off value of &lt; 0.90 pg/ml. Four additional studies (248 participants, various cycle phases) showed that IL‐1β remained unchanged in a wide spectrum of pelvic endometriosis, rASRM I to IV (<a href="./references#CD012179-bbs2-0008" title="BedaiwyMA , FalconeT , SharmaRK , GoldbergJM , AttaranM , NelsonDR , et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Human Reproduction2002;17(2):426‐31. ">Bedaiwy 2002</a>; <a href="./references#CD012179-bbs2-0093" title="OkuH , TsujiY , KashiwamuraSI , AdachiS , KubotaA , OkamuraH , et al. Role of IL‐18 in pathogenesis of endometriosis. Human Reproduction2004;19(3):709‐14. ">Oku 2004</a>; <a href="./references#CD012179-bbs2-0117" title="SzubertM , SuzinJ , DuechlerM , SzuławskaA , CzyżM , Kowalczyk‐AmicoK . Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment. Reproduction, Fertility, and Development2014;26(3):414‐20. ">Szubert 2014</a>), or in only minimal‐mild disease, rASRM I‐II (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>). Taken together, these results demonstrate that IL‐1β has a limited value in detecting pelvic endometriosis. </p> </section> <section id="CD012179-sec-0117"> <p><b>8.5.b. IL‐4 (interleukin ‐ 4)</b></p> <p>One study reported the diagnostic accuracy of IL‐4 (50 women, follicular cycle phase, rASRM I to IV), showing inadequate estimates for both sensitivity and specificity for a cut‐off value ≥ 3.00 pg/ml (0.64, 95% CI 0.45 to 0.80 and 0.65, 95% CI 0.38 to 0.86, respectively). Two other studies reported negative data for this biomarker (195 participants, rASRM I to IV) in either the follicular cycle phase or follicular and luteal cycle phase (<a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>), indicating that IL‐4 is unlikely to be an accurate diagnostic test for endometriosis. </p> </section> <section id="CD012179-sec-0118"> <p><b>8.5.c. IL‐6 (interleukin‐6)</b></p> <p>Eight studies including 12 data sets with a total of 726 participants assessed the diagnostic accuracy of IL‐6 for endometriosis. All the studies evaluated pelvic endometriosis (rASRM I to IV in 6 studies and rASRM I‐II in 2 studies), but were performed at various phases of the menstrual cycle and utilised different cut‐off values (<a href="#CD012179-fig-0011">Figure 11</a>). The cut‐offs varied from &gt; 1.03 pg/ml to &gt; 25.75 pg/ml, whilst one study used a cut‐off of &lt; 10.00 pg/ml. We only included three studies (309 participants, of varying cycle phase, rASRM I to IV) in a meta‐analysis, which revealed the summary sensitivity and specificity of 0.63 (95% CI 0.52 to 0.75) and 0.69 (95% CI 0.57 to 0.82) for the cut‐off threshold &gt; 1.90 to 2.00 pg/ml. The test did not satisfy the criteria for either a replacement or triage test. Forest plots (<a href="#CD012179-fig-0012">Figure 12</a>) and the ROC plot (<a href="#CD012179-fig-0013">Figure 13</a>) showed a high degree of heterogeneity for diagnostic estimates, ranging from 0.20 to 0.89 for sensitivity and from 0.66 to 0.80 for specificity. Individual studies evaluated other cut‐off thresholds, as presented in <a href="./full#CD012179-tbl-0001">summary of findings Table</a>. Studies reported the highest diagnostic estimates for cut‐off value &gt; 12.20 pg/ml (95 participants, follicular cycle phase, rASRM I to IV) with a sensitivity of 0.95 (95% CI 0.87 to 0.99) and a specificity of 0.83 (95% CI 0.65 to 0.94), which met the criteria for a replacement test; however, wide confidence intervals, especially for specificity, advises caution in interpreting these results (<a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>). Two studies compared different cut‐off values, specifically &gt; 1.03 pg/ml versus &gt; 1.90 pg/ml versus &gt; 2.60 pg/ml (<a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>) and &gt; 2.00 pg/ml versus &gt; 4.00 pg/ml versus &gt; 7.50 pg/ml (<a href="./references#CD012179-bbs2-0008" title="BedaiwyMA , FalconeT , SharmaRK , GoldbergJM , AttaranM , NelsonDR , et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Human Reproduction2002;17(2):426‐31. ">Bedaiwy 2002</a>); however, all had wide overlapping confidence intervals and presented inconclusive results (<a href="#CD012179-fig-0014">Figure 14</a>). In contrast, six other studies (473 participants, various phases of menstrual cycle) demonstrated that IL‐6 levels were not affected by the presence of endometriosis when considering different spectra of disease: rASRM I to IV (<a href="./references#CD012179-bbs2-0019" title="Drosdzol‐CopA , Skrzypulec‐PlintaV . Selected cytokines and glycodelin A levels in serum and peritoneal fluid in girls with endometriosis. Journal of Obstetrics and Gynaecology Research2012;38(10):1245‐53. ">Drosdzol‐Cop 2012a</a>; <a href="./references#CD012179-bbs2-0108" title="SeeberB , SammelMD , FanX , GertonGL , ShaunikA , ChittamsJ , et al. Panel of markers can accurately predict endometriosis in a subset of patients. Fertility &amp; Sterility2008;89(5):1073‐81. ">Seeber 2008</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>), rASRM I‐II (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>) or rASRM III to IV (<a href="./references#CD012179-bbs2-0050" title="JeeBC , SuhCS , KimSH , MoonSY . Serum soluble CD163 and interleukin‐6 levels in women with ovarian endometriomas. Gynecologic and Obstetric Investigation2008;66(1):47‐52. ">Jee 2008</a>; <a href="./references#CD012179-bbs2-0113" title="SuenJL , ChangY , ChiuPR , HsiehTH , HsiE , ChenYC , et al. Serum level of IL‐10 is increased in patients with endometriosis, and IL‐10 promotes the growth of lesions in a murine model. American Journal of Pathology2014;184(2):464‐71. ">Suen 2014</a>). Although the reports are conflicting, further testing of IL‐6 in the follicular cycle phase at a cutoff value of &gt; 12.20 pg/ml could reveal some diagnostic benefit. </p> <div class="figure" id="CD012179-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of IL‐6 (all the included evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of IL‐6 (all the included evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Forest plot of IL‐6 with cut‐off values above 1.9‐2 pg/ml for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of IL‐6 with cut‐off values above 1.9‐2 pg/ml for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Summary ROC plot of IL‐6 with cut‐off values ranging &gt; 1.9‐2 pg/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity." data-id="CD012179-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of IL‐6 with cut‐off values ranging &gt; 1.9‐2 pg/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Forest plot of direct comparisons of IL‐6 for detection of endometriosis performed between different cut‐off values in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of direct comparisons of IL‐6 for detection of endometriosis performed between different cut‐off values in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> </section> <section id="CD012179-sec-0119"> <p><b>8.5.d. IL‐8 (interleukin‐8)</b></p> <p>Two studies explored the accuracy of IL‐8 in diagnosing pelvic endometriosis (217 participants, various cycle phases, rASRM I to IV), of which one utilised a cut‐off value of &gt; 24.00 pg/ml and one did not report a diagnostic threshold. Due to the heterogeneity of the methodology, we could not perform a meaningful meta‐analysis. The estimates of sensitivity ranged between 0.49 and 0.62 and of specificity between 0.71 and 0.73 (<a href="./full#CD012179-tbl-0001">summary of findings Table</a>; <a href="#CD012179-fig-0015">Figure 15</a>). An additional study (91 participants, cut‐off value &gt; 25.00 pg/ml) specifically addressed ovarian endometriosis versus other benign ovarian cysts; we present its findings below under 'Blood biomarkers that could differentiate ovarian endometrioma from other benign ovarian cysts in women of reproductive age'. Five other studies (389 participants,various cycle phases) reported negative data for IL‐8 in pelvic endometriosis rASRM I to IV (<a href="./references#CD012179-bbs2-0007" title="BarczE , RozewskaES , KaminskiP , DemkowU , BobrowskaK , MarianowskiL . Angiogenic activity and IL‐8 concentrations in peritoneal fluid and sera in endometriosis. International Journal of Gynaecology and Obstetrics2002;79(3):229‐35. ">Barcz 2002</a>; <a href="./references#CD012179-bbs2-0034" title="GazvaniMR , ChristmasS , QuenbyS , KirwanJ , JohnsonPM , KingslandCR . Peritoneal fluid concentrations of interleukin‐8 in women with endometriosis: relationship to stage of disease. Human Reproduction1998;13(7):1957‐61. ">Gazvani 1998</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; <a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>), rASRM I‐II (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>), or rASRM III to IV (<a href="./references#CD012179-bbs2-0012" title="CaliennoC , TrioC , MontiB , IedaN , CorteseM , VariscoE . MCP‐1 and IL‐8 in serum and ectopic endometrium in women with endometriosis. Italian Journal of Gynaecology and Obstetrics2008;20(1):12‐8. ">Calienno 2008</a>). These conflicting results suggest that IL‐8 has questionable value as a diagnostic test for endometriosis. </p> <div class="figure" id="CD012179-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Summary ROC plot of IL‐8 for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of IL‐8 for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> </div> </section> <section id="CD012179-sec-0120"> <p><b>8.5.e. Interleukins that exhibited no differential expression in endometriosis</b></p> <p>The included studies reported negative findings for endometriosis with additional types of interleukins, as presented in <a href="./appendices#CD012179-sec-0181">Appendix 7</a>. </p> <p> <ol id="CD012179-list-0061"> <li> <p>IL‐2 <a href="./references#CD012179-bbs2-0020" title="Drosdzol‐CopA , Skrzypulec‐PlintaV , StojkoR . Serum and peritoneal fluid immunological markers in adolescent girls with chronic pelvic pain. Obstetrical &amp; Gynecological Survey2012;67(6):374‐81. ">Drosdzol‐Cop 2012b</a>; <a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0072" title="LiJX , DaiSZ , LiuH , CaoYM , LiuSQ . Study on the changes of T‐lymphocyte subsets in the patients with endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]2005;40(1):17‐20. Chinese. ">Li 2005</a>; <a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; 433 participants). </p> </li> <li> <p>IL‐10 (<a href="./references#CD012179-bbs2-0004" title="AndreoliCG , GenroVK , SouzaCA , MichelonT , BilibioJP , ScheffelC , et al. T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertility and Sterility2011;95(8):2477‐80. ">Andreoli 2011</a>; <a href="./references#CD012179-bbs2-0011" title="BraunDP , GebelH , HouseR , RanaN , DmowskiWP . Spontaneous and induced synthesis of cytokines by peripheral blood monocytes in patients with endometriosis. Fertility and Sterility1996;65(6):1125‐9. ">Braun 1996</a>; <a href="./references#CD012179-bbs2-0046" title="HassaH , TanirH Mete , TekinB , KirilmazS D , Sahin MutluF . Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with early‐ and late‐staged endometriosis. Archives of Gynecology and Obstetrics2009;279(6):891‐5. ">Hassa 2009</a>; <a href="./references#CD012179-bbs2-0101" title="PodgaecS , AbraoMS , Dias JrJA , RizzoLV , deOliveiraRM , BaracatEC . Endometriosis: An inflammatory disease with a Th2 immune response component. Human Reproduction2007;22(5):1373‐9. ">Podgaec 2007</a>; 305 participants). </p> </li> <li> <p>IL‐12 (<a href="./references#CD012179-bbs2-0004" title="AndreoliCG , GenroVK , SouzaCA , MichelonT , BilibioJP , ScheffelC , et al. T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertility and Sterility2011;95(8):2477‐80. ">Andreoli 2011</a>; <a href="./references#CD012179-bbs2-0008" title="BedaiwyMA , FalconeT , SharmaRK , GoldbergJM , AttaranM , NelsonDR , et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Human Reproduction2002;17(2):426‐31. ">Bedaiwy 2002</a>; <a href="./references#CD012179-bbs2-0022" title="FairbanksF , AbraoMS , PodgaecS , DiasJAJr , deOliveiraRM , RizzoLV . Interleukin‐12 but not interleukin‐18 is associated with severe endometriosis. Fertility and Sterility2009;91(2):320‐4. ">Fairbanks 2009</a>; <a href="./references#CD012179-bbs2-0066" title="KubatovaA , ErdemA , ErdemM , FiratMutluM , KorucuogluU . Serum cytokine and growth factor levels in patients with endometriosis. Central‐European Journal of Immunology2013;38(4):500‐4. ">Kubatova 2013</a>; <a href="./references#CD012179-bbs2-0113" title="SuenJL , ChangY , ChiuPR , HsiehTH , HsiE , ChenYC , et al. Serum level of IL‐10 is increased in patients with endometriosis, and IL‐10 promotes the growth of lesions in a murine model. American Journal of Pathology2014;184(2):464‐71. ">Suen 2014</a>; <a href="./references#CD012179-bbs2-0115" title="SzczepanskaM , MikolajczykM , RaczynskaP , SkrzypczakJ . The evaluation of IL‐12 levels in peritoneal fluid and serum of women with endometriosis. Ginekologia Polska2001;72(5):408‐17. ">Szczepanska 2001b</a>; 433 participants). </p> </li> <li> <p>IL‐13 (<a href="./references#CD012179-bbs2-0008" title="BedaiwyMA , FalconeT , SharmaRK , GoldbergJM , AttaranM , NelsonDR , et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Human Reproduction2002;17(2):426‐31. ">Bedaiwy 2002</a>; 53 participants). </p> </li> <li> <p>IL‐15 (<a href="./references#CD012179-bbs2-0095" title="OthmanEEDR , HomungD , SalemHT , KhalifaEA , El‐MetwallyTH , Al‐HendyA . Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2008;137(2):240‐6. ">Othman 2008</a>; 138 participants, biomarker below detection limit in both groups). </p> </li> <li> <p>IL‐16 (<a href="./references#CD012179-bbs2-0074" title="LinJ , ZhangXM , DengL , ChenZY , ChenL . Determination of interleukine‐16 levels in peritoneal fluid and serum of women with endometriosis. Zhejiang Daxue Xuebao (Yixueban) [Journal of Zhejiang University (Medical Sciences)]2005;34(3):260‐2. Chinese. ">Lin 2005</a>; <a href="./references#CD012179-bbs2-0138" title="ZhangX , LinJ , DengL , ChenZ , ChenL . Peritoneal fluid and serum concentration of interleukin‐16 in women with endometriosis. Acta Obstetricia et Gynecologica Scandinavica2005;84(3):297‐8. ">Zhang 2005a</a>; 88 participants). </p> </li> <li> <p>IL‐17 (<a href="./references#CD012179-bbs2-0004" title="AndreoliCG , GenroVK , SouzaCA , MichelonT , BilibioJP , ScheffelC , et al. T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertility and Sterility2011;95(8):2477‐80. ">Andreoli 2011</a>; <a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; 181 participants). </p> </li> <li> <p>IL‐18 (<a href="./references#CD012179-bbs2-0022" title="FairbanksF , AbraoMS , PodgaecS , DiasJAJr , deOliveiraRM , RizzoLV . Interleukin‐12 but not interleukin‐18 is associated with severe endometriosis. Fertility and Sterility2009;91(2):320‐4. ">Fairbanks 2009</a>; <a href="./references#CD012179-bbs2-0035" title="GlitzC , SouzaCA , RodiniGP , GenroV , BilibioJP , SengerM , et al. Peritoneal and serum interleukin‐18 levels are not increased in women with minimum or mild endometriosis. Brazilian Journal of Medical and Biological Research2009;42(11):1039‐43. ">Glitz 2009</a>; <a href="./references#CD012179-bbs2-0093" title="OkuH , TsujiY , KashiwamuraSI , AdachiS , KubotaA , OkamuraH , et al. Role of IL‐18 in pathogenesis of endometriosis. Human Reproduction2004;19(3):709‐14. ">Oku 2004</a>; <a href="./references#CD012179-bbs2-0139" title="ZhangY , PengLX , MengL . Measurements of interleukin‐18 in peritoneal fluid and serum of patients with endometriosis. Zhongnan Daxue Xuebao (Yixue Ban) [Journal of Central South University (Medical Sciences)]2005;30(6):731‐2. Chinese. ">Zhang 2005b</a>; 301 participants). </p> </li> <li> <p>IL‐23 (<a href="./references#CD012179-bbs2-0004" title="AndreoliCG , GenroVK , SouzaCA , MichelonT , BilibioJP , ScheffelC , et al. T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertility and Sterility2011;95(8):2477‐80. ">Andreoli 2011</a>: 80 participants). </p> </li> </ol> </p> <p>Many of these interleukins were evaluated by more than one study and are unlikely to be worthy of further investigation as diagnostic biomarkers for endometriosis. </p> </section> </section> <section id="CD012179-sec-0121"> <h6 class="title">8.6. Other immune/inflammatory markers</h6> <section id="CD012179-sec-0122"> <p><b>8.6.a. sCD23 (soluble CD23)</b></p> <p>One study evaluated the diagnostic performance of sCD23 for pelvic endometriosis (97 participants, follicular or luteal cycle phase, rASRM I to IV), demonstrating a sensitivity of 0.25 (95% CI 0.14 to 0.38) and a specificity of 0.93 (95% CI 0.80 to 0.98). Another study (102 participants, menstrual or follicular cycle phase, rASRM I to IV) demonstrated no significant difference in sCD23 levels in women with and without endometriosis, indicating that sCD23 is likely to have limited diagnostic value, albeit further studies are needed to support this statement (<a href="./references#CD012179-bbs2-0102" title="RamosIML , PodgaecS , AbraoMS , deOliveiraR , BaracatEC . Evaluation of CA‐125 and soluble CD‐23 in patients with pelvic endometriosis: A case‐control study. Revista da Associacao Medica Brasileira2012;58(1):26‐32. ">Ramos 2012</a>). </p> </section> <section id="CD012179-sec-0123"> <p><b>8.6.b. Copeptin, vasopressin surrogate</b></p> <p>One study evaluated the accuracy of copeptin in detecting pelvic endometriosis (87 participants, cycle phase not reported, rASRM I to IV), showing a sensitivity of 0.65 (95% CI 0.50 to 0.78) and a specificity of 0.58 (95% CI 0.41 to 0.74). There is insufficient data to draw meaningful conclusions on the findings from this single study. </p> </section> <section id="CD012179-sec-0124"> <p><b>8.6.c. hs‐CRP (high sensitive C‐reactive protein)</b></p> <p>Three studies including six data sets (506 participants, various menstrual cycle phases, rASRM I to IV) explored the diagnostic accuracy of hs‐CRP for pelvic endometriosis, using various cut‐off thresholds, ranging from 0.60 mg/l to 438 mg/l. Five data sets included overlapping populations. We did not perform a meta‐analysis because of the methodological heterogeneity. Diagnostic estimates from the included studies varied, with sensitivities ranging from 0.41 to 0.83 and specificities ranging from 0.47 to 0.87 (<a href="./full#CD012179-tbl-0001">summary of findings Table</a>; <a href="#CD012179-fig-0016">Figure 16</a>; <a href="#CD012179-fig-0017">Figure 17</a>). Studies reported the highest estimates for hs‐CRP with a cut‐off of &gt; 438 mg/l (1 study, 95 participants in follicular cycle phase) with a sensitivity of 0.83 (95% CI 0.72 to 0.91) and a specificity of 0.87 (95% CI 0.69 to 0.96) (<a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>). One group compared hs‐CRP diagnostic estimates in the menstrual, follicular, luteal or combination of all phases of the cycle in a total of 295 participants (<a href="./references#CD012179-bbs2-0125" title="VodolazkaiaA , BossuytX , FassbenderA , KyamaCM , MeulemanC , PeeraerK , et al. A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis. Reproductive Biology and Endocrinology2011;9:113. ">Vodolazkaia 2011</a>). The authors established the best cut‐off values in a ROC analysis, which varied depending on the cycle phase. The diagnostic estimates were low for all evaluations, ranging from 0.54 to 0.68 for sensitivity and from 0.47 to 0.64 for specificity (<a href="#CD012179-fig-0016">Figure 16</a>). Six additional studies (1333 participants, various cycle phases) demonstrated no difference in expression levels of CRP or hs‐CRP in a wide spectrum of pelvic endometriosis, rASRM I to IV (<a href="./references#CD012179-bbs2-0017" title="Dayangan SayanC , OzaksitMG , SarikayaE , Gun EryilmazO , MollamahmutogluL , DeveerR . Serum interleukin‐8, CA‐125 levels, neutrophil‐to‐lymphocyte ratios, and combined markers in the diagnosis of endometriosis. Turkish Journal of Medical Sciences2013;43(3):417‐23. ">Dayangan Sayan 2013</a>; <a href="./references#CD012179-bbs2-0104" title="RileyCF , MoenMH , VidemV . Inflammatory markers in endometriosis: reduced peritoneal neutrophil response in minimal endometriosis. Acta Obstetricia et Gynecologica Scandinavica2007;86(7):877‐81. ">Riley 2007</a>; <a href="./references#CD012179-bbs2-0117" title="SzubertM , SuzinJ , DuechlerM , SzuławskaA , CzyżM , Kowalczyk‐AmicoK . Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment. Reproduction, Fertility, and Development2014;26(3):414‐20. ">Szubert 2014</a>; <a href="./references#CD012179-bbs2-0118" title="ThubertT , SantulliP , MarcellinL , MenardS , M'BayeM , StreuliI , et al. Measurement of hs‐CRP is irrelevant to diagnose and stage endometriosis: prospective study of 834 patients. American Journal of Obstetrics and Gynecology2014;210(6):533 e1‐e10. ">Thubert 2014</a>; <a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a</a>) or when the severity of the disease was not reported (<a href="./references#CD012179-bbs2-0058" title="KianpourM , NematbakhshM , AhmadiSM . C‐reactive protein of serum and peritoneal fluid in endometriosis. Iranian Journal of Nursing and Midwifery Research2012;17(2 Suppl 1):S115‐9. ">Kianpour 2012</a>). The methods included the hs‐CRP assay in <a href="./references#CD012179-bbs2-0118" title="ThubertT , SantulliP , MarcellinL , MenardS , M'BayeM , StreuliI , et al. Measurement of hs‐CRP is irrelevant to diagnose and stage endometriosis: prospective study of 834 patients. American Journal of Obstetrics and Gynecology2014;210(6):533 e1‐e10. ">Thubert 2014</a> (834 participants) and the CRP assay in the other studies (499 participants). A comparison between the two assay methods concluded that hs‐CRP assay had higher diagnostic accuracy than the traditional CRP assay (<a href="./references#CD012179-bbs2-0125" title="VodolazkaiaA , BossuytX , FassbenderA , KyamaCM , MeulemanC , PeeraerK , et al. A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis. Reproductive Biology and Endocrinology2011;9:113. ">Vodolazkaia 2011</a>). Collectively, the available evidence suggests that CRP evaluated by either method is not a reliable biomarker for detecting endometriosis. </p> <div class="figure" id="CD012179-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Forest plot of hs‐CRP for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of hs‐CRP for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Summary ROC plot of hs‐CRP for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Five evaluations (excluding 1 with a cut‐off &gt; 438 μg/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of hs‐CRP for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Five evaluations (excluding 1 with a cut‐off &gt; 438 μg/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis. </p> </div> </div> </div> </section> <section id="CD012179-sec-0125"> <p><b>8.6.d. Other immune system and inflammatory markers that exhibited no differential expression in endometriosis</b></p> <p>The other immune system and inflammatory biomarkers for which only negative data were reported included (<a href="./appendices#CD012179-sec-0181">Appendix 7</a>): </p> <p> <ol id="CD012179-list-0062"> <li> <p>C3a (<a href="./references#CD012179-bbs2-0023" title="FassbenderA , D'HoogheT , MihalyiA , KyamaC , SimsaP , LesseyBA . Plasma C3a‐des‐Arg levels in women with and without endometriosis. American Journal of Reproductive Immunology2009;62(3):187‐95. ">Fassbender 2009</a>; 160 participants); </p> </li> <li> <p>sHLA‐I (<a href="./references#CD012179-bbs2-0018" title="DePlacidoG , AlviggiC , DiP , CarravettaC , MatareseG , LandinoG , et al. Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule‐1 in endometriosis: Relationship with stage and non‐pigmented peritoneal lesions. Human Reproduction1998;13(11):3206‐10. ">De Placido 1998</a>; 30 participants); </p> </li> <li> <p>immunoglobulins: IgA, IgG (<a href="./references#CD012179-bbs2-0084" title="MatveevaNK , VolkovNI , PetrenkoEP , Mit'kinVV , PshenichnikovaTI , SukhikhGT . Immunological studies of peripheral blood in patients with external genital endometriosis and infertility. Akusherstvo i Ginekologiia1990;8:48‐51. ">Matveeva 1990</a>; 119 participants); </p> </li> <li> <p>MPO (<a href="./references#CD012179-bbs2-0016" title="DaSilvaCM , Vilaca BeloA , Passos AndradeS , Peixoto CamposP , Cristina Franca FerreiraM , Lopes da Silva‐FilhoA , et al. Identification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis. Biomedicine &amp; Pharmacotherapy2014;68(7):899‐904. ">Da Silva 2014</a>; 17 participants); </p> </li> <li> <p>NAG (<a href="./references#CD012179-bbs2-0016" title="DaSilvaCM , Vilaca BeloA , Passos AndradeS , Peixoto CamposP , Cristina Franca FerreiraM , Lopes da Silva‐FilhoA , et al. Identification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis. Biomedicine &amp; Pharmacotherapy2014;68(7):899‐904. ">Da Silva 2014</a>; 17 participants); </p> </li> <li> <p>PGE2 (<a href="./references#CD012179-bbs2-0055" title="KhanKN , KitajimaM , YamaguchiN , FujishitaA , NakashimaM , IshimaruT , et al. Role of prostaglandin E2 in bacterial growth in women with endometriosis. Human Reproduction2012;27(12):3417‐24. ">Khan 2012</a>; 86 participants); </p> </li> <li> <p>phospholipid fatty acids (<a href="./references#CD012179-bbs2-0057" title="KhanakiK , NouriM , ArdekaniAM , GhassemzadehA , ShahnaziV , SadeghiMR , et al. Evaluation of the relationship between endometriosis and omega‐3 and omega‐6 polyunsaturated fatty acids. Iranian Biomedical Journal2012;16(1):38‐43. ">Khanaki 2012</a>; 138 participants, 16 fatty acids); </p> </li> <li> <p>PLA2G2A (<a href="./references#CD012179-bbs2-0063" title="KocbekV , BersingerNA , BrglezV , MuellerMD , PetanT , RiznerTL . Phospholipase A2 group IIA is elevated in endometriomas but not inperitoneal fluid and serum of ovarian endometriosis patients. Gynecological Endocrinology2014;31(3):214‐8. ">Kocbek 2014a</a>; 91 participants); </p> </li> <li> <p>RANTES (<a href="./references#CD012179-bbs2-0053" title="KaluE , SumarN , GiannopoulosT , PatelP , CroucherC , SherriffE , et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. Journal of Obstetrics and Gynaecology Research2007;33(4):490‐5. ">Kalu 2007</a>; <a href="./references#CD012179-bbs2-0080" title="MarkhamR , FraserIS , SongJY , YoungL , ChullapramT . Blood and peritoneal fluid concentrations of TNFalpha and RANTES in patients with and without endometriosis. Australian Journal of Medical Science1997;18(4):116‐8. ">Markham 1997a</a>; 72 participants). </p> </li> </ol> </p> <p>Except for RANTES, all other biomarkers from this group were assessed in a single study, and their association with endometriosis remains unclear. </p> </section> </section> </section> <section id="CD012179-sec-0126"> <h5 class="title">9. Nerve growth markers</h5> <section id="CD012179-sec-0127"> <h6 class="title">9.1. Nerve growth markers that exhibited no differential expression in endometriosis</h6> <p>One study (101 participants, cycle phase not reported, rASRM I to IV) evaluated four nerve growth markers (CNTF, GDNF, NGF, NT4), showing no association between any of these tests and endometriosis (<a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>), as presented in <a href="./appendices#CD012179-sec-0181">Appendix 7</a>. Future research needs to confirm the expression of these biomarkers in endometriosis and their value in the diagnosis of the disease. </p> </section> </section> <section id="CD012179-sec-0128"> <h5 class="title">10. Other peptides/proteins shown to influence key events implicated in endometriosis</h5> <section id="CD012179-sec-0129"> <h6 class="title">10.1. Follistatin</h6> <p>Follistatin was only evaluated in the context of ovarian endometrioma and is presented below under 'Blood biomarkers that could differentiate ovarian endometrioma from other benign ovarian cysts in women of reproductive age'. </p> </section> <section id="CD012179-sec-0130"> <h6 class="title">10.2. STX‐5 (syntaxin‐5)</h6> <p>One study reported on the diagnostic performance of STX‐5 in endometriosis (80 participants, cycle phase not reported, rASRM I to IV), using a cut‐off of &gt; 55 ng/ml, with a sensitivity of 0.78 (95% CI 0.66 to 0.88) and a specificity of 0.70 (95% CI 0.46 to 0.88); <a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>. The diagnostic estimates did not meet the criteria for an adequate diagnostic test (replacement or triage), but additional studies need to support this observation. </p> </section> <section id="CD012179-sec-0131"> <h6 class="title">10.3. Other peptides/proteins that exhibited no differential expression in endometriosis</h6> <p>Three additional proteins (DBP (<a href="./references#CD012179-bbs2-0010" title="BorkowskiJ , GmyrekGB , MadejJP , NowackiW , GoludaM , GabrysM , et al. Serum and peritoneal evaluation of vitamin D‐binding protein in women with endometriosis. Postepy Higieny i Medycyny Doswiadczalnej (Online)2008;62:103‐9. ">Borkowski 2008</a>; <a href="./references#CD012179-bbs2-0027" title="FerreroS , GillottDJ , AnseriniP , RemorgidaV , PriceKM , RagniN , et al. Vitamin D binding protein in endometriosis. Journal of the Society for Gynecologic Investigation2005;12(4):272‐7. ">Ferrero 2005a</a>; 171 participants), enolase and PDPK1 (<a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>; 80 participants) were evaluated for their association with endometriosis. Their serum levels did not distinguish women with endometriosis from controls (<a href="./appendices#CD012179-sec-0181">Appendix 7</a>). </p> </section> </section> <section id="CD012179-sec-0132"> <h5 class="title">11. Oxidative stress markers</h5> <section id="CD012179-sec-0133"> <h6 class="title">11.1. Carbonyls</h6> <p>One study (<a href="./references#CD012179-bbs2-0106" title="RosaESJC , Do AmaraVF , MendoncaJL , RosaESACJDS , NakaoLS , NetoOBP , et al. Serum markers of oxidative stress and endometriosis. Clinical and Experimental Obstetrics &amp; Gynecology2014;41(4):371‐4. ">Rosa E Silva 2014</a>) assessed the diagnostic role of carbonyls in endometriosis (108 participants, cycle phase and spectrum of the disease not reported), demonstrating a sensitivity of 0.94 (95% CI 0.85 to 0.98) and a specificity of 0.51 (95% CI 0.35 to 0.67) at a cut‐off value of &lt; 14.9 μm. This approaches the criteria for a SnOUT triage test, but large high quality studies need to confirm this finding. </p> </section> <section id="CD012179-sec-0134"> <h6 class="title">11.2. PON‐1 (paraoxonase‐1)</h6> <p>One study (<a href="./references#CD012179-bbs2-0122" title="VeritFF , ErelO , CelikN . Serum paraoxonase‐1 activity in women with endometriosis and its relationship with the stage of the disease. Human Reproduction2008;23(1):100‐4. ">Verit 2008</a>) reported on the ability of PON‐1 to diagnose pelvic endometriosis (87 participants, follicular cycle phase, rASRM I to IV). The diagnostic estimates were high enough to fulfil the criteria for a replacement test (sensitivity 0.98, 95% CI 0.89 to 1.00 and specificity 0.80, 95% CI 0.64 to 0.91), using a cut‐off threshold of &lt; 141.5 U/ml. Further studies are required to confirm this finding. </p> </section> <section id="CD012179-sec-0135"> <h6 class="title">11.3. Thiols</h6> <p>One study (<a href="./references#CD012179-bbs2-0106" title="RosaESJC , Do AmaraVF , MendoncaJL , RosaESACJDS , NakaoLS , NetoOBP , et al. Serum markers of oxidative stress and endometriosis. Clinical and Experimental Obstetrics &amp; Gynecology2014;41(4):371‐4. ">Rosa E Silva 2014</a>) tested the accuracy of thiols in detecting pelvic endometriosis (108 participants, cycle phase and spectrum of the disease not reported), showing a sensitivity of 0.73 (95% CI 0.61 to 0.83) and a specificity of 0.80 (95% CI 0.65 to 0.91) at a cut‐off value of &lt; 396.44 μm. Further data is required before a comment can be made on its diagnostic role. </p> </section> <section id="CD012179-sec-0136"> <h6 class="title">11.4. Oxidative stress markers that exhibited no differential expression in endometriosis</h6> <p>Additional oxidative stress markers that appeared to have comparable levels in women with and without endometriosis (<a href="./appendices#CD012179-sec-0181">Appendix 7</a>) included ascorbic acid and malondialdehyde (<a href="./references#CD012179-bbs2-0085" title="Mier‐CabreraJ , Jimenez‐ZamudioL , Garcia‐LatorreE , Cruz‐OrozcoO , Hernandez‐GuerreroC . Quantitative and qualitative peritoneal immune profiles, T‐cell apoptosis and oxidative stress‐associated characteristics in women with minimal and mild endometriosis. BJOG: An International Journal of Obstetrics and Gynaecology2011;118(1):6‐16. ">Mier‐Cabrera 2011</a>; 62 participants); GSH, nitrotyrosine, SOD3 and vitamin E (<a href="./references#CD012179-bbs2-0097" title="PaivaP , LappasM , BarkerG , HealeyM . Using symptom scores, lifestyle measures and biochemical markers to create a test for endometriosis. Journal of Endometriosis2014;6(3):135‐43. ">Paiva 2014</a>; 101 participants); HSP70 (<a href="./references#CD012179-bbs2-0056" title="KhanKN , KitajimaM , InoueT , TateishiS , FujishitaA , NakashimaM , et al. Additive effects of inflammation and stress reaction on Toll‐like receptor 4‐mediated growth of endometriotic stromal cells. Human Reproduction2013;28(10):2794‐803. ">Khan 2013</a>; <a href="./references#CD012179-bbs2-0069" title="LambrinoudakiIV , AugouleaA , ChristodoulakosGE , EconomouEV , KaparosG , KontoravdisA , et al. Measurable serum markers of oxidative stress response in women with endometriosis. Fertility and Sterility2009;91(1):46‐50. ">Lambrinoudaki 2009</a>; 116 participants); and IMA and TRX (<a href="./references#CD012179-bbs2-0069" title="LambrinoudakiIV , AugouleaA , ChristodoulakosGE , EconomouEV , KaparosG , KontoravdisA , et al. Measurable serum markers of oxidative stress response in women with endometriosis. Fertility and Sterility2009;91(1):46‐50. ">Lambrinoudaki 2009</a>; 66 participants). </p> <p>Although the diagnostic studies for these biomarkers are encouraging (<a href="#CD012179-fig-0018">Figure 18</a>), there is insufficient evidence to draw meaningful conclusions regarding any biomarker from this group, and further research is recommended to confirm the positive and negative findings presented above. </p> <div class="figure" id="CD012179-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Summary ROC plot of oxidative stress biomarkers for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG18.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of oxidative stress biomarkers for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> </div> </section> </section> <section id="CD012179-sec-0137"> <h5 class="title">12. Post‐transcriptional regulators of gene expression (microRNAs)</h5> <p>There were two eligible studies that evaluated the role of microRNAs (miRs) in detecting endometriosis (<a href="#CD012179-fig-0019">Figure 19</a>). One study (85 participants, follicular or luteal cycle phase) assessed diagnostic accuracy of six microRNAs in pelvic endometriosis, rASRM I to IV (<a href="./references#CD012179-bbs2-0128" title="WangWT , ZhaoYN , HanBW , HongSJ , ChenYQ , WangX , et al. Circulating microRNAs identified in a genome‐wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis [Study on polymorphism of human leukocyte antigen I in patients with endometriosis]. Journal of Clinical Endocrinology and Metabolism2013;98(1):281‐9. ">Wang 2013a</a>). </p> <div class="figure" id="CD012179-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Summary ROC plot of microRNAs for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG19.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of microRNAs for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> </div> <p> <ol id="CD012179-list-0063"> <li> <p>miR‐9* (sensitivity 0.68, 95% CI 0.55 to 0.80 and specificity 0.96, 95% CI 0.80 to 1.00). </p> </li> <li> <p>miR‐122 (sensitivity 0.80, 95% CI 0.68 to 0.89 and specificity 0.76, 95% CI 0.55 to 0.91). </p> </li> <li> <p>miR‐141* (sensitivity 0.72, 95% CI 0.59 to 0.83 and specificity 0.96, 95% CI 0.80 to 1.00). </p> </li> <li> <p>miR‐145* (sensitivity 0.70, 95% CI 0.57 to 0.81 and specificity 0.96, 95% CI 0.80 to 1.00). </p> </li> <li> <p>miR‐199a (sensitivity 0.78, 95% CI 0.66 to 0.88 and specificity 0.76, 95% CI 0.55 to 0.91). </p> </li> <li> <p>miR‐532‐3p (sensitivity 0.80, 95% CI 0.68 to 0.89 and specificity 0.92, 95% CI 0.74 to 0.99). </p> </li> </ol> </p> <p>The authors did not report the cut‐off values for any of the tested biomarkers.</p> <p>Another group published data on diagnostic performance of three microRNAs (40 participants, follicular or luteal cycle phase) in moderate‐severe pelvic endometriosis, rASRM III to IV (<a href="./references#CD012179-bbs2-0051" title="JiaSZ , YangY , LangJ , SunP , LengJ . Plasma miR‐17‐5p, miR‐20a and miR‐22 are down‐regulated in women with endometriosis. Human Reproduction2013;28(2):322‐30. ">Jia 2013</a>): miR‐17‐5 (sensitivity 0.70, 95% CI 0.46 to 0.88 and specificity 0.70, 95% CI 0.46 to 0.88 for the cut‐off of &lt; 0.9057); miR‐20a (sensitivity 0.60, 95% CI 0.36 to 0.81 and specificity 0.90, 95% CI 0.68 to 0.99, for the cut‐off of &lt; 0.6879) and miR‐22 (sensitivity 0.90, 95% CI 0.68 to 0.99 and specificity 0.80, 95% CI 0.56 to 0.94 for the cut‐off of &lt; 0.5647). Both <a href="./references#CD012179-bbs2-0051" title="JiaSZ , YangY , LangJ , SunP , LengJ . Plasma miR‐17‐5p, miR‐20a and miR‐22 are down‐regulated in women with endometriosis. Human Reproduction2013;28(2):322‐30. ">Jia 2013</a> and <a href="./references#CD012179-bbs2-0128" title="WangWT , ZhaoYN , HanBW , HongSJ , ChenYQ , WangX , et al. Circulating microRNAs identified in a genome‐wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis [Study on polymorphism of human leukocyte antigen I in patients with endometriosis]. Journal of Clinical Endocrinology and Metabolism2013;98(1):281‐9. ">Wang 2013a</a> varied in laboratory methodology and approach to quantifying and analysing the data. MiR‐9*, miR‐141* and miR‐145* met the criteria of a SpIN triage test, and miR‐532‐30, miR‐20a and miR‐22 approached these criteria. While several microRNAs show some promise as diagnostic markers for endometriosis, the two published studies identified completely independent microRNA biomarkers. These results require further validation in a large, well‐defined population with a wide spectrum of disease, using a standardised reproducible methodology. </p> </section> <section id="CD012179-sec-0138"> <h5 class="title">13. Tumour markers</h5> <section id="CD012179-sec-0139"> <h6 class="title">13.1. CA‐15.3 (cancer antigen‐15.3)</h6> <p>Two studies (<a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a</a>; <a href="./references#CD012179-bbs2-0090" title="MuscatelloR , CucinelliF , FulghesuA , LanzoneA , CarusoA , MancusoS . Multiple serum marker assay in the diagnosis of endometriosis. Gynecological Endocrinology1992;6:265‐9. ">Muscatello 1992</a>) (207 participants, various phases of menstrual cycle, rASRM I to IV) assessed the diagnostic performance of CA‐15.3 in endometriosis with substantially heterogeneous estimates. Each study used different cut‐off thresholds, so we did not include them in a meta‐analysis. In both studies the levels of CA‐15.3 were not significantly different in women with and without endometriosis, although the diagnostic test estimates were calculated. None of the included studies exhibited high diagnostic accuracy, with sensitivities ranging from 0.65 to 0.04 and specificities from ranging 0.62 to 0.92. </p> </section> <section id="CD012179-sec-0140"> <h6 class="title">13.2. CA‐19.9 (cancer antigen‐19.9)</h6> <p>Seven studies (8 data sets, 793 participants, various phases of menstrual cycle, rASRM I to IV) explored the role of CA‐19.9 in pelvic endometriosis. Three evaluations were performed in an overlapping population (<a href="./references#CD012179-bbs2-0045" title="HaradaT , KubotaT , AsoT . Usefulness of CA19‐9 versus CA125 for the diagnosis of endometriosis. Fertility and Sterility2002;78(4):733‐9. ">Harada 2002</a>; <a href="./references#CD012179-bbs2-0068" title="KurdogluZ , GursoyR , KurdogluM , ErdemM , ErdemO , ErdemA . Comparison of the clinical value of CA 19‐9 versus CA 125 for the diagnosis of endometriosis. Fertility and Sterility2009;92(5):1761‐3. ">Kurdoglu 2009</a>; <a href="./references#CD012179-bbs2-0076" title="MabroukM , ElmakkyA , CaramelliE , FarinaA , MignemiG , VenturoliS , et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Archives of Gynecology and Obstetrics2012;285(5):1307‐12. ">Mabrouk 2012</a>; <a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>; <a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a</a>; <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>). Studies used very diverse cut‐off thresholds, ranging from &gt; 7.5 U/ml to &gt; 37.0 U/ml, while two studies did not report the cut‐off. In view of inconsistencies in the methods, a meta‐analysis was legitimate only for three studies with a total of 309 participants that assessed CA‐19.9 for a cut‐off value &gt; 37.0 U/ml. The summary sensitivity was 0.36 (95% CI 0.26 to 0.45) and the summary specificity was 0.87 (95% CI 0.75 to 0.99) (<a href="./references#CD012179-bbs2-0045" title="HaradaT , KubotaT , AsoT . Usefulness of CA19‐9 versus CA125 for the diagnosis of endometriosis. Fertility and Sterility2002;78(4):733‐9. ">Harada 2002</a>; <a href="./references#CD012179-bbs2-0068" title="KurdogluZ , GursoyR , KurdogluM , ErdemM , ErdemO , ErdemA . Comparison of the clinical value of CA 19‐9 versus CA 125 for the diagnosis of endometriosis. Fertility and Sterility2009;92(5):1761‐3. ">Kurdoglu 2009</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>) (<a href="#CD012179-fig-0020">Figure 20</a>). One study from this subgroup (80 participants, all cycle phases, rASRM I to IV) demonstrated that the serum levels of CA‐19.9 were comparable between the control and endometriosis groups (<a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>). Other evaluations of this biomarker were reported separately, and none presented clinically meaningful diagnostic estimates, with a sensitivity ranging from 0.36 to 0.73 and a specificity from 0.56 to 0.90 (see <a href="./full#CD012179-tbl-0001">summary of findings Table</a>; <a href="#CD012179-fig-0021">Figure 21</a>). An additional study (118 participants, follicular cycle phase; <a href="./references#CD012179-bbs2-0039" title="GuerrieroS , AjossaS , PaolettiAM , MaisV , AngiolucciM , MelisGB . Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma. Obstetrics and Gynecology1996;88(3):403‐7. ">Guerriero 1996a</a>) addressed only ovarian endometriosis versus other benign ovarian cysts and is reported separately (see 'Blood biomarkers that could differentiate ovarian endometrioma from other benign ovarian cysts in women of reproductive age'). </p> <div class="figure" id="CD012179-fig-0020"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 20</div> </div> <hr class="top"/><img alt="Summary ROC plot of CA‐19.9 with a cut‐off value &gt; 37 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity." data-id="CD012179-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG20.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of CA‐19.9 with a cut‐off value &gt; 37 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0021"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 21</div> </div> <hr class="top"/><img alt="Forest plot of CA‐19.9 (all the evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG21.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of CA‐19.9 (all the evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> </section> <section id="CD012179-sec-0141"> <h6 class="title">13.3. CA‐72 (TAG‐72) (cancer antigen‐72 or tumour associated glycoprotein‐72)</h6> <p>Two studies (<a href="./references#CD012179-bbs2-0088" title="MoloMW , KellyM , RadwanskaE , BinorZ . Preoperative serum CA‐125 and CA‐72 in predicting endometriosis in infertility patients. Journal of Reproductive Medicine1994;39(12):964‐6. ">Molo 1994</a>; <a href="./references#CD012179-bbs2-0090" title="MuscatelloR , CucinelliF , FulghesuA , LanzoneA , CarusoA , MancusoS . Multiple serum marker assay in the diagnosis of endometriosis. Gynecological Endocrinology1992;6:265‐9. ">Muscatello 1992</a>) evaluated the role of CA‐72 in detecting pelvic endometriosis in varying phases of menstrual cycle, using different cut‐off values. One study (35 participants in the follicular cycle phase, rASRM stage not reported) reported a sensitivity 0.05 (95% CI 0.00 to 0.26) and a specificity 0.75 (95% CI 0.48 to 0.93) for the cut‐off &gt; 4.0 U/ml; <a href="./references#CD012179-bbs2-0088" title="MoloMW , KellyM , RadwanskaE , BinorZ . Preoperative serum CA‐125 and CA‐72 in predicting endometriosis in infertility patients. Journal of Reproductive Medicine1994;39(12):964‐6. ">Molo 1994</a>. A second study (119 participants in luteal cycle phase, rASRM I to IV) demonstrated a sensitivity of 0.09 (95% CI 0.04 to 0.17) and a specificity of 0.89 (95% CI 0.75 to 0.97) for the cut‐off value &gt; 6.0 U/ml; <a href="./references#CD012179-bbs2-0090" title="MuscatelloR , CucinelliF , FulghesuA , LanzoneA , CarusoA , MancusoS . Multiple serum marker assay in the diagnosis of endometriosis. Gynecological Endocrinology1992;6:265‐9. ">Muscatello 1992</a>. A meta‐analysis was not performed as the methodology was heterogeneous, but both presented unacceptably low sensitivities indicating no clinically applicable alteration of blood CA‐72 levels in the presence of endometriosis, which shows that this biomarker is not suitable for detecting disease. </p> </section> <section id="CD012179-sec-0142"> <h6 class="title">13.4. CA‐125 (cancer antigen‐125)</h6> <p>Forty‐five studies including 60 data sets with a total of 5534 participants explored the accuracy of CA‐125 in the diagnosis of endometriosis. The included evaluations were performed in varying phases of the menstrual cycle for different spectra of the disease and using a broad range of cut‐off thresholds, from &gt; 10.0 U/ml to &gt; 42.0 U/ml (<a href="./full#CD012179-tbl-0001">summary of findings Table</a>; <a href="#CD012179-fig-0022">Figure 22</a>). Since a sufficient number of studies assessed CA‐125 for most of the diagnostic cut‐offs, the studies for overall pelvic and ovarian endometriosis were included in the analysis for each cut‐off threshold, with a subsequent sensitivity analyses after excluding the data for ovarian endometriosis. We grouped the tests by clinically relevant target cut‐off ranges as follows. </p> <div class="figure" id="CD012179-fig-0022"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 22</div> </div> <hr class="top"/><img alt="Forest plot of CA‐125 (all the included evaluations) for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG22.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of CA‐125 (all the included evaluations) for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <p> <ol id="CD012179-list-0064"> <li> <p>CA‐125 with the cut‐off values of &gt; 10.0 to 14.7 U/ml (5 studies 769 participants, cycle phase varied, rASRM stage varied) had a mean sensitivity of 0.70 (95% CI 0.63 to 0.77) and mean sensitivity of 0.64 (95% CI 0.47 to 0.82), excluding two overlapping evaluations (<a href="#CD012179-fig-0023">Figure 23</a>). </p> </li> <li> <p>CA‐125 with a cut‐off threshold of &gt; 16.0 to 17.6 U/ml (5 studies, 430 participants, cycle phase varied, rASRM stage varied) had a mean sensitivity of 0.56 (95% CI 0.24 to 0.88) and mean specificity of 0.91 (95% CI 0.75 to 1.00) (<a href="#CD012179-fig-0024">Figure 24</a>). </p> </li> <li> <p>CA‐125 with a cut‐off threshold of &gt; 20.0 U/ml (6 studies, 1304 participants, cycle phase varied, rASRM stage varied) had a mean sensitivity of 0.67 (95% CI 0.50 to 0.85) and mean specificity of 0.69 (95% CI 0.58 to 0.80) (<a href="#CD012179-fig-0025">Figure 25</a>). This group included two studies that specifically aimed to differentiate ovarian endometriosis from the other benign ovarian masses. </p> </li> <li> <p>CA‐125 with a cut‐off of &gt; 25.0 to 26.0 U/ml (3 studies, 963 participants, cycle phase varied, rASRM stage varied) had a summary sensitivity of 0.73 (95% CI 0.67 to 0.79) and specificity of 0.70 (95% CI 0.63 to 0.77) (<a href="#CD012179-fig-0026">Figure 26</a>). In this group, two studies assessed overall pelvic endometriosis, whilst one study looked at ovarian endometriosis versus other ovarian cysts. </p> </li> <li> <p>CA‐125 with a cut‐off of &gt; 30.0 to 33.0 U/ml (6 studies, 1206 participants, cycle phase varied, rASRM stage varied) had a mean sensitivity of 0.62 (95% CI 0.45 to 0.79) and specificity of 0.76 (95% CI 0.53 to 1.00) (<a href="#CD012179-fig-0027">Figure 27</a>). Two studies included in the analysis focused on differentiation of ovarian endometriosis from the other ovarian cysts. </p> </li> <li> <p>CA‐125 with a cut‐off threshold of &gt; 35.0 to 36.0 U/ml (27 studies, 3276 participants, cycle phase varied, rASRM stage varied) had a mean sensitivity of 0.40 (95% CI 0.32 to 0.49) and specificity of 0.91 (95% CI 0.88 to 0.94) (<a href="#CD012179-fig-0028">Figure 28</a>). Meta‐analysis included two studies differentiating ovarian endometrioma from other ovarian cysts. </p> </li> <li> <p>Only two studies reported CA‐125 with a cut‐off of &gt; 42.0 to 43.0 U/ml, of which one (104 participants, cut‐off value &gt; 42.0 U/ml) assessed the performance of CA‐125 in differentiating ovarian endometrioma from other benign ovarian cysts (presented separately). The second study (62 participants, cycle phase not reported, rASRM III to IV, cut‐off value &gt; 43.0 U/ml) was not confined to ovarian disease and included any type of endometriosis, demonstrating a sensitivity of 1.00 (95% CI 0.92 to 1.00) and a specificity of 0.80 (95% CI 56 to 0.94). The studies were not combined in a meta‐analysis due to the heterogeneity of the included populations and paucity of the data. </p> </li> <li> <p>The cut‐off thresholds were not reported in four evaluations of CA‐125, three of which had overlapping populations and were presented separately (<a href="./full#CD012179-tbl-0001">summary of findings Table</a>). </p> </li> </ol> </p> <div class="figure" id="CD012179-fig-0023"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 23</div> </div> <hr class="top"/><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 10‐14.7 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 5 studies (the data for 2 evaluations (CA‐125 &gt; 11.5 U/ml and CA‐125 &gt; 13.5 U/ml were not included as overlapping populations with already included study)." data-id="CD012179-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG23.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 10‐14.7 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 5 studies (the data for 2 evaluations (CA‐125 &gt; 11.5 U/ml and CA‐125 &gt; 13.5 U/ml were not included as overlapping populations with already included study). </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0024"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 24</div> </div> <hr class="top"/><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 16‐17.6 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) ad by 95% prediction region (dashed line)." data-id="CD012179-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG24.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 16‐17.6 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) ad by 95% prediction region (dashed line). </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0025"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 25</div> </div> <hr class="top"/><img alt="Summary ROC plot of CA‐125 with cut‐off values &gt; 20 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line)." data-id="CD012179-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG25.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values &gt; 20 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0026"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 26</div> </div> <hr class="top"/><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 25‐26 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity." data-id="CD012179-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG26.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 25‐26 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0027"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 27</div> </div> <hr class="top"/><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 30‐33 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line)." data-id="CD012179-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG27.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 30‐33 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0028"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 28</div> </div> <hr class="top"/><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 35‐36 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line)." data-id="CD012179-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG28.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 35‐36 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). </p> </div> </div> </div> <p>Overall, none of the cut‐off thresholds for CA‐125 subjected to a meta‐analysis met the criteria for either a replacement or triage test. Only CA‐125, with a cut‐off value &gt; 16.0 to 17.6 U/ml approached the criteria for a SpIN triage test, but results showed a substantial degree of heterogeneity and wide confidence intervals. Even though the reported diagnostic estimates for CA‐125 with a cut‐off of &gt; 43.0 U/ml met the criteria for a replacement test, this cut‐off value came from an individual study and only for moderate‐severe forms of endometriosis. This is consistent with the commonly reported observation that CA‐125 levels were significantly increased in advanced stages of endometriosis and minimally altered in minimal‐mild disease. Further large, well‐designed diagnostic studies are required to evaluate the role of CA‐125 with a cut‐off &gt; 43.0 U/ml in a population with a wide spectrum of endometriosis. </p> <p>Two further studies (112 participants, follicular or follicular and luteal cycle phase) showed no association between CA‐125 and endometriosis when assessing the full spectrum of the disease (rASRM I to IV) (<a href="./references#CD012179-bbs2-0104" title="RileyCF , MoenMH , VidemV . Inflammatory markers in endometriosis: reduced peritoneal neutrophil response in minimal endometriosis. Acta Obstetricia et Gynecologica Scandinavica2007;86(7):877‐81. ">Riley 2007</a>) or only minimal‐mild endometriosis (<a href="./references#CD012179-bbs2-0006" title="BarbosaCP , SouzaAM , BiancoB , ChristofoliniD , BachFAM , LimaGR . Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. Sao Paulo Medical Journal = Revista Paulista de Medicina2009;127(6):342‐5. ">Barbosa 2009</a>), as presented in <a href="./appendices#CD012179-sec-0181">Appendix 7</a>. </p> <p>A meta‐analysis was undertaken for each specific cut‐off value of CA‐125 and included the studies that assessed its ability to detect pelvic endometriosis as well as the studies that aimed to determine if an ovarian mass was an endometrioma. The estimates from the studies that specifically evaluated ovarian endometrioma are also reported separately under 'Blood biomarkers that could differentiate ovarian endometrioma from other benign ovarian cysts in women of reproductive age' with the aim of evaluating the role of the test in differential diagnosis of ovarian masses in reproductive‐aged women. </p> <section id="CD012179-sec-0143"> <p><b>Direct comparisons for CA‐125</b></p> <p>Eight studies presented direct head‐to‐head comparisons between different cut‐off thresholds for CA‐125. </p> <p> <ol id="CD012179-list-0065"> <li> <p>&gt; 20.0 U/ml versus &gt; 35.0 U/ml (<a href="./references#CD012179-bbs2-0009" title="BilibioJP , SouzaCA , RodiniGP , AndreoliCG , GenroVK , deContoE , et al. Serum prolactin and CA‐125 levels as biomarkers of peritoneal endometriosis. Gynecologic and Obstetric Investigation2014;78(1):45‐52. ">Bilibio 2014</a>). </p> </li> <li> <p>&gt; 16.0 U/ml versus &gt;35.0 U/ml (<a href="./references#CD012179-bbs2-0026" title="FerreiraCA , CamargosAF . Assessement of serum concentration CA‐125 in the diagnosis of endometriosis [Avaliaçåo da dosagem do CA‐125 sérico no diagnóstico da endometriose]. Jornal Brasileiro de Gynecologia1994;104(9):311‐4. ">Ferreira 1994</a>). </p> </li> <li> <p>&gt; 30.0 U/ml versus &gt; 36.0 U/ml (<a href="./references#CD012179-bbs2-0028" title="FlorioP , ReisFM , TorresPB , CalonaciF , TotiP , BocchiC , et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstetrics and Gynecology2007;110(3):594‐600. ">Florio 2007</a>). </p> </li> <li> <p>&gt; 12.8 U/ml versus &gt; 35.0 U/ml (<a href="./references#CD012179-bbs2-0032" title="GagneD , RivardM , PageM , LepineM , PlatonC , ShazandK , et al. Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA‐125 levels. Fertility and Sterility2003; Vol. 80, issue 4:876‐85. ">Gagne 2003a</a>). </p> </li> <li> <p>&gt; 20.0 U/ml versus &gt; 25.0 U/ml versus &gt; 35.0 U/ml (<a href="./references#CD012179-bbs2-0040" title="GuerrieroS , MaisV , AjossaS , PaolettiAM , AngiolucciM , MelisGB . Transvaginal ultrasonography combined with CA‐125 plasma levels in the diagnosis of endometrioma. Fertility and Sterility1996;65(2):293‐8. ">Guerriero 1996b</a>). </p> </li> <li> <p>&gt; 20.0 U/ml versus &gt; 26.0 U/ml versus &gt; 30.0 U/ml versus &gt; 35.0 U/ml (<a href="./references#CD012179-bbs2-0061" title="KitawakiJ , IshiharaH , KoshibaH , KiyomizuM , TeramotoM , KitaokaY . Usefulness and limits of CA‐125 in diagnosis of endometriosis without associated ovarian endometriomas. Human Reproduction2005;20(7):1999‐2003. ">Kitawaki 2005</a>). </p> </li> <li> <p>&gt; 10.0 U/ml versus &gt; 20.0 U/ml (<a href="./references#CD012179-bbs2-0105" title="RosaE Silva ACJS , RosaE Silva JC , FerrianiRA . Serum CA‐125 in the diagnosis of endometriosis. International Journal of Gynaecology and Obstetrics2007;96(3):206‐7. ">Rosa E Silva 2007</a>). </p> </li> <li> <p>&gt; 20.0 U/ml versus &gt;35.0 U/ml (<a href="./references#CD012179-bbs2-0135" title="YangF , FangAH , GuRF . Value of CA125 (carbon hydrate tumor‐associated antigen) and endometrial antibodies for the detections of endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]1994;29(3):147‐149, 189. Chinese. ">Yang 1994</a>). </p> </li> </ol> </p> <p>Neither threshold appeared to be superior in most studies, and even when the diagnostic performance was improved when a different threshold was utilised, none of the threshold levels met the criteria for an adequate replacement or triage diagnostic test for endometriosis (<a href="#CD012179-fig-0029">Figure 29</a>). Two studies performed head‐to‐head comparisons between different phases of menstrual cycle: &gt; 11.5 U/ml follicular versus &gt; 13.5 U/ml luteal versus &gt; 12.5 U/ml all cycle phases (<a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>); and menstrual versus follicular versus luteal, no cut‐off reported (<a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>). The test performance appeared to be improved in the follicular phase in one study (<a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>) and in the menstrual or follicular phases in another study (<a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>); however, the estimates were still lower than the criteria for an adequate replacement or triage test (<a href="#CD012179-fig-0030">Figure 30</a>). Twenty‐one studies directly compared the diagnostic performance of CA‐125 with other blood biomarkers (<a href="./references#CD012179-bbs2-0009" title="BilibioJP , SouzaCA , RodiniGP , AndreoliCG , GenroVK , deContoE , et al. Serum prolactin and CA‐125 levels as biomarkers of peritoneal endometriosis. Gynecologic and Obstetric Investigation2014;78(1):45‐52. ">Bilibio 2014</a>; <a href="./references#CD012179-bbs2-0017" title="Dayangan SayanC , OzaksitMG , SarikayaE , Gun EryilmazO , MollamahmutogluL , DeveerR . Serum interleukin‐8, CA‐125 levels, neutrophil‐to‐lymphocyte ratios, and combined markers in the diagnosis of endometriosis. Turkish Journal of Medical Sciences2013;43(3):417‐23. ">Dayangan Sayan 2013</a>; <a href="./references#CD012179-bbs2-0028" title="FlorioP , ReisFM , TorresPB , CalonaciF , TotiP , BocchiC , et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstetrics and Gynecology2007;110(3):594‐600. ">Florio 2007</a>; <a href="./references#CD012179-bbs2-0029" title="FlorioP , ReisFM , TorresPB , CalonaciF , AbraoMS , NascimentoLL , et al. High serum follistatin levels in women with ovarian endometriosis. Human Reproduction2009;24(10):2600‐6. ">Florio 2009</a>; <a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>; <a href="./references#CD012179-bbs2-0045" title="HaradaT , KubotaT , AsoT . Usefulness of CA19‐9 versus CA125 for the diagnosis of endometriosis. Fertility and Sterility2002;78(4):733‐9. ">Harada 2002</a>; <a href="./references#CD012179-bbs2-0068" title="KurdogluZ , GursoyR , KurdogluM , ErdemM , ErdemO , ErdemA . Comparison of the clinical value of CA 19‐9 versus CA 125 for the diagnosis of endometriosis. Fertility and Sterility2009;92(5):1761‐3. ">Kurdoglu 2009</a>; <a href="./references#CD012179-bbs2-0076" title="MabroukM , ElmakkyA , CaramelliE , FarinaA , MignemiG , VenturoliS , et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Archives of Gynecology and Obstetrics2012;285(5):1307‐12. ">Mabrouk 2012</a>; <a href="./references#CD012179-bbs2-0081" title="MartinezS , GarridoN , CoperiasJL , PardoF , DescoJ , Garcia‐VelascoJA , et al. Serum interleukin‐6 levels are elevated in women with minimal‐mild endometriosis. Human Reproduction2007;22(3):836‐42. ">Martinez 2007</a>; <a href="./references#CD012179-bbs2-0086" title="MihalyiA , GevaertO , KyamaCM , SimsaP , PochetN , DeSmetF , et al. Non‐invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Human Reproduction2010;25(3):654‐64. ">Mihalyi 2010</a>; <a href="./references#CD012179-bbs2-0087" title="MohamedML , ElBeheryMM , MansourSAEA . Comparative study between VEGF‐A and CA‐125 in diagnosis and follow‐up of advanced endometriosis after conservative laparoscopic surgery. Archives of Gynecology and Obstetrics2013;287(1):77‐82. ">Mohamed 2013</a>; <a href="./references#CD012179-bbs2-0088" title="MoloMW , KellyM , RadwanskaE , BinorZ . Preoperative serum CA‐125 and CA‐72 in predicting endometriosis in infertility patients. Journal of Reproductive Medicine1994;39(12):964‐6. ">Molo 1994</a>; <a href="./references#CD012179-bbs2-0090" title="MuscatelloR , CucinelliF , FulghesuA , LanzoneA , CarusoA , MancusoS . Multiple serum marker assay in the diagnosis of endometriosis. Gynecological Endocrinology1992;6:265‐9. ">Muscatello 1992</a>; <a href="./references#CD012179-bbs2-0092" title="OhataY , HaradaT , MiyakodaH , TaniguchiF , IwabeT , TerakawaN . Serum interleukin‐8 levels are elevated in patients with ovarian endometrioma. Fertility and Sterility2008;90(4):994‐9. ">Ohata 2008</a>; <a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>; <a href="./references#CD012179-bbs2-0111" title="SomiglianaE , ViganoP , TirelliAS , FelicettaI , TorresaniE , VignaliM , et al. Use of the concomitant serum dosage of CA 125, CA 19‐9 and interleukin‐6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Human Reproduction2004;19(8):1871‐6. ">Somigliana 2004</a>; <a href="./references#CD012179-bbs2-0119" title="TokmakA , UgurM , TongucE , VarT , MoralogluO , OzaksitG . The value of urocortin and Ca‐125 in the diagnosis of endometrioma. Archives of Gynecology and Obstetrics2011;283(5):1075‐9. ">Tokmak 2011</a>; <a href="./references#CD012179-bbs2-0120" title="TutenA , KucurM , ImamogluM , KayaB , AcikgozAS , YilmazN , et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics2014;290(1):75‐82. ">Tuten 2014a</a>; <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>; <a href="./references#CD012179-bbs2-0131" title="WildRA , HirisaveV , BiancoA , PodczaskiES , DemersLM . Endometrial antibodies versus CA‐125 for the detection of endometriosis. Fertility and Sterility1991;55(1):90‐4. ">Wild 1991a</a>; <a href="./references#CD012179-bbs2-0135" title="YangF , FangAH , GuRF . Value of CA125 (carbon hydrate tumor‐associated antigen) and endometrial antibodies for the detections of endometriosis. Zhonghua Fuchanke Zazhi [Chinese Journal of Obstetrics and Gynecology]1994;29(3):147‐149, 189. Chinese. ">Yang 1994</a>). In view of the unsatisfactory diagnostic performance of CA‐125 as a diagnostic or triage test, we do not discuss these comparisons in detail. </p> <div class="figure" id="CD012179-fig-0029"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 29</div> </div> <hr class="top"/><img alt="Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different cut‐off values in 8 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG29.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different cut‐off values in 8 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0030"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 30</div> </div> <hr class="top"/><img alt="Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different phases of menstrual cycle in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG30.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different phases of menstrual cycle in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> </section> </section> <section id="CD012179-sec-0144"> <h6 class="title">13.5. Tumour markers that exhibited no differential expression in endometriosis</h6> <p>There was no significant difference in the serum levels for several other tumour markers in women with and without endometriosis (<a href="./appendices#CD012179-sec-0181">Appendix 7</a>), including AFP, c‐erbB‐2 (HER‐2/neu) (<a href="./references#CD012179-bbs2-0099" title="PhilippoussisF , GagneD , HugoP , GosselinD . Concentrations of alpha‐fetoprotein, insulin‐like growth factor binding protein‐3, c‐erbB‐2, and epidermal growth factor in serum of patients with endometriosis. Journal of the Society for Gynecologic Investigation2004;11(3):175‐81. ">Philippoussis 2004</a>; 72 participants) and HE4 (<a href="./references#CD012179-bbs2-0043" title="HallamaaM , SuvitieP , HuhtinenK , MatomakiJ , PoutanenM , PerheentupaA . Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecologic Oncology2012;125(3):667‐72. ">Hallamaa 2012</a>; 175 participants). Additional studies need to confirm these data. </p> </section> </section> <section id="CD012179-sec-0145"> <h5 class="title">14. Combined blood tests</h5> <p>There were 28 combined tests, comprised of two to six blood biomarkers that were evaluated as diagnostic tests for endometriosis and two other tests that attempted to discriminate ovarian endometriosis from other benign masses. We present the data for all the evaluated combined biomarkers, including the cut‐off values and the analytical methods, in <a href="./full#CD012179-tbl-0001">summary of findings Table</a> and <a href="#CD012179-fig-0031">Figure 31</a>. Twenty‐three tests combined CA‐125 with other blood biomarkers (<a href="#CD012179-fig-0032">Figure 32</a>). Each set of biomarkers was tested in individual clinical trials that varied with respect to the selection of the biomarkers constituting the test and the population studied. The most promising results were reported for eight combined tests (<a href="#CD012179-fig-0033">Figure 33</a>). </p> <div class="figure" id="CD012179-fig-0031"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 31</div> </div> <hr class="top"/><img alt="Forest plot of the combined tests (all the included evaluations) for detection of endometriosis, which consist of the combinations of 2‐6 blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG31.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of the combined tests (all the included evaluations) for detection of endometriosis, which consist of the combinations of 2‐6 blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0032"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 32</div> </div> <hr class="top"/><img alt="Forest plot of the combined tests for detection of endometriosis, which consist of the combinations of CA‐125 with other blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG32.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of the combined tests for detection of endometriosis, which consist of the combinations of CA‐125 with other blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <div class="figure" id="CD012179-fig-0033"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 33</div> </div> <hr class="top"/><img alt="Forest plot of the most promising combined tests of blood biomarkers for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG33.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of the most promising combined tests of blood biomarkers for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <p> <ol id="CD012179-list-0066"> <li> <p>miR‐199a + miR‐542‐3p (85 participants, follicular or luteal cycle phase, rASRM I to IV) with a sensitivity of 0.97 (95% CI 0.88 to 1.00) and a specificity of 0.88 (95% CI 0.69 to 0.97), demonstrating estimates that reached the criteria for either replacement or SnOUT triage test (<a href="./references#CD012179-bbs2-0128" title="WangWT , ZhaoYN , HanBW , HongSJ , ChenYQ , WangX , et al. Circulating microRNAs identified in a genome‐wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis [Study on polymorphism of human leukocyte antigen I in patients with endometriosis]. Journal of Clinical Endocrinology and Metabolism2013;98(1):281‐9. ">Wang 2013a</a>). </p> </li> <li> <p>CA‐125 +/CCR1 +/MCP‐1 (151 participants, follicular cycle phase; rASRM I to IV) with a sensitivity of 0.92 (95% CI 0.85 to 0.97) and a specificity of 0.82 (95% CI 0.68 to 0.91), demonstrating diagnostic estimates that approached that of a replacement or SnOUT triage test (<a href="./references#CD012179-bbs2-0002" title="AgicA , DjalaliS , WolflerMM , HalisG , DiedrichK , HornungD . Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reproductive Sciences2008;15(9):906‐11. ">Agic 2008</a>). </p> </li> <li> <p>miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p (85 participants, follicular or luteal cycle phase; rASRM I to IV) with a sensitivity of 0.93 (95% CI 0.84 to 0.98) and a specificity of 0.96 (95% CI 0.80 to 1.00), demonstrating diagnostic estimates that approached that of a replacement or SnOUT triage test (<a href="./references#CD012179-bbs2-0128" title="WangWT , ZhaoYN , HanBW , HongSJ , ChenYQ , WangX , et al. Circulating microRNAs identified in a genome‐wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis [Study on polymorphism of human leukocyte antigen I in patients with endometriosis]. Journal of Clinical Endocrinology and Metabolism2013;98(1):281‐9. ">Wang 2013a</a>). </p> </li> <li> <p>CA‐125 + STX‐5 + LN‐1, cut‐off not reported (80 participants, cycle phase not reported, rASRM I to IV) with a sensitivity of 0.95 (95% CI 0.86 to 0.99) and a specificity of 0.70 (95% CI 0.46 to 0.88), meeting the criteria for SnOUT triage test (<a href="./references#CD012179-bbs2-0096" title="OzhanE , KokcuA , YanikK , GunaydinM . Investigation of diagnostic potentials of nine different biomarkers in endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;178:128‐33. ">Ozhan 2014</a>). </p> </li> <li> <p>IL‐6 &gt; 12.20 pg/ml + TNF‐α &gt;12.45 pg/ml (96 participants, follicular cycle phase, rASRM I to IV) with a sensitivity of 0.70 (95% CI 0.57 to 0.80) and a specificity of 1.00 (95% CI 0.88 to 1.00), meeting the criteria for SpIN triage test (<a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>). </p> </li> <li> <p>IL‐6 &gt; 12.20 pg/ml + CRP &gt; 438 μg/ml (95 participants, follicular cycle phase, rASRM I to IV) with a sensitivity of 0.75 (95% CI 0.63 to 0.85) and a specificity of 1.00 (95% CI 0.88 to 1.00), meeting the criteria for SpIN triage test (<a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>). </p> </li> <li> <p>TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml (95 participants, follicular cycle phase, rASRM I to IV) with a sensitivity of 0.74 (95% CI 0.61 to 0.84) and a specificity of 1.00 (95% CI 0.88 to 1.00), meeting the criteria for SpIN triage test (<a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>). </p> </li> <li> <p>IL‐6 &gt; 12.20 pg/ml + TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml (95 participants, follicular cycle phase, rASRM I to IV) with a sensitivity of 0.63 (95% CI 0.50 to 0.75) and a specificity of 1.00 (95% CI 0.88 to 1.00), meeting the criteria for SpIN triage test (<a href="./references#CD012179-bbs2-0030" title="FodaAA , AalIAA . Role of some biomarkers in chronic pelvic pain for early detection of endometriosis in infertile women. Middle East Fertility Society Journal2012;17(3):187‐94. ">Foda 2012</a>). </p> </li> </ol> </p> <p>With a few exceptions, the panels of multiple biomarkers did not appear to be superior to some single biomarker tests. These findings need to be confirmed in large, well‐designed diagnostic studies and independent test populations. </p> </section> </section> <section id="CD012179-sec-0146"> <h4 class="title">Blood biomarkers that could differentiate ovarian endometrioma from other benign ovarian cysts in women of reproductive age </h4> <p>Seven studies evaluated blood biomarkers for their potential to distinguish ovarian endometrioma from other benign ovarian masses, with six formally evaluating diagnostic test performance and one study presenting negative findings. We summarise the evaluated biomarkers in a forest plot (<a href="#CD012179-fig-0034">Figure 34</a>) and describe them here. </p> <div class="figure" id="CD012179-fig-0034"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 34</div> </div> <hr class="top"/><img alt="Forest plot of the tests for detection of ovarian endometriosis performed through comparisons in women with endometriosis versus other benign ovarian cysts in 6 studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG34.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of the tests for detection of ovarian endometriosis performed through comparisons in women with endometriosis versus other benign ovarian cysts in 6 studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <section id="CD012179-sec-0147"> <h5 class="title">1. Angiogenesis/growth factors and their receptors</h5> <section id="CD012179-sec-0148"> <h6 class="title">1.1. Urocortin</h6> <p>Two studies, including three data sets with a total of 168 participants, assessed the accuracy of urocortin in detecting ovarian endometriosis (<a href="#CD012179-fig-0035">Figure 35</a>). One study evaluated two different cut‐offs in the same population (80 participants, cycle phase not reported, rASRM III to IV; <a href="./references#CD012179-bbs2-0028" title="FlorioP , ReisFM , TorresPB , CalonaciF , TotiP , BocchiC , et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstetrics and Gynecology2007;110(3):594‐600. ">Florio 2007</a>): urocortin with a cut‐off of &gt; 29.00 pg/ml had a sensitivity of 0.97 (95% CI 0.87 to 1.00) and a specificity of 0.85 (95% CI 0.70 to 0.94), meeting the criteria for a replacement test; and urocortin with a cut‐off of &gt; 33.00 pg/ml had a sensitivity of 0.88 (95% CI 0.73 to 0.96) and a specificity of 0.90 (95% CI 0.76 to 0.97), approaching the criteria for a SpIN triage test. Another study (88 participants, follicular cycle phase, rASRM III to IV; <a href="./references#CD012179-bbs2-0119" title="TokmakA , UgurM , TongucE , VarT , MoralogluO , OzaksitG . The value of urocortin and Ca‐125 in the diagnosis of endometrioma. Archives of Gynecology and Obstetrics2011;283(5):1075‐9. ">Tokmak 2011</a>) demonstrated urocortin levels that were not statistically different in women with and without endometriosis. The test was still performed at a cut‐off of &gt; 41.60 pg/ml, demonstrating a sensitivity of 0.76 (95% CI 0.61 to 0.88) and a specificity of 0.46 (95% CI 0.31 to 0.61). We did not perform a meta‐analysis in view of the heterogeneity of the cut‐off thresholds between studies. Further evaluation of urocortin across the spectrum of endometriosis may help to clarify its diagnostic role in endometriosis. </p> <div class="figure" id="CD012179-fig-0035"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 35</div> </div> <hr class="top"/><img alt="Summary ROC plot of urocortin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 29 pg/ml and &gt; 33 pg/ml) were performed in the same population. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG35.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of urocortin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 29 pg/ml and &gt; 33 pg/ml) were performed in the same population. The data were not assessed by meta‐analysis. </p> </div> </div> </div> </section> </section> <section id="CD012179-sec-0149"> <h5 class="title">2. Immune system and inflammatory markers</h5> <section id="CD012179-sec-0150"> <h6 class="title">2.1. IL‐8 (interleukin‐8)</h6> <p>One study assessed the performance of IL‐8 in detecting ovarian endometriosis (91 participants, follicular or luteal cycle phase, cut‐off value &gt;25.00 pg/ml; <a href="./references#CD012179-bbs2-0092" title="OhataY , HaradaT , MiyakodaH , TaniguchiF , IwabeT , TerakawaN . Serum interleukin‐8 levels are elevated in patients with ovarian endometrioma. Fertility and Sterility2008;90(4):994‐9. ">Ohata 2008</a>), demonstrating a sensitivity of 0.71 (95% CI 0.59 to 0.82) and a specificity of 0.81 (95% CI 0.58 to 0.95) (<a href="./full#CD012179-tbl-0001">summary of findings Table</a>; <a href="#CD012179-fig-0015">Figure 15</a>). The diagnostic estimates were higher compared to those reported for overall pelvic endometriosis but remained far below the criteria for either replacement or triage test, and there were insufficient data for meaningful comparisons. </p> </section> <section id="CD012179-sec-0151"> <h6 class="title">2.2. Immune system and inflammatory markers that exhibited no differential expression in endometriosis </h6> <p>One study (95 participants, cycle phase not reported) demonstrated no significant difference in peripheral levels of IL‐6 and sCD163 when women with ovarian endometrioma were compared to a group with other benign ovarian cysts (<a href="./references#CD012179-bbs2-0050" title="JeeBC , SuhCS , KimSH , MoonSY . Serum soluble CD163 and interleukin‐6 levels in women with ovarian endometriomas. Gynecologic and Obstetric Investigation2008;66(1):47‐52. ">Jee 2008</a>). This supports the negative findings reported for IL‐6 in overall pelvic endometriosis (see above). The data for sCD163 is insufficient to comment on its diagnostic role. </p> </section> </section> <section id="CD012179-sec-0152"> <h5 class="title">3. Other peptides/proteins shown to influence key events implicated in endometriosis</h5> <section id="CD012179-sec-0153"> <h6 class="title">3.1. Follistatin</h6> <p>One study evaluated follistatin (104 participants, follicular cycle phase, ovarian endometriosis, rASRM III to IV; <a href="./references#CD012179-bbs2-0029" title="FlorioP , ReisFM , TorresPB , CalonaciF , AbraoMS , NascimentoLL , et al. High serum follistatin levels in women with ovarian endometriosis. Human Reproduction2009;24(10):2600‐6. ">Florio 2009</a>) and showed a high sensitivity of 0.92 (95% CI 0.81 to 0.98) and high specificity of 0.92 (95% CI 0.81 to 0.98), using a cut‐off value of &gt; 1433.00 pg/ml. The diagnostic estimates approached the criteria for either a replacement or both SnOUT and SpIN triage test, but further validation in larger studies that evaluate a wider spectrum of disease is required. </p> </section> </section> <section id="CD012179-sec-0154"> <h5 class="title">4. Tumour markers</h5> <section id="CD012179-sec-0155"> <h6 class="title">4.1. CA‐19.9 (cancer antigen‐19.9)</h6> <p>One study (118 participants, follicular cycle phase; <a href="./references#CD012179-bbs2-0039" title="GuerrieroS , AjossaS , PaolettiAM , MaisV , AngiolucciM , MelisGB . Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma. Obstetrics and Gynecology1996;88(3):403‐7. ">Guerriero 1996a</a>) evaluated the performance of CA‐19.9 at a cut‐off value &gt; 12 U/ml in differentiating ovarian endometriosis from other benign ovarian cysts. The reported diagnostic estimates (sensitivity 0.62, 95% CI 0.45 to 0.77 and specificity 0.70, 95% CI 0.58 to 0.79) were below the diagnostic thresholds for either replacement or triage test, and this was similar to the findings reported for CA‐19.9 in overall pelvic endometriosis (<a href="#CD012179-fig-0021">Figure 21</a>). </p> </section> <section id="CD012179-sec-0156"> <h6 class="title">4.2. CA‐125 (cancer antigen‐125)</h6> <p>Seven studies assessed CA‐125 in differentiating ovarian endometriosis from other ovarian cysts, using several cut‐off values. </p> <p> <ol id="CD012179-list-0067"> <li> <p>CA‐125 with a cut‐off value of &gt; 20 U/ml (<a href="./references#CD012179-bbs2-0040" title="GuerrieroS , MaisV , AjossaS , PaolettiAM , AngiolucciM , MelisGB . Transvaginal ultrasonography combined with CA‐125 plasma levels in the diagnosis of endometrioma. Fertility and Sterility1996;65(2):293‐8. ">Guerriero 1996b</a>; <a href="./references#CD012179-bbs2-0119" title="TokmakA , UgurM , TongucE , VarT , MoralogluO , OzaksitG . The value of urocortin and Ca‐125 in the diagnosis of endometrioma. Archives of Gynecology and Obstetrics2011;283(5):1075‐9. ">Tokmak 2011</a>; 189 women, follicular cycle phase) had sensitivities of 0.79 and 0.88 (95% CI 0.60 to 0.92 and 0.74 to 0.96) and specificities of 0.56 and 0.63 (95% CI 0.43 to 0.67 and 0.48 to 0.77). </p> </li> <li> <p>CA‐125 with a cut‐off value of ≥ 25 U/ml (<a href="./references#CD012179-bbs2-0040" title="GuerrieroS , MaisV , AjossaS , PaolettiAM , AngiolucciM , MelisGB . Transvaginal ultrasonography combined with CA‐125 plasma levels in the diagnosis of endometrioma. Fertility and Sterility1996;65(2):293‐8. ">Guerriero 1996b</a>; 101 women, follicular cycle phase) demonstrated a sensitivity of 0.76 (95% CI 0.56 to 0.90) and a specificity of 0.67 (95% CI 0.55 to 0.77). </p> </li> <li> <p>CA‐125 with a cut‐off value of &gt; 30 U/ml (<a href="./references#CD012179-bbs2-0028" title="FlorioP , ReisFM , TorresPB , CalonaciF , TotiP , BocchiC , et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstetrics and Gynecology2007;110(3):594‐600. ">Florio 2007</a>; <a href="./references#CD012179-bbs2-0092" title="OhataY , HaradaT , MiyakodaH , TaniguchiF , IwabeT , TerakawaN . Serum interleukin‐8 levels are elevated in patients with ovarian endometrioma. Fertility and Sterility2008;90(4):994‐9. ">Ohata 2008</a>; 171 women, various cycle phases) exhibited sensitivities of 0.75 and 0.57 (95% CI 0.59 to 0.87 and 0.44 to 0.69) and specificities of 0.85 and 0.94 (95% CI 0.70 to 0.94 and 0.73 to 1.00). </p> </li> <li> <p>CA‐125 with a cut‐off value of &gt; 35 U/ml (<a href="./references#CD012179-bbs2-0040" title="GuerrieroS , MaisV , AjossaS , PaolettiAM , AngiolucciM , MelisGB . Transvaginal ultrasonography combined with CA‐125 plasma levels in the diagnosis of endometrioma. Fertility and Sterility1996;65(2):293‐8. ">Guerriero 1996b</a>; 101 women, follicular cycle phase) had a sensitivity of 0.59 (95% CI 0.39 to 0.76) and a specificity of 0.79 (95% CI 0.68 to 0.88). </p> </li> <li> <p>CA‐125 with a cut‐off value of &gt; 36 U/ml (<a href="./references#CD012179-bbs2-0029" title="FlorioP , ReisFM , TorresPB , CalonaciF , AbraoMS , NascimentoLL , et al. High serum follistatin levels in women with ovarian endometriosis. Human Reproduction2009;24(10):2600‐6. ">Florio 2009</a>; 80 women, follicular cycle phase) had a sensitivity of 0.65 (95% CI 0.98 to 0.79) and a specificity of 0.90 (95% CI 0.76 to 0.97). </p> </li> <li> <p>CA‐125 with a cut‐off value of &gt; 42 U/ml (<a href="./references#CD012179-bbs2-0029" title="FlorioP , ReisFM , TorresPB , CalonaciF , AbraoMS , NascimentoLL , et al. High serum follistatin levels in women with ovarian endometriosis. Human Reproduction2009;24(10):2600‐6. ">Florio 2009</a>, 104 women, follicular cycle phase) had a sensitivity of 0.44 (95% CI 0.30 to 0.59) and a specificity of 0.90 (95% CI 0.79 to 0.97). None of the tests met the criteria for a replacement or triage test and CA‐125 with a cut‐off value &gt; 36 U/ml only approached the criteria of a SpIN triage test; however, there were insufficient data to perform meaningful analyses specific for ovarian endometrioma for any of the cut‐offs. </p> </li> </ol> </p> </section> </section> <section id="CD012179-sec-0157"> <h5 class="title">5. Combined blood tests</h5> <p>Two combinations of biomarkers were specifically assessed for their ability to distinguish ovarian endometrioma from other ovarian cysts. </p> <p> <ol id="CD012179-list-0068"> <li> <p>CA‐125 + CA‐19.9 with the cut‐off values ≥ 25 U/ml and ≥ 12 U/ml, respectively (<a href="./references#CD012179-bbs2-0039" title="GuerrieroS , AjossaS , PaolettiAM , MaisV , AngiolucciM , MelisGB . Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma. Obstetrics and Gynecology1996;88(3):403‐7. ">Guerriero 1996a</a>; 118 women, follicular cycle phase) demonstrated a sensitivity of 0.90 (95% CI 0.76 to 0.97) with a specificity of 0.41 (95% CI 0.3 to 0.52) when either positive biomarker was considered and a sensitivity of 0.54 (95% CI 0.37 to 0.70) with a specificity of 0.90 (95% CI 0.81 to 0.96) when both positive biomarkers were included. </p> </li> <li> <p>CA‐125 + IL‐8 with the cut‐off values &gt; 30 U/ml and ≥ 25 U/ml, respectively (<a href="./references#CD012179-bbs2-0092" title="OhataY , HaradaT , MiyakodaH , TaniguchiF , IwabeT , TerakawaN . Serum interleukin‐8 levels are elevated in patients with ovarian endometrioma. Fertility and Sterility2008;90(4):994‐9. ">Ohata 2008</a>; 91 women, follicular or luteal cycle phase) had a sensitivity of 0.86 (95% CI 0.75 to 0.93) and a specificity of 0.72 (95% CI 0.47 to 0.90). </p> </li> </ol> </p> <p>Small numbers of studies assessed each test evaluated for their ability to distinguish ovarian endometriosis from other benign masses, and we could not draw a firm conclusion. The available evidence is scant; however, several biomarkers showed some diagnostic potential as summarised in '<a href="#CD012179-sec-0160">Summary of main results</a>' under 'Tests to be validated for their diagnostic potential'. Further evaluations of these biomarkers are necessary to improve the certainty with regard to their diagnostic value in ovarian endometriosis. </p> </section> </section> <section id="CD012179-sec-0158"> <h4 class="title">Investigation of heterogeneity and sensitivity analyses</h4> <p>The potential sources of heterogeneity are outlined in <a href="#CD012179-sec-0044">Secondary objectives</a>. Although we attempted to assess these sources, there were not enough studies evaluating each test to make this a meaningful analysis, except for the meta‐analysis comprised of 27 studies for CA‐125 with a cut‐off value &gt; 35 to 36 U/ml. </p> <p> <ol id="CD012179-list-0069"> <li> <p>Two studies were published between 1986 and 1989; 13 studies, between 1990 and 1999; 9 studies, between 2000 and 2009; and 3 studies, between 2010 and 2014. </p> </li> <li> <p>Fourteen studies took place in Europe, five studies in Asia, four studies in North America, three studies in South America, and one study in the Middle East. </p> </li> <li> <p>Nineteen studies used a single‐gate design, and eight studies had a two‐gate design.</p> </li> <li> <p>One study assessed only minimal‐mild endometriosis (rASRM I to II); 3 studies, only moderate‐severe disease (rASRM III to IV); one study did not provide information on the severity, and 22 studies evaluated a wide spectrum of endometriosis (rASRM I to IV). Of these 22 studies, 11 presented separate diagnostic estimates for different rASRM stages in addition to the data for the entire group, but we did not include this information in the review and did not consider it in the assessment of heterogeneity. </p> </li> <li> <p>Thirteen studies used histopathology in adjunct to laparoscopy as a reference standard, while 14 studies relied on visual inspection of pelvic cavity. </p> </li> <li> <p>Two studies were specific for the diagnosis of ovarian endometrioma, one study assessed only peritoneal endometriosis, and the remaining 24 studies evaluated overall pelvic endometriosis. </p> </li> <li> <p>Nine studies evaluated the diagnostic performance of CA‐125 in the follicular cycle phase; six studies, in the luteal phase; two studies, in the follicular or luteal phase; and three studies, in all cycle phases. Seven studies did not report the cycle phase. </p> </li> <li> <p>Nineteen studies included various clinical presentations (pain ± infertility ± ovarian mass), of which one study reported separate estimates for populations with infertility and with pelvic pain, one study included only participants with pelvic pain, three studies were confined to women presenting with infertility, three studies evaluated only women with ovarian mass, and one study did not specify clinical presentation. </p> </li> </ol> </p> <p>There was no significant difference in sensitivity or specificity between the studies with regard to the study design (single‐gate versus two‐gate studies), the rASRM stages of endometriosis, the reference standard (histological confirmation versus laparoscopic visualisation alone), the target condition (ovarian versus overall pelvic endometriosis), the menstrual cycle phase of testing or the clinical presentations (pain, infertility, ovarian mass versus infertility only or pain only). </p> <p>With regards to the geographical areas of the studies, studies based in North America reported higher sensitivity compared to the other continents (P = 0.0003), but we were unable to identify the reason for this difference. The other significant factor was year of publication. Studies published after 2010 reported lower estimates of sensitivity compared to the studies published before 2000 (P = 0.026), which is likely to be an indicator that other things have changed in the laboratory methodology including sample processing and types of assays. </p> <p>We were unable to explore the effect of the following potential sources of heterogeneity.</p> <p> <ul id="CD012179-list-0070"> <li> <p>Age (adolescents versus later reproductive years): only one study presented separate data for different age groups (younger than 25 years old and 25 to 41 years) in addition to the estimates for the entire included population, and all the remaining studies reported data for the whole reproductive age group. </p> </li> <li> <p>Methodological quality: low versus unclear or high risk: all the studies were of low methodological quality with high or unclear risk of bias. </p> </li> </ul> </p> <p>We could not formally assess observer variability bias or bias related to interpretation of results in this review. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012179-sec-0159" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012179-sec-0159"></div> <section id="CD012179-sec-0160"> <h3 class="title" id="CD012179-sec-0160">Summary of main results</h3> <p>We evaluated the diagnostic performance for 47 of the 122 blood biomarkers included in this review. Only four biomarkers were assessed in a sufficient number of studies for a meta‐analysis: CA‐125 for different cut‐offs, CA‐19.9 for a cut‐off value of &gt; 37 U/ml, IL‐6 for a cut‐off value of &gt; 1.90 to 2.00 pg/ml and anti‐endometrial antibodies. None of the meta‐analyses revealed a test with the diagnostic accuracy for a suitable replacement test (sensitivity ≥ 0.94 and specificity ≥ 0.79) or triage test (either a sensitivity ≥ 0.95 with specificity ≥ 0.50, SnOUT, or a sensitivity ≥ 0.50 with a specificity ≥ 0.95, SpIN). </p> <p>CA‐125 was the most studied biomarker, and studies analysed multiple cut‐off values within the following groups: &gt; 10.0 to 14.7 U/ml, &gt;16.0 to 17.6 U/ml, &gt; 20.0 U/ml, &gt; 25.0 to 26.0 U/ml, &gt; 30.0 to 33.0 U/ml, &gt; 35.0 to 36.0 U/ml, &gt; 42.0 to 43.0 U/ml. None of these tests were sensitive or specific enough to be considered as a replacement or triage test. The summary estimates of the mean sensitivity and the mean specificity of CA‐125 did not all show the expected pattern (higher sensitivity and lower specificity with lower thresholds), but this was likely related to the indirect nature of the comparisons and heterogeneous study groups from different populations. The cut‐off &gt; 16.0 to 17.6 U/ml was the best performing of all the CA‐125 thresholds subjected to meta‐analysis, but it only approached the criteria for a SpIN triage test and showed substantial heterogeneity. CA‐125 with a cut‐off of &gt; 43.0 U/ml reached the criteria for a replacement test for detecting advanced endometriosis, but only one study demonstrated this, and the data for a wide spectrum of disease was lacking. </p> <p>The sensitivity of CA‐19.9 in detecting endometriosis was too low to meet the criteria for a replacement or triage test. Although only the cut‐off value of &gt; 37.0 U/ml was adequately assessed for this biomarker, other thresholds reported in individual studies did not show promising results. </p> <p>In this review anti‐endometrial antibodies and IL‐6 with a cut‐off value of &gt; 1.90 to 2.00 pg/ml displayed unsatisfactory diagnostic estimates to qualify for either a replacement or triage test. There were too few studies to perform a meaningful evaluation for other cut‐off values of IL‐6. Although, IL‐6 with a cut‐off of &gt; 12.20 pg/ml, had a sufficiently high sensitivity and specificity to satisfy the criteria for a replacement test, it was explored in only one study and warrants further validation. </p> <p>Readers should interpret the findings of the meta‐analyses presented in this review with caution. Considering both the level of heterogeneity and the high/unclear risk of bias of the included studies, the results do not seem to be reliable enough to inform clinical practice. </p> <p>The remaining biomarkers were classified as follows.</p> <p> <ul id="CD012179-list-0071"> <li> <p>Tests to be validated for their diagnostic potential. This group included:</p> <ul id="CD012179-list-0072"> <li> <p>those with an adequate diagnostic performance, but insufficient data to confidently comment on their diagnostic role (less than three studies with the diagnostic estimates meeting the criteria for either a replacement or triage test); and </p> </li> <li> <p>tests where the diagnostic estimates approached the criteria for replacement or triage tests in a small number of studies and where it is possible that they would reach this criteria in further studies (less than three studies with the diagnostic estimates within 5% of the criteria for either replacement or triage tests). These tests are presented in <a href="#CD012179-tbl-0005">Table 4</a>. </p> </li> </ul> </li> <li> <p>Tests of limited diagnostic value (at least three studies demonstrating low diagnostic estimates that do not meet or approach the criteria for either replacement or triage test, or report negative findings). We advise against further evaluation of these biomarkers in the diagnosis of endometriosis. We present these tests in Appendix 8. </p> </li> <li> <p>Tests that appear to have limited diagnostic value, but where there is insufficient data to confidently comment on their diagnostic role (less than three studies with low diagnostic estimates or negative findings). We present the full list of tests from this group in <a href="./appendices#CD012179-sec-0184">Appendix 9</a>. We advise considering further investigation with a focus of specific phases of menstrual cycle, specific types of endometriosis, different cut‐off values or different laboratory methods. </p> </li> </ul> </p> <div class="table" id="CD012179-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Blood biomarkers to be validated for their diagnostic potential in endometriosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Blood biomarkers <sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Replacement test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SnOUT triage test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SpIN triage test</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>1. Angiogenesis and growth markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF &gt; 680 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF &gt; 236 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>2. High‐throughput markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolome by ESI‐MS/MS (SMOH C16:1 + PCaa C36:2/PCae C34:2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proteome by SELDI‐TOF‐MS (6 peaks with molecular weights of 1.63, 3.05, 3.53, 3.77, 5.05 and 5,07 Da) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>3. Immune system and inflammatory markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>4. Oxidative stress markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PON‐1 &lt; 141.5 U/l</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbonyls &lt; 14.9 μM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>5. Post‐transcriptional regulators of gene expression (microRNAs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐9*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐141*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐145*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐20a &lt; 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐22 &lt; 0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐532‐3p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6. Tumour markers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 (cut‐off value &gt; 43 U/ml)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>7. Combined blood tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml + CRP &gt; 438 μg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐199a + miR‐542‐3p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + STX‐5 + LN‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 17.6 IU/ml + VEGF &gt; 236 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + CA‐19‐9 + survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 50 IU/ml +/or CCR1 &gt; 1.16 +/or MCP‐1 &gt; 140 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 20 IU/ml + MCP‐1 &gt; 152.744 pg/ml + leptin &gt; 3.14 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + IL‐8 + TNF‐α</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP (in menstrual phase of the cycle)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>8. Tests that specifically differentiate endometrioma from other benign ovarian cysts in women of reproductive age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urocortin &gt; 29 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urocortin &gt; 33 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follistatin &gt; 1433 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 30 U/ml and &gt; 36 U/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 ≥ 25 U/ml + CA‐19.9 ≥ 22 U/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Notes:</p> <p><b>+</b> meets the criteria </p> <p> <ul id="CD012179-list-0073"> <li> <p>Replacement test: sensitivity ≥ 94 and specificity ≥ 79</p> </li> </ul> <ul id="CD012179-list-0074"> <li> <p>SnOUT triage test: sensitivity ≥ 95 and specificity ≥ 50</p> </li> </ul> <ul id="CD012179-list-0075"> <li> <p>SpIN triage test: sensitivity ≥ 50 and specificity ≥ 95</p> </li> </ul> </p> <p><b>±</b> approaches the criteria (within 5% of the pre‐defined criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> This group included: tests with an adequate diagnostic performance, but insufficient data to confidently comment on their diagnostic role (less than 3 studies with the diagnostic estimates meeting the criteria for either a replacement or triage test); and tests where the diagnostic estimates were approaching the criteria for replacement or triage tests in a small number of studies, and it is possible that they would reach this criteria if further studies were performed (less than 3 studies with the diagnostic estimates within 5% of the criteria for either replacement or triage tests). </p> <p>For a comprehensive list of all biomarkers with their biological annotation, please see <a href="./appendices#CD012179-sec-0169">Appendix 1</a>. </p> </div> </div> </section> <section id="CD012179-sec-0161"> <h3 class="title" id="CD012179-sec-0161">Strengths and weaknesses of the review</h3> <p>This review is part of a comprehensive review series on minimally invasive biomarkers for the diagnosis of endometriosis. </p> <p>The strengths of this review are the following.</p> <p> <ol id="CD012179-list-0076"> <li> <p>A very large number of studies, including data for 15,141 women from 141 studies, which allowed meta‐analyses for some blood biomarker tests. </p> </li> <li> <p>A very thorough search of the current literature, including studies written in languages other than English. </p> </li> <li> <p>Data extraction by two independent reviewers and use of a modified QUADAS‐2 tool to perform quality assessments. </p> </li> <li> <p>Stringent selection criteria, ensuring that eligible studies used prospectively collected samples and only included women of reproductive age, which minimised the risk of bias in interpreting the reference standard and index test. </p> </li> <li> <p>Attempts to contact study authors to obtain any missing information required to assess eligibility and critically appraise the studies. </p> </li> <li> <p>The inclusion of studies that reported negative findings (i.e. demonstrated that biomarker levels did not significantly differ in endometriosis), which provided a more comprehensive evaluation of diagnostic role of the biomarkers and identified the tests of no value in diagnosing the disease. </p> </li> </ol> </p> <p>The main limitation of this review is that there were a low number of small, heterogeneous studies for the majority of the evaluated index tests. This may undermine the reliability of the summary estimates from the meta‐analyses and is likely to have contributed to the marked variability in sensitivity and specificity seen for most index tests. For the vast majority of minimally invasive diagnostic tests (or combinations of tests), no meta‐analysis was possible. The studies varied with respect to the included populations, severity of endometriosis, menstrual cycle phase at testing, laboratory methods and the cut‐off thresholds for index tests. We could not formally explore sources of heterogeneity for the majority of tests due to the low number of studies in most evaluations. Also, most of the included studies evaluated the diagnostic cut‐off thresholds using a ROC analysis without any subsequent validation in an independent cohort. Lack of validation of the diagnostic data in conjunction with the low number of studies for the majority of the presented tests contributed to the low quality of evidence presented in this review. We now have an available standardised methodology for fluid biospecimen collection, processing and storage, and we recommend adhering to these standards in future diagnostic studies (<a href="./references#CD012179-bbs2-0426" title="RahmiogluN , FassbenderA , VitonisAF , TworogerSS , HummelshojL , D’HoogheTM , et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking armonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. Fertility and Sterility2014;102(5):1233‐43. ">Rahimoglu 2014</a>). </p> <p>Additional weaknesses of this review series are the following.</p> <p> <ol id="CD012179-list-0077"> <li> <p>The variation in the selection of the case and control groups with inclusion of participants that may not reflect a clinically representative population. The reported prevalence of endometriosis in this and the other reviews was generally higher (16% to 84%) than previously reported (6% to 10% in the general female population and 35% to 50% in symptomatic women) (<a href="./references#CD012179-bbs2-0404" title="GiudiceLC , KaoLC . Endometriosis. Lancet2004;364:1789‐99. ">Giudice 2004</a>). This may reflect a high level of surgical diagnostic expertise but could be due to pre‐selection of more challenging cases in tertiary referral centres, and there is a high risk of patient selection bias in most of the studies. Selection bias appeared to be reduced but not eliminated by consecutively enrolling participants; however, the information on the method of enrolment was missing in most of the included studies. More than a third of the included studies (61/141, 43%) had a two‐gate design and included a wide group of participants who underwent surgery for various indications. Inclusion of healthy asymptomatic individuals or participants with other pathological conditions represents a potential selection bias with regard to the control group, which could have biased the test outcomes. Thirty‐four studies included either women with a limited spectrum of endometriosis (N = 26) or they did not provide information on the severity of target condition (N = 8). we included these studies to avoid omission of potentially valuable diagnostic information, but each of the above factors could skew the diagnostic estimates in either direction and subsequently interfere with the interpretation of the index test results. It was not possible to evaluate population and disease spectrum effects on the data because there were too few reports for most of the blood biomarkers. </p> </li> <li> <p>We could not rule out inappropriate assignment to the endometriosis and control groups in many studies. Surgical misdiagnosis is a potential cause of bias as most of the included studies did not adequately describe the number and experience of the surgical team, the surgical diagnostic criteria and the surgical methods. We now have a standardised technique for performing laparoscopy, and we recommend that any future studies use this method (<a href="./references#CD012179-bbs2-0385" title="BeckerCM , LauferMR , StrattonP , Hummelshojl , MissmerSA , ZondervanKT , et al. World Endometriosis Research Foundation Endometriosis Phenome and biobanking harmonization project: I. Surgical phenotype data collection in endometriosis research. Fertility and Sterility2014;102(5):1213‐22. ">Becker 2014</a>). Additionally, we did not confine the studies included in this review to those that reported histological confirmation of endometriotic lesions. Although a recent ESHRE guideline stated that evidence is lacking to support laparoscopy without histology to confirm endometriosis (<a href="./references#CD012179-bbs2-0398" title="DunselmanGA , VermeulenN , BeckerC , Calhaz‐JorgeC , D'HoogheT , DeBieB , et al. ESHRE guideline: management of women with endometriosis. Human Reproduction2014;29(3):400‐12. ">Dunselman 2014</a>), the clinical significance of histological verification remains debatable. Diagnosis by surgical visualisation only remains a common clinical practice and can be considered reliable when an accurate inspection of the abdominal cavity is performed by experienced surgeons. We chose to include the 66 studies that only reported surgical visualisation as the reference standard, and we did not wish to lose this potentially valuable information. However, this could impact the accuracy of assignment to the case and control groups. </p> </li> <li> <p>The methodology of systematic reviews of diagnostic test accuracy is still emerging, and there are no well‐established criteria for replacement or triage diagnostic tests, therefore we chose criteria that were both realistic and clinically applicable to assist in the interpretation of the complex results. For a replacement test, we considered the threshold reported by the one and the only systematic review on accuracy of the reference standard (laparoscopy) in detecting endometriosis to be the most objective (<a href="./references#CD012179-bbs2-0444" title="WykesCB , ClarkTJ , KhanKS . Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG ‐ an International Journal of Obstetrics and Gynaecology2004;111:1204‐12. ">Wykes 2004</a>). The meta‐analysis was published in 2004 and included four eligible studies comprising 433 women. We acknowledge the limitations associated with emphasising a single review, particularly if it does not present the latest and possibly more accurate data that reflect advances in surgical expertise and technology. Several studies on accuracy of laparoscopy in detecting endometriosis have been published in the last decade; however, their results were not addressed in a systematic way. A further systematic analysis to evaluate the accuracy of laparoscopy was beyond the scope of this review. The criteria for triage tests utilised the common concepts of SnOUT and SpIN in medical statistics, and the cut‐offs were set at levels we considered to be clinically relevant (see <a href="#CD012179-sec-0039">Role of index test(s)</a>). We encourage the readers to apply independent interpretations of the presented diagnostic estimates by using thresholds that may be more applicable to specific populations and clinical circumstances. </p> </li> </ol> </p> </section> <section id="CD012179-sec-0162"> <h3 class="title" id="CD012179-sec-0162">Applicability of findings to the review question</h3> <p>Based on our use of the QUADAS‐2, we assigned a low rank (high concern) to clinical applicability with respect to patient selection in 51% of the studies (72/141). This occurred when the set of participants in the study was broader that seen in clinical practice or when the spectrum of the target condition was limited and the findings may not be applicable to the review question and to clinical practice. We judged the applicability of the index test and reference standard to be satisfactory using the QUADAS‐2 tool for all studies. However, the majority of included studies took place in academic institutions with a high level of expertise in laboratory techniques, and the index test outcome measures may not be able to be reproduced in all institutions or extrapolated to general practice. </p> <p>We excluded some potentially relevant well‐designed studies, as they did not directly address the review question. For example, we excluded studies that reported on biomarkers with differential expression in endometriosis, but that did not provide enough information to assess the diagnostic performance of the biomarker. Additionally, we excluded most of the studies that compared endometrioma with other ovarian masses, as they either did not meet our inclusion criteria for reproductive age or assessed the numbers of cysts rather than the number of participants. Therefore we could not fully address the review question on non‐invasive diagnosis of ovarian endometriosis. We also excluded some forms of endometriosis, such as bladder, ureteric or endometriosis involving the extrapelvic sites (e.g. umbilicus, hernia sacs, abdominal wall, lung, kidney, etc.), as they are informed predominantly by case reports or small case series, and diagnostic laparoscopy is not an applicable reference test for these conditions. Although these target conditions are rare, from a clinical perspective the diagnostic options for these forms of endometriosis remain unclear. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012179-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Sequential approach to non‐invasive testing of endometriosis." data-id="CD012179-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Sequential approach to non‐invasive testing of endometriosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Flow of the studies identified in literature search for systematic review on imaging modalities for a non‐invasive diagnosis of endometriosis." data-id="CD012179-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Flow of the studies identified in literature search for systematic review on imaging modalities for a non‐invasive diagnosis of endometriosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD012179-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012179-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of Glycodelin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 9 ng/ml and &gt; 18 ng/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Summary ROC plot of Glycodelin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 9 ng/ml and &gt; 18 ng/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of VEGF for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Summary ROC plot of VEGF for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of proteome by SELDI‐TOF‐MS for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of proteins determined by molecular weight (MW) in daltons (Da). The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Summary ROC plot of proteome by SELDI‐TOF‐MS for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of proteins determined by molecular weight (MW) in daltons (Da). The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of anti‐endometrial Abs for detection of endometriosis. Plot shows study‐specific estimates of sensitivity and specificity (squares) with 95% CI (black line), country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of anti‐endometrial Abs for detection of endometriosis. Plot shows study‐specific estimates of sensitivity and specificity (squares) with 95% CI (black line), country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of anti‐endometrial Abs, IgG for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 4 studies (the data for Anti‐endometrial Abs (MW 26/34/42 kd) were not included, considering it as a separate test)." data-id="CD012179-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Summary ROC plot of anti‐endometrial Abs, IgG for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 4 studies (the data for Anti‐endometrial Abs (MW 26/34/42 kd) were not included, considering it as a separate test). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of TNF‐α for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Summary ROC plot of TNF‐α for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of IL‐6 (all the included evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of IL‐6 (all the included evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of IL‐6 with cut‐off values above 1.9‐2 pg/ml for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Forest plot of IL‐6 with cut‐off values above 1.9‐2 pg/ml for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of IL‐6 with cut‐off values ranging &gt; 1.9‐2 pg/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity." data-id="CD012179-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Summary ROC plot of IL‐6 with cut‐off values ranging &gt; 1.9‐2 pg/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of direct comparisons of IL‐6 for detection of endometriosis performed between different cut‐off values in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Forest plot of direct comparisons of IL‐6 for detection of endometriosis performed between different cut‐off values in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of IL‐8 for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Summary ROC plot of IL‐8 for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG16.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of hs‐CRP for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Forest plot of hs‐CRP for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG17.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of hs‐CRP for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Five evaluations (excluding 1 with a cut‐off &gt; 438 μg/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>Summary ROC plot of hs‐CRP for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Five evaluations (excluding 1 with a cut‐off &gt; 438 μg/ml) were performed on overlapping populations. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG18.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of oxidative stress biomarkers for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Summary ROC plot of oxidative stress biomarkers for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG19.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of microRNAs for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>Summary ROC plot of microRNAs for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates different biomarkers from this group, each assessed in a single study. The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG20.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of CA‐19.9 with a cut‐off value &gt; 37 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity." data-id="CD012179-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p>Summary ROC plot of CA‐19.9 with a cut‐off value &gt; 37 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG21.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of CA‐19.9 (all the evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p>Forest plot of CA‐19.9 (all the evaluations) for detection of endometriosis. Plot shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG22.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of CA‐125 (all the included evaluations) for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p>Forest plot of CA‐125 (all the included evaluations) for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG23.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 10‐14.7 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 5 studies (the data for 2 evaluations (CA‐125 &gt; 11.5 U/ml and CA‐125 &gt; 13.5 U/ml were not included as overlapping populations with already included study)." data-id="CD012179-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 10‐14.7 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). Meta‐analysis was performed for 5 studies (the data for 2 evaluations (CA‐125 &gt; 11.5 U/ml and CA‐125 &gt; 13.5 U/ml were not included as overlapping populations with already included study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG24.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 16‐17.6 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) ad by 95% prediction region (dashed line)." data-id="CD012179-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 24</div> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 16‐17.6 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) ad by 95% prediction region (dashed line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG25.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of CA‐125 with cut‐off values &gt; 20 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line)." data-id="CD012179-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 25</div> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values &gt; 20 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG26.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 25‐26 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity." data-id="CD012179-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 26</div> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 25‐26 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary sensitivity and specificity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG27.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 30‐33 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line)." data-id="CD012179-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 27</div> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 30‐33 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG28.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 35‐36 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line)." data-id="CD012179-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 28</div> <div class="figure-caption"> <p>Summary ROC plot of CA‐125 with cut‐off values ranging &gt; 35‐36 U/ml for detection of endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG29.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different cut‐off values in 8 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 29</div> <div class="figure-caption"> <p>Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different cut‐off values in 8 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG30.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different phases of menstrual cycle in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 30</div> <div class="figure-caption"> <p>Forest plot of direct comparisons of CA‐125 for detection of endometriosis performed between different phases of menstrual cycle in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG31.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of the combined tests (all the included evaluations) for detection of endometriosis, which consist of the combinations of 2‐6 blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 31</div> <div class="figure-caption"> <p>Forest plot of the combined tests (all the included evaluations) for detection of endometriosis, which consist of the combinations of 2‐6 blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG32.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of the combined tests for detection of endometriosis, which consist of the combinations of CA‐125 with other blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 32</div> <div class="figure-caption"> <p>Forest plot of the combined tests for detection of endometriosis, which consist of the combinations of CA‐125 with other blood biomarkers. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG33.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of the most promising combined tests of blood biomarkers for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 33</div> <div class="figure-caption"> <p>Forest plot of the most promising combined tests of blood biomarkers for detection of endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG34.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of the tests for detection of ovarian endometriosis performed through comparisons in women with endometriosis versus other benign ovarian cysts in 6 studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD012179-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 34</div> <div class="figure-caption"> <p>Forest plot of the tests for detection of ovarian endometriosis performed through comparisons in women with endometriosis versus other benign ovarian cysts in 6 studies. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-AFig-FIG35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-AFig-FIG35.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of urocortin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 29 pg/ml and &gt; 33 pg/ml) were performed in the same population. The data were not assessed by meta‐analysis." data-id="CD012179-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 35</div> <div class="figure-caption"> <p>Summary ROC plot of urocortin for detection of endometriosis. Each point represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the shape designates the tests with different cut‐off values. The bars correspond to 95% CIs of each individual evaluation. Two evaluations (&gt; 29 pg/ml and &gt; 33 pg/ml) were performed in the same population. The data were not assessed by meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-AFig-FIG35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-001" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-001.xxx" target="_blank"><b></b></a></p> </div><img alt="Glycodelin‐A (&gt; 2.07 ng/ml)." data-id="CD012179-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-001.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>Glycodelin‐A (&gt; 2.07 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-002" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-002.xxx" target="_blank"><b></b></a></p> </div><img alt="Glycodelin (&gt; 9.0 ng/ml)." data-id="CD012179-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-002.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p>Glycodelin (&gt; 9.0 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-003" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-003.xxx" target="_blank"><b></b></a></p> </div><img alt="Glycodelin (&gt; 18 ng/ml)." data-id="CD012179-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-003.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p>Glycodelin (&gt; 18 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-004" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-004.xxx" target="_blank"><b></b></a></p> </div><img alt="IGFBP‐3 (&gt; 200 ng/ml)." data-id="CD012179-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-004.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p>IGFBP‐3 (&gt; 200 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-005" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-005.xxx" target="_blank"><b></b></a></p> </div><img alt="IGFBP‐3 (&gt; 210 ng/ml)." data-id="CD012179-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-005.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p>IGFBP‐3 (&gt; 210 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-006" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-006.xxx" target="_blank"><b></b></a></p> </div><img alt="VEGF (&gt; 1.5 pg/ml)." data-id="CD012179-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-006.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p>VEGF (&gt; 1.5 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-006.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-007" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-007.xxx" target="_blank"><b></b></a></p> </div><img alt="VEGF (&gt; 236 pg/ml)." data-id="CD012179-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-007.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 7</div> <div class="figure-caption"> <p>VEGF (&gt; 236 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-007.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-008" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-008.xxx" target="_blank"><b></b></a></p> </div><img alt="VEGF‐A (&gt; 680 pg/ml)." data-id="CD012179-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-008.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 8</div> <div class="figure-caption"> <p>VEGF‐A (&gt; 680 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-008.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-009" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-009.xxx" target="_blank"><b></b></a></p> </div><img alt="Urocortin (&gt; 29 pg/ml), endometrioma." data-id="CD012179-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-009.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 9</div> <div class="figure-caption"> <p>Urocortin (&gt; 29 pg/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-009.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-010" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-010.xxx" target="_blank"><b></b></a></p> </div><img alt="Urocortin (&gt; 33 pg/ml), endometrioma." data-id="CD012179-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-010.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 10</div> <div class="figure-caption"> <p>Urocortin (&gt; 33 pg/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-010.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-011" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-011.xxx" target="_blank"><b></b></a></p> </div><img alt="Urocortin (&gt; 41.6 pg/ml), endometrioma." data-id="CD012179-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-011.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 11</div> <div class="figure-caption"> <p>Urocortin (&gt; 41.6 pg/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-011.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-012" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-012.xxx" target="_blank"><b></b></a></p> </div><img alt="Survivin (cut‐off not reported)." data-id="CD012179-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-012.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 12</div> <div class="figure-caption"> <p>Survivin (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-012.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-013" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-013.xxx" target="_blank"><b></b></a></p> </div><img alt="sICAM‐1 (&lt; 243 ng/ml)." data-id="CD012179-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-013.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 13</div> <div class="figure-caption"> <p>sICAM‐1 (&lt; 243 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-013.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-014" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-014.xxx" target="_blank"><b></b></a></p> </div><img alt="sICAM‐1 (&lt; 254.6 ng/ml)." data-id="CD012179-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-014.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 14</div> <div class="figure-caption"> <p>sICAM‐1 (&lt; 254.6 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-014.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-015" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-015.xxx" target="_blank"><b></b></a></p> </div><img alt="sICAM‐1 (&gt; 241.46 µg/ml)." data-id="CD012179-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-015.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 15</div> <div class="figure-caption"> <p>sICAM‐1 (&gt; 241.46 µg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-015.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-016" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-016.xxx" target="_blank"><b></b></a></p> </div><img alt="LN‐1 (&gt; 1110.0 pg/ml)." data-id="CD012179-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-016.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 16</div> <div class="figure-caption"> <p>LN‐1 (&gt; 1110.0 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-016.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-017" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-017.xxx" target="_blank"><b></b></a></p> </div><img alt="Metabolome by ESI‐MS/MS (SMOH C16:1 + PCaa C36:2/ PCae C34:2) age‐/BMI‐adjusted." data-id="CD012179-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-017.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 17</div> <div class="figure-caption"> <p>Metabolome by ESI‐MS/MS (SMOH C16:1 + PCaa C36:2/ PCae C34:2) age‐/BMI‐adjusted.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-017.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-018" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-018.xxx" target="_blank"><b></b></a></p> </div><img alt="Proteome by SELDI‐TOF‐MS (3 peaks with the molecular weight of 3,956.00, 11,710.00 and 6,986.00 Da)." data-id="CD012179-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-018.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 18</div> <div class="figure-caption"> <p>Proteome by SELDI‐TOF‐MS (3 peaks with the molecular weight of 3,956.00, 11,710.00 and 6,986.00 Da). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-018.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-019" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-019.xxx" target="_blank"><b></b></a></p> </div><img alt="Proteome by SELDI‐TOF MS (5 peaks with molecular weights of 4159.00, 5264.00, 5603.00, 9861.00 and 10,533.00 Da)." data-id="CD012179-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-019.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 19</div> <div class="figure-caption"> <p>Proteome by SELDI‐TOF MS (5 peaks with molecular weights of 4159.00, 5264.00, 5603.00, 9861.00 and 10,533.00 Da). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-019.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-020" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-020.xxx" target="_blank"><b></b></a></p> </div><img alt="Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 9,926.31, 10,072.2, 6,753.04, 4,302.67, 9,328.49 Da)." data-id="CD012179-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-020.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 20</div> <div class="figure-caption"> <p>Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 9,926.31, 10,072.2, 6,753.04, 4,302.67, 9,328.49 Da). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-020.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-021" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-021.xxx" target="_blank"><b></b></a></p> </div><img alt="Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 2,831.02, 7,554.66, 4,241.29, 2,953.25, 9,927.73 Da)." data-id="CD012179-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-021.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 21</div> <div class="figure-caption"> <p>Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 2,831.02, 7,554.66, 4,241.29, 2,953.25, 9,927.73 Da). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-021.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-022" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-022.xxx" target="_blank"><b></b></a></p> </div><img alt="Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 11,366.3, 5,712.69, 10,070.7, 3,017.68, 3,824.44 Da)." data-id="CD012179-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-022.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 22</div> <div class="figure-caption"> <p>Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 11,366.3, 5,712.69, 10,070.7, 3,017.68, 3,824.44 Da). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-022.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-023" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-023.xxx" target="_blank"><b></b></a></p> </div><img alt="Proteome by SELDI‐TOF‐MS (6 peaks with molecular weights of 1629.00 3047.00, 3526.00, 3774.00, 5046.00 and 5068.00 Da)." data-id="CD012179-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-023.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 23</div> <div class="figure-caption"> <p>Proteome by SELDI‐TOF‐MS (6 peaks with molecular weights of 1629.00 3047.00, 3526.00, 3774.00, 5046.00 and 5068.00 Da). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-023.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-024" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-024.xxx" target="_blank"><b></b></a></p> </div><img alt="Prolactin (&gt; 14.8 ng/ml)." data-id="CD012179-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-024.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 24</div> <div class="figure-caption"> <p>Prolactin (&gt; 14.8 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-024.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-025" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-025.xxx" target="_blank"><b></b></a></p> </div><img alt="Prolactin (&gt; 20 ng/ml)." data-id="CD012179-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-025.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 25</div> <div class="figure-caption"> <p>Prolactin (&gt; 20 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-025.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-026" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-026.xxx" target="_blank"><b></b></a></p> </div><img alt="Anti‐endometrial Abs, IgG." data-id="CD012179-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-026.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 26</div> <div class="figure-caption"> <p>Anti‐endometrial Abs, IgG.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-026.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-027" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-027.xxx" target="_blank"><b></b></a></p> </div><img alt="Anti‐endometrial Abs (MW 26/34/42 kd)." data-id="CD012179-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-027.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 27</div> <div class="figure-caption"> <p>Anti‐endometrial Abs (MW 26/34/42 kd).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-027.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-028" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-028.xxx" target="_blank"><b></b></a></p> </div><img alt="Anti‐laminin auto Abs, IgG (&gt; 1 U/ml)." data-id="CD012179-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-028.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 28</div> <div class="figure-caption"> <p>Anti‐laminin auto Abs, IgG (&gt; 1 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-028.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-029" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-029.xxx" target="_blank"><b></b></a></p> </div><img alt="sCD23 (cut‐off not reported)." data-id="CD012179-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-029.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 29</div> <div class="figure-caption"> <p>sCD23 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-029.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-030" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-030.xxx" target="_blank"><b></b></a></p> </div><img alt="MCP‐1 (&gt; 100 pg/ml)." data-id="CD012179-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-030.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 30</div> <div class="figure-caption"> <p>MCP‐1 (&gt; 100 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-030.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-031" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-031.xxx" target="_blank"><b></b></a></p> </div><img alt="Copeptin (&gt; 251.18 pg/ml)." data-id="CD012179-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-031.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 31</div> <div class="figure-caption"> <p>Copeptin (&gt; 251.18 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-031.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-032" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-032.xxx" target="_blank"><b></b></a></p> </div><img alt="hs‐CRP (&gt; 0.61 mg/l)." data-id="CD012179-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-032.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 32</div> <div class="figure-caption"> <p>hs‐CRP (&gt; 0.61 mg/l).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-032.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-033" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-033.xxx" target="_blank"><b></b></a></p> </div><img alt="hs‐CRP (&gt; 0.62 mg/l)." data-id="CD012179-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-033.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 33</div> <div class="figure-caption"> <p>hs‐CRP (&gt; 0.62 mg/l).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-033.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-034" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-034.xxx" target="_blank"><b></b></a></p> </div><img alt="hs‐CRP (&gt; 0.70 mg/l)." data-id="CD012179-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-034.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 34</div> <div class="figure-caption"> <p>hs‐CRP (&gt; 0.70 mg/l).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-034.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-035" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-035.xxx" target="_blank"><b></b></a></p> </div><img alt="hs‐CRP (&gt; 0.73 mg/l)." data-id="CD012179-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-035.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 35</div> <div class="figure-caption"> <p>hs‐CRP (&gt; 0.73 mg/l).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-035.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-036" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-036.xxx" target="_blank"><b></b></a></p> </div><img alt="hs‐CRP (&gt; 438 μg/ml)." data-id="CD012179-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-036.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 36</div> <div class="figure-caption"> <p>hs‐CRP (&gt; 438 μg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-036.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-037" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-037.xxx" target="_blank"><b></b></a></p> </div><img alt="hs‐CRP (cut‐off not reported)." data-id="CD012179-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-037.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 37</div> <div class="figure-caption"> <p>hs‐CRP (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-037.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-038" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-038.xxx" target="_blank"><b></b></a></p> </div><img alt="IFN‐γ (&lt; 76 pg/ml)." data-id="CD012179-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-038.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 38</div> <div class="figure-caption"> <p>IFN‐γ (&lt; 76 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-038.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-039" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-039.xxx" target="_blank"><b></b></a></p> </div><img alt="MIF (&gt; 0.57 ng/ml)." data-id="CD012179-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-039.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 39</div> <div class="figure-caption"> <p>MIF (&gt; 0.57 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-039.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-040" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-040.xxx" target="_blank"><b></b></a></p> </div><img alt="TNF‐α (&gt; 12.45 pg/ml)." data-id="CD012179-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-040.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 40</div> <div class="figure-caption"> <p>TNF‐α (&gt; 12.45 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-040.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-041" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-041.xxx" target="_blank"><b></b></a></p> </div><img alt="TNF‐α (&lt; 45.6 pg/ml)." data-id="CD012179-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-041.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 41</div> <div class="figure-caption"> <p>TNF‐α (&lt; 45.6 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-041.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-042" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-042.xxx" target="_blank"><b></b></a></p> </div><img alt="TNF‐α (cut‐off not reported)." data-id="CD012179-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-042.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 42</div> <div class="figure-caption"> <p>TNF‐α (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-042.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-043" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-043.xxx" target="_blank"><b></b></a></p> </div><img alt="Neutrophils (&gt; 4058/ml)." data-id="CD012179-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-043.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 43</div> <div class="figure-caption"> <p>Neutrophils (&gt; 4058/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-043.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-044" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-044.xxx" target="_blank"><b></b></a></p> </div><img alt="NLR (&gt; 2.19)." data-id="CD012179-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-044.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 44</div> <div class="figure-caption"> <p>NLR (&gt; 2.19).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-044.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-045" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-045.xxx" target="_blank"><b></b></a></p> </div><img alt="WBC (&gt; 6400/ml)." data-id="CD012179-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-045.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 45</div> <div class="figure-caption"> <p>WBC (&gt; 6400/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-045.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-046" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-046.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐1β (&lt; 0.9 pg/ml)." data-id="CD012179-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-046.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 46</div> <div class="figure-caption"> <p>IL‐1β (&lt; 0.9 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-046.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-047" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-047.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐4 (≥ 3 pg/ml)." data-id="CD012179-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-047.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 47</div> <div class="figure-caption"> <p>IL‐4 (≥ 3 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-047.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-048" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-048.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 1.03 pg/ml)." data-id="CD012179-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-048.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 48</div> <div class="figure-caption"> <p>IL‐6 (&gt; 1.03 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-048.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-049" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-049.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 1.9 pg/ml)." data-id="CD012179-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-049.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 49</div> <div class="figure-caption"> <p>IL‐6 (&gt; 1.9 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-049.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-050" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-050.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 2 pg/ml)." data-id="CD012179-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-050.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 50</div> <div class="figure-caption"> <p>IL‐6 (&gt; 2 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-050.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-051" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-051.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 2.6 pg/ml)." data-id="CD012179-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-051.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 51</div> <div class="figure-caption"> <p>IL‐6 (&gt; 2.6 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-051.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-052" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-052.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 4 pg/ml)." data-id="CD012179-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-052.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 52</div> <div class="figure-caption"> <p>IL‐6 (&gt; 4 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-052.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-053" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-053.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 7.5 pg/ml)." data-id="CD012179-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-053.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 53</div> <div class="figure-caption"> <p>IL‐6 (&gt; 7.5 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-053.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-054" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-054.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&lt; 10 pg/ml)." data-id="CD012179-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-054.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 54</div> <div class="figure-caption"> <p>IL‐6 (&lt; 10 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-054.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-055" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-055.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 12.2 pg/ml)." data-id="CD012179-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-055.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 55</div> <div class="figure-caption"> <p>IL‐6 (&gt; 12.2 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-055.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-056" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-056.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 15.4 pg/ml)." data-id="CD012179-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-056.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 56</div> <div class="figure-caption"> <p>IL‐6 (&gt; 15.4 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-056.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-057" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-057.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 25.75 pg/ml)." data-id="CD012179-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-057.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 57</div> <div class="figure-caption"> <p>IL‐6 (&gt; 25.75 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-057.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-058" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-058.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (cut‐off not reported)." data-id="CD012179-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-058.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 58</div> <div class="figure-caption"> <p>IL‐6 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-058.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-059" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-059.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐8 (&gt; 24 pg/ml)." data-id="CD012179-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-059.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 59</div> <div class="figure-caption"> <p>IL‐8 (&gt; 24 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-059.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-060" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-060.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐8 (≥ 25 pg/ml), endometrioma." data-id="CD012179-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-060.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 60</div> <div class="figure-caption"> <p>IL‐8 (≥ 25 pg/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-060.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-061" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-061.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐8 (cut‐off not reported)." data-id="CD012179-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-061.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 61</div> <div class="figure-caption"> <p>IL‐8 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-061.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-062" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-062.xxx" target="_blank"><b></b></a></p> </div><img alt="Follistatin (&gt; 1433 pg/ml), endometrioma." data-id="CD012179-fig-0097" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-062.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 62</div> <div class="figure-caption"> <p>Follistatin (&gt; 1433 pg/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-062.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-063" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-063.xxx" target="_blank"><b></b></a></p> </div><img alt="STX‐5 (&gt; 55 ng/ml)." data-id="CD012179-fig-0098" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-063.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 63</div> <div class="figure-caption"> <p>STX‐5 (&gt; 55 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-063.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-064" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-064.xxx" target="_blank"><b></b></a></p> </div><img alt="Carbonyls (&lt; 14.9 μM)." data-id="CD012179-fig-0099" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-064.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 64</div> <div class="figure-caption"> <p>Carbonyls (&lt; 14.9 μM).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-064.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-065" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-065.xxx" target="_blank"><b></b></a></p> </div><img alt="PON‐1 (&lt; 141.5 U/l)." data-id="CD012179-fig-0100" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-065.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 65</div> <div class="figure-caption"> <p>PON‐1 (&lt; 141.5 U/l).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-065.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-066" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-066.xxx" target="_blank"><b></b></a></p> </div><img alt="Thiols (&lt; 396.44 μM)." data-id="CD012179-fig-0101" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-066.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 66</div> <div class="figure-caption"> <p>Thiols (&lt; 396.44 μM).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-066.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-067" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-067.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐9* (cut‐off not reported)." data-id="CD012179-fig-0102" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-067.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 67</div> <div class="figure-caption"> <p>miR‐9* (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-067.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-068" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-068.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐17‐5 (&lt; 0.9057)." data-id="CD012179-fig-0103" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-068.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 68</div> <div class="figure-caption"> <p>miR‐17‐5 (&lt; 0.9057).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-068.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-069" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-069.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐20a (&lt; 0.6879)." data-id="CD012179-fig-0104" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-069.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 69</div> <div class="figure-caption"> <p>miR‐20a (&lt; 0.6879).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-069.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-070" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-070.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐22 (&lt; 0.5647)." data-id="CD012179-fig-0105" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-070.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 70</div> <div class="figure-caption"> <p>miR‐22 (&lt; 0.5647).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-070.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-071" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-071.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐122 (cut‐off not reported)." data-id="CD012179-fig-0106" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-071.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 71</div> <div class="figure-caption"> <p>miR‐122 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-071.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-072" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-072.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐141* (cut‐off not reported)." data-id="CD012179-fig-0107" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-072.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 72</div> <div class="figure-caption"> <p>miR‐141* (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-072.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-073" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-073.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐145* (cut‐off not reported)." data-id="CD012179-fig-0108" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-073.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 73</div> <div class="figure-caption"> <p>miR‐145* (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-073.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-074" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-074.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐199a (cut‐off not reported)." data-id="CD012179-fig-0109" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-074.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 74</div> <div class="figure-caption"> <p>miR‐199a (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-074.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-075" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-075.xxx" target="_blank"><b></b></a></p> </div><img alt="miR‐532‐3p (cut‐off not reported)." data-id="CD012179-fig-0110" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-075.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 75</div> <div class="figure-caption"> <p>miR‐532‐3p (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-075.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-076" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-076.xxx" target="_blank"><b></b></a></p> </div><img alt="Ca‐15.3 (&gt; 15 IU/ml)." data-id="CD012179-fig-0111" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-076.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 76</div> <div class="figure-caption"> <p>Ca‐15.3 (&gt; 15 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-076.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-077" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-077.xxx" target="_blank"><b></b></a></p> </div><img alt="Ca‐15.3 (&gt; 30 IU/ml)." data-id="CD012179-fig-0112" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-077.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 77</div> <div class="figure-caption"> <p>Ca‐15.3 (&gt; 30 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-077.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-078" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-078.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐19.9 (&gt; 7.5 IU/ml)." data-id="CD012179-fig-0113" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-078.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 78</div> <div class="figure-caption"> <p>CA‐19.9 (&gt; 7.5 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-078.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-079" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-079.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐19.9 (&gt; 9.5 IU/ml)." data-id="CD012179-fig-0114" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-079.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 79</div> <div class="figure-caption"> <p>CA‐19.9 (&gt; 9.5 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-079.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-080" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-080.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐19.9 (&gt; 10.67 IU/ml)." data-id="CD012179-fig-0115" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-080.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 80</div> <div class="figure-caption"> <p>CA‐19.9 (&gt; 10.67 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-080.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-081" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-081.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐19.9 (≥ 12 U/ml), endometrioma." data-id="CD012179-fig-0116" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-081.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 81</div> <div class="figure-caption"> <p>CA‐19.9 (≥ 12 U/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-081.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-082" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-082.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐19.9 (&gt; 37 IU/ml)." data-id="CD012179-fig-0117" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-082.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 82</div> <div class="figure-caption"> <p>CA‐19.9 (&gt; 37 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-082.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-083" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-083.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐19.9 (cut‐off not reported)." data-id="CD012179-fig-0118" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-083.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 83</div> <div class="figure-caption"> <p>CA‐19.9 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-083.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-084" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-084.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐72 (TAG‐72) (&gt; 4 U/ml)." data-id="CD012179-fig-0119" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-084.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 84</div> <div class="figure-caption"> <p>CA‐72 (TAG‐72) (&gt; 4 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-084.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-085" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-085.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐72 (TAG‐72) (&gt; 6 U/ml)." data-id="CD012179-fig-0120" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-085.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 85</div> <div class="figure-caption"> <p>CA‐72 (TAG‐72) (&gt; 6 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-085.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-086" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-086.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 10 IU/ml)." data-id="CD012179-fig-0121" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-086.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 86</div> <div class="figure-caption"> <p>CA‐125 (&gt; 10 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-086.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-087" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-087.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 11 U/ml)." data-id="CD012179-fig-0122" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-087.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 87</div> <div class="figure-caption"> <p>CA‐125 (&gt; 11 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-087.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-088" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-088.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 11.5 U/ml)." data-id="CD012179-fig-0123" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-088.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 88</div> <div class="figure-caption"> <p>CA‐125 (&gt; 11.5 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-088.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-089" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-089.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 12.5 U/ml)." data-id="CD012179-fig-0124" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-089.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 89</div> <div class="figure-caption"> <p>CA‐125 (&gt; 12.5 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-089.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-090" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-090.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 12.8 U/ml)." data-id="CD012179-fig-0125" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-090.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 90</div> <div class="figure-caption"> <p>CA‐125 (&gt; 12.8 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-090.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-091" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-091.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 13.5 U/ml)." data-id="CD012179-fig-0126" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-091.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 91</div> <div class="figure-caption"> <p>CA‐125 (&gt; 13.5 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-091.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-092" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-092.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 14.7 IU/ml)." data-id="CD012179-fig-0127" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-092.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 92</div> <div class="figure-caption"> <p>CA‐125 (&gt; 14.7 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-092.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-093" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-093.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 16 U/ml)." data-id="CD012179-fig-0128" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-093.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 93</div> <div class="figure-caption"> <p>CA‐125 (&gt; 16 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-093.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-094" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-094.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 17.6 IU/ml)." data-id="CD012179-fig-0129" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-094.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 94</div> <div class="figure-caption"> <p>CA‐125 (&gt; 17.6 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-094.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-095" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-095.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 20 IU/ml)." data-id="CD012179-fig-0130" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-095.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 95</div> <div class="figure-caption"> <p>CA‐125 (&gt; 20 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-095.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-096" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-096.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 20 U/ml), endometrioma." data-id="CD012179-fig-0131" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-096.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 96</div> <div class="figure-caption"> <p>CA‐125 (&gt; 20 U/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-096.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-097" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-097.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 25 U/ml), endometrioma." data-id="CD012179-fig-0132" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-097.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 97</div> <div class="figure-caption"> <p>CA‐125 (&gt; 25 U/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-097.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-098" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-098.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 26 IU/ml)." data-id="CD012179-fig-0133" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-098.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 98</div> <div class="figure-caption"> <p>CA‐125 (&gt; 26 IU/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-098.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-099" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-099.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 30 U/ml)." data-id="CD012179-fig-0134" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-099.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 99</div> <div class="figure-caption"> <p>CA‐125 (&gt; 30 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-099.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-100" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-100.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 30 U/ml), endometrioma." data-id="CD012179-fig-0135" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-100.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 100</div> <div class="figure-caption"> <p>CA‐125 (&gt; 30 U/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-100.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-101" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-101.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 33 U/ml)." data-id="CD012179-fig-0136" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-101.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 101</div> <div class="figure-caption"> <p>CA‐125 (&gt; 33 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-101.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-102" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-102.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml)." data-id="CD012179-fig-0137" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-102.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 102</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-102.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-103" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-103.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml), endometrioma." data-id="CD012179-fig-0138" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-103.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 103</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-103.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-104" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-104.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 36 U/l) endometrioma." data-id="CD012179-fig-0139" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-104.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 104</div> <div class="figure-caption"> <p>CA‐125 (&gt; 36 U/l) endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-104.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-105" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-105.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 42 U/l), endometrioma." data-id="CD012179-fig-0140" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-105.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 105</div> <div class="figure-caption"> <p>CA‐125 (&gt; 42 U/l), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-105.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-106" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-106.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 43 U/ml)." data-id="CD012179-fig-0141" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-106.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 106</div> <div class="figure-caption"> <p>CA‐125 (&gt; 43 U/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-106.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-107" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-107.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (cut‐off not reported)." data-id="CD012179-fig-0142" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-107.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 107</div> <div class="figure-caption"> <p>CA‐125 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-107.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-108" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-108.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (cut‐off not reported)." data-id="CD012179-fig-0143" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-108.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 108</div> <div class="figure-caption"> <p>CA‐125 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-108.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-109" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-109.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (cut‐off not reported)." data-id="CD012179-fig-0144" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-109.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 109</div> <div class="figure-caption"> <p>CA‐125 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-109.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-110" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-110.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (cut‐off not reported)." data-id="CD012179-fig-0145" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-110.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 110</div> <div class="figure-caption"> <p>CA‐125 (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-110.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-111" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-111.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 ≥ 25 U/ml +/or CA‐19.9 ≥ 12 U/ml), endometrioma." data-id="CD012179-fig-0146" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-111.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 111</div> <div class="figure-caption"> <p>Combined test (CA‐125 ≥ 25 U/ml +/or CA‐19.9 ≥ 12 U/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-111.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-112" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-112.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 ≥ 25 U/ml + Ca‐19.9 ≥ 12 U/ml), endometrioma." data-id="CD012179-fig-0147" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-112.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 112</div> <div class="figure-caption"> <p>Combined test (CA‐125 ≥ 25 U/ml + Ca‐19.9 ≥ 12 U/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-112.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-113" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-113.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 19.8 U/l + Prolactin &gt; 14.8 ng/ml)." data-id="CD012179-fig-0148" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-113.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 113</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 19.8 U/l + Prolactin &gt; 14.8 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-113.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-114" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-114.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 35 U/l + Prolactin &gt; 20 ng/ml)." data-id="CD012179-fig-0149" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-114.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 114</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 35 U/l + Prolactin &gt; 20 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-114.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-115" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-115.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 17.6 IU/ml + VEGF &gt; 236 pg/ml)." data-id="CD012179-fig-0150" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-115.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 115</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 17.6 IU/ml + VEGF &gt; 236 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-115.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-116" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-116.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 20 U/l + Anti‐endometrial Abs &gt; 0.3 A‐value)." data-id="CD012179-fig-0151" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-116.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 116</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 20 U/l + Anti‐endometrial Abs &gt; 0.3 A‐value).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-116.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-117" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-117.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 x NLR; (&gt; 43.1)." data-id="CD012179-fig-0152" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-117.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 117</div> <div class="figure-caption"> <p>Combined test (CA‐125 x NLR; (&gt; 43.1).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-117.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-118" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-118.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 30 U/ml +/or IL‐8 ≥ 25 pg/ml), endometrioma." data-id="CD012179-fig-0153" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-118.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 118</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 30 U/ml +/or IL‐8 ≥ 25 pg/ml), endometrioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-118.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-119" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-119.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + IL‐8) (cut‐off not reported)." data-id="CD012179-fig-0154" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-119.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 119</div> <div class="figure-caption"> <p>Combined test (CA‐125 + IL‐8) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-119.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-120" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-120.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml)." data-id="CD012179-fig-0155" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-120.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 120</div> <div class="figure-caption"> <p>Combined test (IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-120.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-121" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-121.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (IL‐6 &gt; 12.2 pg/ml + CRP &gt; 438 μg/ml)." data-id="CD012179-fig-0156" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-121.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 121</div> <div class="figure-caption"> <p>Combined test (IL‐6 &gt; 12.2 pg/ml + CRP &gt; 438 μg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-121.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-122" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-122.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml)." data-id="CD012179-fig-0157" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-122.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 122</div> <div class="figure-caption"> <p>Combined test (TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-122.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-123" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-123.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (miR‐199a + miR‐122) (cut‐off not reported)." data-id="CD012179-fig-0158" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-123.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 123</div> <div class="figure-caption"> <p>Combined test (miR‐199a + miR‐122) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-123.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-124" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-124.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (miR‐199a + miR‐542‐3p) (cut‐off not reported)." data-id="CD012179-fig-0159" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-124.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 124</div> <div class="figure-caption"> <p>Combined test (miR‐199a + miR‐542‐3p) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-124.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-125" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-125.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (Ca‐125 + Ca 19‐9 + Survivin) (cut‐off not reported)." data-id="CD012179-fig-0160" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-125.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 125</div> <div class="figure-caption"> <p>Combined test (Ca‐125 + Ca 19‐9 + Survivin) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-125.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-126" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-126.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + STX‐5 + LN‐1) (cut‐off not reported)." data-id="CD012179-fig-0161" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-126.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 126</div> <div class="figure-caption"> <p>Combined test (CA‐125 + STX‐5 + LN‐1) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-126.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-127" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-127.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 35 IU/ml +/or CA‐19.9 &gt; 37 IU/ml +/or IL‐6 &gt; 2 pg/ml)." data-id="CD012179-fig-0162" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-127.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 127</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 35 IU/ml +/or CA‐19.9 &gt; 37 IU/ml +/or IL‐6 &gt; 2 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-127.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-128" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-128.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 50 IU/mL +/ or CCR1 &gt; 1.16 +/or MCP‐1 &gt; 140 pg/ml)." data-id="CD012179-fig-0163" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-128.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 128</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 50 IU/mL +/ or CCR1 &gt; 1.16 +/or MCP‐1 &gt; 140 pg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-128.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-129" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-129.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (Ca‐125 &gt; 20 mIU/ml + MCP‐1 &gt; 152.74 pg/ml + Leptin &gt; 3.14 ng/ml)." data-id="CD012179-fig-0164" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-129.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 129</div> <div class="figure-caption"> <p>Combined test (Ca‐125 &gt; 20 mIU/ml + MCP‐1 &gt; 152.74 pg/ml + Leptin &gt; 3.14 ng/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-129.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-130" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-130.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test CA‐125 + IL‐8 + TNF‐α) (cut‐off not reported)." data-id="CD012179-fig-0165" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-130.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 130</div> <div class="figure-caption"> <p>Combined test CA‐125 + IL‐8 + TNF‐α) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-130.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-131" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-131.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml)." data-id="CD012179-fig-0166" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-131.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 131</div> <div class="figure-caption"> <p>Combined test (IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-131.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-132" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-132.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + VEGF + annexin V + glycodelin] ‐ MLR (cut‐off not reported)." data-id="CD012179-fig-0167" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-132.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 132</div> <div class="figure-caption"> <p>Combined test (CA‐125 + VEGF + annexin V + glycodelin] ‐ MLR (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-132.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-133" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-133.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + VEGF + annexin V + glycodelin] ‐ LS‐SVM (cut‐off not reported)." data-id="CD012179-fig-0168" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-133.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 133</div> <div class="figure-caption"> <p>Combined test (CA‐125 + VEGF + annexin V + glycodelin] ‐ LS‐SVM (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-133.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-134" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-134.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + VEGF + annexin V + sICAM‐1) ‐ MLR or LS‐SVM (cut‐off not reported)." data-id="CD012179-fig-0169" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-134.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 134</div> <div class="figure-caption"> <p>Combined test (CA‐125 + VEGF + annexin V + sICAM‐1) ‐ MLR or LS‐SVM (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-134.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-135" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-135.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 &gt; 20 mIU/ml + MCP‐1 &gt; 53.5 pg/ml + Leptin &gt; 29.1 ng/ml + MIF &gt; 14.7 ng/ml)." data-id="CD012179-fig-0170" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-135.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 135</div> <div class="figure-caption"> <p>Combined test (CA‐125 &gt; 20 mIU/ml + MCP‐1 &gt; 53.5 pg/ml + Leptin &gt; 29.1 ng/ml + MIF &gt; 14.7 ng/ml). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-135.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-136" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-136.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p) (cut‐off not reported)." data-id="CD012179-fig-0171" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-136.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 136</div> <div class="figure-caption"> <p>Combined test (miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-136.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-137" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-137.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported)." data-id="CD012179-fig-0172" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-137.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 137</div> <div class="figure-caption"> <p>Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-137.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-138" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-138.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported)." data-id="CD012179-fig-0173" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-138.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 138</div> <div class="figure-caption"> <p>Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-138.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-139" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-139.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported)." data-id="CD012179-fig-0174" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-139.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 139</div> <div class="figure-caption"> <p>Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-139.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-140" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-140.xxx" target="_blank"><b></b></a></p> </div><img alt="Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported)." data-id="CD012179-fig-0175" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-140.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 140</div> <div class="figure-caption"> <p>Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-140.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-141" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-141.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 20 U/ml), Bilibio 2014." data-id="CD012179-fig-0176" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-141.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 141</div> <div class="figure-caption"> <p>CA‐125 (&gt; 20 U/ml), Bilibio 2014.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-141.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-142" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-142.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml), Bilibio 2014." data-id="CD012179-fig-0177" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-142.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 142</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml), Bilibio 2014.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-142.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-143" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-143.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 16 U/ml), Ferreira 1994." data-id="CD012179-fig-0178" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-143.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 143</div> <div class="figure-caption"> <p>CA‐125 (&gt; 16 U/ml), Ferreira 1994.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-143.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-144" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-144.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml), Ferreira 1994." data-id="CD012179-fig-0179" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-144.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 144</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml), Ferreira 1994.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-144.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-145" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-145.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 30 U/ml), Florio 2007." data-id="CD012179-fig-0180" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-145.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 145</div> <div class="figure-caption"> <p>CA‐125 (&gt; 30 U/ml), Florio 2007.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-145.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-146" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-146.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 36 U/ml), Florio 2007." data-id="CD012179-fig-0181" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-146.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 146</div> <div class="figure-caption"> <p>CA‐125 (&gt; 36 U/ml), Florio 2007.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-146.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-147" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-147.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 12.8 U/ml), Gagne 2003a." data-id="CD012179-fig-0182" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-147.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 147</div> <div class="figure-caption"> <p>CA‐125 (&gt; 12.8 U/ml), Gagne 2003a.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-147.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-148" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-148.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml), Gagne 2003a." data-id="CD012179-fig-0183" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-148.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 148</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml), Gagne 2003a.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-148.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-149" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-149.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 20 U/ml), Guerriero 1996b." data-id="CD012179-fig-0184" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-149.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 149</div> <div class="figure-caption"> <p>CA‐125 (&gt; 20 U/ml), Guerriero 1996b.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-149.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-150" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-150.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (≥ 25 U/ml), Guerriero 1996b." data-id="CD012179-fig-0185" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-150.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 150</div> <div class="figure-caption"> <p>CA‐125 (≥ 25 U/ml), Guerriero 1996b.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-150.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-151" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-151.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml), Guerriero 1996b." data-id="CD012179-fig-0186" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-151.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 151</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml), Guerriero 1996b.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-151.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-152" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-152.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 20 U/ml), Kitawaki 2005." data-id="CD012179-fig-0187" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-152.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 152</div> <div class="figure-caption"> <p>CA‐125 (&gt; 20 U/ml), Kitawaki 2005.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-152.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-153" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-153.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 26 U/ml), Kitawaki 2005." data-id="CD012179-fig-0188" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-153.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 153</div> <div class="figure-caption"> <p>CA‐125 (&gt; 26 U/ml), Kitawaki 2005.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-153.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-154" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-154.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 30 U/ml), Kitawaki 2005." data-id="CD012179-fig-0189" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-154.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 154</div> <div class="figure-caption"> <p>CA‐125 (&gt; 30 U/ml), Kitawaki 2005.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-154.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-155" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-155.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml), Kitawaki 2005." data-id="CD012179-fig-0190" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-155.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 155</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml), Kitawaki 2005.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-155.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-156" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-156.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 10 U/ml), Rosa E Silva 2007." data-id="CD012179-fig-0191" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-156.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 156</div> <div class="figure-caption"> <p>CA‐125 (&gt; 10 U/ml), Rosa E Silva 2007.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-156.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-157" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-157.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 20 U/ml), Rosa E Silva 2007." data-id="CD012179-fig-0192" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-157.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 157</div> <div class="figure-caption"> <p>CA‐125 (&gt; 20 U/ml), Rosa E Silva 2007.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-157.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-158" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-158.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 20 U/ml), Yang 1994." data-id="CD012179-fig-0193" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-158.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 158</div> <div class="figure-caption"> <p>CA‐125 (&gt; 20 U/ml), Yang 1994.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-158.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-159" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-159.xxx" target="_blank"><b></b></a></p> </div><img alt="CA‐125 (&gt; 35 U/ml), Yang 1994." data-id="CD012179-fig-0194" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-159.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 159</div> <div class="figure-caption"> <p>CA‐125 (&gt; 35 U/ml), Yang 1994.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-159.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-160" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-160.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 1.03 pg/ml), Othman 2008." data-id="CD012179-fig-0195" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-160.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 160</div> <div class="figure-caption"> <p>IL‐6 (&gt; 1.03 pg/ml), Othman 2008.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-160.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-161" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-161.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 1.9 pg/ml), Othman 2008." data-id="CD012179-fig-0196" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-161.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 161</div> <div class="figure-caption"> <p>IL‐6 (&gt; 1.9 pg/ml), Othman 2008.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-161.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-162" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-162.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 2.6 pg/ml), Othman 2008." data-id="CD012179-fig-0197" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-162.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 162</div> <div class="figure-caption"> <p>IL‐6 (&gt; 2.6 pg/ml), Othman 2008.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-162.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-163" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-163.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 2 pg/ml), Bedaiwy 2002." data-id="CD012179-fig-0198" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-163.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 163</div> <div class="figure-caption"> <p>IL‐6 (&gt; 2 pg/ml), Bedaiwy 2002.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-163.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-164" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-164.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 4 pg/ml), Bedaiwy 2002." data-id="CD012179-fig-0199" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-164.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 164</div> <div class="figure-caption"> <p>IL‐6 (&gt; 4 pg/ml), Bedaiwy 2002.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-164.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012179-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/urn:x-wiley:14651858:media:CD012179:CD012179-TST-165" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_t/tCD012179-TST-165.xxx" target="_blank"><b></b></a></p> </div><img alt="IL‐6 (&gt; 7.5 pg/ml), Bedaiwy 2002." data-id="CD012179-fig-0200" src="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-165.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 165</div> <div class="figure-caption"> <p>IL‐6 (&gt; 7.5 pg/ml), Bedaiwy 2002.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012179/media/CDSR/CD012179/image_n/nCD012179-TST-165.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012179-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Biomarkers evaluated as a diagnostic test for endometriosis</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Review question</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>What is the diagnostic accuracy of the blood biomarkers in detecting pelvic endometriosis (peritoneal endometriosis, endometrioma, deep infiltrating endometriosis)? </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Importance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>A simple and reliable non‐invasive test for endometriosis with the potential to either replace laparoscopy or to triage patients in order to reduce surgery, would minimise surgical risk and reduce diagnostic delay </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Reproductive aged women with suspected endometriosis or persistent ovarian mass, or women undergoing infertility work‐up or gynaecological laparoscopy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Settings</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Hospitals (public or private of any level), outpatient clinics (general gynaecology, reproductive medicine, pelvic pain) or research laboratories </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Reference standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Cross‐sectional of a single‐gate design (N = 25) or a two‐gate design (N = 44); unable to determine if single‐ or two‐gate design for 1 study; prospective enrolment; a single study could assess more than one test </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="5" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Overall judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Poor quality of most of the studies (no study had a 'low risk' assessment in all 4 domains) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Patient selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High risk: 31 studies; unclear risk: 32 studies; low risk: 7 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Index test interpretation bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High risk: 56 studies; unclear risk: 12 studies; low risk: 2 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Reference standard interpretation bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>High risk: 0 studies; unclear risk: 30 studies; low risk: 40 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Flow and timing selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>High risk: 11 studies; unclear risk: 3 studies; low risk: 56 studies</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b> Applicability concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Concerns regarding patient selection</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High concern: 32 studies; unclear concern: 5 studies; low concern: 33 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Concerns regarding index test</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>High concern: 0 studies; unclear concern: 4 studies; low concern: 66 studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Concerns regarding reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>High concern: 0 studies; unclear concern: 0 studies; low concern: 70 studies</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Diagnostic criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Replacement test: sensitivity ≥ 94 and specificity ≥ 79<br/> SnOUT triage test: sensitivity ≥ 95 and specificity ≥ 50<br/> SpIN triage test: sensitivity ≥ 50 and specificity ≥ 95 </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> Test </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> N participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> Diagnostic estimates (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b> Implications</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>True positives</b> </p> <p><b>(endometriosis)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>False positives (incorrectly classified as endometriosis)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>True negatives (disease‐free)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>False negatives (incorrectly</b> </p> <p><b>classified as disease‐free)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>1. Angiogenesis and growth factors and their receptors</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycodelin‐A</p> <p>cut‐off threshold &gt; 2.07 ng/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM stage I‐IV<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.70 to 0.91);</p> <p>spec = 0.79 (0.63 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycodelin<sup>a#</sup> </p> <p>cut‐off threshold &gt; 9.0 ng/ml</p> <p>follicular cycle phase</p> <p>rASRM stage I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.51 to 0.87);</p> <p>spec = 0.35 (0.14 to 0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycodelin<sup>a#</sup> </p> <p>cut‐off threshold &gt; 18 ng/ml</p> <p>any cycle phase</p> <p>rASRM stage I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.62 (0.48 to 0.74);</p> <p>spec = 0.44 (0.28 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGFBP‐3 (insulin‐like growth factor‐binding protein‐3)<sup>a*</sup> </p> <p>cut‐off threshold &gt; 200 ng/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.51 to 0.87);</p> <p>spec = 0.29 (0.10 to 0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGFBP‐3 (insulin‐like growth factor‐binding protein‐3)<sup>a*</sup> </p> <p>cut‐off threshold &gt; 210 ng/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.55 (0.42 to 0.68);</p> <p>spec = 0.44 (0.28 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF (vascular endothelial growth factor)</p> <p>cut‐off threshold &gt; 1.5 pg/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.50 (0.37 to 0.63);</p> <p>spec = 0.61 (0.45 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF (vascular endothelial growth factor)</p> <p>cut‐off threshold &gt; 236 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.92 (0.83 to 0.97);</p> <p>spec = 0.77 (0.58 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches the criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF (vascular endothelial growth factor)</p> <p>cut‐off threshold &gt; 680 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.93 (0.78 to 0.99);</p> <p>spec = 0.97 (0.83 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test and approaches criteria for a replacement test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urocortin<sup>a&amp;</sup> </p> <p>cut‐off threshold &gt; 29 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.97 (0.87 to 1.00);</p> <p>spec = 0.85 (0.70 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urocortin<sup>a&amp;</sup> </p> <p>cut‐off threshold &gt; 33 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.88 (0.73 to 0.96);</p> <p>spec = 0.90 (0.76 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urocortin</p> <p>cut‐off threshold &gt; 41.6 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.76 (0.61 to 0.88);</p> <p>spec = 0.46 (0.31 to 0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>2. Apoptosis markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survivin</p> <p>cut‐off threshold not reported</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.07 (0.02 to 0.20);<br/> spec = 0.90 (0.68 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>3. Cell adhesion molecules and other matrix‐related proteins</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a#</sup> </p> <p>cut‐off threshold &lt; 243 ng/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.55 (0.42 to 0.68);</p> <p>spec = 0.50 (0.34 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a#</sup> </p> <p>cut‐off threshold &lt; 254.6 ng/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.39 to 0.94);</p> <p>spec = 0.29 (0.10 to 0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)</p> <p>cut‐off threshold &gt; 241.46 µg/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.60 (0.41 to 0.77);</p> <p>spec = 0.87 (0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LN‐1 (laminin‐1)</p> <p>cut‐off threshold &gt; 1110.0 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM II‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.72 (0.58 to 0.83);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>4. High‐throughput molecular markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metabolome by ESI‐MS/MS</p> <p>(SMOH C16:1 + PCaa C36:2/ PCae C34:2)</p> <p>any cycle phase</p> <p>rASRM III‐IV<sup>e</sup> </p> <p>age/body mass index‐adjusted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.76 to 0.97);</p> <p>spec = 0.85 (0.72 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria of a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF‐MS</p> <p>(3 peaks with the MW 3956.00, 11,710.00 and 6986.00 Da)</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.88 (0.62 to 0.98);</p> <p>spec = 0.80 (0.52 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 4159.00, 5264.00, 5603.00, 9861.00 and 10,533.00 Da) </p> <p>follicular/ luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.65 to 0.89);</p> <p>spec = 0.59 (0.42 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 9926.31, 10,072.2, 6753.04, 4302.67, 9328.49 Da) </p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.40 (0.26 to 0.56);</p> <p>spec = 0.82 (0.60 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 2831.02, 7554.66, 4241.29, 2953.25, 9927.73 Da) </p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.38 (0.27 to 0.51);</p> <p>spec = 0.85 (0.68 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF MS (5 peaks with MW 11,366.3, 5712.69, 10,070.7, 3017.68, 3824.44 Da) </p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.53 (0.39to 0.66);</p> <p>spec = 0.82 (0.65 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteome by SELDI‐TOF‐MS</p> <p>(6 peaks with MW 1629, 3047, 3526, 3774, 5046 and 5068 Da)</p> <p>any cycle phase</p> <p>rASRM II‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.66 (0.52 to 0.77);</p> <p>spec = 0.99 (0.93 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies using standardised methodology is recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>5. Hormonal markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolactin<sup>1a^</sup> </p> <p>cut‐off threshold &gt; 14.8 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.44 (0.32 to 0.58);</p> <p>spec = 0.94 (0.80 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolactin<sup>1a^</sup> </p> <p>cut‐off threshold &gt; 20 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.21 (0.11 to 0.33);</p> <p>spec = 1.00 (0.90 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>6. Immune system and inflammatory markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐endometrial Abs</p> <p>cut‐off threshold ‐ definitions for positive result varied</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM I‐IV in 3 studies; not reported in 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>759 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.81 (0.76 to 0.87);</p> <p>spec = 0.75 (0.46 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates did not meet the predetermined criteria for triage or replacement test; varying methodologies and populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐endometrial Abs (MW of 26/34/42 kd)</p> <p>cut‐off threshold: dark band in the blot for at least 1 Ab</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 1.00 (0.81 to 1.00);</p> <p>spec = 0.39 (0.17 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐laminin auto Abs</p> <p>cut‐off threshold &gt; 1 U/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.40 (0.26 to 0.57);</p> <p>spec = 0.88 (0.70 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sCD23 (soluble CD23)</p> <p>cut‐off threshold: absorbance value of ELISA &gt; control mean ± 2SD (standard deviations)</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.25 (0.14 to 0.38);</p> <p>spec = 0.93 (0.80 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCP‐1 (monocyte chemotactic protein‐1)</p> <p>cut‐off threshold &gt; 100 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.51 to 0.77);</p> <p>spec = 0.61 (0.45 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Copeptin</p> <p>cut‐off threshold &gt; 251.2 pg/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.50 to 0.78);</p> <p>spec = 0.58 (0.41 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.62 mg/l</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.62 (0.55 to 0.68);</p> <p>spec = 0.56 (0.45 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.73 mg/l</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.52 to 0.82);</p> <p>spec = 0.47 (0.24 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.61 mg/l</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.54 (0.43 to 0.65);</p> <p>spec = 0.50 (0.33 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)</p> <p>cut‐off threshold &gt;438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.83 (0.72 to 0.91);</p> <p>spec = 0.87 (0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 0.70 mg/l</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.59 (0.47 to 0.70);</p> <p>spec = 0.64 (0.46 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.41 (0.30 to 0.53);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ (interferon‐gamma)</p> <p>cut‐off threshold &lt; 76 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.48 to 0.84);</p> <p>spec = 0.65 (0.38 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MIF (macrophage migration inhibitory factor)</p> <p>cut‐off threshold &gt; 0.57 ng/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.51 to 0.78);</p> <p>spec = 0.66 (0.49 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (tumour necrosis factor alpha)</p> <p>cut‐off threshold &gt;12.45 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.89 (0.79 to 0.96);</p> <p>spec = 0.87 (0.69 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (tumour necrosis factor alpha)</p> <p>cut‐off threshold &lt; 45.6 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.48 to 0.84);</p> <p>spec = 0.35 (0.14 to 0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (tumour necrosis factor alpha)</p> <p>cut‐off threshold not reported</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.79 (0.69 to 0.88);<br/> spec = 0.74 (0.57 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutrophils</p> <p>cut‐off threshold &gt; 4058 cells/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.53 to 0.80);</p> <p>spec = 0.60 (0.45 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NLR (neutrophil‐to‐lymphocyte ratio)</p> <p>cut‐off threshold &gt; 2.19</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.76 (0.62 to 0.87);</p> <p>spec = 0.82 (0.69 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (white blood cells)</p> <p>cut‐off threshold &gt; 6400 cells/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.64 (0.49 to 0.77);</p> <p>spec = 0.54 (0.39 to 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐1β (interleukin ‐ 1beta)</p> <p>cut‐off threshold &lt; 0.9 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.63 to 0.94);</p> <p>spec = 0.35 (0.14 to 0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐4 (interleukin ‐ 4)</p> <p>cut‐off threshold ≥ 3 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.64 (0.45 to 0.80);</p> <p>spec = 0.65 (0.38 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 1.03 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.81 (0.70 to 0.89);</p> <p>spec = 0.51 (0.39 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a$, a^</sup> </p> <p>cut‐off threshold &gt; 1.9‐2.0 pg/ml</p> <p>cycle phase varied</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.63 (0.52 to 0.75);</p> <p>spec = 0.69 (0.57 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates did not meet the predetermined criteria for a triage or replacement test; varying cycle phase across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a$</sup> </p> <p>cut‐off threshold &gt; 2.6 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.60 (0.48 to 0.72);</p> <p>spec = 0.70 (0.58 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a^</sup> </p> <p>cut‐off threshold &gt; 4 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.74 to 0.94);</p> <p>spec = 0.80 (0.63 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)<sup>a^</sup> </p> <p>cut‐off threshold &gt; 7.5 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.90);</p> <p>spec = 0.86 (0.70 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &lt; 10 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.51 to 0.87);</p> <p>spec = 0.18 (0.04 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &gt; 12.2 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.95 (0.87 to 0.99);</p> <p>spec = 0.83 (0.65 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &gt; 15.4 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.89 (0.75 to 0.97);</p> <p>spec = 0.82 (0.67 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold &gt; 25.75 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.39 to 0.94);</p> <p>spec = 0.83 (0.73 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 (interleukin ‐ 6)</p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.59 (0.47 to 0.70);</p> <p>spec = 0.76 (0.60 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐8 (interleukin ‐ 8)</p> <p>cut‐off threshold &gt; 24 pg/ml</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.76 (0.60 to 0.89);</p> <p>spec = 0.73 (0.58 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐8 (interleukin ‐ 8)</p> <p>cut‐off threshold &gt; 25 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.59 to 0.82);</p> <p>spec = 0.81 (0.58 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐8 (interleukin ‐ 8)</p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.49 (0.37 to 0.60);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>7. Other peptides and proteins shown to influence key events implicated in endometriosis</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follistatin</p> <p>cut‐off threshold &gt; 1433 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.92 (0.81 to 0.98);</p> <p>spec = 0.92 (0.81 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement and SnOUT or SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>STX‐5 (syntaxin ‐ 5)</p> <p>cut‐off threshold &gt; 55 ng/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.66 to 0.88);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>8. Oxidative stress markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyls</p> <p>cut‐off threshold &lt; 14.9 μM</p> <p>cycle phase not specified</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.94 (0.85 to 0.98);</p> <p>spec = 0.51 (0.35 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PON‐1 (paraoxonase‐1)</p> <p>cut‐off threshold &lt; 141.5 U/l</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.98 (0.89 to 1.00);</p> <p>spec = 0.80 (0.64 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement or SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiols cut‐off threshold &lt; 396.44 μM cycle phase not specified</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.61 to 0.83);</p> <p>spec = 0.80 (0.65 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>9. Post‐transcriptional regulators of gene expression (microRNAs)</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐9*</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.68 (0.55 to 0.80);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐17‐5</p> <p>cut‐off threshold &lt; 0.9057</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.70 (0.46 to 0.88);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐20a</p> <p>cut‐off threshold &lt; 0.6879</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.60 (0.36 to 0.81);</p> <p>spec = 0.90 (0.68 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐22</p> <p>cut‐off threshold &lt; 0.5647</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.68 to 0.99);</p> <p>spec = 0.80 (0.56 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement or SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐122</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.89);</p> <p>spec = 0.76 (0.55 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐141*</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.72 (0.59 to 0.83);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐145*</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.70 (0.57 to 0.81);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.66 to 0.88);</p> <p>spec = 0.76 (0.55 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐532‐3p</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.89);</p> <p>spec = 0.92 (0.74 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>10. Tumour markers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐15.3 (cancer antigen‐15.3)</p> <p>cut‐off threshold &gt; 15.04 U/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.50 to 0.78);</p> <p>spec = 0.62 (0.45 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐15.3 (cancer antigen‐15.3)</p> <p>cut‐off threshold &gt; 30 U/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.04 (0.01 to 0.10);</p> <p>spec = 0.92 (0.79 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a#</sup> </p> <p>cut‐off threshold &gt; 7.5 IU/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.73 (0.57 to 0.85);</p> <p>spec = 0.56 (0.38 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a#</sup> </p> <p>cut‐off threshold &gt;9.5 IU/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.55 (0.45 to 0.64);</p> <p>spec = 0.58 (0.47 to 0.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)</p> <p>cut‐off threshold &gt; 10.67 IU/ml</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.65 (0.50 to 0.78);</p> <p>spec = 0.62 (0.45 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)</p> <p>cut‐off threshold ≥ 12 IU/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.62 (0.45 to 0.77);</p> <p>spec = 0.70 (0.58 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.5. CA‐19.9 (cancer antigen‐19.9)</p> <p>cut‐off threshold &gt; 37 IU/ml</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.36 (0.26 to 0.45);</p> <p>spec = 0.87 (0.75 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates did not meet the predetermined criteria for a triage or replacement test; varying cycle phase across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a#</sup> </p> <p>cut‐off threshold not specified</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>d,e</sup> </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.53 (0.36 to 0.68);</p> <p>spec = 0.90 (0.68 to 0.99)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.36 (0.25 to 0.48);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; varying populations across the studies; unclear thresholds </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐72 (TAG‐72) (cancer antigen‐72 or tumour</p> <p>associated glycoprotein‐72)</p> <p>cut‐off threshold &gt; 4 U/ml</p> <p>follicular cycle phase</p> <p>rASRM stage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.05 (0.00 to 0.26);</p> <p>spec = 0.75 (0.48 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐72 (TAG‐72) (cancer antigen‐72 or tumour</p> <p>associated glycoprotein‐72)</p> <p>cut‐off threshold &gt; 6 U/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.09 (0.04 to 0.17);</p> <p>spec = 0.89 (0.75 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a!, a%, a*</sup> </p> <p>cut‐off threshold &gt; 10‐14.7 U/ml</p> <p>cycle phase varied</p> <p>rASRM stage varied</p> <p>2 evaluations excluded as overlapping populations (CA‐125 cut‐off &gt; 11.5 U/ml and cut‐off &gt; 13.5 U/ml, <a href="./references#CD012179-bbs2-0126" title="VodolazkaiaA , El‐AalamatY , PopovicD , MihalyiA , BossuytX , KyamaCM , et al. Evaluation of a panel of 28 biomarkers for the non‐invasive diagnosis of endometriosis. Human Reproduction2012;27:2698‐711. ">Vodolazkaia 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.70 (0.63 to 0.77);</p> <p>spec = 0.64 (0.47 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a!</sup> </p> <p>cut‐off threshold &gt; 11.5 U/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV<sup>b</sup> (excluded from the above group as overlapping evaluation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.67 to 0.96);</p> <p>spec = 0.65 (0.38 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125) <sup>a!</sup> </p> <p>cut‐off threshold &gt; 13.5 U/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>b</sup> (excluded from the above group as overlapping evaluation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.79 (0.54 to 0.94);</p> <p>spec = 0.31 (0.11 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a#</sup> </p> <p>cut‐off value &gt; 16‐17.6 U/ml</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM stage varied (I in 1 study, I‐IV in 4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.56 (0.24 to 0.88);</p> <p>spec = 0.91 (0.75 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates approach the criteria for a SpIN triage test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a@, a^, a&amp;, a*, a!!</sup> </p> <p>cut‐off value &gt; 20 IU/ml</p> <p>cycle phase varied</p> <p>rASRM stage varied (1 study<sup>c</sup>, 2 studies<sup>d</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1304 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.67 (0.50 to 0.85);</p> <p>spec = 0.69 (0.58 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a^, a&amp;</sup> </p> <p>cut‐off value &gt; 25‐26 U/ml</p> <p>cycle phase varied; not specified in 1 study</p> <p>rASRM stage varied (1 study<sup>d</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>963 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.73 (0.67 to 0.79);</p> <p>spec = 0.70 (0.63 to 0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a$, a&amp;</sup> </p> <p>cut‐off value &gt; 30‐33 U/ml (1 study &gt; 33 U/ml)</p> <p>cycle phase varied (not specified in 2 studies)</p> <p>rASRM stage varied (2 studies<sup>d</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.62 (0.45 to 0.79);</p> <p>spec = 0.76 (0.53 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)<sup>a@, a#, a$, a%, a&amp;, a!!</sup> </p> <p>cut‐off value &gt; 35‐36 U/ml (1 study &gt; 36 U/ml)</p> <p>cycle phase varied; not specified in 7 studies</p> <p>rASRM stage varied; not reported in 2 studies (1 study<sup>c</sup>, 2 studies<sup>d</sup>, 1 study<sup>e</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3447 (27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates:</p> <p>Sens = 0.40 (0.32 to 0.49);</p> <p>spec = 0.91 (0.88 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Summary estimates do not meet the predetermined criteria for a triage or replacement test; varying populations across the studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125);<sup>a$</sup> </p> <p>cut‐off value &gt; 42 U/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.44 (0.30 to 0.59);</p> <p>spec = 0.90 (0.79 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)</p> <p>cut‐off value &gt; 43 U/ml</p> <p>cycle phase not reported</p> <p>rASRM III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 1.00 (0.92 to 1.00);</p> <p>spec = 0.80 (0.56 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 (cancer antigen‐125)</p> <p>cut‐off value not specified</p> <p>menstrual cycle phase<sup>a##</sup> </p> <p>rASRM I‐IV</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>follicular cycle phase<sup>a##</sup> </p> <p>rASRM I‐IV</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>d,e</sup> </p> <p><sup>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</sup> </p> <p>luteal cycle phase<sup>a##</sup> </p> <p>rASRM I‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>119 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>60 (1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>54</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>33</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>2</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>26</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>18</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>29</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>7</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.72 (0.56 to 0.85);</p> <p>spec = 0.79 (0.54 to 0.94)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.65 (0.54 to 0.75);</p> <p>spec = 0.72 (0.55 to 0.86)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.82 (0.67 to 0.93);</p> <p>spec = 0.90 (0.68 to 0.99)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Sens = 0.68 (0.56 to 0.78);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; 1 study approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended with defined cut‐off value; varying populations and undefined cut‐off values; not combined in meta‐analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><i><b>11. Combined test ‐ 2 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/or CA‐19.9 U/ml<sup>a#</sup> </p> <p>cut‐of threshold CA‐125 ≥ 25 U/ml; CA‐19.9 ≥ 12 U/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.76 to 0.97);</p> <p>spec = 0.41 (0.30 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 U/ml<sup>a#</sup> </p> <p>cut‐of threshold CA‐125 ≥ 25 U/ml; CA‐19.9 ≥ 12 U/ml</p> <p>follicular cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.54 (0.37 to 0.70);</p> <p>spec = 0.90 (0.81 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + Prolactin<sup>a$</sup> </p> <p>cut‐off threshold CA‐125 &gt; 19.8 U/l; Prolactin &gt; 14.8 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.78 (0.66 to 0.87);</p> <p>spec = 0.88 (0.73 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + Prolactin<sup>a$</sup> </p> <p>cut‐off threshold CA‐125 &gt; 35 U/l; Prolactin &gt; 20 ng/ml</p> <p>luteal cycle phase</p> <p>rASRM I‐IV<sup>c</sup> </p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.44 (0.32 to 0.58);</p> <p>spec = 0.44 (0.32 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF</p> <p>cut‐off threshold CA‐125 &gt; 17.6 U/ml; VEGF &gt; 236 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.77 (0.65 to 0.86);</p> <p>spec = 0.93 (0.78 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + anti‐endometrial Abs</p> <p>cut‐off threshold CA‐125 &gt; 20 U/l; anti‐endometrial Abs &gt; 0.3 A‐value</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> <p>selection or classification method not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens= 0.61 (0.41 to 0.78);</p> <p>spec = 0.79 (0.49 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 x NLR</p> <p>cut‐off threshold &gt; 43.1</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> <p>combined test ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.66 to 0.90);</p> <p>spec = 0.86 (0.73 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/or IL‐8</p> <p>cut‐off threshold CA‐125 &gt; 30 U/ml; IL‐8 ≥ 25 pg/ml</p> <p>follicular or luteal cycle phase</p> <p>rASRM III‐IV<sup>d</sup> </p> <p>combined test ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.75 to 0.93);</p> <p>spec = 0.72 (0.47 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + IL‐8</p> <p>cut‐off threshold not specified</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and by ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.71 (0.64 to 0.77);</p> <p>spec= 0.71 (0.61 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 + TNF‐α</p> <p>cut‐off threshold IL‐6 &gt; 12.2 pg/ml; TNF‐α &gt; 12.45 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.70 (0.57 to 0.80);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 + CRP</p> <p>cut‐off threshold IL‐6 &gt;12.2 pg/ml; CRP &gt; 438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.75 (0.63 to 0.85);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α + CRP</p> <p>cut‐off threshold NF‐α &gt; 12.45 pg/ml; CRP &gt; 438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.74 (0.61 to 0.84);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a + miR‐542‐3p</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by discriminant and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.97 (0.88 to 1.00);</p> <p>spec = 0.88 (0.69 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a + miR‐122</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by discriminant and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.80 (0.68 to 0.89);</p> <p>spec = 0.80 (0.59 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>12. Combined test ‐ 3 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19‐9 + survivin</p> <p>cut‐off threshold not specified</p> <p>follicular cycle phase</p> <p>rASRM stage not reported<sup>e</sup> </p> <p>combined test by logistic regression and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.88 (0.73 to 0.96);</p> <p>spec = 0.90 (0.68 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + STX‐5 + LN‐1</p> <p>cut‐off threshold not specified</p> <p>cycle phase not specified</p> <p>rASRM I‐IV</p> <p>combined test by multivariate logistic regression and ROC<br/> analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.95 (0.86 to 0.99);</p> <p>spec = 0.70 (0.46 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SnOUT triage test and approaches criteria for a replacement test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/or CA‐19.9 +/or IL‐6</p> <p>cut‐off threshold CA‐125 &gt; 35 U/ml; CA‐19.9 &gt; 37 U/ml; IL‐6 &gt; 2 pg/ml</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.42 (0.28 to 0.58);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 +/ or CCR1 +/or MCP‐1</p> <p>CA‐125 &gt; 50 U/ml; CCR1 &gt; 1.16; MCP‐1 &gt; 140 pg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>selection or classification method not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.92 (0.85 to 0.97);</p> <p>spec = 0.82 (0.68 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + MCP‐1 + Leptin</p> <p>cut‐off threshold CA‐125 &gt; 20 U/ml; MCP‐1 &gt; 152.7 pg/ml; Leptin &gt; 3.14 ng/ml</p> <p>any cycle phase</p> <p>rASRM II‐IV</p> <p>combined test by a two‐tiered algorithm using classification and regression tree (CART)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.49 (0.36 to 0.62);</p> <p>spec = 0.94 (0.86 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + IL‐8 + TNF‐α</p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.81 to 0.95);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐6 + TNF‐α + CRP</p> <p>cut‐off threshold IL‐6 &gt; 12.2 pg/ml; TNF‐α &gt; 12.45 pg/ml; CRP &gt; 438 μg/ml</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.63 (0.50 to 0.75);</p> <p>spec = 1.00 (0.88 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>13. Combined test ‐ 4 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF + annexin V + glycodelin<sup>a#</sup> </p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> <p>combined test by multivariate logistic regression and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.48 to 0.98);</p> <p>spec = 0.75 (0.35 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF + annexin V + glycodelin<sup>a#</sup> </p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> <p>combined test by a least squares support vector machines model (LS‐SVM) and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.48 to 0.98);</p> <p>spec = 0.63 (0.24 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + VEGF + annexin V + sICAM‐1</p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV<sup>b</sup> </p> <p>combined test by either multivariate logistic regression or a least squares support vector machines model (LS‐SVM) and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.82 (0.48 to 0.98);</p> <p>spec = 0.75 (0.35 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + MCP‐1 + Leptin + MIF</p> <p>cut‐off threshold CA‐125 &gt; 20 U/ml; MCP‐1 &gt; 53.5 pg/ml; Leptin &gt; 29.1 ng/ml; MIF &gt; 14.7 ng/ml </p> <p>any cycle phase</p> <p>rASRM II‐IV</p> <p>combined test by a two‐tiered algorithm using classification and regression tree (CART)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 1.00 (0.94 to 1.00);</p> <p>spec = 0.35 (0.24 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p</p> <p>cut‐off threshold not specified</p> <p>follicular or luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by discriminant and ROC analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.93 (0.84 to 0.98);</p> <p>spec = 0.96 (0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; meets criteria for a SpIN triage test and approaches criteria for a replacement test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><i><b>14. Combined test ‐ 6 blood biomarkers</b> </i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>any cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.85 to 0.94);</p> <p>spec = 0.53 (0.42 to 0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP <sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>menstrual cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.90 (0.76 to 0.97);</p> <p>spec = 0.74 (0.49 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions; approaches criteria for a replacement and SnOUT triage test; further diagnostic test accuracy studies recommended </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>follicular cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.58 (0.46 to 0.69);</p> <p>spec = 0.72 (0.55 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP<sup>a$</sup> </p> <p>cut‐off threshold not specified</p> <p>luteal cycle phase</p> <p>rASRM I‐IV</p> <p>combined test by multivariate analysis using stepwise logistic regression and ROC analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sens = 0.86 (0.76 to 0.93);</p> <p>spec = 0.71 (0.54 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to draw meaningful conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><sup>a</sup> Same biomarker was tested in the same/overlapping cohort; similar symbol designates studies/groups of studies with overlapping cohorts, hence can not be combined in meta‐analysis </p> <p><sup>b</sup> Only for US‐negative endometriosis </p> <p><sup>c</sup> Only peritoneal endometriosis </p> <p><sup>d</sup> Only ovarian endometriosis versus other benign ovarian cysts </p> <p><sup>e</sup> Only deep infiltrating endometriosis or endometrioma + deep infiltrating endometriosis </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>MW</b> : molecular weight; <b>rASRM</b> : revised American Society for Reproductive Medicine; <b>ROC</b>: receiver operating characteristic </p> <p>For a comprehensive list of all biomarkers with their biological annotation, please see <a href="./appendices#CD012179-sec-0169">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Biomarkers evaluated as a diagnostic test for endometriosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012179-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Staging of endometriosis, rASRM classification</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Location of endometriosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Extent</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Depth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 1 cm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1‐3 cm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 3 cm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Peritoneum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Superficial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ovary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R Superficial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L Superficial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Posterior cul‐de‐sac obliteration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Partial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Complete</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adhesions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&lt; 1/3 Enclosure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/3‐2/3 Enclosure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 2/3 Enclosure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ovary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Tube</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L Filmy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Stage ·1 (Minimal) ‐ score 1‐5; Stage II (Mild) ‐ score 6‐15; Stage III (Moderate) ‐ score 16‐40; Stage IV (Severe) ‐ score &gt;40 </p> <p><sup>a</sup>If the fimbriated end of the fallopian tube is completely enclosed, change the point assignment to 16 (<a href="./references#CD012179-bbs2-0382" title="American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertility and Sterility1997;67(5):817‐21. ">ASRM 1997</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Staging of endometriosis, rASRM classification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012179-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood biomarkers evaluated in this review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Biomarker</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Angiogenesis and growth factors and their receptors</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycodelin‐A (PP14 or PAEP) (or placental protein 14 or progestogen‐associated endometrial protein)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF (vascular endothelial growth factor)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGFBP‐3 (insulin‐like growth factor‐binding protein‐3)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urocortin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leptin<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Apoptosis markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Annexin V<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Survivin</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Cell adhesion molecules and other matrix‐related proteins</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LN‐1 (laminin‐1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>High‐throughput molecular markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proteome</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Hormonal markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prolactin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Immune system and inflammatory markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Autoantibodies</p> <p> <ul id="CD012179-list-0001"> <li> <p>Anti‐endometrial Abs (anti‐endometrial auto antibodies)<sup>a</sup> </p> </li> <li> <p>Anti‐laminin‐1 Abs (anti‐laminin auto antibodies)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immune cells</p> <p> <ul id="CD012179-list-0002"> <li> <p>Neutrophils<sup>a</sup> </p> </li> <li> <p>NLR (neutrophil‐to‐lymphocyte ratio)<sup>a</sup> </p> </li> <li> <p>WBC (white blood cells)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemokines</p> <p> <ul id="CD012179-list-0003"> <li> <p>CCR1 (C‐C motif receptor 1)</p> </li> <li> <p>MCP‐1 (monocyte chemotactic protein‐1)<sup>a</sup> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interleukins</p> <p> <ul id="CD012179-list-0004"> <li> <p>IL‐1β (interleukin ‐ 1β)<sup>a</sup> </p> </li> <li> <p>IL‐4 (interleukin ‐ 4)<sup>a</sup> </p> </li> <li> <p>IL‐6 (interleukin ‐ 6)<sup>a</sup> </p> </li> <li> <p>IL‐8 (interleukin ‐ 8)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other cytokines</p> <p> <ul id="CD012179-list-0005"> <li> <p>IFN‐γ (interferon‐gamma)<sup>a</sup> </p> </li> <li> <p>MIF (macrophage migration inhibitory factor)<sup>a</sup> </p> </li> <li> <p>TNF‐α (tumour necrosis factor alpha)<sup>a</sup> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other immune/inflammatory markers</p> <p> <ul id="CD012179-list-0006"> <li> <p>sCD23 (soluble CD23, low‐affinity IgE receptor)<sup>a</sup> </p> </li> </ul> <ul id="CD012179-list-0007"> <li> <p>Copeptin, <i>vasopressin surrogate</i> </p> </li> <li> <p>hs‐CRP (high sensitive C‐reactive protein)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Other peptides and proteins shown to influence key events implicated in endometriosis</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Follistatin, <i>activin‐binding protein; involved in diverse activities from embryonic development to cell secretion</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>STX‐5 (syntaxin‐5), <i>protein belonging to syntaxin‐family, a vesicular membrane fusion protein receptor in endoplasmic reticulum membrane</i> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Oxidative stress markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbonyls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thiols</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PON‐1 (paraoxonase‐1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Post‐transcriptional regulators of gene expression (microRNAs)</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐9*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐141*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐17‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐145*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐20a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐199a</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐532‐3p</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Tumour markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐15.3 (cancer antigen‐15.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐72 (TAG‐72) (cancer antigen‐72 or (tumour associated glycoprotein‐72])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 (cancer antigen‐125)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Blood biomarkers that did not exhibit differential expression in endometriosis and for which diagnostic performance was not assessed</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Angiogenesis and growth factors and their receptors</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angiogenic activity of serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGF‐1 (insulin‐like growth factor‐1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAC (circulating angiogenic cells)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGF‐2 (insulin‐like growth factor‐2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EGF (epidermal growth factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGFBP‐3 (insulin‐like growth factor binding protein‐3)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sEGF‐R (soluble epidermal growth factor‐receptor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leptin<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sFlt‐1 (sVEGFR‐1] (soluble fms‐like tyrosine kinase or variant of VEGF receptor 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDGF (platelet derived growth factor)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycodelin‐A (PP14 or PAEP] (or placental protein 14 or progestogen‐associated endometrial protein)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF (vascular endothelial growth factor)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGF (hepatocyte growth factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Apoptosis markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Annexin V<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sFas (soluble Fas)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apoptotic cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>anti‐survivin Abs (anti‐survivin antibodies)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Cell adhesion molecules and other matrix‐related proteins</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biglycan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sE‐selectin (soluble E selectin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sICAM‐1 (soluble form of intercellular‐adhesion molecule‐1)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMP‐9 (matrix metalloproteinase‐9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Cytoskeleton molecules</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CK 19 (Cytokeratin‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i><b>DNA‐repair and telomere maintenance molecules</b> </i> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TL (telomere length)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Hormonal markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E2 (oestradiol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LH (luteinizing hormone)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH (follicle stimulating hormone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progesterone</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Immune system and inflammatory markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Autoantibodies</p> <p> <ul id="CD012179-list-0008"> <li> <p>Anti‐endometrial Abs (anti‐endometrial auto antibodies)<sup>a</sup> </p> </li> <li> <p>Anti‐sperm Abs (anti‐sperm auto antibodies)</p> </li> <li> <p>Anti‐ZP Abs (anti‐zona pellucida auto antibodies)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Interleukins</p> <p> <ul id="CD012179-list-0009"> <li> <p>IL‐1β<sup>a</sup> </p> </li> <li> <p>IL‐2</p> </li> <li> <p>IL‐4 <sup>a</sup> </p> </li> <li> <p>IL‐6 <sup>a</sup> </p> </li> <li> <p>IL‐8 <sup>a</sup> </p> </li> <li> <p>IL‐10</p> </li> <li> <p>IL‐12</p> </li> <li> <p>IL‐15</p> </li> <li> <p>IL‐16</p> </li> <li> <p>IL‐18</p> </li> <li> <p>IL‐13</p> </li> <li> <p>IL‐17</p> </li> <li> <p>IL‐23</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemokines</p> <p> <ul id="CD012179-list-0010"> <li> <p>MCP‐1 (monocyte chemotactic protein‐1)<sup>a</sup> </p> </li> </ul> </p> <p>other Cytokines</p> <p> <ul id="CD012179-list-0011"> <li> <p>Epo (erythropoietin)</p> </li> <li> <p>GM‐CSF (granulocyte/macrophage‐colony stimulating factor)</p> </li> <li> <p>IFN‐γ (interferon‐gamma)<sup>a</sup> MIF (macrophage migration inhibitory factor)<sup>a</sup> </p> </li> <li> <p>TNF‐α (tumour necrosis factor alpha)<sup>a</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immune cells</p> <p> <ul id="CD012179-list-0012"> <li> <p>Peripheral blood mononuclear cells:</p> <ul id="CD012179-list-0013"> <li> <p>Lymphocytes (overall and subpopulations of B‐ and T‐cells)</p> </li> <li> <p>Monocytes/macrophages</p> </li> <li> <p>Neutrophils<sup>a</sup> </p> </li> <li> <p>NLR (neutrophil‐to‐lymphocyte ratio)<sup>a</sup> </p> </li> <li> <p>NK (natural killer cells)</p> </li> <li> <p>NKR (natural killer cells receptors)</p> </li> <li> <p>Tregs (Regulatory T cells)</p> </li> <li> <p>WBC (white blood cells)<sup>a</sup> </p> </li> </ul> </li> <li> <p>Other blood cells and blood cell parameters</p> <ul id="CD012179-list-0014"> <li> <p>Haemoglobin</p> </li> <li> <p>MPV (mean platelet volume)</p> </li> <li> <p>Platelet count</p> </li> <li> <p>PLR (platelet/lymphocyte ratio</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other immune/inflammatory markers</p> <p> <ul id="CD012179-list-0015"> <li> <p>C3a (anaphylatoxin)</p> </li> </ul> <ul id="CD012179-list-0016"> <li> <p>sCD23 (soluble CD23, low‐affinity IgE receptor)<sup>a</sup> </p> </li> </ul> <ul id="CD012179-list-0017"> <li> <p>sCD163 (soluble haemoglobin scavenger receptor)</p> </li> </ul> <ul id="CD012179-list-0018"> <li> <p>CRP (C‐reactive protein)<sup>a</sup> </p> </li> </ul> <ul id="CD012179-list-0019"> <li> <p>sHLA‐I (soluble human leukocyte class I antigens)</p> </li> </ul> <ul id="CD012179-list-0020"> <li> <p>Immunoglobulins: IgA, IgG</p> </li> <li> <p>MPO (myeloperoxidase)</p> </li> </ul> <ul id="CD012179-list-0021"> <li> <p>NAG (N‐acetyl‐b‐Dglucosaminidase)</p> </li> </ul> <ul id="CD012179-list-0022"> <li> <p>PGE2 (prostaglandin E2)</p> </li> </ul> <ul id="CD012179-list-0023"> <li> <p>Phospholipid fatty acids</p> </li> </ul> <ul id="CD012179-list-0024"> <li> <p>PLA2G2A (phospholipase A2 group IIA)</p> </li> </ul> <ul id="CD012179-list-0025"> <li> <p>RANTES (regulated on activation, normal T cell expressed and secreted)</p> </li> </ul> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Nerve growth markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CNTF (ciliary Neurotrophic Factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NGF (nerve growth factor)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDNF (glial cell‐derived neurotrophic factor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NT4 (neurotrophin 4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Other peptides and proteins shown to influence key events implicated in endometriosis</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>DBP (vitamin D binding protein), <i>component of Gc‐globulin and is the major plasma carrier protein of vitamin D metabolites, responsible for the transport of fat and endotoxins, important factor in the actin scavenging system, plays an important role in the immune system</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Enolase (phosphopyruvate hydratase], <i>a glycolytic enzyme, frequently associated with autoimmune diseases</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>PDPK1 (phosphoinositide dependent protein kinase 1), <i>a master kinase involved in the signalling pathways</i> </p> <p><i>activated by several growth factors and hormones (glucose metabolism, cellular proliferation, cellular survival, and angiogenesis)</i> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Oxidative stress markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ascorbic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrotyrosine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSH (glutathione)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOD3 (superoxide dismutase‐3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HSP70 (heat shock protein 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TRX (Thioredoxin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IMA (Ischemia‐modified albumin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malondialdehyde</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><i><b>Tumour markers</b> </i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AFP (alpha‐fetoprotein)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>c‐erbB‐2 (HER‐2/neu] (erythroblastosis oncogene B or human epidermal growth factor receptor‐2 derived from glioblastoma) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐19.9 (cancer antigen‐19.9)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HE4 (human epididymal secretory protein E4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 (cancer antigen‐125)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><sup>a</sup> Biomarkers that belong to both groups (evaluated as a diagnostic test for endometriosis in some studies and did not exhibit differential expression in endometriosis in the other studies). </p> <p>For a comprehensive list of all biomarkers with their biological annotation, please see <a href="./appendices#CD012179-sec-0169">Appendix 1</a>. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood biomarkers evaluated in this review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012179-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Application of the QUADAS‐2 tool for assessment of methodological quality of the included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 1 ‐ Patient selection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe methods of patient selection and included patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection bias, spectrum bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review Question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women of reproductive age with clinically suspected endometriosis (symptoms, clinical examination ± presence of pelvic mass), scheduled for surgical exploration of pelvic/abdominal cavity for confirmation of the diagnosis ± treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study objectives, study population, selection (inclusion/exclusion criteria), study design, clinical presentation, age, number of enrolled and number of available for analysis, setting, place and period of the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was a consecutive or random sample of patients enrolled?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If a consecutive sample or a random sample of the eligible participants was included in the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If a consecutive sample or a random sample of the eligible participants was not included in the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Did the study avoid inappropriate exclusions?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If inclusion and exclusion criteria were presented and all participants with suspected endometriosis were included, with an exception for those who either had a history of medical conditions or were on medical therapy that would have potentially interfered with interpretation of index test (e.g. malignancy, pregnancy, autoimmune disorders, infectious diseases, treatment with hormonal or immunomodulator substances); refused to participate in the study; or were unfit for surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study excluded the participants based on education level, psychosocial factors, genetic testing or phenotype or excluded participants with any comorbidities commonly present in general population, including a population that could have undergone a testing for endometriosis in clinical setting (hypertension, asthma, obesity, benign gastrointestinal or renal disease, etc) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study did not provide clear definition of the selection (inclusion/exclusion) criteria and 'no' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 3</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was a 'two‐gate' design avoided?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study had a single set of inclusion criteria, defined by the clinical presentation (i.e. only participants in whom the target condition is suspected) ‐ a single‐gate design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study had more than one set of inclusion criteria in respect to clinical presentation (i.e. participants suspected of target condition and participants with alternative diagnosis in whom the target condition would not be suspected in clinical practice) ‐ a two‐gate study design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If it was unclear whether a two‐gate deign was avoided or not</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the selection of patients have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for all the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 3 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns about applicability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Are there concerns that the included patients do not match the review question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study includes only clinically relevant population that would have undergone index test in real practice and includes representative form of target condition </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study population differed from the population defined in the review question in terms of demographic features and comorbidity (e.g. studies with multiple sets of inclusion criteria with respect to clinical presentation including either healthy controls or alternative diagnosis controls that would not have undergone index test in real practice). Further, if target condition diagnosed in the study population was not representative of the entire spectrum of disease, such as limited spectrum of severity (e.g. only mild forms) or limited type of endometriosis (e.g. only deep infiltrating endometriosis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear (e.g. severity of endometriosis was not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 2 ‐ Index test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the index test, how it was conducted and interpreted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test review bias, clinical review bias, interobserver variation bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any type of blood‐based biomarker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index test name, description of positive case definition by index test as reported, threshold for positive result, examiners (number, level of expertise, blinding), interobserver variability, conflict of interests </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Were the index test results interpreted without knowledge of the results of the reference standard?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the operators performing/interpreting index test were unaware of the results of the reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the operators performing/interpreting index test were not blinded to the results of the reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>If a threshold was used, was it pre‐specified?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If study clearly provided a threshold for positive result and was defined before execution/interpretation of index test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If a threshold for positive result was not provided or not defined prior to test execution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If it was unclear whether a threshold was pre‐specified or not</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 3</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was a menstrual cycle phase considered in interpreting the index test?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all the included participants were in the same phase of menstrual cycle, if the study reported subgroup analyses per cycle phase, or if study reported the pooled estimates after impact of the cycle phase on biomarker expression was not detected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If study included participants in different phases of menstrual cycle, but effect of cycle phase on index test was not assessed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the cycle phase was not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the conduct or interpretation of the index test have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for all the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 3 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns about applicability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We considered all types of blood‐based biomarkers as eligible, therefore all the included studies were classified as 'low concern', unless 'unclear' judgement was applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not consider the studies where index tests other than blood‐based biomarkers were included (or excluded information on other index tests reported in addition to blood tests) or where index test looked at other target conditions not specified in the review (e.g. studies aimed at classifying pelvic masses as benign and malignant); therefore none of the included studies was classified as 'high concern' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If study reported, but did not present sufficient information on any of the following: laboratory method, sample handling, reagents used or experience of the test operators </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 3 ‐ Reference standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the reference standard, how it was conducted and interpreted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Verification bias, bias in estimation of diagnostic accuracy due to inadequate reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Target condition ‐ pelvic endometriosis, ovarian endometriosis, deep infiltrating endometriosis. Reference standard ‐ visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Target condition, prevalence of target condition in the sample, reference standard, description of positive case definition by reference test as reported, examiners (number, level of expertise, blinding), interobserver variability, conflict of interests </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Is the reference standard likely to correctly classify the target condition?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the study reported at least one of the following: surgical procedure was described in sufficient detail; criteria for positive reference standard were stated; diagnosis was confirmed by histopathology; or the procedure was performed by a team with high level of expertise in diagnosis/surgical treatment of target condition, including tertiary referral centres for endometriosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If reference standard did not classify target condition correctly; considering the inclusion criteria and nature of the reference standard, none of the studies were classified as 'no' for this item </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If information on execution of the reference standard, its interpretation or operators was unclear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Were the reference standard results interpreted without knowledge of the results of the index tests?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If operators performing the reference test were unaware of the results of the index test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If operators performing the reference test were aware of the results of the index test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for both of the above 2 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 2 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 2 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns about applicability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Considering the inclusion criteria, all the studies were classified as 'low concern', unless 'unclear' judgement was applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We excluded the studies where participants did not undergo surgery for diagnosis of endometriosis; therefore none of the included studies were classified as 'high concern' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only studies where laparoscopy/laparotomy served as a reference test were included; therefore none of the included studies were classified as 'unclear concern' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Domain 4 ‐ Flow and timing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe any participants who did not receive the index tests or reference standard or who were excluded from the 2 x 2 table; describe the interval and any interventions between index tests (sample collection) and the reference standard </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease progression bias, bias of diagnostic performance due to missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 12‐month interval between index test (sample collection) and reference standard ‐ endometriosis may progress over the time, so we had chosen an arbitrary time interval of 12 months as an acceptable time interval between the index test and surgical confirmation of diagnosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Informaton collected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time interval between index test (sample collection) and reference standard, withdrawals (overall number of reported and if explanation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 1</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Was there an appropriate interval between index test (sample collection) and reference standard?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If time interval was reported and was less than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We excluded all the studies where time interval was longer than 12 months; therefore none of the included studies were classified as 'no' for this item </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If time interval was not stated clearly, but authors description allowed us to assume that the interval was reasonably short </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 2</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Did all patients receive the same reference standard?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all participants underwent laparoscopy/laparotomy as a reference standard. Considering the inclusion criteria, all the studies were classified as 'yes' for this item, as anticipated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all participants did not undergo surgery or had alternative reference standard or if only a subset of participants had surgery as reference standard, but the information on this population was not available in isolation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear. Considering the inclusion criteria, none of the included studies were classified as 'unclear' for this item </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Signalling question 3</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Were all patients included in the analysis?</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If all the participants were included in the analysis or if the participants were excluded because they did not meet inclusion criteria prior to execution of index test or if the withdrawals were less than 5% of the enrolled population (arbitrary selected cut‐off) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If any participants were excluded from the analysis because of uninterpretable results, inability to undergo either index test or reference standard, or unclear reasons </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If this information was unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Could the patient flow have introduced bias?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'yes' classification for all the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'no' classification for any of the above 3 questions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If 'unclear' classification for any of the above 3 questions and 'high risk' judgement was not applicable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Application of the QUADAS‐2 tool for assessment of methodological quality of the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012179-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Blood biomarkers to be validated for their diagnostic potential in endometriosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Blood biomarkers <sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Replacement test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SnOUT triage test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SpIN triage test</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>1. Angiogenesis and growth markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF &gt; 680 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF &gt; 236 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>2. High‐throughput markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolome by ESI‐MS/MS (SMOH C16:1 + PCaa C36:2/PCae C34:2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proteome by SELDI‐TOF‐MS (6 peaks with molecular weights of 1.63, 3.05, 3.53, 3.77, 5.05 and 5,07 Da) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>3. Immune system and inflammatory markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>4. Oxidative stress markers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PON‐1 &lt; 141.5 U/l</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbonyls &lt; 14.9 μM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>5. Post‐transcriptional regulators of gene expression (microRNAs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐9*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐141*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐145*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐20a &lt; 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐22 &lt; 0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐532‐3p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6. Tumour markers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 (cut‐off value &gt; 43 U/ml)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>7. Combined blood tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml + CRP &gt; 438 μg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐199a + miR‐542‐3p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + STX‐5 + LN‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 17.6 IU/ml + VEGF &gt; 236 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + CA‐19‐9 + survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 50 IU/ml +/or CCR1 &gt; 1.16 +/or MCP‐1 &gt; 140 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 20 IU/ml + MCP‐1 &gt; 152.744 pg/ml + leptin &gt; 3.14 ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + IL‐8 + TNF‐α</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP (in menstrual phase of the cycle)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>8. Tests that specifically differentiate endometrioma from other benign ovarian cysts in women of reproductive age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urocortin &gt; 29 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urocortin &gt; 33 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follistatin &gt; 1433 pg/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 &gt; 30 U/ml and &gt; 36 U/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>+</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125 ≥ 25 U/ml + CA‐19.9 ≥ 22 U/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>±</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Notes:</p> <p><b>+</b> meets the criteria </p> <p> <ul id="CD012179-list-0073"> <li> <p>Replacement test: sensitivity ≥ 94 and specificity ≥ 79</p> </li> </ul> <ul id="CD012179-list-0074"> <li> <p>SnOUT triage test: sensitivity ≥ 95 and specificity ≥ 50</p> </li> </ul> <ul id="CD012179-list-0075"> <li> <p>SpIN triage test: sensitivity ≥ 50 and specificity ≥ 95</p> </li> </ul> </p> <p><b>±</b> approaches the criteria (within 5% of the pre‐defined criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup> This group included: tests with an adequate diagnostic performance, but insufficient data to confidently comment on their diagnostic role (less than 3 studies with the diagnostic estimates meeting the criteria for either a replacement or triage test); and tests where the diagnostic estimates were approaching the criteria for replacement or triage tests in a small number of studies, and it is possible that they would reach this criteria if further studies were performed (less than 3 studies with the diagnostic estimates within 5% of the criteria for either replacement or triage tests). </p> <p>For a comprehensive list of all biomarkers with their biological annotation, please see <a href="./appendices#CD012179-sec-0169">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Blood biomarkers to be validated for their diagnostic potential in endometriosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012179/full#CD012179-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012179-tbl-0006"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 Glycodelin‐A (&gt; 2.07 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 Glycodelin (&gt; 9.0 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 Glycodelin (&gt; 18 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 IGFBP‐3 (&gt; 200 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 IGFBP‐3 (&gt; 210 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 VEGF (&gt; 1.5 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">7 VEGF (&gt; 236 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">8 VEGF‐A (&gt; 680 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">9 Urocortin (&gt; 29 pg/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">10 Urocortin (&gt; 33 pg/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">11 Urocortin (&gt; 41.6 pg/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">12 Survivin (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">13 sICAM‐1 (&lt; 243 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">14 sICAM‐1 (&lt; 254.6 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">15 sICAM‐1 (&gt; 241.46 µg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">16 LN‐1 (&gt; 1110.0 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">17 Metabolome by ESI‐MS/MS (SMOH C16:1 + PCaa C36:2/ PCae C34:2) age‐/BMI‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">18 Proteome by SELDI‐TOF‐MS (3 peaks with the molecular weight of 3,956.00, 11,710.00 and 6,986.00 Da) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">19 Proteome by SELDI‐TOF MS (5 peaks with molecular weights of 4159.00, 5264.00, 5603.00, 9861.00 and 10,533.00 Da) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">20 Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 9,926.31, 10,072.2, 6,753.04, 4,302.67, 9,328.49 Da) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">21 Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 2,831.02, 7,554.66, 4,241.29, 2,953.25, 9,927.73 Da) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">22 Proteome by SELDI‐TOF MS (5 peaks with molecular weight of 11,366.3, 5,712.69, 10,070.7, 3,017.68, 3,824.44 Da) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">23 Proteome by SELDI‐TOF‐MS (6 peaks with molecular weights of 1629.00 3047.00, 3526.00, 3774.00, 5046.00 and 5068.00 Da) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">24 Prolactin (&gt; 14.8 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">25 Prolactin (&gt; 20 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">26 Anti‐endometrial Abs, IgG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">27 Anti‐endometrial Abs (MW 26/34/42 kd) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">28 Anti‐laminin auto Abs, IgG (&gt; 1 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">29 sCD23 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">30 MCP‐1 (&gt; 100 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">31 Copeptin (&gt; 251.18 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">32 hs‐CRP (&gt; 0.61 mg/l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">33 hs‐CRP (&gt; 0.62 mg/l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">34 hs‐CRP (&gt; 0.70 mg/l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">35 hs‐CRP (&gt; 0.73 mg/l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">36 hs‐CRP (&gt; 438 μg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">37 hs‐CRP (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">38 IFN‐γ (&lt; 76 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">39 MIF (&gt; 0.57 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">40 TNF‐α (&gt; 12.45 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">41 TNF‐α (&lt; 45.6 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">42 TNF‐α (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">43 Neutrophils (&gt; 4058/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">44 NLR (&gt; 2.19) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">45 WBC (&gt; 6400/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">46 IL‐1β (&lt; 0.9 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">47 IL‐4 (≥ 3 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">48 IL‐6 (&gt; 1.03 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">49 IL‐6 (&gt; 1.9 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">50 IL‐6 (&gt; 2 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">51 IL‐6 (&gt; 2.6 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">52 IL‐6 (&gt; 4 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">53 IL‐6 (&gt; 7.5 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">54 IL‐6 (&lt; 10 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">55 IL‐6 (&gt; 12.2 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">56 IL‐6 (&gt; 15.4 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">57 IL‐6 (&gt; 25.75 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">58 IL‐6 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">59 IL‐8 (&gt; 24 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">60 IL‐8 (≥ 25 pg/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">61 IL‐8 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">62 Follistatin (&gt; 1433 pg/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">63 STX‐5 (&gt; 55 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">64 Carbonyls (&lt; 14.9 μM) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">65 PON‐1 (&lt; 141.5 U/l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">66 Thiols (&lt; 396.44 μM) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">67 miR‐9* (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">68 miR‐17‐5 (&lt; 0.9057) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">69 miR‐20a (&lt; 0.6879) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">70 miR‐22 (&lt; 0.5647) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">71 miR‐122 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">72 miR‐141* (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">73 miR‐145* (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">74 miR‐199a (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">75 miR‐532‐3p (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">76 Ca‐15.3 (&gt; 15 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">77 Ca‐15.3 (&gt; 30 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">78 CA‐19.9 (&gt; 7.5 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">79 CA‐19.9 (&gt; 9.5 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">80 CA‐19.9 (&gt; 10.67 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">81 CA‐19.9 (≥ 12 U/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">82 CA‐19.9 (&gt; 37 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">83 CA‐19.9 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">84 CA‐72 (TAG‐72) (&gt; 4 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">85 CA‐72 (TAG‐72) (&gt; 6 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">86 CA‐125 (&gt; 10 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">87 CA‐125 (&gt; 11 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">88 CA‐125 (&gt; 11.5 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">89 CA‐125 (&gt; 12.5 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">90 CA‐125 (&gt; 12.8 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">91 CA‐125 (&gt; 13.5 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">92 CA‐125 (&gt; 14.7 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">93 CA‐125 (&gt; 16 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">94 CA‐125 (&gt; 17.6 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">95 CA‐125 (&gt; 20 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1115</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">96 CA‐125 (&gt; 20 U/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">97 CA‐125 (&gt; 25 U/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">98 CA‐125 (&gt; 26 IU/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">99 CA‐125 (&gt; 30 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>943</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">100 CA‐125 (&gt; 30 U/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">101 CA‐125 (&gt; 33 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">102 CA‐125 (&gt; 35 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3266</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">103 CA‐125 (&gt; 35 U/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">104 CA‐125 (&gt; 36 U/l) endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">105 CA‐125 (&gt; 42 U/l), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">106 CA‐125 (&gt; 43 U/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">107 CA‐125 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">108 CA‐125 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">109 CA‐125 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">110 CA‐125 (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">111 Combined test (CA‐125 ≥ 25 U/ml +/or CA‐19.9 ≥ 12 U/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">112 Combined test (CA‐125 ≥ 25 U/ml + Ca‐19.9 ≥ 12 U/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">113 Combined test (CA‐125 &gt; 19.8 U/l + Prolactin &gt; 14.8 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">114 Combined test (CA‐125 &gt; 35 U/l + Prolactin &gt; 20 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">115 Combined test (CA‐125 &gt; 17.6 IU/ml + VEGF &gt; 236 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">116 Combined test (CA‐125 &gt; 20 U/l + Anti‐endometrial Abs &gt; 0.3 A‐value) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">117 Combined test (CA‐125 x NLR; (&gt; 43.1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">118 Combined test (CA‐125 &gt; 30 U/ml +/or IL‐8 ≥ 25 pg/ml), endometrioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">119 Combined test (CA‐125 + IL‐8) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">120 Combined test (IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">121 Combined test (IL‐6 &gt; 12.2 pg/ml + CRP &gt; 438 μg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">122 Combined test (TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">123 Combined test (miR‐199a + miR‐122) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">124 Combined test (miR‐199a + miR‐542‐3p) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">125 Combined test (Ca‐125 + Ca 19‐9 + Survivin) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">126 Combined test (CA‐125 + STX‐5 + LN‐1) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">127 Combined test (CA‐125 &gt; 35 IU/ml +/or CA‐19.9 &gt; 37 IU/ml +/or IL‐6 &gt; 2 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">128 Combined test (CA‐125 &gt; 50 IU/mL +/ or CCR1 &gt; 1.16 +/or MCP‐1 &gt; 140 pg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">129 Combined test (Ca‐125 &gt; 20 mIU/ml + MCP‐1 &gt; 152.74 pg/ml + Leptin &gt; 3.14 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">130 Combined test CA‐125 + IL‐8 + TNF‐α) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">131 Combined test (IL‐6 &gt; 12.2 pg/ml + TNF‐α &gt; 12.45 pg/ml + CRP &gt; 438 μg/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">132 Combined test (CA‐125 + VEGF + annexin V + glycodelin] ‐ MLR (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">133 Combined test (CA‐125 + VEGF + annexin V + glycodelin] ‐ LS‐SVM (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">134 Combined test (CA‐125 + VEGF + annexin V + sICAM‐1) ‐ MLR or LS‐SVM (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">135 Combined test (CA‐125 &gt; 20 mIU/ml + MCP‐1 &gt; 53.5 pg/ml + Leptin &gt; 29.1 ng/ml + MIF &gt; 14.7 ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">136 Combined test (miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">137 Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">138 Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">139 Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">140 Combined test (CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP) (cut‐off not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">141 CA‐125 (&gt; 20 U/ml), Bilibio 2014 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">142 CA‐125 (&gt; 35 U/ml), Bilibio 2014 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">143 CA‐125 (&gt; 16 U/ml), Ferreira 1994 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">144 CA‐125 (&gt; 35 U/ml), Ferreira 1994 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">145 CA‐125 (&gt; 30 U/ml), Florio 2007 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">146 CA‐125 (&gt; 36 U/ml), Florio 2007 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">147 CA‐125 (&gt; 12.8 U/ml), Gagne 2003a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">148 CA‐125 (&gt; 35 U/ml), Gagne 2003a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">149 CA‐125 (&gt; 20 U/ml), Guerriero 1996b <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">150 CA‐125 (≥ 25 U/ml), Guerriero 1996b <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">151 CA‐125 (&gt; 35 U/ml), Guerriero 1996b <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">152 CA‐125 (&gt; 20 U/ml), Kitawaki 2005 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">153 CA‐125 (&gt; 26 U/ml), Kitawaki 2005 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">154 CA‐125 (&gt; 30 U/ml), Kitawaki 2005 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">155 CA‐125 (&gt; 35 U/ml), Kitawaki 2005 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">156 CA‐125 (&gt; 10 U/ml), Rosa E Silva 2007 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">157 CA‐125 (&gt; 20 U/ml), Rosa E Silva 2007 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">158 CA‐125 (&gt; 20 U/ml), Yang 1994 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">159 CA‐125 (&gt; 35 U/ml), Yang 1994 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">160 IL‐6 (&gt; 1.03 pg/ml), Othman 2008 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">161 IL‐6 (&gt; 1.9 pg/ml), Othman 2008 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">162 IL‐6 (&gt; 2.6 pg/ml), Othman 2008 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">163 IL‐6 (&gt; 2 pg/ml), Bedaiwy 2002 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">164 IL‐6 (&gt; 4 pg/ml), Bedaiwy 2002 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">165 IL‐6 (&gt; 7.5 pg/ml), Bedaiwy 2002 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012179/references#CD012179-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012179&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012179-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012179-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012179-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012179-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pt#CD012179-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD012179-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012179\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012179"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012179\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012179\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012179"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012179\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012179"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012179\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012179\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012179"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012179&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012179';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012179/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012179/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012179%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727323903"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012179/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727323907"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012179/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea93e29559377',t:'MTc0MDcyNzMyNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 